Engineered glycosyltransferase and steviol glycoside glucosylation process
By providing highly active engineered glycosyltransferase and sucrose synthase, the problems of high demand for glycosyl donors and by-product generation in large-scale production of sugar conjugates are solved, and efficient and low-cost sugar conjugate preparation is achieved. .
Patent Information
- Application Number
- CN202411099043.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-03-30
- Filing Date
- 2018-02-01
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art requires a large amount of glycosyl donors in the mass production of sugar conjugates, increasing costs, and the nucleotide circulation system, while reducing by-products, still needs to be improved to improve efficiency.
Provides engineered glycosyltransferases (GT) and sucrose synthase (SuS), which have high activity and encoded polypeptide sequences for the preparation of products with beta-glucose bonds, including rebaudioside, by optimizing polypeptides Mutation set of sequences to improve enzyme activity and efficiency.
The efficient preparation of sugar conjugates is achieved, which reduces the demand for sugar-sized donors, improves reaction efficiency, reduces the generation of by-products, and reduces production costs.
Smart Images

Figure CN118956802A_ABST
Abstract
Description
[0001] This application is a divisional application of an application filed on February 1, 2018, with application number 201880024548.6 and invention name “Engineering glycosyltransferase and steviol glycoside glucosylation method”.
[0002] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 454,417, filed February 3, 2017, and U.S. Provisional Patent Application Serial No. 62 / 479,262, filed March 30, 2017, both of which are hereby incorporated by reference in their entirety for all purposes. Field of the Invention
[0003] The present invention provides engineered glycosyltransferase (GT) enzymes, polypeptides having GT activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention provides engineered sucrose synthase (SuS) enzymes, polypeptides having SuS activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention also provides compositions comprising GT enzymes and methods of using engineered GT enzymes to prepare products having β-glucose linkages. The present invention also provides compositions and methods for producing rebaudiosides (e.g., rebaudioside M, rebaudioside A, rebaudioside I, and rebaudioside D). The present invention also provides compositions comprising SuS enzymes and methods of using the same. Methods for producing GT and SuS enzymes are also provided.
[0004] Reference to a sequence listing, table or computer program
[0005] An official copy of the sequence listing is submitted with this specification as a text file in ASCII format via EFS-Web, with the file name "CX8-162WO3_ST25.txt", the creation date of which is January 24, 2018, and the size of which is 31,100 kilobytes. The sequence listing submitted via EFS-Web is part of this specification and is incorporated herein by reference in its entirety. Background of the Invention
[0007] Glycosyltransferase (GT) is an enzyme that transfers glycosyl residues from activated nucleoside sugars to monomeric and polymeric acceptor molecules (e.g., other sugars, proteins, lipids, and other organic substrates) after translation. Therefore, these enzymes utilize activated donor sugar substrates containing substituted phosphate leaving groups. Donor sugar substrates (i.e., "glycosyl donors") are typically activated to nucleoside diphosphate sugars. However, other sugars are also used, such as nucleoside monophosphate sugars, lipid phosphates, and unsubstituted phosphates (see, e.g., Lairson et al., Ann. Rev. Biochem., 77: 25.1-25.35
[2008] ). Based on the stereochemistry of substrates and reaction products, GTs are classified as retaining enzymes or invertases. In reactions where the stereochemistry of the anomeric bond of the donor is retained (e.g., α to α), GTs are retaining enzymes. In reactions where stereochemistry is converted (e.g., α to β), GTs are invertases. These glycosylation products participate in a variety of metabolic pathways and processes. In fact, the biosynthesis of many disaccharides, oligosaccharides and polysaccharides involves the action of multiple glycosyltransferases. The transfer of the glucosyl moiety can change the biological activity, solubility and intracellular transport characteristics of the receptor. GT has been used for the targeted synthesis of specific compounds (such as glycoconjugates and glycosides), as well as for the production of differentially glycosylated drugs, biological probes or natural product libraries. In some methods, the large-scale use of GT for glycoconjugate synthesis requires a large amount of glycosyl donors, which increases the cost of this method. Nucleotide recycling systems have been developed to allow the resynthesis of glycosyl donors from released nucleotides. These recycling systems also reduce the amount of nucleotide by-products formed during the reaction, thereby reducing the inhibition caused by GT. However, there is still a need for improved methods suitable for large-scale production of glycoconjugates by GT. SUMMARY OF THE INVENTION
[0009] The present invention provides engineered glycosyltransferase (GT) enzymes, polypeptides having GT activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention provides engineered sucrose synthase (SuS) enzymes, polypeptides having SuS activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention also provides compositions comprising GT enzymes and methods of using engineered GT enzymes to prepare products having β-glucose bonds. The present invention also provides compositions and methods for producing rebaudiosides (e.g., rebaudioside M, rebaudioside A, rebaudioside I, and rebaudioside D). The present invention also provides compositions comprising SuS enzymes and methods of using the same. Methods for producing GT and SuS enzymes are also provided.
[0010] The present invention provides engineered glycosyltransferases comprising a polypeptide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2. In some embodiments, the engineered glycosyltransferase comprises a polypeptide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2. NO:4, 8, 32, 232, 348, 548, 562, 696, 758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884 ,3016,3082,3244,3346,3502,3696,3956,4256,4550,4684,4838,4876,5066,5290,5372 , 5562, 5708, 5976, 6138, 6288, 6468, 6864, 7324, 7388, 7784 and / or 8088 having polypeptides having 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity. In some additional embodiments, the engineered glycosyltransferase comprises a polypeptide having at least 90% sequence identity to SEQ ID NO: 4, 8, 32, 232, 348, 548, 562, 696, 758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884, 3016, 3082, 3244, 3346, 3502, 3696, 3956, 4256, 4550, 4684, 4838, 4876, 5066, 5290, 5372, 5562, 5708, 5976, 6138, 6288, 6468, 6864, 7324, 7388, 7784 and / or 8088. In some additional embodiments, the engineered glycosyltransferase comprises a polypeptide having at least 91% sequence identity to SEQ ID NO: 4, 8, 32, 232, 348, 548, 562, 696, 758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884, 3016, 3082, 3244, 3346, 3502, 3696, 3956, 4256, 4550, 4684, 4838, 4876, 5066, 5290, 5372, 5562, 5708, 5976, 6138, 6288, 6468, 6864, 7324, 7388, 7784 and / or 8088. In some additional embodiments, the engineered glycosyltransferase comprises a glycosyltransferase corresponding to SEQ ID NO: 4, 8, 32,88, 6468, 6864, 7324, 7388, 7784, and / or 8088. In some additional embodiments, the engineered glycosyltransferase comprises a polypeptide having at least 93% sequence identity to SEQ ID NO: 4, 8, 32, 232, 348, 548, 562, 696, 758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884, 3016, 3082, 3244, 3346, 3502, 3696, 3956, 4256, 4550, 4684, 4838, 4876, 5066, 5290, 5372, 5562, 5708, 5976, 6138, 6288, 6468, 6864, 7324, 7388, 7784 and / or 8088. In some additional embodiments, the engineered glycosyltransferase comprises a polypeptide having at least 94% sequence identity to SEQ ID NO: 44, 8, 32, 232, 348, 548, 562, 696, 758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884, 3016, 3082, 3244, 3346, 3502, 3696, 3956, 4256, 4550, 4684, 4838, 4876, 5066, 5290, 5372, 5562, 5708, 5976, 6138, 6288, 6468, 6864, 7324, 7388, 7784 and / or 8088. In some additional embodiments, the engineered glycosyltransferase comprises a polypeptide corresponding to SEQ ID NO: 4, 8, 32, 232, 348, 548, 562, 696, 758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884, 3016, 3082, 3244, 3346, 3502, 3696, 3956, 4256, 4550, 4684, 4838, 4876, 5066, 5290, 5372, 5562, 5708, 5976, 6138, 6288, 6468, 6864, 7324, 7388,7784 and / or 8088 have polypeptides with at least 95% sequence identity. In some additional embodiments, the engineered glycosyltransferase comprises a polypeptide having at least 96% sequence identity to SEQ ID NO: 4, 8, 32, 232, 348, 548, 562, 696, 758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884, 3016, 3082, 3244, 3346, 3502, 3696, 3956, 4256, 4550, 4684, 4838, 4876, 5066, 5290, 5372, 5562, 5708, 5976, 6138, 6288, 6468, 6864, 7324, 7388, 7784 and / or 8088. In some additional embodiments, the engineered glycosyltransferase comprises a polypeptide having at least 97% sequence identity to SEQ ID NO: 4, 8, 32, 232, 348, 548, 562, 696, 758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884, 3016, 3082, 3244, 3346, 3502, 3696, 3956, 4256, 4550, 4684, 4838, 4876, 5066, 5290, 5372, 5562, 5708, 5976, 6138, 6288, 6468, 6864, 7324, 7388, 7784 and / or 8088. In some additional embodiments, the engineered glycosyltransferase comprises a polypeptide having at least 98% sequence identity to SEQ ID NO: 44, 8, 32, 232, 348, 548, 562, 696, 758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884, 3016, 3082, 3244, 3346, 3502, 3696, 3956, 4256, 4550, 4684, 4838, 4876, 5066, 5290, 5372, 5562, 5708, 5976, 6138, 6288, 6468, 6864, 7324, 7388, 7784 and / or 8088. In some additional embodiments, the engineered glycosyltransferase comprises a polypeptide corresponding to SEQ ID NO: 44, 8, 32, 232, 348, 548, 562, 696, 758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884, 3016, 3082, 3244, 3346, 3502, 3696, 3956, 4256, 4550, 4684, 4838, 4876, 5066, 5290, 5372, 5562, 5708, 5976, 6138, 6288, 6468,6864, 7324, 7388, 7784 and / or 8088 polypeptides having at least 99% sequence identity. In some additional embodiments, the engineered glycosyltransferase comprises a polypeptide selected from SEQ ID NO: 4, 8, 32, 232, 348, 548, 562, 696, 758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884, 3016, 3082, 3244, 3346, 3502, 3696, 3956, 4256, 4550, 4684, 4838, 4876, 5066, 5290, 5372, 5562, 5708, 5976, 6138, 6288, 6468, 6864, 7324, 7388, 7784, and / or 8088. In some additional embodiments, the engineered glycosyltransferase is selected from the group consisting of a beta-1,2-glycosyltransferase and a beta-1,3-glycosyltransferase.In some additional embodiments, the engineered glycosyltransferase preferentially uses a sugar donor other than uracil-diphosphate. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a variant engineered glycosyltransferase provided in the following tables: Table 2.1, 3.1, 5.1, 6.1, 6.3, 8.1, 9.1, 9.2, 9.4, 11.1, 12.1, 14.1, 15.1, 15.2, 15.3, 16.1, 17.1, 43.1, 43.2, 44.2, 45.1, 45.3, 46.1, 46.2, 46.3, 47.1, 47.2, 47.3, 48.1, 48.2, 49.1, 49.3, 50.1, 50.2, 50.3, 50.4, 51.1, 51.2, 52.1, 53.1, 53.3, 54.1, 54.2, 54.3, 55 .1, 55.2, 55.3, 56.1, 56.2, 56.3, 57.1, 58.1, 58.2, 58.3, 59.1, 59.3, 59.3, 60.1, 60.2, 61.1, 61.2, 62.1, 62.2, 63.1, 63.2, 64.1, 64.2, 65.1, 65.2, 66.1, 66 .2, 67.1, 67.2, 67.3, 68.1, 68.2, 69.1, 69.2, 70.1, 70.2, 71.1, 71.2, 71.3, 72.1, 72.2, 72.3, 73.1, 73.2, 74.1, 74.2, 74.3, 75.1, 75.2, 75.3, 77.1 and / or 77.2. The present invention provides engineered glycosyltransferases comprising a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the following sequences: SEQ ID NO: 6, 8,10、12、14、16、18、20、22、24、26、28、30、22、34、36、38、40、42、44、46、48、50、52、54、56、58、60、62、64、66、68、70、76、78、80、82、84、86、88、90、92、94、96、98、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、136、138、140、142、144、146、148、150、152、154、156、158、160、162、164、166、168、170、172、174、176、178、180、182、184、186、188、190、192、194、196、198、200、202、204、206、208、210、212、214、216、218、220、222、224、226、228、230、232、234、236、238、240、242、244、246、248、250、252、254、256、258、260、262、264、266、268、270、272、274、276、278、280、282、284、286、288、290、292、294、296、298、300、302、304、306、308、310、312、314、316、318、320、322、324、326、328、330、332、334、336、338、340、342、344、346、348、350、352、354、356、358、360、362、364、366、368、370、372、374、376、378、380、382、384、386、388、390、392、394、396、398、400、402、404、406、408、410、412、414、416、418、420、422、424、426、428、430、432、434、436、438、440、442、444、446、448、450、452、454、456、458、460、462、464、466、468、470、472、474、476、478、480、482、484、486、488、490、492、494、496、498、500、502、504、506、508、510、512、514、516、518、520、522、524、526、528、530、532、534、536、538、540、542、544、546、548、550、552、554、556、558、560、562、564、566、568、570、572、574、576、578、580、582、584、586、588、590、592、594、596、598、600、602、604、606、608、610、612、614、616、618、620、622、624、626、628、630、632、634、636、638、640、642、644、646、648、650、652、654、656、658、660、662、664、666、668、670、672、674、676、678、680、682、684、686、688、690、692、694、696、698、700、702、704、706、708、710、712、714、716、718、720、722、724、726、728、730、732、734、736、738、740、742、744、746、748、750、752、754、770、772、774、776、778、780、782、784、786、788、790、792、794、796、798、800、802、804、806、808、810、812、814、816、818、820、822、824、826、828、830、832、834、836、838、840、842、844、846、848、850、852、854、856、858、860、862、864、866、868、870、872、874、876、878、880、882、884、886、888、890、892、894、896、898、900、902、904、906、908、910、912、914、916、918、920、922、924、926、928、930、932、934、936、938、940、942、944、946、948、950、952、954、956、958、960、962、964、966、968、970、972、974、976、978、980、982、984、986、988、990、992、994、996、998、1000、1002、1004、1006、1008、1010、1012、1014、1016、1018、1020、1022、1024、1026、1028、1030、1032、1034、1036、1038、1040、1042、1044、1046、1048、1050、1052、1054、1056、1058、1060、1062、1064、1066、1068、1070、1072、1074、1076、1078、1290、1292、1294、2596、2598、2600、2602、2604、2606、2608、2610、2612、2614、2616、2618、2620、2622、2624、2626、2628、2630、2632、2634、2636、2638、2640、2642、2644、2646、2648、2650、2652、2654、2656、2658、2660、2662、2664、2666、2668、2670、2672、2674、2676、2678、2680、2682、2684、2686、2688、2690、2692、2694、2696、2698、2700、2702、2704、2706、2708、2710、2712、2714、2716、2718、2720、2722、2724、2726、2728、2730、2732、2734、2736、2738、2740、2742、2744、2746、2748、2750、2752、2754、2756、2758、2760、2762、2764、2766、2768、2770、2772、2774、2776、2778、2780、2782、2784、2786、2788、2790、2792、2794、2796、2798、2800、2802、2804、2806、2808、2810、2812、2814、2816、2818、2820、2822、2824、2826、2828、2830、2832、2834、2836、2838、2840、2842、2844、2846、2848、2850、2852、2854、2856、2858、2860、2862、2864、2866、2868、2870、2872、2874、2876、2878、2880、2882、2884、2886、2888、2890、2892、2894、2896、2898、2900、2902、2904、2906、2908、2910、2912、2914、2916、2918、2920、2922、2924、2926、2928、2830、2932、2934、2936、2938、2940、2942、2944、2946、2948、2950、2952、2954、2956、2958、2960、2962、2964、2966、2968、2970、2972、2974、2976、2978、2980、2982、2984、2986、2988、2990、2992、2994、2996、2998、3000、3002、3004、3006、3008、3010、3012、3014、3016、3018、3020、3022、3024、3026、3028、3030、3032、3034、3036、3038、3040、3042、3044、3046、3048、3050、3052、3054、3056、3058、3060、3062、3064、3066、3068、3070、3072、3074、3076、3078、3080、3082、3084、3086、3088、3090、3092、3094、3096、3098、3100、3102、3104、3106、3108、3110、3112、3114、3116、3118、3120、3122、3124、3126、3128、3130、3132、3134、3136、3138、3140、3142、3144、3146、3148、3150、3152、3154、3156、3158、3160、3162、3164、3166、3168、3170、3172、3174、3176、3178、3180、3182、3184、3186、3188、3190、3192、3194、3196、3198、3200、3202、3204、3206、3208、3210、3212、3214、3216、3218、3220、3222、3224、3226、3228、3230、3232、3234、3236、3238、3240、3242、3244、3246、3248、3250、3252、3254、3256、3258、3260、3262、3264、3266、3268、3270、3272、3274、3276、3278、3280、3282、3284、3286、3288、3290、3292、3294、3296、3298、3300、3302、3304、3306、3308、3310、3312、3314、3316、3318、3320、3322、3324、3326、3328、3330、3332、3334、3336、3338、3340、3342、3344、3346、3348、3350、3352、3354、3356、3358、3360、3362、3364、3366、3368、3370、3372、3374、3376、3378、3380、3382、3384、3386、3388、3390、3392、3394、3396、3398、3400、3402、3404、3406、3408、3410、3412、3414、3416、3418、3420、3422、3424、3426、3428、3430、3432、3434、3436、3438、3440、3442、3444、3446、3448、3450、3452、3454、3456、3458、3460、3462、3464、3466、3468、3470、3472、3474、3476、3478、3480、3482、3484、3486、3488、3490、3492、3494、3496、3498、3500、3502、3504、3506、3508、3510、3512、3514、3516、3518、3520、3522、3524、3526、3528、3530、3532、3534、3536、3538、3540、3542、3544、3546、3548、3550、3552、3554、3556、3558、3560、3562、3564、3566、3568、3570、3572、3574、3576、3578、3580、3582、3584、3586、3588、3590、3592、3594、3596、3598、3600、3602、3604、3606、3608、3610、3612、3614、3616、3618、3620、3622、3624、3626、3628、3630、3632、3634、3636、3638、3640、3642、3644、3646、3648、3650、3652、3654、3656、3658、3660、3662、3664、3666、3668、3670、3672、3674、3676、3678、3680、3682、3684、3686、3688、3690、3692、3694、3696、3698、3700、3702、3704、3706、3708、3710、3712、3714、3716、3718、3720、3722、3724、3726、3728、3730、3732、3734、3736、3738、3740、3742、3744、3746、3748、3750、3752、3754、3756、3758、3760、3762、3764、3766、3768、3770、3772、3774、3776、3778、3780、3782、3784、3786、3788、3790、3792、3794、3796、3798、3800、3802、3804、3806、3808、3810、3812、3814、3816、3818、3820、3822、3824、3826、3828、3830、3832、3834、3836、3838、3840、3842、3844、3846、3848、3850、3852、3854、3856、3858、3860、3862、3864、3866、3868、3870、3872、3874、3876、3878、3880、3882、3884、3886、3888、3890、3892、3894、3896、3898、3900、3902、3904、3906、3908、3910、3912、3914、3916、3918、3920、3922、3924、3926、3928、3930、3932、3934、3936、3938、3940、3942、3944、3946、3948、3950、3952、3954、3956、3958、3960、3962、3964、3966、3968、3970、3972、3974、3976、3978、3980、3982、3984、3986、3988、3990、3992、3994、3996、3998、4000、4002、4004、4006、4008、4010、4012、4014、4016、4018、4020、4022、4024、4026、4028、4030、4032、4034、4036、4038、4040、4042、4044、4046、4048、4050、4052、4054、4056、4058、4060、4062、4064、4066、4068、4070、4072、4074、4076、4078、4080、4082、4084、4086、4088、4090、4092、4094、4096、4098、4100、4102、4104、4106、4108、4110、4112、4114、4116、4118、4120、4122、4124、4126、4128、4130、4132、4134、4136、4138、4140、4142、4144、4146、4148、4150、4152、4154、4156、4158、4160、4162、4164、4166、4168、4170、4172、4174、4176、4178、4180、4182、4184、4186、4188、4190、4192、4194、4196、4198、4200、4202、4204、4206、4208、4210、4212、4214、4216、4218、4220、4222、4224、4226、4228、4230、4232、4234、4236、4238、4240、4242、4244、4246、4248、4250、4252、4254、4256、4258、4260、4262、4264、4266、4268、4270、4272、4274、4276、4278、4280、4282、4284、4286、4288、4290、4292、4294、4296、4298、4300、4302、4304、4306、4308、4310、4312、4314、4316、4318、4320、4322、4324、4326、4328、4330、4332、4334、4336、4338、4340、4342、4344、4346、4348、4350、4352、4354、4356、4358、4360、4362、4364、4366、4368、4370、4372、4374、4376、4378、4380、4382、4384、4386、4388、4390、4392、4394、4396、4398、4400、4402、4404、4406、4408、4410、4412、4414、4416、4418、4420、4422、4424、4426、4428、4430、4432、4434、4436、4438、4440、4442、4444、4446、4448、4450、4452、4454、4456、4458、4460、4462、4464、4466、4468、4470、4472、4474、4476、4478、4480、4482、4484、4486、4488、4490、4492、4494、4496、4498、4500、4502、4504、4506、4508、4510、4512、4514、4516、4518、4520、4522、4524、4526、4528、4530、4532、4534、4536、4538、4540、4542、4544、4546、4548、4550、4552、4554、4556、4558、4560、4562、4564、4566、4568、4570、4572、4574、4576、4578、4580、4582、4584、4586、4588、4590、4592、4594、4596、4598、4600、4602、4604、4606、4608、4610、4612、4614、4616、4618、4620、4622、4624、4626、4628、4630、4632、4634、4636、4638、4640、4642、4644、4646、4648、4650、4652、4654、4656、4658、4660、4662、4664、4666、4668、4670、4672、4674、4676、4678、4680、4682、4684、4686、4688、4690、4692、4694、4696、4698、4700、4702、4704、4706、4708、4710、4712、4714、4716、4718、4720、4722、4724、4726、4728、4730、4732、4734、4736、4738、4740、4742、4744、4746、4748、4750、4752、4754、4756、4758、4760、4762、4764、4766、4768、4770、4772、4774、4776、4778、4780、4782、4784、4786、4788、4790、4792、4794、4796、4798、4800、4902、4804、4806、4808、4810、4812、4814、4816、4818、4820、4822、4824、4826、4828、4830、4832、4834、4836、4838、4840、4842、4844、4846、4848、4850、4852、4854、4856、4858、4860、4862、4864、4866、4868、4870、4872、4874、4876、4878、4880、4882、4884、4886、4888、4890、4892、4894、4896、4898、4900、4902、4904、4906、4908、4910、4912、4914、4916、4918、4920、4922、4924、4926、4928、4930、4932、4934、4936、4938、4940、4942、4944、4946、4948、4950、4952、4954、4956、4958、4960、4962、4964、4966、4968、4970、4972、4974、4976、4978、4980、4982、4984、4986、4988、4990、4992、4994、4996、4998、5000、5002、5004、5006、5008、5010、5012、5014、5016、5018、5020、5022、5024、5026、5028、5030、5032、5034、5036、5038、5040、5042、5044、5046、5048、5050、5052、5054、5056、5058、5060、5062、5064、5066、5068、5070、5072、5074、5076、5078、5080、5082、5084、5086、5088、5090、5092、5094、5096、5098、5100、5102、5104、5106、5108、5110、5112、5114、5116、5118、5120、5122、5124、5126、5128、5130、5132、5134、5136、5138、5140、5142、5144、5146、5148、5150、5152、5154、5156、5158、5160、5162、5164、5166、5168、5170、5172、5174、5176、5178、5180、5182、5184、5186、5188、5190、5192、5194、5196、5198、5200、5202、5204、5206、5208、5210、5212、5214、5216、5218、5220、5222、5224、5226、5228、5230、5232、5234、5236、5238、5240、5242、5244、5246、5248、5250、5252、5254、5256、5258、5260、5262、5264、5266、5268、5270、5272、5274、5276、5278、5280、5282、5284、5286、5288、5290、5292、5294、5296、5298、5300、5302、5304、5306、5308、5310、5312、5314、5316、5318、5320、5322、5324、5326、5328、5330、5332、5334、5336、5338、5340、5342、5344、5346、5348、5350、5352、5354、5356、5358、5360、5362、5364、5366、5368、5370、5372、5374、5376、5378、5380、5382、5384、5386、5388、5390、5392、5394、5396、5398、5400、5402、5404、5406、5408、5410、5412、5414、5416、5418、5420、5422、5424、5426、5428、5430、5432、5434、5436、5438、5440、5442、5444、5446、5448、5450、5452、5454、5456、5458、5460、5462、5464、5466、5468、5470、5472、5474、5476、5478、5480、5482、5484、5486、5488、5490、5492、5494、5496、5498、5500、5502、5504、5506、5508、5510、5512、5514、5516、5518、5520、5522、5524、5526、5528、5530、5532、5534、5536、5538、5540、5542、5544、5546、5548、5550、5552、5554、5556、5558、5560、5562、5564、5566、5568、5570、5572、5574、5576、5578、5580、5582、5584、5586、5588、5590、5592、5594、5596、5598、5600、5602、5604、5606、5608、5610、5612、5614、5616、5618、5620、5622、5624、5626、5628、5630、5632、5634、5636、5638、5640、5642、5644、5646、5648、5650、5652、5654、5656、5658、5660、5662、5664、5666、5668、5670、5672、5674、5676、5678、5680、5682、5684、5686、5688、5690、5692、5694、5696、5698、5700、5702、5704、5706、5708、5710、5712、5714、5716、5718、5720、5722、5724、5726、5728、5730、5732、5734、5736、5738、5740、5742、5744、5746、5748、5750、5752、5754、5756、5758、5760、5762、5764、5766、5768、5770、5772、5774、5776、5778、5780、5782、5784、5786、5788、5790、5792、5794、5796、5798、5800、5802、5804、5806、5808、5810、5812、5814、5816、5818、5820、5822、5824、5826、5828、5830、5832、5834、5836、5838、5840、5842、5844、5846、5848、5850、5852、5854、5856、5858、5860、5862、5864、5866、5868、5870、5872、5874、5876、5878、5880、5882、5884、5886、5888、5890、5892、5894、5896、5898、5900、5902、5904、5906、5908、5910、5912、5914、5916、5918、5920、5922、5924、5926、5928、5930、5932、5934、5936、5938、5940、5942、5944、5946、5948、5950、5952、5954、5956、5958、5960、5962、5964、5966、5968、5970、5972、5974、5976、5978、5980、5982、5984、5986、5988、5990、5992、5994、5996、5998、6000、6002、6004、6006、6008、6010、6012、6014、6016、6018、6020、6022、6024、6026、6028、6030、6032、6034、6036、6038、6040、6042、6044、6046、6048、6050、6052、6054、6056、6058、6060、6062、6064、6066、6068、6070、6072、6074、6076、6078、6080、6082、6084、6086、6088、6090、6092、6094、6096、6098、6100、6102、6104、6106、6108、6110、6112、6114、6116、6118、6120、6122、6124、6126、6128、6130、6132、6134、6136、6138、6140、6142、6144、6146、6148、6150、6152、6154、6156、6158、6160、6162、6164、6166、6168、6170、6172、6174、6176、6178、6180、6182、6184、6186、6188、6190、6192、6194、6196、6198、6200、6202、6204、6206、6208、6210、6212、6214、6216、6218、6220、6222、6224、6226、6228、6230、6232、6234、6236、6238、6240、6242、6244、6246、6248、6250、6252、6254、6256、6258、6260、6262、6264、6266、6268、6270、6272、6274、6276、6278、6280、6282、6284、6286、6288、6290、6292、6294、6296、6298、6300、6302、6304、6306、6308、6310、6312、6314、6316、6318、6320、6322、6324、6326、6328、6330、6332、6334、6336、6338、6340、6342、6344、6346、6348、6350、6352、6354、6356、6358、6360、6362、6364、6366、6368、6370、6372、6374、6376、6378、6380、6382、6384、6386、6388、6390、6392、6394、6396、6398、6400、6402、6404、6406、6408、6410、6412、6414、6416、6418、6420、6422、6424、6426、6428、6430、6432、6434、6436、6438、6440、6442、6444、6446、6448、6450、6452、6454、6456、6458、6460、6462、6464、6466、6468、6470、6472、6474、6476、6478、6480、6482、6484、6486、6488、6490、6492、6494、6496、6498、6500、6502、6504、6506、6508、6510、6512、6514、6516、6518、6520、6522、6524、6526、6528、6530、6532、6534、6536、6538、6540、6542、6544、6546、6548、6550、6552、6554、6556、6558、6560、6562、6564、6566、6568、6570、6572、6574、6576、6578、6580、6582、6584、6586、6588、6590、6592、6594、6596、6598、6600、6602、6604、6606、6608、6610、6612、6614、6616、6618、6620、6622、6624、6626、6628、6630、6632、6634、6636、6638、6640、6642、6644、6646、6648、6650、6652、6654、6656、6658、6660、6662、6664、6666、6668、6670、6672、6674、6676、6678、6680、6682、6684、6686、6688、6690、6692、6694、6696、6698、6700、6702、6704、6706、6708、6710、6712、6714、6716、6718、6720、6722、6724、6726、6728、6730、6732、6734、6736、6738、6740、6742、6744、6746、6748、6750、6752、6754、6756、6758、6760、6762、6764、6766、6768、6770、6772、6774、6776、6778、6780、6782、6784、6786、6788、6790、6792、6794、6796、6798、6800、6802、6804、6806、6808、6810、6812、6814、6816、6818、6820、6822、6824、6826、6828、6830、6832、6834、6836、6838、6840、6842、6844、6846、6848、6850、6852、6854、6856、6858、6860、6862、6864、6866、6868、6870、6872、6874、6876、6878、6880、6882、6884、6886、6888、6890、6892、6894、6896、6898、6900、6902、6904、6906、6908、6910、6912、6914、6916、6918、6920、6922、6924、6926、6928、6930、6932、6934、6936、6938、6940、6942、6944、6946、6948、6950、6952、6954、6956、6958、6960、6962、6964、6966、6968、6970、6972、6974、6976、6978、6980、6982、6984、6986、6988、6990、6992、6994、6996、6998、7000、7002、7004、7006、7008、7010、7012、7014、7016、7018、7020、7022、7024、7026、7028、7030、7032、7034、7036、7038、7040、7042、7044、7046、7048、7050、7052、7054、7056、7058、7060、7062、7064、7066、7068、7070、7072、7074、7076、7078、7080、7082、7084、7086、7088、7090、7092、7094、7096、7098、7100、7102、7104、7106、7108、7110、7112、7114、7116、7118、7120、7122、7124、7126、7128、7130、7132、7134、7136、7138、7140、7142、7144、7146、7148、7150、7152、7154、7156、7158、7160、7162、7164、7166、7168、7170、7172、7174、7176、7178、7180、7182、7184、7186、7188、7190、7192、7194、7196、7198、7200、7202、7204、7206、7208、7210、7212、7214、7216、7218、7220、7222、7224、7226、7228、7230、7232、7234、7236、7238、7240、7242、7244、7246、7248、7250、7252、7254、7256、7258、7260、7262、7264、7266、7268、7270、7272、7274、7276、7278、7280、7282、7284、7286、7288、7290、7292、7294、7296、7298、7300、7302、7304、7306、7308、7310、7312、7314、7316、7318、7320、7322、7324、7326、7328、7330、7332、7334、7336、7338、7340、7342、7344、7346、7348、7350、7352、7354、7356、7358、7360、7362、7364、7366、7368、7370、7372、7374、7376、7378、7380、7382、7384、7386、7388、7390、7392、7394、7396、7398、7400、7402、7404、7406、7408、7410、7412、7414、7416、7418、7420、7422、7424、7426、7428、7430、7432、7434、7436、7766、7768、7770、7772、7774、7776、7778、7780、7782、7784、7786、7788、7790、7792、7794、7796、7798、7800、7812、7814、7816、7818、7820、7822、7824、7826、7828、7830、7832、7834、7836、7838、7840、7842、7844、7846、7848、7850、7852、7854、7856、7858、7860、7862、7864、7866、7868、7870、7872、7874、7876、7878、7880、7882、7884、7886、7888、7890、7892、7894、7896、7898、7900、7902、7904、7906、7908、7910、7912、7914、7916、7918、7920、7922、7924、7926、7928、7930、7932、7934、7936、7938、7940、7942、7944、7946、7948、7950、7952、7954、7956、7958、7960、7962、7964、7966、7968、7970、7972、7974、7976、7978、7980、7982、7984、7986、7988、7990、7992、7994、7996、7998、8000、8002、8004、8006、8008、8010、8012、8014、8016、8018、8020、8022、8024、8026、8028、8030、8032、8034、8036、8038、8040、8042、8044、8046、8048、8050、8052、8054、8056、8058、8060、8062、8064、8066、8068、8070、8072、8074、8076、8078、8080、8082、8084、8086、8088、8090、8092、8094、8096、8098、8100、8102、8104、8106、8108、8110、8112、8114、8116、8118、8120、8122、8124、8126、8128、8130、8132、8134、8136、8138、8140、8142、8144、8146、8148、8150、8152、8154、8156、8158、8160、8162、8164、8166、8168、8170、8172、8174、8176、8178、8180、8182、8184、8186、8188、8190、8192、8194、8196、8198、8200、8202、8204、8206、8208、8210、8212、8214、8216、8218、8220、8222、8224、8226、8228、8230、8232、8234、8236、8238、8240、8242、8244、8246、8248、8250、8252、8254、8256、8258、8260、8262、8264、8266、8268、8270、8272、8274、8276、8278、8280、8282、8284、8286、8288、8290、8292、8294、8296、8298、8300、8302、8304、8306、8308、8310、8312、8314、8316、8318、8320、8322、8324、8326、8328、8330、8332、8334、8336、8338、8340、8342、8344、8346、8348、8350、8352、8354、8356、8358、8360、8362、8364、8366、8368、8482、8484、8486、8488、8490、8492、8494、8496、8498、8500、8502、8504、8506、8508、8510、8512、8514、8516、8518、8520、8522、8524、8526、8528、8530、8532、8534、8536、8538、8540、8542、8544、8546、8548、8550、8552、8554、8556、8558、8560、8562、8564、8566、8568、8570、8572、8574、8576、8578、8580、8582、8584、8586、8588、8590、8592、8594、8596、8598、8600, 8602, 8604, 8606, 8608, 8610, 8612, 8614, 8616, 8618, 8620, 8622, 8624, 8626, 8628, 8630, 8632, 8634, 8636, 8638, 8640, 8642, 8644, 8646, 8648, 8650, 8652, 8654, 8656, 8658, 8660, 8662, 8664, 8666, 8668, 8670, 8672, 8674, 8676, 8678, 8680, 868 2. 8684, 8686, 8688, 8690, 8692, 8694, 8696, 8698, 8700, 8702, 8704, 8706, 8708, 8710, 8712, 8714, 8716, 8718, 8720, 8722, 8724, 8726, 8728, 8730, 8732, 8734, 8736, 8738, 8740, 8742, 8744, 8746, 8748, 8750, 8752, 8754, 8756, 8758, 8760, 8762, 8764, 8 766, 8768, 8770, 8772, 8774, 8776, 8778, 8780, 8782, 8784, 8786, 8788, 8790, 8792, 8794, 8796, 9108, 9110, 9112, 9114, 9116, 9118, 9120, 9122, 9124, 9126, 9128, 9130, 9132, 9134, 9136, 9138, 9140, 9142, 9144, 9146, 9148, 9150, 9152, 9154, 9156, 9158 , 9160, 9162, 9164, 9166, 9168, 9170, 9172, 9174, 9176, 9178, 9180, 9182, 9184, 9186, 9188, 9190, 9192, 9194, 9196, 9198, 9200, 9202, 9204, 9206, 9208, 9210, 9212, 9214, 9216, 9218, 9220, 9222, 9224, 9226, 9228, 9230, 9232, 9234, 9236, 9238, and / or 9240.
[0011] In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 10, 10 / 309, 262, 278 / 284 / 311 / 339 / 360, 283, 307, 309, 339 / 361, 344 / 361, and 361, wherein the positions are numbered with reference to SEQ ID NO: 4. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from the group consisting of: 10- / 309R, 262K, 262L, 278L / 284I / 311G / 339A / 360G, 283T, 307V, 309L / N / R / S, 339A / 361G, 344I / 361G, and 361G, wherein the positions are numbered with reference to SEQ ID NO: 4. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from the group consisting of: R10- / V309R, R262K, R262L, Y278L / T284I / R311G / V339A / N360G, S283T, L307V, V309L / N / R / S, V339A / S361G, V344I / S361G, and S361G, wherein the positions are numbered with reference to SEQ ID NO: 4. In still other embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and / or 30. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and / or 30. In still other embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and / or 30.
[0012] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 112 / 172 / 283 / 318, 112 / 261 / 318, 112 / 282 / 283 / 431, 137 / 283, 137 / 283 / 431, 163 / 318, 261 / 283 / 306 / 337, 261 / 283 / 337, 261 / 337, 269 / 318, 282 / 283, 282 / 283 / 431, 283, 283 / 306 / 308 / 360, 283 / 306 / 337 / 426, 283 / 318 / 337 / 360, 283 / 360, 318, 360 and 431, wherein the positions are numbered with reference to SEQ ID NO: 8. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from the group consisting of: 112S / 172S / 283Q / 318E, 112S / 261S / 318E, 112S / 282T / 283Q / 431E, 137K / 283Q, 137K / 283Q / 431E, 163K / 318E, 261S / 283Q / 306V / 337F, 26 1S / 283Q / 337F, 261S / 337S, 269T / 318E, 282T / 283Q, 282T / 283Q / 431E, 283Q, 283Q / 306V / 308S / 360G, 283Q / 306V / 337S / 426V, 283Q / 318E / 337S / 360G, 283Q / 360G, 318E, 360G and 431E, wherein the positions are numbered with reference to SEQ ID NO: 8.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from the group consisting of: E112S / T172S / T283Q / T318E, E112S / R261S / T318E, E112S / S282T / T283Q / Q431E, N137K / T283Q, N137K / T283Q / Q431E, L163K / T318E, R261S / T283Q / L306V / W337F, R261S / T283Q / W337F, R261S / W337S, Q269T / T318E, S282T / T283Q, S282T / T283Q / Q431E, T283Q, T283Q / L306V / R308S / S360G, T283Q / L306V / W337S / A426V, T283Q / T318E / W337S / S360G, T283Q / S360G, T318E, S360G, and Q431E, wherein the positions are numbered with reference to SEQ ID NO: 8. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68 and / or 70. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68 and / or 70. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises SEQ ID NO: 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68 and / or 70.
[0013] The present invention also provides engineered glycosyltransferases, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 4, 6, 22, 64, 74, 84, 87, 97, 106, 110, 112, 137, 139, 154, 159, 169, 179, 191, 195, 198, 199, 207, 233, 259, 261, 262, 306, 347, 356, 396, 417, 421, 427, and 435, wherein the positions are numbered with reference to SEQ ID NO: 32. In yet other embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from the group consisting of: 4P, 6P, 22A / L / H / P, 64P, 74W, 84A / G, 87A / H, 97S, 106D / G / S / T, 110S, 112A / P, 137G, 139P, 154A / L / Q / V, 159M / R, 169T, 179V, 191R, 195G, 198M / S / V, 199A / D / G / K / Q / S, 207L, 233R, 259Q, 261A / H / P / W, 262G, 306V, 347D, 356G, 396R, 417A / R / P, 421V, 427A, and 435Q / R, wherein the positions are with reference to SEQ ID NO: ID NO: 32. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from the group consisting of: K4P, E6P, Q22A / L / H / P, F64P, R74W, L84A / G, M87A / H, A97S, L106D / G / S / T, A110S, E112A / P, N137G, R139P, H154A / L / Q / V, Q159M / R , D169T, S179V, S191R, N195G, I198M / S / V, L199A / D / G / K / Q / S, I207L, I233R, H259Q, R261A / H / P / W, T262G, L306V, G347D, S356G, Y396R, E417A / R / P, Y421V, R427A, and V435Q / R, wherein the positions are numbered with reference to SEQ ID NO: 32.
[0014] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 22 / 84 / 87 / 154 / 198 / 199 / 356, 22 / 84 / 87 / 154 / 198 / 199 / 306 / 356, 22 / 84 / 87 / 154 / 199 / 306 / 356, 22 / 84 / 87 / 154 / 199 / 306 / 356, 22 / 84 / 87 / 154 / 199 / 306 / 356, 22 / 84 / 87 / 154 / 199 / 306 / 356. / 356、22 / 84 / 87 / 198 / 199 / 306 / 356、22 / 84 / 87 / 198 / 199 / 356、22 / 84 / 87 / 199 / 306 / 356、22 / 84 / 87 / 199 / 356、22 / 84 / 154 / 198 / 199 / 207 / 306、22 / 84 / 154 / 198 / 199 / 306、22 / 84 / 154 / 198 / 199 / 356、22 / 84 / 154 / 198 / 199 / 356、22 / 84 / 154 / 198 / 199 / 356、22 / 84 / 154 / 199 / 356、22 / 84 / 154 / 199 / 207、22 / 84 / 154 / 1 99 / 356、22 / 84 / 154 / 207 / 306 / 356、22 / 84 / 154 / 306 / 356、22 / 84 / 154 / 198 / 199 / 306 / 356、22 / 84 / 154 / 198 / 199、22 / 84 / 154 / 198 / 199 / 306 / 356、22 / 84 / 1 54 / 199 / 306 / 356、22 / 84 / 154 / 199 / 356、22 / 84 / 154 / 199 / 356、22 / 84 / 198 / 199 / 306 / 356、22 / 84 / 199 / 356、22 / 84 / 207 / 356、22 / 84 / 356、22 / 84 / 154 / 198 / 199 / 306 / 356、22 / 87 / 154 / 198 / 199 / 356、22 / 87 / 154 / 199 / 306 / 356、22 / 87 / 154 / 322 / 356、22 / 87 / 154 / 198 / 199 / 356、22 / 87 / 154 / 199 / 356、22 / 87 / 154 / 1 98 / 199 / 207 / 306 / 356、22 / 87 / 154 / 199 / 207 / 356、22 / 87 / 154 / 199 / 356、22 / 87 / 154 / 199 / 306 / 356、22 / 87 / 198 / 199 / 306 / 356、22 / 87 / 198 / 199 / 306 / 356、22 / 87 / 198 / 199 / 207 / 356, 22 / 87 / 198 / 199 / 356, 22 / 87 / 199 / 356, 22 / 87 / 199 / 356, 22 / 154 / 198 / 199 / 207 / 306 / 356, 22 / 154 / 198 / 199 / 356, 22 / 154 / 199 / 356, 22 / 154 / 198 / 1 99 / 306 / 356, 22 / 154 / 199 / 356, 22 / 154 / 199 / 207 / 306 / 356, 22 / 198 / 199 / 356, 22 / 198 / 199 / 207 / 329 / 356, 22 / 199 / 356, 22 / 207 / 356, 22 / 356 and 84 / 154 / 198 / 199, wherein the positions are numbered with reference to SEQ ID NO:32. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from the group consisting of: 22P / 84G / 87H / 154L / 198S / 199A / 356G, 22P / 84G / 87H / 154L / 198S / 199S / 306V / 356G, 22P / 84G / 87H / 154L / 198S / 199S / 306V / 356G, 22P / 84G / 87H / 154L / 199K / 306V / 356G, 154L / 356G, 22P / 84G / 87H / 154V / 198S / 199S / 306V / 356G, 22P / 84G / 87H / 154V / 199K / 306V / 356G, 22 P / 84G / 87H / 198S / 199A / 306V / 356G, 22P / 84G / 87H / 198S / 199K / 356G, 22P / 84G / 87H / 198S / 199S / 306 V / 356G, 22P / 84G / 87H / 198S / 199S / 356G, 22P / 84G / 87H / 199A / 306V / 356G, 22P / 84G / 87H / 199S / 356 G、22P / 84G / 154L / 198S / 199A / 207L / 306V、22P / 84G / 154L / 198S / 199A / 306V、22P / 84G / 154L / 198S / 199A / 356G, 22P / 84G / 154L / 198S / 199K / 356G, 22P / 84G / 154L / 198S / 199S / 356G, 22P / 84G / 154L / 19 9A / 356G, 22P / 84G / 154L / 199K / 207L, 22P / 84G / 154L / 199S / 356G, 22P / 84G / 154L / 207L / 306V / 356G,22P / 84G / 154L / 306V / 356G,22P / 84G / 154V / 198S / 199A / 306V / 356G、22P / 84G / 154V / 198S / 199K、22P / 84G / 154V / 198S / 199K / 306V / 356G、22P / 84G / 154V / 199A / 306V / 356G、22P / 84G / 154V / 199A / 356G、22P / 84G / 154V / 199S / 356G、22P / 84G / 198S / 199K / 306V / 356G、22P / 84G / 199S / 356G、22P / 84G / 207L / 356G、22P / 84G / 356G、22P / 84V / 154V / 198S / 199S / 306V / 356G、22P / 87H / 154L / 198S / 199K / 356G、22P / 87H / 154L / 199A / 306V / 356G、22P / 87H / 154L / 322S / 356G、22P / 87H / 154V / 198S / 199K / 356G、22P / 87H / 154V / 199S / 356G、22P / 87H / 154V / 198S / 199S / 207L / 306V / 356G、22P / 87H / 154V / 199A / 207L / 356G、22P / 87H / 154V / 199K / 356G、22P / 87H / 154V / 199S / 306V / 356G、22P / 87H / 198S / 199A / 306V / 356G、22P / 87H / 198S / 199K / 306V / 356G、22P / 87H / 198S / 199S / 207L / 356G、22P / 87H / 198S / 199K / 356G、22P / 87H / 199A / 356G、22P / 87H / 199K / 356G、22P / 154L / 198S / 199A / 207L / 306V / 356G、22P / 154L / 198S / 199A / 356G、22P / 154L / 199A / 356G、22P / 154V / 198S / 199S / 306V / 356G、22P / 154V / 199A / 356G、22P / 154V / 199K / 207L / 306V / 356G、22P / 198S / 199A / 356G、22P / 198S / 199K / 207L / 329C / 356G、22P / 199A / 356G、22P / 207L / 356G、22P / 356G and 84G / 154L / 198S / 199K, wherein the positions are numbered with reference to SEQ ID NO: 32. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from the group consisting of: Q22P / L84G / M87H / H154L / I198S / L199A / S356G, Q22P / L84G / M87H / H154L / I198S / L199S / L306V / S356G, Q22P / L84G / M87H / H154L / L199K / L306V / S356G, Q22P / L84G / M87H / H154L / L199K / L306V / S356G, Q22P / L84G / M87H / H154L / I198S / L199A / S356G. 56G, Q22P / L84G / M87H / H154V / L199K / L306V / S356G, Q22P / L84G / M87H / I 198S / L199A / L306V / S356G, Q22P / L84G / M87H / I198S / L199K / S356G, Q22 P / L84G / M87H / I198S / L199S / L306V / S356G, Q22P / L84G / M87H / I198S / L1 99S / S356G, Q22P / L84G / M87H / L199A / L306V / S356G, Q22P / L84G / M87H / L1 99S / S356G, Q22P / L84G / H154L / I198S / L199A / I207L / L306V, Q22P / L84G / H154L / I198S / L199A / L306V、Q22P / L84G / H154L / I198S / L199A / S356G、 Q22P / L84G / H154L / I198S / L199K / S356G, Q22P / L84G / H154L / I198S / L19 9S / S356G, Q22P / L84G / H154L / L199A / S356G, Q22P / L84G / H154L / L199K / I 207L, Q22P / L84G / H154L / L199S / S356G, Q22P / L84G / H154L / I207L / L306 V / S356G, Q22P / L84G / H154L / L306V / S356G, Q22P / L84G / H154V / I198S / L 199A / L306V / S356G, Q22P / L84G / H154V / I198S / L199K, Q22P / L84G / H154 V / I198S / L199K / L306V / S356G, Q22P / L84G / H154V / L199A / L306V / S356G,Q22P / L84G / H154V / L199A / S356G、Q22P / L84G / H154V / L199S / S356G、Q22P / L84G / I198S / L199K / L306V / S356G、Q22P / L84G / L199S / S356G、Q22P / L84G / I207L / S356G、Q22P / L84G / S356G、Q22P / L84V / H154V / I198S / L199S / L306V / S356G、Q22P / M87H / H154L / I198S / L199K / S356G、Q22P / M87H / H154L / L199A / L306V / S356G、Q22P / M87H / H154L / P322S / S356G、Q22P / M87H / H154V / I198S / L199K / S356G、Q22P / M87H / H154V / L199S / S356G、Q22P / M87H / H154V / I198S / L199S / I207L / L306V / S356G、Q22P / M87H / H154V / L199A / I207L / S356G、Q22P / M87H / H154V / L199K / S356G、Q22P / M87H / H154V / L199S / L306V / S356G、Q22P / M87H / I198S / L199A / L306V / S356G、Q22P / M87H / I198S / L199K / L306V / S356G、Q22P / M87H / I198S / L199S / I207L / S356G、Q22P / M87H / I198S / L199K / S356G、Q22P / M87H / L199A / S356G、Q22P / M87H / L199K / S356G、Q22P / H154L / I198S / L199A / I207L / L306V / S356G、Q22P / H154L / I198S / L199A / S356G、Q22P / H154L / L199A / S356G、Q22P / H154V / I198S / L199S / L306V / S356G、Q22P / H154V / L199A / S356G、Q22P / H154V / L199K / I207L / L306V / S356G、Q22P / I198S / L199A / S356G、Q22P / I198S / L199K / I207L / G329C / S356G、Q22P / L199A / S356G、Q22P / I207L / S356G、Q22P / S356G and L84G / H154L / I198S / L199K, wherein the positions are numbered with reference to SEQ ID NO: 32. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214 , 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 28 2, 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 346, and 1290. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: NO:76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 1 16, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 15 2, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224,226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 346, and 1290. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO:76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214 , 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 28 2, 284, 286, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 346 and 1290.
[0015] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 64 / 106 / 109 / 112 / 131 / 159 / 233 / 421 / 427 / 431, 64 / 106 / 109 / 112 / 417 / 421 / 427 / 431, 64 / 106 / 109 / 139 / 179 / 417 / 421 / 427 / 431, 64 / 106 / 109 / 233 / 347 / 427 / 431, 64 / 106 / 109 / 112 / 347 / 417 / 421 / 427 / 431, / 417 / 421、64 / 106 / 431、64 / 106 / 109 / 112 / 131 / 179 / 417 / 427 / 431、64 / 106 / 109 / 417 / 421 / 427 / 431 / 439、64 / 106 / 112 / 139 / 159 / 179 / 204 / 396 / 417、64 / 1 06 / 112 / 159 / 179 / 417 / 421、64 / 106 / 204 / 417 / 421 / 427、64 / 109 / 112 / 139 / 159 / 179 / 417 / 431、64 / 109 / 112 / 139 / 417、64 / 109 / 139 / 233 / 417 / 421、64 / 109 / 159 / 179 / 204 / 233 / 417 / 421、64 / 109 / 417 / 421、64 / 109 / 417 / 421、64 / 139 / 233 / 417 / 427 / 431 / 439、64 / 139 / 347 / 417 / 421 / 427 / 431、64 / 417 / 421 / 431、1 06 / 109 / 112 / 131 / 159 / 179 / 417 / 421、106 / 109 / 112 / 131 / 159 / 204 / 347 / 417 / 421 / 427、106 / 109 / 112 / 204 / 347 / 421 / 439、106 / 109 / 112 / 261 / 417 / 431、10 6 / 109 / 112 / 347 / 427, 106 / 109 / 139 / 427 / 431, 106 / 109 / 417 / 421 / 427, 106 / 112 / 159 / 204 / 233 / 417 / 421 / 427 / 431, 106 / 112 / 233 / 417, 106 / 112 / 396 / 417 / 421, 106 / 139 / 159 / 233 / 347 / 417 / 421 / 427 / 431, 106 / 233 / 421 / 427, 106 / 417, 106 / 109 / 139 / 347 / 417 / 421 / 427, 106 / 109, 106 / 109 / 139 / 233 / 417 / 421,106 / 109 / 139 / 417、106 / 109 / 233 / 427 / 431、106 / 112 / 159 / 179 / 204 / 417 / 421、106 / 112 / 159 / 179 / 233 / 417 / 421 / 427 / 439、106 / 131 / 179 / 233 / 421 / 427 / 431、106 / 139 / 421、106 / 347 / 417 / 427 / 431、109 / 112 / 131 / 159 / 179 / 439、109 / 112 / 13 1 / 159 / 417 / 421、109 / 112 / 139 / 179 / 417 / 427、109 / 112 / 159 / 179 / 417 / 421、109 / 112 / 159 / 417 / 427、109 / 112 / 179 / 204 / 233 / 417 / 421 / 427、109 / 112 / 179 / 347 / 417、109 / 112 / 204 / 233 / 417、109 / 112 / 204 / 427、109 / 112 / 233 / 417 / 431、109 / 1 12 / 417 / 421 / 427、109 / 112 / 417 / 427 / 431、109 / 131 / 139 / 179 / 261 / 396 / 421、109 / 131 / 204、109 / 139 / 179 / 417 / 421 / 427、109 / 139 / 179 / 417 / 427、109 / 179 / 233 / 421、109 / 204 / 417 / 431、109 / 417 / 421、109 / 417 / 427 / 431、112 / 131 / 179 / 204 / 417 / 421 / 431, 179 / 417 / 421, 233 / 417 / 421 / 427 / 431 and 347 / 417, wherein the positions are numbered with reference to SEQ ID NO: 232. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 64P / 106S / 109R / 112P / 131P / 159R / 233R / 421V / 427L / 431D, 64P / 106S / 109R / 112P / 417A / 421V / 427A / 431D, 64P / 106S / 109R / 139P / 179L / 417R / 421V / 427L / 431D,64P / 106S / 109R / 233R / 347D / 427A / 431D、64P / 106S / 112P / 347D / 417A / 421V、64P / 106S / 139P / 179L / 233R / 417A / 427A / 431D、64P / 106S / 417R / 421V、64P / 106S / 431D、64P / 106T / 109R / 112P / 131P / 179L / 417R / 427A / 431D、64P / 106T / 109R / 417A / 421V / 427L / 431D / 439P、64P / 106T / 112P / 139P / 159R / 179V / 204D / 396R / 417A、64P / 106T / 112P / 159R / 179L / 417R / 421V、64P / 106T / 204D / 417A / 421V / 427A、64P / 109R / 112P / 139P / 159R / 179L / 417R / 431D、64P / 109R / 112P / 139P / 417A、64P / 109R / 139P / 233R / 417R / 421V、64P / 109R / 159R / 179V / 204D / 233R / 417R / 421V、64P / 109R / 417A / 421V、64P / 109R / 417R / 421V、64P / 139P / 233R / 417R / 427L / 431D / 439P、64P / 139P / 347D / 417R / 421V / 427L / 431D、64P / 417R / 421V / 431D、106S / 109R / 112P / 131P / 159R / 179L / 417A / 421V、106S / 109R / 112P / 131P / 159R / 204D / 347D / 417A / 421V / 427L、106S / 109R / 112P / 204D / 347D / 421V / 439P、106S / 109R / 112P / 261P / 417R / 431D、106S / 109R / 112P / 347D / 427A、106S / 109R / 139P / 427A / 431D、106S / 109R / 417R / 421V / 427L、106S / 112P / 159R / 204D / 233R / 417R / 421V / 427A / 431D、106S / 112P / 233R / 417R、106S / 112P / 396R / 417R / 421V、106S / 139P / 159R / 233R / 347D / 417R / 421V / 427A / 431D、106S / 233R / 421V / 427A、106S / 417A、106T / 109R / 139P / 347D / 417A / 421V / 427A、106T / 109R、106T / 109R / 139P / 233R / 417R / 421V、106T / 109R / 139P / 417R、106T / 109R / 233R / 427A / 431D、106T / 112P / 159R / 179L / 204D / 417A / 421V、106T / 112P / 159R / 179V / 233R / 417A / 421V / 427L / 439P、106T / 131P / 179L / 233R / 421V / 427L / 431D、106T / 139P / 421V、106T / 347D / 417R / 427A / 431D、109R / 112P / 131P / 159R / 179V / 439P、109R / 112P / 131P / 159R / 417R / 421V、109R / 112P / 139P / 179V / 417R / 427A、109R / 112P / 159R / 179V / 417R / 421V、109R / 112P / 159R / 417R / 427L、109R / 112P / 179V / 204D / 233R / 417A / 421V / 427L、109R / 112P / 179V / 347D / 417R、109R / 112P / 204D / 233R / 417R、109R / 112P / 204D / 427A、109R / 112P / 233R / 417A / 431D、109R / 112P / 417A / 421V / 427L、109R / 112P / 417A / 427A / 431D、109R / 131P / 139P / 179V / 261P / 396R / 421V、109R / 131P / 204D、109R / 139P / 179L / 417R / 421V / 427A、109R / 139P / 179L / 417R / 427L、109R / 179V / 233R / 421V、109R / 204D / 417R / 431D、109R / 417R / 421V、109R / 417R / 427A / 431D、112P / 131P / 179V / 204D / 417R / 421V / 427L、112P / 131P / 179L / 347D / 417R / 421V、112P / 139P / 179V / 204D / 233R / 347D / 427L、112P / 159R / 417R / 421V、112P / 417R / 421V、131P / 179L / 233R / 417R / 427A、139P / 233R / 417A、159R / 347D / 417A / 421V / 431D、179V / 417R / 421V、233R / 417R / 421V / 427L / 431D and 347D / 417R, wherein the positions are numbered with reference to SEQ ID NO: 232. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: F64P / L106S / L109R / E112P / S131P / Q159R / I233R / Y421V / R427L / Q431D, F64P / L106S / L109R / E112P / E417A / Y421V / R427A / Q431D, F64P / L106S / L109R / R139P / S179L / E417R / Y421V / R427L / Q431D, 33R / G347D / R427A / Q431D, F64P / L106S / E112P / G347D / E417A / Y421V, F64P / L106S / R139P / S179L / I233R / E417A / R427A / Q431D, F64P / L106 S / E417R / Y421V, F64P / L106S / Q431D, F64P / L106T / L109R / E112P / S131P / S179L / E417R / R427A / Q431D, F64P / L106T / L109R / E417A / Y421V / R 427L / Q431D / K439P, F64P / L106T / E112P / R139P / Q159R / S179V / G204D / Y396R / E417A, F64P / L106T / E112P / Q159R / S179L / E417R / Y421V, F6 4P / L106T / G204D / E417A / Y421V / R427A, F64P / L109R / E112P / R139P / Q159R / S179L / E417R / Q431D, F64P / L109R / E112P / R139P / E417A, F64P / L109R / R139P / I233R / E417R / Y421V, F64P / L109R / Q159R / S179V / G204D / I233R / E417R / Y421V, F64P / L109R / E417A / Y421V, F64P / L109R / E41 7R / Y421V, F64P / R139P / I233R / E417R / R427L / Q431D / K439P, F64P / R139P / G347D / E417R / Y421V / R427L / Q431D, F64P / E417R / Y421V / Q431D,L106S / L109R / E112P / S131P / Q159R / S179L / E417A / Y421V、L106S / L109R / E112P / S131P / Q159R / G204D / G347D / E417A / Y421V / R427L、L106S / L109R / E112P / G204D / G347D / Y421V / K439P、L106S / L109R / E112P / R261P / E417R / Q431D、L106S / L109R / E112P / G347D / R427A、L106S / L109R / R139P / R427A / Q431D、L106S / L109R / E417R / Y421V / R427L、L106S / E112P / Q159R / G204D / I233R / E417R / Y421V / R427A / Q431D、L106S / E112P / I233R / E417R、L106S / E112P / Y396R / E417R / Y421V、L106S / R139P / Q159R / I233R / G347D / E417R / Y421V / R427A / Q431D、L106S / I233R / Y421V / R427A、L106S / E417A、L106T / L109R / R139P / G347D / E417A / Y421V / R427A、L106T / L109R、L106T / L109R / R139P / I233R / E417R / Y421V、L106T / L109R / R139P / E417R、L106T / L109R / I233R / R427A / Q431D、L106T / E112P / Q159R / S179L / G204D / E417A / Y421V、L106T / E112P / Q159R / S179V / I233R / E417A / Y421V / R427L / K439P、L106T / S131P / S179L / I233R / Y421V / R427L / Q431D、L106T / R139P / Y421V、L106T / G347D / E417R / R427A / Q431D、L109R / E112P / S131P / Q159R / S179V / K439P、L109R / E112P / S131P / Q159R / E417R / Y421V、L109R / E112P / R139P / S179V / E417R / R427A、L109R / E112P / Q159R / S179V / E417R / Y421V、L109R / E112P / Q159R / E417R / R427L、L109R / E112P / S179V / G204D / I233R / E417A / Y421V / R427L, L109R / E112P / S179V / G347D / E417R, L109R / E112P / G20 4D / I233R / E417R, L109R / E112P / G204D / R427A, L109R / E112P / I233R / E417A / Q431D, L109R / E112P / E417A / Y421V / R 427L, L109R / E112P / E417A / R427A / Q431D, L109R / S131P / R139P / S179V / R261P / Y396R / Y421V, L109R / S131P / G204 D. L109R / R139P / S179L / E417R / Y421V / R427A, L109R / R139P / S179L / E417R / R427L, L109R / S179V / I233R / Y421V, L1 09R / G204D / E417R / Q431D, L109R / E417R / Y421V, L109R / E417R / R427A / Q431D, E112P / S131P / S179V / G204D / E417R / Y421V / R427L, E112P / S131P / S179L / G347D / E417R / Y421V, E112P / R139P / S179V / G204D / I233R / G347D / R427L, E11 1V, I233R / E417R / Y421V / R427L / Q431D, and G347D / E417R, wherein the positions are numbered with reference to SEQ ID NO: 232. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 418, 420, 422, 424, 426, 428, 430, 432, 434,436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 492, 494, 496 and / or 498. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: NO:348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 38 4, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 418, 420, 422 , 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 492, 494, 496 and / or 498. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: NO:348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 38 4, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 418, 420, 422 , 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 492, 494, 496, and / or 498. ,
[0016] The present invention also provides engineered glycosyltransferases, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 106 / 112 / 204 / 347 / 396 / 417, 106 / 112 / 204 / 347 / 396 / 417 / 427, 106 / 112 / 204 / 347 / 396 / 417 / 427 / 431, 112 / 204 / 347 / 396 / 417 / 427, 112 / 204 / 347 / 396 / 417 / 427 / 431, and 204 / 347 / 396 / 417 / 431, wherein the positions are numbered with reference to SEQ ID NO: 348. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 106S / 112P / 204D / 347D / 396Y / 417R, 106S / 112P / 204D / 347D / 396Y / 417R / 427A, 106S / 112P / 204D / 347D / 396Y / 417R / 427A / 431D, 112P / 204D / 347D / 396Y / 417R / 427A, 112P / 204D / 347D / 396Y / 417R / 427A / 431D, and 204D / 347D / 396Y / 417R / 431D, wherein the positions are numbered with reference to SEQ ID NO: 348. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: L106S / E112P / G204D / G347D / R396Y / E417R, L106S / E112P / G204D / G347D / R396Y / E417R / R427A, L106S / E112P / G204D / G347D / R396Y / E417R 47D / R396Y / E417R / R427A / Q431D, E112P / G204D / G347D / R396Y / E417R / R427A, E112P / G204D / G347D / R396Y / E417R / R427A / Q431D, and G204D / G347D / R396Y / E417R / Q431D, wherein the positions are numbered with reference to SEQ ID NO: 348. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 500, 502, 504, 506, 508, and / or 510. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 95% identical to any one of the following sequences: SEQ ID NO: 500, 502, 504, 506, 508 and / or 510.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises SEQ ID NO: 500, 502, 504, 506, 508 and / or 510.
[0017] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14 / 100, 28 / 44 / 365 / 407, 38 / 118 / 290 / 351 / 375 / 401 / 422, 38 / 178 / 401, 38 / 290 / 351 / 401 / 422, 54 / 413, 74 / 102 / 137 / 161 / 259 / 289, 9 2 / 118, 98 / 233, 102 / 161 / 250 / 435, 110 / 222 / 250 / 259 / 435, 118 / 156 / 178 / 290 / 375 / 401 / 422, 137 / 161 / 435, 137 / 169, 159 / 169 / 173 / 300 / 424 / 438, 185 / 290 / 401 / 422, 290 / 351 / 401 and 435 / 438, wherein the positions are numbered with reference to SEQ ID NO: 348. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14V / 100F, 28M / 44V / 365I / 407E, 38R / 118A / 290E / 351G / 375P / 401L / 422M, 38R / 178V / 401L, 38R / 290E / 351G / 401L / 422M, 54P / 413L, 74W / 102K / 137G / 161L / 259S / 289S, 92L / 118A, 98 8A, 185R / 290E / 401L / 422M, 290E / 351G / 401L, and 435Q / 438A, wherein the positions are numbered with reference to SEQ ID NO: 348.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: I14V / L100F, I28M / I44V / V365I / A407E, K38R / S118A / D290E / A351G / D375P / W401L / I422M, K38R / A178V / W401L, K38R / D290E / A351G / W401L / I422M, T54P / V413L, R74W / R102K / N137G / D161L / H259S / K289S, I92L / S118A, D98P / I Q424E / M438A, K185R / D290E / W401L / I422M, D290E / A351G / W401L, and V435Q / M438A, wherein the positions are numbered with reference to SEQ ID NO: 348. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any of the following sequences: SEQ ID NO: 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 222, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546 and / or 548. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any of the following sequences: SEQ ID NO: 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 222, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546 and / or 548. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 222, 524, 526, 528, 530, 532, 534, 536, 538, 540, 542, 544, 546 and / or 548.
[0018] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14 / 28 / 38 / 74 / 100 / 102 / 118 / 161 / 169 / 178 / 233 / 250 / 407 / 422 / 438, 14 / 28 / 38 / 74 / 102 / 156 / 159 / 233 / 250 / 289 / 413 / 422 / 424 / 435 / 438, 14 / 28 / 38 / 100 / 102 / 110 / 159 / 161 / 233 / 259 / 290 / 300 / 351 / 435, 14 / 28 / 38 / 110 / 137 / 161 / 222 / 289 / 401、14 / 28 / 44 / 74 / 98 / 102 / 137 / 159 / 161 / 185 / 222 / 250、14 / 28 / 44 / 92、14 / 28 / 44 / 161 / 169、14 / 28 / 44 / 375、14 / 28 / 54 / 161 / 185 / 413、14 / 2 8 / 54 / 365、14 / 28 / 74 / 98 / 100 / 102 / 161 / 173 / 178 / 233 / 250 / 259 / 290 / 407、14 / 28 / 92 / 100 / 102 / 159 / 161 / 169 / 233、14 / 28 / 92 / 100 / 102 / 159 / 161 / 233 / 351 / 422、14 / 28 / 92 / 100 / 102 / 422 / 424 / 435、14 / 28 / 92 / 100 / 161 / 222 / 233 / 289 / 300、14 / 28 / 100 / 137 / 156 / 161 / 222 / 259 / 289 / 365 / 401 / 435 / 438、14 / 28 / 100 / 156 / 161 / 250、14 / 28 / 102 / 118 / 137 / 161 / 185 / 222 / 250 / 259 / 401、14 / 28 / 159 / 289 / 290 / 300、14 / 28 / 159 / 365 / 435、14 / 28 / 35、14 / 38 / 74 / 110 / 156 / 161 / 173 / 178 / 222 / 300、14 / 38 / 100 / 102 / 161 / 173 / 178 / 222 / 250 / 375 / 401 / 413、44 / 74 / 100 / 102 / 161 / 233 / 365 / 435 / 438、14 / 74 / 110 / 159 / 161 / 169 / 173 / 250 / 259 / 290 / 375 / 407 / 422、14 / 74 / 161 / 375 / 401、14 / 92 / 98 / 100 / 159 / 161 / 259 / 365 / 422 / 424 / 435、14 / 110 / 156 / 161 / 375 / 401 / 435 / 438、14 / 159 / 161 / 365 / 435 / 438、14 / 161 / 222 / 250 / 259 / 289 / 375 / 401 / 413、14 / 161 / 222 / 250 / 435 / 438、14 / 161 / 300、28、28 / 38 / 92 / 98 / 100 / 102 / 156 / 161、28 / 44 / 74 / 401、28 / 44 / 92 / 161 / 222 / 300 / 413、28 / 44 / 98 / 100 / 102 / 118、28 / 44 / 118 / 156 / 161 / 222 / 289 / 435 / M438、28 / 44 / 289 / 290 / 351 / 422、28 / 44 / 435 / 438、28 / 54 / 92 / 159 / 161 / 290、28 / 54 / 159 / 290 / 438、28 / 54 / 250 / 439、28 / 74 / 156 / 159 / 161 / 178 / 300 / 365 / 435 / 438、28 / 74 / 156 / 161 / 365 / 407、28 / 74 / 161 / 290 / 365、28 / 92 / 100 / 102 / 110 / 161 / 185 / 250 / 300 / 375 / 435、28 / 92 / 98 / 100 / 110 / 156 / 161 / 401、28 / 92 / 118 / 159 / 222 / 250 / 259 / 300 / 407、28 / 156 / 161 / 185 / 435 / 438、28 / 156 / 161 / 233 / 259 / 300 / 435、28 / 98 / 100 / 102 / 161 / 185 / 351 / 401 / 435 / 438、38 / 161 / 300 / 438、74 / 98 / 100 / 102 / 110 / 118 / 161 / 178 / 250 / 289 / 290 / 300 / 435 / 438、74 / 98 / 100 / 102 / 118 / 156 / 159 / 161 / 435 / 438、74 / 156 / 161 / 173 / 178 / 424 / 435、74 / 375 / 435、98 / 100 / 118 / 159 / 161 / 300、98 / 100 / 156 / 159 / 161 / 178 / 259 / 289 / 290 / 351 / 422、102 / 137 / 159 / 161 / 422 / 424、118、137 / 159 / 161 / 185 / 300 / 351 / 365 / 435、156 / 159 / 161 / 169、159 / 161 / 222 / 290 / 375 / 407、159 / 161 / 401 and 161 / 259 / 289 / 435 / 438, wherein the positions are numbered with reference to SEQ ID NO:548. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14V / 28M / 38R / 74 / 100F / 102K / 118A / 161L / 169G / 178V / 233W / 250R / 407E / 422M / 438A, 14V / 28M / 38R / 74W / 102K / 156A / 159M / 233W / 250A / 289S / 413L / 422M / 424E / 435R / 438A, 14V / 28M / 38R / 100F / 102K / 118A / 161L / 169G / 178V / 233W / 250R / 407E / 422M / 438A. S / 290E / 300Q / 351G / 435Q、14V / 28M / 38R / 110G / 137G / 161L / 222R / 289S / 401L、14V / 28M / 44V / 74W / 98P / 102K / 137G / 159M / 161L / 185R / 222R / 250A , 14V / 28M / 44V / 92L, 14V / 28M / 44V / 161L / 169S, 14V / 28M / 44V / 375P, 14V / 28M / 54P / 161L / 185R / 413L, 14V / 28M / 54P / 365I, 14V / 28M / 74W / 98P / 10 0F / 102K / 161L / 173G / 178V / 233W / 250A / 259S / 290E / 407E, 14V / 28M / 92 L / 100F / 102K / 159M / 161L / 169S / 233W、14V / 28M / 92L / 100F / 102K / 159M / 161L / 233W / 351G / 422M, 14V / 28M / 92L / 100F / 102K / 422M / 424E / 435Q, 14 V / 28M / 92L / 100F / 161L / 222R / 233W / 289S / 300Q、14V / 28M / 100F / 137G / 1 56A / 161L / 222R / 259S / 289S / 365I / 401L / 435R / 438A, 14V / 28M / 100F / 15 6A / 161L / 250R, 14V / 28M / 102K / 118A / 137G / 161L / 185R / 222R / 250R / 259 P / 401L, 14V / 28M / 159M / 289S / 290E / 300Q, 14V / 28M / 159M / 365I / 435Q, 1 4V / 28M / 351G, 14V / 38R / 74W / 110G / 156A / 161L / 173G / 178V / 222R / 300Q,14V / 38R / 100F / 102K / 161L / 173G / 178V / 222R / 250R / 375P / 401L / 413L、44V / 74W / 100F / 102K / 161L / I33W / 365I / 435G / 438A、14V / 74W / 110G / 159M / 161L / 169G / 173G / 250A / 259P / 290E / 375P / 407E / 422M、14V / 74W / 161L / 375P / 401L、14V / 92L / 98P / 100F / 159M / 161L / 259P / 365I / 422M / 424E / 435R、14V / 110G / 156A / 161L / 375P / 401L / 435EM438A、14V / 159M / 161L / 365I / 435E / 438A、14V / 161L / 222R / 250R / 259S / 289S / 375P / 401L / 413L、14V / 161L / 222R / 250R / 435Q / 438A、14V / 161L / 300Q、28M、28M / 38R / 92L / 98P / 100F / 102K / 156A / 161L、28M / 44V / 74W / 401L、28M / 44V / 92L / 161L / 222R / 300Q / 413L、28M / 44V / 98P / 100F / 102K / 118A、28M / 44V / 118A / 156A / 161L / 222R / 289S / 435Q / 438A、28M / 44V / 289S / 290E / 351G / 422M、28M / 44V / 435R / 438A、28M / 54P / 92L / 159M / 161L / 290E、28M / 54P / 159M / 290E / 438A、28M / 54P / 250R / 439N、28M / 74W / 156A / 159M / 161L / 178V / 300Q / 365I / 435Q / 438A、28M / 74W / 156A / 161L / 365I / 407E、28M / 74W / 161L / 290E / 365I、28M / 92L / 98P / 100F / 110G / 156A / 161L / 401L、28M / 92L / 100F / 102K / 110G / 161L / 185R / 250A / 300Q / 375P / 435Q、28M / 92L / 118A / 159M / 222R / 250R / 259P / 300Q / 407E、28M / 98P / 100F / 102K / 161L / 185R / 351G / 401L / 435E / 438A、28M / 156A / 161L / 185R / 435R / 438A、28M / 156A / 161L / 233W / 259S / 300Q / 435R, 38R / 161L / 300Q / 438A, 74W / 98 P / 100F / 102K / 110G / 118A / 161L / 178V / 250R / 289S / 290E / 300Q / 435E / 438 A. 74W / 98P / 100F / 102K / 118A / 156A / 159M / 161L / 435E / 438A, 74W / 156A / 161L / 173G / 178V / 424E / 435E, 74W / 375P / 435G, 98P / 100F / 118A / 159M / 16 59S / 289S / 435R / 438A, wherein the positions are numbered with reference to SEQ ID NO: 548. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: I14V / I28M / K38R / R74W / L100F / R102K / S118A / D161L / D169G / A178V / I233W / T250R / A407E / I422M / M438A, I14V / I28M / K38R / R74W / R102K / S156A / Q159M / I233W / T250A / K289S / V413L / I422M / Q424E / V435R / M438A, I14V / I28M / K38R / R74W / L100F / R102K / S118A / D161L / D169G / A178V / I233W 02K / A110G / Q159M / D161L / I233W / H259S / D290E / D300Q / A351G / V435Q, I14 V / I28M / K38R / A110G / N137G / D161L / K222R / K289S / W401L, I14V / I28M / I44 V / R74W / D98P / R102K / N137G / Q159M / D161L / K185R / K222R / T250A, I14V / I2 8M / I44V / I92L, I14V / I28M / I44V / D161L / D169S, I14V / I28M / I44V / D375P,I14V / I28M / T54P / D161L / K185R / V413L、I14V / I28M / T54P / V365I、I14V / I28M / R74W / D98P / L100F / R102K / D161L / R173G / A178V / I233W / T250A / H259S / D290E / A407E、I14V / I28M / I92L / L100F / R102K / Q159M / D161L / D169S / I233W、I14V / I28M / I92L / L100F / R102K / Q159M / D161L / I233W / A351G / I422M、I14V / I28M / I92L / L100F / R102K / I422M / Q424E / V435Q、I14V / I28M / I92L / L100F / D161L / K222R / I233W / K289S / D300Q、I14V / I28M / L100F / N137G / S156A / D161L / K222R / H259S / K289S / V365I / W401L / V435R / M438A、I14V / I28M / L100F / S156A / D161L / T250R、I14V / I28M / R102K / S118A / N137G / D161L / K185R / K222R / T250R / H259P / W401L、I14V / I28M / Q159M / K289S / D290E / D300Q、I14V / I28M / Q159M / V365I / V435Q、I14V / I28M / A351G、I14V / K38R / R74W / A110G / S156A / D161L / R173G / A178V / K222R / D300Q、I14V / K38R / L100F / R102K / D161L / R173G / A178V / K222R / T250R / D375P / W401L / V413L、I44V / R74W / L100F / R102K / D161L / I233W / V365I / V435G / M438A、I14V / R74W / A110G / Q159M / D161L / D169G / R173G / T250A / H259P / D290E / D375P / A407E / I422M、I14V / R74W / D161L / D375P / W401L、I14V / I92L / D98P / L100F / Q159M / D161L / H259P / V365I / I422M / Q424E / V435R、I14V / A110G / S156A / D161L / D375P / W401L / V435E / M438A、I14V / Q159M / D161L / V365I / V435E / M438A、I14V / D161L / K222R / T250R / H259S / K289S / D375P / W401L / V413L、I14V / D161L / K222R / T250R / V435Q / M438A、I14V / D161L / D300Q、I28M、I28M / K38R / I92L / D98P / L100F / R102K / S156A / D161L、I28M / I44V / R74W / W401L、I28M / I44V / I92L / D161L / K222R / D300Q / V413L、I28M / I44V / D98P / L100F / R102K / S118A、I28M / I44V / S118A / S156A / D161L / K222R / K289S / V435Q / M438A、I28M / I44V / K289S / D290E / A351G / I422M、I28M / I44V / V435R / M438A、I28M / T54P / I92L / Q159M / D161L / D290E、I28M / T54P / Q159M / D290E / M438A、I28M / T54P / T250R / K439N、I28M / R74W / S156A / Q159M / D161L / A178V / D300Q / V365I / V435Q / M438A、I28M / R74W / S156A / D161L / V365I / A407E、I28M / R74W / D161L / D290E / V365I、I28M / D98P / L100F / R102K / D161L / K185R / A351G / W401L / V435E / M438A、I28M / I92L / L100F / R102K / A110G / D161L / K185R / T250A / D300Q / D375P / V435Q、I28M / I92L / S118A / Q159M / K222R / T250R / H259P / D300Q / A407E、I28M / S156A / D161L / K185R / V435R / M438A、I28M / S156A / D161L / I233W / H259S / D300Q / V435R、I28M / I92L / D98P / L100F / A110G / S156A / D161L / W401L、K38R / D161L / D300Q / M438A、R74W / D98P / L100F / R102K / A110G / S118A / D161L / A178V / T250R / K289S / D290E / D300Q / V435E / M438A、R74W / D98P / L100F / R102K / S118A / S156A / Q159M / D161L / V435E / M438A, R74W / S156A / D161L / R173G / A178V / Q424E / V435E, R74W / D3 75P / V435G, D98P / L100F / S118A / Q159M / D161L / D300Q, D98P / L100F / S156A / Q159M / D161L / A178V / H259S / K289S / D290E / A351G / I4 22M, R102K / N137G / Q159M / D161L / I422M / Q424E, S118A, N137G / Q159M / D161L / K185R / D300Q / A351G / V365I / V435Q, S156A / Q159M / D161L / D169S, Q159M / D161L / K222R / D290E / D375P / A407E, Q159M / D161L / W401L, and D161L / H259S / K289S / V435R / M438A, wherein the positions are numbered with reference to SEQ ID NO: 548. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 548. IDNO:550, 552, 554, 556, 558, 560, 562, 564, 566, 568, 570, 572, 574, 576, 578, 580, 5 82, 584, 586, 588, 590, 592, 594, 596, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616 , 618, 620, 622, 624, 626, 628, 630, 632, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678 and 680, wherein the positions are numbered with reference to SEQ ID NO:548. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 550, 552, 554, 556, 558, 560, 562, 564, 566, 568, 570, 572, 574, 576, 578, 580, 582, 584, 586, 588, 590, 592, 594, 596, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616, 618, 620, 622, 624, 626, 628,630, 632, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678 and 680, wherein the positions are numbered with reference to SEQ ID NO: 548.
[0019] In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 550, 552, 554, 556, 558, 560, 562, 564, 566, 568, 570, 572, 574, 576, 578, 580, 582, 584, 586, 588, 590, 592, 594, 596, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616, 618, 620, 622, 624, 626, 628, 630, 632, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678 and 680, wherein the positions are numbered with reference to SEQ ID NO: 548.
[0020] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 19 / 44 / 110 / 191 / 198 / 199 / 208 / 300 / 365, 19 / 75 / 76 / 87 / 92 / 199 / 207 / 208, 19 / 87 / 92 / 191 / 199 / 209 / 413 / 435, 44 / 76 / 197 / 199 / 208 / 351, 44 / 87 / 92 / 137 / 159 / 199 / 209, 44 / 87 / 137 / 159 / 169 / 191 / 199 / 208, 44 / 87 / 137 / 159 / 169 / 191 / 199 / 208. 7 / 191 / 197 / 209 / 289 / 401、44 / 87 / 199 / 208、75 / 76 / 87 / 92、75 / 76 / 87 / 92 / 290 / 300、75 / 76 / 87 / 191、75 / 76 / 87 / 191 / 197 / 199 / 209 / 300、75 / 87 / 92 / 169 / 207 / 208 / 300 / 413 / 435、75 / 87 / 110 / 137 / 169 / 191 / 199 / 208 / 209 / 289 / 435、75 / 87 / 110 / 191 / 197 / 198 / 207 / 208 / 289 / 290 / 300 / 401 / 413 、75 / 87 / 300、75 / 110 / 197 / 199 / 208 / 290 / 300 / 401 / 413、76 / 92 / 199 / 209、87 / 92 / 197 / 198 / 199 / 208 / 300、87 / 137 / 435、87 / 169 / 191 / 199 / 207 / 209 / 401 / 413、87 / 191 / 198 / 199 / 222 / 244 / 289 / 300 / 435、87 / 92 / 110 / 169 / 199 / 207 / 209 / 290 / 300、87 / 92 / 159 / 169 / 191 / 198 / 290 / 413 / 435、87 / 92 / 159 / 191 / 199 / 208 / 209 / 289 / 290、87 / 92 / 208 / 401、87 / 435、92 / 137 / 191 / 199 / 209、92 / 197 / 199 / 207 / 208 / 401、137 / 198 / 199 / 207 / 208 / 426 / 435、137 / 199 / 208 / 209 / 290 / 435、137 / 365、159 / 197 / 199 / 207 / 209、169 / 191 / 197 / 199 / 207 / 208、169 / 197 / 199 / 207 / 209 / 222 / 300 / 413 / 435、191 / 207 / 208 / 289 / 290 / 413 / 435 and 197 / 198 / 199 / 208 / 209, wherein the positions are numbered with reference to SEQ ID NO:562. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 19L / 44V / 110G / 191R / 198M / 199K / 208A / 300Q / 365I, 19L / 75L / 76R / 87W / 92L / 199K / 207L / 208A, 19L / 87W / 92L / 191R / 199K / 209G / 413L / 435Q, 44V / 76R / 197R / 199K / 208D / 351G, 44V / 87W / 92L / 137G / 159M / 199K / 209G, 44V / 87W / 92L / 191R / 199K / 208D / 351G. / 137G / 159M / 169S / 191R / 199K / 208D、44V / 87W / 137G / 191R / 197R / 209G / 289S / 401L、44V / 87W / 199K / 208A、75L / 76R / 87W / 92L、75L / 76R / 87W / 92L / 290E / 300Q、75L / 76R / 87W / 191R、75L / 76R / 87W / 191R / 197R / 199K / 209G / 300Q, 75L / 87W / 92L / 169S / 207L / 208A / 300Q / 413L / 435Q, 75L / 87 W / 110G / 137G / 169S / 191R / 199K / 208A / 209G / 289S / 435Q, 75L / 87W / 110G / 191R / 197R / 198M / 207L / 208D / 289S / 290E / 300Q / 401L / 413L, 75L / 8 7W / 300Q, 75L / 110G / 197R / 199K / 208A / 290E / 300Q / 401L / 413L, 76R / 92 L / 199K / 209G, 87L / 92L / 197R / 198M / 199K / 208D / 300Q, 87W / 137G / 435R , 87W / 169S / 191R / 199K / 207L / 209G / 401L / 413L, 87W / 191R / 198M / 199K / 222R / 244L / 289S / 300Q / 435R, 87W / 92L / 110G / 169S / 199K / 207L / 209 G / 290E / 300Q, 87W / 92L / 159M / 169S / 191R / 198M / 290E / 413L / 435Q, 87W / 92L / 159M / 191R / 199K / 208A / 209G / 289S / 290E, 87W / 92L / 208A / 401L,87W / 435R、92L / 137G / 191R / 199K / 209G、92L / 197R / 199K / 207L / 208D / 401L、137G / 198M / 199K / 207L / 208D / 426V / 435R, 137G / 199K / 208A / 209G / 290E / 435R, 137G / 365I, 159M / 197R / 199K / 20 7L / 209G, 169S / 191R / 197R / 199K / 207L / 208D, 169S / 197R / 199K / 207L / 209G / 222R / 300Q / 413L / 435R, 191R / 207L / 208A / 289S / 290E / 413L / 435Q and 197R / 198M / 199K / 208D / 209G, wherein the positions are numbered with reference to SEQ ID NO: 562. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: V19L / I44V / A110G / S191R / I198M / A199K / K208A / D300Q / V365I, V19L / I75L / S76R / M87W / I92L / A199K / I207L / K208A, V19L / M87 W / I92L / S191R / A199K / Q209G / V413L / V435Q, I44V / S76R / Q197R / A199K / K208D / A351G, I44V / M87W / I92L / N137G / Q159M / A199K / Q209G, I44V / M87W / N137G / Q159M / G169S / S191R / A199K / K2 08D, I44V / M87W / N137G / S191R / Q197R / Q209G / K289S / W401L, I44V / M87W / A199K / K208A, I75L / S76R / M87W / I92L, I75L / S76R / M87W / I92L / D290E / D300Q, I75L / S76R / M87W / S191R, I75L / S7 6R / M87W / S191R / Q197R / A199K / Q209G / D300Q, I75L / M87W / I92L / G169S / I207L / K208A / D300Q / V413L / V435Q, I75L / M87W / A110G / N137G / G169S / S191R / A199K / K208A / Q209G / K289S / V435Q,I75L / M87W / A110G / S191R / Q197R / I198M / I207L / K208D / K289S / D290E / D300Q / W401L / V41L, I75L / M87W / D300Q, I75L / A110G / Q197R / A199K / K208A / D290E / D300Q / W401L / V413L, S76R / I92L / A199K / Q209G, M87L / I92L / Q197R / I198M / A199K / K208D / D300Q, M87W / N137G / V435R, M87W / G169S / S191R / A199K / I207L / Q209G / W401L / V413L, M87W / S191R / I198M / A199K / K222R / P244L / K289S / D300Q / V435R, M8 7W / I92L / A110G / G169S / A199K / I207L / Q209G / D290E / D300Q, M87W / I92L / Q159M / G169S / S191R / I198M / D290E / V413L / V435Q, M87W / I9 2L / Q159M / S191R / A199K / K208A / Q209G / K289S / D290E, M87W / I92L / K208A / W401L, M87W / V435R, I92L / N137G / S191R / A199K / Q209G, I 92L / Q197R / A199K / I207L / K208D / W401L, N137G / I198M / A199K / I207L / K208D / A426V / V435R, N137G / A199K / K208A / Q209G / D290E / V43 Q197R / I198M / A199K / K208D / Q209G, wherein the positions are numbered with reference to SEQ ID NO: 562. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any of the following sequences: SEQ ID NO: 682, 684, 686, 688, 690, 692, 694, 696, 698, 700, 702, 704, 706, 708, 710,712, 714, 716, 718, 720, 722, 724, 726, 728, 730, 732, 734, 736, 738, 740, 742, 744, 746, 748, 750, 752 and / or 754. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 682, 684, 686, 688, 690, 692, 694, 696, 698, 700, 702, 704, 706, 708, 710, 712, 714, 716, 718, 720, 722, 724, 726, 728, 730, 732, 734, 736, 738, 740, 742, 744, 746, 748, 750, 752 and / or 754. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises SEQ ID NO: 682, 684, 686, 688, 690, 692, 694, 696, 698, 700, 702, 704, 706, 708, 710, 712, 714, 716, 718, 720, 722, 724, 726, 728, 730, 732, 734, 736, 738, 740, 742, 744, 746, 748, 750, 752, and / or 754.
[0021] The present invention also provides engineered glycosyltransferases, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 22, 25, 51, 56, 71, 78, 80, 81, 88, 157, 185 / 208 / 230 / 252 / 255 / 290 / 365, 189 / 206 / 208 / 365, 200, 208 / 365 / 435, 243, 245, 249, 259, 262 / 401, 279, 282, 284, 304 / 322 / 365 / 401, 308, 338, 339, 352, 362, 364, 365 / 401 / 413 / 435, 366, and 374, wherein the positions are numbered with reference to SEQ ID NO: 696. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 22L, 25L, 25V, 51A, 56L, 71R, 78E, 78F, 78G, 78I, 78K, 78M, 78P, 78Q, 78R, 80L, 81C, 88I, 88K, 88V, 157G, 157Q, 185R / 208A / 230S / 252N / 255N / 290E / 365I, 189L / 206K / 208A / 365I, 200N, 200S, 208A / 365I / 4 84T, 304P / 322S / 365I / 401L, 308F, 308Y, 338C, 339D, 352Q, 362T, 364G, 365I / 401L / 413L / 435Q, 366A and 374T, wherein the positions are numbered with reference to SEQ ID NO: 696.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: P22L, I25L, I25V, K51A, N56L, Q71R, L78E, L78F, L78G, L78I, L78K, L78M, L78P, L78Q, L78R, T80L, H81C, R88I, R88K, R88V, L157G, L157Q, K185R / K208A / E230S / S252N / S255N / D290E / V365I, I189L / M206K / K208A / V365I, K200N, K200S, K208A / V365I / V 435Q, I243C, I243L, I243M, I243V, I243Y, L245G, L249E, L249H, L249I, L249M , L249N, L249P, L249S, L249T, L249Y, H259G, H259S, H259Y, T262S / W401L, S27 9G, S282T, S284T, S304P / P322S / V365I / W401L, R308F, R308Y, V338C, P339D, F352Q, L362T, S364G, V365I / W401L / V413L / V435Q, C366A, and S374T, wherein the positions are numbered with reference to SEQ ID NO: 696. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: NO:4684, 4686, 4688, 4690, 4692, 4694, 4696, 4698, 4700, 4702, 4704, 4706, 4708, 4710, 4712, 4714 ,4716,4718,4720,4722,4724,4726,4728,4730,4732,4734,4736,4738,4740,4742,4744,4746,4 4790, 4792, 4794, 4796, 4798, 4800, 4902, 4804, 4806, 4808, 4810, and 4812.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any of the following sequences: SEQ ID NO: 4684, 4686, 4688, 4690, 4692, 4694, 4696, 4698, 4700, 4702, 4704, 4706, 4708, 4710, 4712, 4714, 4716, 4718, 4720, 4722, 4724, 4726, 4728, 4730, 4732, 4734, 4736, 4738, 4740, 4742, 4744, 4746, 4747. 4788, 4790, 4792, 4794, 4796, 4798, 4800, 4902, 4804, 4806, 4808, 4810, and 4812. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: NO:4684, 4686, 4688, 4690, 4692, 4694, 4696, 4698, 4700, 4702, 4704, 4706, 4708, 4710, 4712, 4714 ,4716,4718,4720,4722,4724,4726,4728,4730,4732,4734,4736,4738,4740,4742,4744,4746,4 4790, 4792, 4794, 4796, 4798, 4800, 4902, 4804, 4806, 4808, 4810, and 4812.
[0022] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 51 / 56, 51 / 56 / 243 / 249 / 282 / 353 / 362 / 366, 51 / 56 / 243 / 249 / 308 / 362 / 364, 51 / 56 / 249 / 353, 51 / 56 / 249 / 362 / 364、51 / 56 / 249 / 362 / 366、51 / 243 / 249 / 308 / 353、51 / 243 / 249 / 348 / 362 / 366、51 / 249、51 / 249 / 282 / 284 / 364、51 / 249 / 282 / 353 / 366、51 / 249 / 284 / 308 / 362 / 366、5 1 / 249 / 353 / 362 / 364, 51 / 353 / 362, 56, 56 / 243 / 249 / 282 / 364 / 366, 56 / 243 / 364 / 366, 56 / 249, 56 / 249 / 284 / 353, 56 / 249 / 353, 56 / 284 / 366, 243 / 249 / 282 / 284 / 362 / 364 / 366 6, 243 / 249 / 308 / 353 / 366, 243 / 249 / 353 / 362 / 366, 243 / 282 / 353 / 362 / 364, 243 / 282 / 362 / 364 / 366, 243 / 308 / 353, 249 / 353 / 362 / 366, 282, 308 / 366 and 362 / 366, wherein the positions are numbered with reference to SEQ ID NO: 4684.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 51A / 56H, 51A / 56H / 243L / 249E / 282T / 353Y / 362M / 366S, 51A / 56H / 243L / 249E / 308F / 362M / 364G, 51A / 56H / 249M / 362M / 364G, 51A / 56H / 249M / 362M / 366S. 66S, 51A / 56H / 249Y / 353Y, 51A / 243L / 249E / 308F / 353Y, 51A / 243L / 249E / 348S / 362M / 366V, 51A / 249E / 3 53Y / 362M / 364G, 51A / 249M, 51A / 249M / 282T / 284T / 364G, 51A / 249M / 282T / 353Y / 366S, 51A / 249Y / 284T / 3 08F / 362M / 366V, 51A / 353Y / 362M, 56H, 56H / 243L / 249E / 282T / 364G / 366V, 56H / 243L / 364G / 366V, 56H / 2 49M / 284T / 353Y, 56H / 249M / 353Y, 56H / 249Y, 56H / 284T / 366V, 243L / 249E / 282T / 284T / 362M / 364G / 366S, : 243L / 249M / 308F / 353Y / 366A, 243L / 249Y / 353Y / 362M / 366S, 243L / 282T / 353Y / 362M / 364G, 243L / 282T / 362M / 364G / 366V, 243L / 308F / 353Y, 249Y / 353Y / 362M / 366S, 282T, 308F / 366A, and 362M / 366A, wherein the positions are numbered with reference to SEQ ID NO: 4684.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: K51A / N56H, K51A / N56H / I243L / L249E / S282T / W353Y / L362M / C366S, K51A / N56H / I243L / L249E / R308F / L362M / S364G, K51A / N56H / L249M / L362M / S364G, K51A / N56H / L249M / L362M / C366S, K51A / N56H / I243L / L249E / R308F / L362M / S364G 1A / N56H / L249Y / W353Y, K51A / I243L / L249E / R308F / W353Y, K51A / I243L / L249E / A348S / L362M / C366V, K51A / L249E / W353Y / L362M / S364G, K51A / L249M, K51A / L249M / S282T / S284T / S364G, K51A / L249M / S282T / W353Y / C366S, K51A / L249Y / S284T / R308 F / L362M / C366V, K51A / W353Y / L362M, N56H, N56H / I243L / L249E / S282T / S364G / C366V, N56H / I243L / S364G / C366V, N56H / L2 49M / S284T / W353Y, N56H / L249M / W353Y, N56H / L249Y, N56H / S284T / C366V, I243L / L249E / S282T / S284T / L362M / S364G / C366S , I243L / L249M / R308F / W353Y / C366A, I243L / L249Y / W353Y / L362M / C366S, I243L / S282T / W353Y / L362M / S364G, I243L / S282T / L362M / S364G / C366V, I243L / R308F / W353Y, L249Y / W353Y / L362M / C366S, S282T, R308F / C366A, and L362M / C366A, wherein the positions are numbered with reference to SEQ ID NO: 4684.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 4814, 4816, 4818, 4820, 4822, 4824, 4826, 4828, 4830, 4832, 4834, 4836, 4838, 4840, 4842, 4844, 4846, 4848, 4850, 4852, 4854, 4856, 4858, 4860, 4862, 4864, 4866, 4868, 4870, 4872, and 4874. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 4814, 4816, 4818, 4820, 4822, 4824, 4826, 4828, 4830, 4832, 4834, 4836, 4838, 4840, 4842, 4844, 4846, 4848, 4850, 4852, 4854, 4856, 4858, 4860, 4862, 4864, 4866, 4868, 4870, 4872, and 4874. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 4814, 4816, 4818, 4820, 4822, 4824, 4826, 4828, 4830, 4832, 4834, 4836, 4838, 4840, 4842, 4844, 4846, 4848, 4850, 4852, 4854, 4856, 4858, 4860, 4862, 4864, 4866, 4868, 4870, 4872, and 4874.
[0023] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 25, 25 / 56 / 353, 25 / 243 / 249 / 259 / 366, 25 / 243 / 249 / 362, 25 / 362 / 366, 51, 51 / 56 / 200 / 243 / 249 / 259 / 338, 51 / 56 / 362, 51 / 71 / 249 / 279 / 284 / 362 / 366, 56 / 243 / 249 / 259 / 366, 56 / 362 / 366, 51 / 71 / 249 / 279 / 284 / 362 / 366, 56 / 243 / 249 / 259 / 362. 36, 353 / 362, 405, 411, 428, and 439, wherein the positions are numbered with reference to SEQ ID NO: 4838.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 25L, 25L / 56L / 353Y, 25V / 243M / 249I / 362M, 25V / 243M / 249Y / 259G / 366A, 25V / 362M / 366S, 51A, 51A / 56L / 200S / 243M / 249I / 259G / 338C , 51A / 56L / 362M, 51A / 71R / 249M / 279G / 284T / 362M / 366S, 56L / 243M / 249M, 56L / 243M / 249Y, 56L / 362M / 366A, 70S / 198D / 259E / 313S, 85E, 88C / 173S, 88I, 110S, 159N, 163K, 171D, 171E, 171P, 171V , 174E, 174S, 175N, 177K, 177P, 177S, 198D, 198D / 313S, 198D / 313S / 428S, 198E, 198S, 198T, 200 S / 243M / 249Y / 259G, 208E, 208G, 208I, 208L, 208N, 208T, 208V, 208W / 320I, 209A, 209E / 234Q, 222 428K, 439D, and 439Q, wherein the positions are numbered with reference to SEQ ID NO: 4838.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: I25L, I25L / H56L / W353Y, I25V / L243M / E249I / L362M, I25V / L243M / E249Y / H259G / V366A, I25V / L362M / V366S, K51A, K51A / H56L / K200S / L243M / E249I / H259G / V338C, K51A / H56L / K200S / L243M / E249I / H259G / V338C, K51A / H56L / K200S / L243M / E249I / H259G / V338D, K51A / H56L / K200S / L243M / E249I / H259G / V338E 1A / H56L / L362M, K51A / Q71R / E249M / S279G / S284T / L362M / V366S, H56L / L243M / E249M, H56L / L243M / E249Y, H56L / L 362M / V366A, P70S / I198D / H259E / F313S, A85E, R88C / R173S, R88I, A110S, Q159N, L163K, K171D, K171E, K171P, K171 V, L174E, L174S, E175N, Q177K, Q177P, Q177S, I198D, I198D / F313S, I198D / F313S / V428S, I198E, I198S, I198T, K2 00S / L243M / E249Y / H259G, K208E, K208G, K208I, K208L, K208N, K208T, K208V, K208W / V320I, Q209A, Q209E / R234Q, K : 222P, E226R, E226T, R234A, R234E, R234H / N408D, R234T, L243M / V338C / L362M / V366S, S253A, L256A, H259N, H259S, H259T, Q265A, P272D, K289H, K289T, P322V, K336E, W353Y / L362M, E405Q, R411T, V428K, K439D and K439Q, wherein the positions are numbered with reference to SEQ ID NO: 4838.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any of the following sequences: SEQ ID NO: 4876, 4878, 4880, 4882, 4884, 4886, 4888, 4890, 4892, 4894, 4896, 4898, 4900, 4902, 4904, 4906, 4908, 4910, 4912, 4914, 4916, 4918, 4920, 4922, 4924, 4926, 4928, 4930, 4932, 4934, 4936, 4938, 4940, 4942, 4944, 4945, 4946, 4947, 4948, 4949, 4950, 4951, 4952, 4953, 4954, 4955, 4956, 4957, 4958, 4959, 4960, 4961, 4962, 4964, 4965, 4966, 4967, 4968, 4969, 4970, 4971, 4972, 4973, 4974, 4975 496, 4968, 4970, 4972, 4974, 4976, 4978, 4980, 4982, 4984, 4986, 4988, 4990, 4992, 4994, 4996, 4998, 5000, 5002, 5004, 5006, 5008, 5010, 5012, 5014, and 5016. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: NO:4876, 4878, 4880, 4882, 4884, 4886, 4888, 4890, 4892, 4894, 4896, 4898, 4900, 4902, 4904, 4906, 4908, 4 910, 4912, 4914, 4916, 4918, 4920, 4922, 4924, 4926, 4928, 4930, 4932, 4934, 4936, 4938, 4940, 4942, 4944, 4 4956, 4958, 4960, 4962, 4964, 4966, 4968, 4970, 4972, 4974, 4976, 4978, 4980, 4982, 4984, 4986, 4988, 4990, 4992, 4994, 4996, 4998, 5000, 5002, 5004, 5006, 5008, 5010, 5012, 5014, and 5016.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 4876, 4878, 4880, 4882, 4884, 4886, 4888, 4890, 4892, 4894, 4896, 4898, 4900, 4902, 4904, 4906, 4908, 4910, 4912, 4914, 4916, 4918, 4920, 4922, 4924, 4926, 4928, 4930, 4932, 4934, 4936, 4938, 4940, 4942, 4944, 4946, 4947, 4948, 4950, 4951, 4952, 4953, 4954, 4955, 4956, 4957, 4958, 4959, 4960, 4961, 4962, 4964, 4965, 4966, 4967, 4968, 4969, 4970, 4971, 4972, 4973, 4974, 4975 4956, 4958, 4960, 4962, 4964, 4966, 4968, 4970, 4972, 4974, 4976, 4978, 4980, 4982, 4984, 4986, 4988, 4990, 4992, 4994, 4996, 4998, 5000, 5002, 5004, 5006, 5008, 5010, 5012, 5014, and 5016.
[0024] The present invention also provides engineered glycosyltransferases, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 8, 9, 25, 25 / 198 / 209, 25 / 200 / 209 / 338, 25 / 200 / 243 / 249, 25 / 209 / 243, 25 / 209 / 243 / 249, 25 / 209 / 243 / 259, 25 / 209 / 249 / 259 / 36 6, 25 / 209 / 259, 25 / 209 / 279 / 366, 25 / 209 / 289 / 366, 25 / 249, 25 / 259 / 279, 25 / 259 / 279 / 289, 25 / 279 / 284, 25 / 279 / 284 / 289, 25 / 289, 34, 53, 54, 55, 61, 69, 70, 73, 79, 87, 91, 107, 108, 111, 141, 153, 15 8, 174, 190, 194, 198, 198 / 200 / 209 / 243 / 249 / 289, 198 / 249 / 338, 200 / 209 / 366, 201, 205, 209, 209 / 249 / 259 / 279 / 338 / 366, 209 / 249 / 259 / 289, 209 / 249 / 279 / 284 / 289, 209 / 249 / 338, 209 / 279 / 289, 20 9 / 366, 234 / 297, 238, 247, 249 / 259, 252, 253, 254, 256, 259 / 366, 279, 279 / 338, 289, 297, 308, 321, 322, 327, 336, 338, 341, 342, 364, 366, 388, 392, 411, 412, 414, 426, 430, 432, 446 and 449, wherein the positions are numbered with reference to SEQ ID NO: 4876. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 8D, 8L, 9G, 25H / 209E / 243M / 249Y, 25L, 25L / 198D / 209E, 25L / 200S / 209E / 338C, 25L / 200S / 243M / 249M, 25L / 209E / 243M, 25L / 209E / 249Y, 3M / 249Y, 25L / 209E / 243M / 259G, 25L / 209E / 249I / 259G / 366A, 25L / 209E / 259G, 25L / 209E / 279G / 366A, 25L / 209E / 289T / 366A, 25L / 249I, 25L / 259G / 279G, 25L / 259G / 279G / 289T, 25L / 279G / 284T,25L / 279G / 284T / 289T, 25L / 289T, 34I, 53C, 53L, 53R, 53V, 54P, 54V, 55T, 55W, 61S, 69N, 69Q, 69S, 69T , 70K, 73S, 79G, 79S, 79V, 87L, 87M, 87R, 91Q, 91R, 91T, 107A, 107C, 107T, 108C, 111C, 111G, 141M, 153S , 158Q, 174M, 190R, 194Q, 198D, 198D / 200S / 209E / 243M / 249Y / 289T, 198D / 249M / 338C, 200S / 209E / 36 6A, 201P, 201T, 205P, 209E, 209E / 249I / 259G / 289T, 209E / 249M / 338C, 209E / 249Y / 259G / 279G / 338C / 3 66A, 209E / 249Y / 279G / 284T / 289T, 209E / 279G / 289T, 209E / 366A, 234H / 297A, 238K, 247A, 247L, 249M / 259G, 252A, 252E, 252Q, 253G, 253P, 254G, 254M, 254P, 256D, 256T, 256W, 259G / 366A, 279G, 279G / 338 C, 289T, 297A, 308C, 308L, 308T, 321D, 322M, 322R, 322T, 327L, 336M, 336Y, 338C, 341V, 342R, 364S, 366A, 388T, 388V, 392H, 392Q, 41 IE, 41 1S, 412H, 412T, 414L, 426T, 430R, 432T, 446F and 449L, wherein the positions are numbered with reference to SEQ ID NO: 4876. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: T8D, T8L, V9G, I25H / Q209E / L243M / E249Y, I25L, I25L / I198D / Q209E, I25L / K200S / Q209E / V338C, I25L / K200S / L243M / E249M, I25L / Q209E / L243M, I25L / Q209E / L243M / E249Y, I25L / Q209E / L243M / H259G, I25L / Q209E / E24 9I / H259G / V366A, I25L / Q209E / H259G, I25L / Q209E / S279G / V366A, I25L / Q209E / K289T / V366A,I25L / E249I, I25L / H259G / S279G, I25L / H259G / S279G / K289T, I25L / S279G / S284T, I25L / S279G / S284T / K289T, I25L / K289T, V34I, K5 3C, K53L, K53R, K53V, T54P, T54V, S55T, S55W, T61S, D69N, D69Q, D69S, D69T, P70K, E73S, P79G, P79S, P79V, W87L, W87M, W87R, I91Q, I 91R, I91T, L107A, L107C, L107T, M108C, S111C, S111G, L141M, A153S, P158Q, L174M, K190R, S194Q, I198D, I198D / K200S / Q209E / L243 M / E249Y / K289T, I198D / E249M / V338C, K200S / Q209E / V366A, E201P, E201T, K205P, Q209E, Q209E / E249I / H259G / K289T, Q209E / E249M / V338C, Q209E / E249Y / H259G / S279G / V338C / V366A, Q209E / E249Y / S279G / S284T / K289T, Q209E / S279G / K289T, Q209E / V366A, R234H / G 297A, A238K, K247A, K247L, E249M / H259G, S252A, S252E, S252Q, S253G, S253P, S254G, S254M, S254P, L256D, L256T, L256W, H259G / V3 88T, S388V, K392H, K392Q, R411E, R411S, R412H, R412T, M414L, A426T, K430R, K432T, S446F, and S449L, wherein the positions are numbered with reference to SEQ ID NO: 4876. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any of the following sequences: SEQ ID NO: 5018, 5020, 5022, 5024, 5026, 5028, 5030, 5032, 5034, 5036, 5038,5040, 5042, 5044, 5046, 5048, 5050, 5052, 5054, 5056, 5058, 5060, 5062, 5064, 5066, 5068, 5070, 5072, 5074, 5076, 5078, 5080, 5082, 5084, 5086, 5088, 5090, 5092, 509 4. 5096, 5098, 5100, 5102, 5104, 5106, 5108, 5110, 5112, 5114, 5116, 5118, 5120, 5122, 5124, 5126, 5128, 5130, 5132, 5134, 5136, 5138, 5140, 5142, 5144, 5146, 5148, 51 50, 5152, 5154, 5156, 5158, 5160, 5162, 5164, 5166, 5168, 5170, 5172, 5174, 5176, 5178, 5180, 5182, 5184, 5186, 5188, 5190, 5192, 5194, 5196, 5198, 5200, 5202, 5204, 5 206, 5208, 5210, 5212, 5214, 5216, 5218, 5220, 5222, 5224, 5226, 5228, 5230, 5232, 5234, 5236, 5238, 5240, 5242, 5244, 5246, 5248, 5250, 5252, 5254, 5256, 5258, and 5260. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: NO:5018, 5020, 5022, 5024, 5026, 5028, 5030, 5032, 5034, 5036, 5038, 5040, 5042, 5044, 5046, 5048, 5050, 5052, 5054, 5056, 5058, 5060, 5062, 5064, 5066, 5068, 5070, 5072, 5074, 5076, 5078, 5080, 5082, 5084, 5086, 5088, 5090, 5092, 509 4. 5096, 5098, 5100, 5102, 5104, 5106, 5108, 5110, 5112, 5114, 5116, 5118, 5120, 5122, 5124, 5126, 5128, 5130, 5132, 5134, 5136, 5138, 5140, 5142, 5144, 5146, 5148, 5150, 5152, 5154, 5156, 5158, 5160, 5162, 5164, 5166, 5168, 5170, 5172,5240, 5242, 5244, 5246, 5248, 5250, 5252, 5254, 5256, 5258, and 5260. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: SEQ ID NO: IDNO:5018, 5020, 5022, 5024, 5026, 5028, 5030, 5032, 5034, 5036, 5038, 5040, 5042, 5044, 5 046, 5048, 5050, 5052, 5054, 5056, 5058, 5060, 5062, 5064, 5066, 5068, 5070, 5072, 5074, 507 6. 5078, 5080, 5082, 5084, 5086, 5088, 5090, 5092, 5094, 5096, 5098, 5100, 5102, 5104, 5106, 5108, 5110, 5112, 5114, 5116, 5118, 5120, 5122, 5124, 5126, 5128, 5130, 5132, 5134, 5136, 51 38, 5140, 5142, 5144, 5146, 5148, 5150, 5152, 5154, 5156, 5158, 5160, 5162, 5164, 5166, 5168, 5170, 5172, 5174, 5176, 5178, 5180, 5182, 5184, 5186, 5188, 5190, 5192, 5194, 5196, 5198, 5 200, 5202, 5204, 5206, 5208, 5210, 5212, 5214, 5216, 5218, 5220, 5222, 5224, 5226, 5228, 5230, 5232, 5234, 5236, 5238, 5240, 5242, 5244, 5246, 5248, 5250, 5252, 5254, 5256, 5258, and 5260.
[0025] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 88, 88 / 110, 88 / 110 / 159 / 198 / 200, 88 / 110 / 159 / 198 / 234 / 259 / 265, 88 / 110 / 159 / 198 / 259 ...00, 88 / 110 / 159 / 198 / 200, 88 / 110 / 159 / 198 / 200, 88 / 110 8 / 110 / 198、88 / 110 / 234、88 / 159 / 198、88 / 198、88 / 198 / 200 / 259、88 / 198 / 259、88 / 259、88 / 259 / 265、110 / 259 / 265 / 411、159 / 198 / 411、159 / 259 / 411、171 / 174 / 175 / 177 / 208 / 320 / 428 / 439、171 / 175 / 177 / 208 / 320 / 428、171 / 177、171 / 177 / 226 / 428 / 439、171 / 208 / 320、171 / 208 / 320 / 428、171 / 208 / 428、174 / 175 / 177 / 208 / 320 / 42 8, 174 / 175 / 428, 174 / 320, 198, 198 / 200, 198 / 200 / 234, 198 / 234, 198 / 259, 208, 208 / 320 / 331 / 428, 208 / 320 / 428, 208 / 428, 234, 259, 320 / 428 and 428, wherein the positions are numbered with reference to SEQ ID NO: 5066.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 88I, 88I / 110D, 88I / 110D / 159N / 198D / 234T / 259N / 265A, 88I / 110D / 159N / 198D / 259E, 88I / 110D / 159N / 198E / 200S, 88I / 110D / 198D, 88I / 110D / 159N / 198D / 234T / 259N / 265A, D / 198S, 88I / 110D / 234T, 88I / 159N / 198D, 88I / 198D / 200S / 259E, 88I / 198D / 259E, 88I / 198S, 88I / 2 59E / 265A, 88I / 259N, 110D / 259N / 265A / 411T, 159N / 198E / 411T, 159N / 259E / 411T, 171E / 177P / 226T / 428K / 439D, 171E / 208E / 320I, 171E / 208E / 320I / 428K, 171E / 208E / 428K, 171P / 174E / 175N / 177P / 20 8W / 320I / 428K / 439D, 171P / 175N / 177P / 208L / 320I / 428K, 171P / 177P, 174E / 175N / 177P / 208E / 320I / 428K, 174E / 175N / 428K, 174E / 320I, 198D, 198D / 200S / 234E, 198D / 234Q, 198E / 200S, 198E / 259E, 208E, 208E / 320I / 428K, 208E / 428K, 208L / 320I / 331C / 428K, 234E, 259E, 320I / 428K and 428K, wherein the positions are numbered with reference to SEQ ID NO: 5066.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: R88I, R88I / A110D, R88I / A110D / Q159N / I198D / R234T / G259N / Q265A, R88I / A110D / Q159N / I198D / G259E, R88I / A110D / Q159N / I198E / K200S, R88I / A110D / I198D, R88I / A110D / Q159N / I198D / R234T / G259N / Q265A S, R88I / A110D / R234T, R88I / Q159N / I198D, R88I / I198D / K200S / G259E, R88I / I198D / G259E, R88I / I198S, R88I / G259E / Q265A, R88I / G259N, A110D / G259N / Q265A / R411T, Q159N / I198E / R411T, Q159N / G259E / R411T, K171E / Q177P / E226T / V42 8K / K439D, K171E / K208E / V320I, K171E / K208E / V320I / V428K, K171E / K208E / V428K, K171P / L174E / E175N / Q177P / K208W / V320I / V428K / K439D, K171P / E175N / Q177P / K208L / V320I / V428K, K171P / Q177P, L174E / E175N / Q177P / K208E / V320I / V 428K, L174E / E175N / V428K, L174E / V320I, I198D, I198D / K200S / R234E, I198D / R234Q, I198E / K200S, I198E / G259E, K208E, K208E / V320I / V428K, K208E / V428K, K208L / V320I / R331C / V428K, R234E, G259E, V320I / V428K, and V428K, wherein the positions are numbered with reference to SEQ ID NO: 5066.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 5262, 5264, 5266, 5268, 5270, 5272, 5274, 5276, 5278, 5280, 5282, 5284, 5286, 5288, 5290, 5292, 5294, 5296, 5298, 5300, 5302, 5304, 5306, 5308, 5310, 5312, 5314, 5316, 5318, 5320, 5322, 5324, 5326, 5328, 5330, 5332, 5334, 5336, 5338, 5340, and 5342. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 5262, 5264, 5266, 5268, 5270, 5272, 5274, 5276, 5278, 5280, 5282, 5284, 5286, 5288, 5290, 5292, 5294, 5296, 5298, 5300, 5302, 5304, 5306, 5308, 5310, 5312, 5314, 5316, 5318, 5320, 5322, 5324, 5326, 5328, 5330, 5332, 5334, 5336, 5338, 5340, and 5342. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 5262, 5264, 5266, 5268, 5270, 5272, 5274, 5276, 5278, 5280, 5282, 5284, 5286, 5288, 5290, 5292, 5294, 5296, 5298, 5300, 5302, 5304, 5306, 5308, 5310, 5312, 5314, 5316, 5318, 5320, 5322, 5324, 5326, 5328, 5330, 5332, 5334, 5336, 5338, 5340, and 5342.
[0026] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2, 7, 25 / 61 / 208 / 252 / 253, 25 / 61 / 428, 25 / 107 / 208 / 320 / 428, 25 / 208 / 247 / 252 / 253 / 364 / 428, 25 / 247 / 249 / 252 / 364 / 428, 38 、53 / 54 / 55 / 153 / 201、53 / 54 / 308 / 392、53 / 171 / 308 / 392、54、61 / 107 / 208 / 252 / 253 / 254 / 364 / 428、61 / 208 / 252 / 254 / 428、64、68、73 / 87 / 201、91 / 201 / 439 / 444、99、106、107、107 / 208 / 320 / 364 / 428、 107 / 247 / 249 / 252 / 254 / 364, 107 / 247 / 252, 107 / 247 / 428, 109, 159, 169, 171, 172, 177, 179, 190, 190 / 208 / 247 / 252 / 428, 222, 233, 233 / 269, 247 / 249 / 252 / 254 / 320 / 428, 249 / 252 / 253 / 254, 249 / 2 428, 428 / 434, 431 , 435, and 438, wherein the positions are numbered with reference to SEQ ID NO: 5290. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2L, 2N, 7P, 25L / 61S / 208N / 252E / 253G, 25L / 61S / 428K, 25L / 107T / 208E / 320I / 428K, 25L / 208E / 247L / 252E / 253G / 364S / 428K, 25L / 247L / 249I / 252E / 364S / 428K, 38Q, 53R / 54V / 55T / 153S / 201P, 53V / 54V / 308L / 392H, 53V / 171P / 308L / 392H, 54A, 6 1S / 107T / 208N / 252E / 253G / 254M / 364S / 428K, 61S / 208W / 252E / 254M / 428K, 64S, 68K, 73S / 87M / 201P,91T / 201P / 439D / 444H, 99P, 106T, 107A, 107A / 208N / 320I / 364S / 428K, 107A / 247A / 249I / 252E / 254M / 364S, 107A / 247A / 252E, 107A / 247A / 428K, 109S, 159L, 169C, 169E, 169L, 169Q, 169V, 1 71S, 171T, 171V, 172H, 172N, 177P, 179A, 179S, 190R, 190R / 208N / 247L / 252E / 428K, 222A, 233 C, 233G, 233K, 233L, 233M, 233Q, 233Q / 269R, 233V, 247A / 249I / 252E / 254M / 320I / 428K, 249I / 2 52E / 253G / 254M, 249I / 252E / 254M / 428K, 251L, 252E / 253G / 254M, 253G / 320I, 259T, 264A, 289 S, 296A, 296H, 296Q, 300G, 308L, 308L / 327L / 439D, 317R, 318T, 320I, 320I / 364S / 428K, 320I / 4 547F, 428I, 428K, 428Q, 428R, 428S, 431E, 431R, 435C, 435K, 435M, 435Q, 435R, 435T and 438Q, wherein the positions are numbered with reference to SEQ ID NO: 5290. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: E2L, E2N, T7P, I25L / T61S / K208N / S252E / S253G, I25L / T61S / V428K, I25L / L107T / K208E / V320I / V428K, I25L / K208E / K247L / S252E / S253G / G364S / V428K, I25L / K247L / Y249I / S252E / G364S / V428K, R38Q, K53R / T54V / S55T / A153S / E201P, K53V / T54V / R3 08L / K392H, K53V / K171P / R308L / K392H, T54A, T61S / L107T / K208N / S252E / S253G / S254M / G364S / V428K,T61S / K208W / S252E / S254M / V428K, F64S, N68K, E73S / W87M / E201P, I91T / E201P / K439D / Y444H, E99P, S106T, L107A, L107 A / K208N / V320I / G364S / V428K, L107A / K247A / Y249I / S252E / S254M / G364S, L107A / K247A / S252E, L107A / K247A / V428K, R1 09S, N159L, G169C, G169E, G169L, G169Q, G169V, K171S, K171T, K171V, T172H, T172N, Q177P, V179A, V179S, K190R, K190R / K208N / K247L / S252E / V428K, K222A, W233C, W233G, W233K, W233L, W233M, W233Q, W233Q / Q269R, W233V, K247A / Y249I / S25 2E / S254M / V320I / V428K, Y249I / S252E / S253G / S254M, Y249I / S252E / S254M / V428K, A251L, S252E / S253G / S254M, S253G / V320I, E259T, F264A, K289S, R296A, R296H, R296Q, D300G, R308L, R308L / F327L / K439D, S317R, E318T, V320I, V320I / G364 S / V428K, V320I / V428K, D347H, D347K, D347P, D347R, G404T, N408R, R417P, Q424A, Q424W, A427L, A427R, V428E / D434N, V428F, V428I, V428K, V428Q, V428R, V428S, D431E, D431R, V435C, V435K, V435M, V435Q, V435R, V435T and A438Q, wherein the positions are numbered with reference to SEQ ID NO: 5290. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 5344, 5346, 5348, 5350, 5352, 5354, 5356, 5358, 5360, 5362, 5364, 5366, 5368, 5370, 5372, 5374, 5376, 5378, 5380, 5382, 5384, 5386, 5388, 5390, 5392, 5394, 5396,5398, 5400, 5402, 5404, 5406, 5408, 5410, 5412, 5414, 5416, 5418, 5420, 5422, 5424, 5426, 5428, 5430, 5432, 5434, 5436, 5438, 5440, 5442, 5444, 5446, 5448, 5450, 5452, 5454, 5456, 5458, 5460, 5462, 5464, 5466, 5468, 5470 70, 5472, 5474, 5476, 5478, 5480, 5482, 5484, 5486, 5488, 5490, 5492, 5494, 5496, 5498, 5500, 5502, 5504, 5506, 5508, 5510, 5512, 5514, 5516, 5518, 5520, 5522, 5524, 5526, 5528, 5530, 5532, 5534, 5536, 5538, 5540, and 5542. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: NO:5344, 5346, 5348, 5350, 5352, 5354, 5356, 5358, 5360, 5362, 5364, 5366 ,5368,5370,5372,5374,5376,5378,5380,5382,5384,5386,5388,5390,53 92, 5394, 5396, 5398, 5400, 5402, 5404, 5406, 5408, 5410, 5412, 5414, 5416, 5418, 5420, 5422, 5424, 5426, 5428, 5430, 5432, 5434, 5436, 5438, 5440, 544 2. 5444, 5446, 5448, 5450, 5452, 5454, 5456, 5458, 5460, 5462, 5464, 5466, 5468, 5470, 5472, 5474, 5476, 5478, 5480, 5482, 5484, 5486, 5488, 5490, 5492 , 5494, 5496, 5498, 5500, 5502, 5504, 5506, 5508, 5510, 5512, 5514, 5516, 5518, 5520, 5522, 5524, 5526, 5528, 5530, 5532, 5534, 5536, 5538, 5540, and 5542. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 5344, 5346, 5348, 5350, 5352, 5354, 5356,5358, 5360, 5362, 5364, 5366, 5368, 5370, 5372, 5374, 5376, 5378, 5380, 5382, 5384, 5386, 5388, 5390, 5392, 5394, 5396, 5398, 5400, 5402, 5404, 5406, 5408, 5410, 5412, 5414, 5416, 5418, 5420, 5422, 5424, 5426, 5428, 5430, 5432, 5434, 5436, 5438, 5440, 5442, 5444, 5446, 5448, 5450 50, 5452, 5454, 5456, 5458, 5460, 5462, 5464, 5466, 5468, 5470, 5472, 5474, 5476, 5478, 5480, 5482, 5484, 5486, 5488, 5490, 5492, 5494, 5496, 5498, 5500, 5502, 5504, 5506, 5508, 5510, 5512, 5514, 5516, 5518, 5520, 5522, 5524, 5526, 5528, 5530, 5532, 5534, 5536, 5538, 5540, and 5542.
[0027] The present invention also provides engineered glycosyltransferases, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2, 49, 73, 87, 87 / 88, 87 / 88 / 94 / 159 / 177 / 208, 87 / 88 / 159 / 198, 87 / 88 / 177 / 198 / 249, 87 / 88 / 208, 87 / 159 / 177, 87 / 159 / 320, 87 / 177 / 249, 87 / 198, 87 / 198 / 199, 87 / 198 / 208 / 320, 87 / 208 / 320, 87 / 320, 87 / 88 / 159 / 198. , 88 / 177 / 320, 88 / 198, 88 / 199, 88 / 199 / 208, 88 / 208, 88 / 208 / 249 / 320, 88 / 320, 113, 134, 135, 158, 159 / 177 / 198, 159 / 177 / 208, 159 / 198 / 208 / 320, 171, 173, 177 / 198, 177 / 208, 195, 214, 222, 253, 256, 257, 268, 272, 289, 300, 302, 330, 348, 374, 392, 399, 408, 411, 412, 437, 439, 445, and 453, wherein the positions are with reference to SEQ ID NO:5372.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of 2G, 2H, 2P, 49A, 73P, 73T, 87M, 87M / 88R, 87M / 88R / 94K / 159Q / 177P / 208E, 87M / 88R / 159Q / 198E, 87M / 88R / 177P / 198E / 249I, 87M / 88R / 208E, 87 M / 159Q / 177P, 87M / 159Q / 320I, 87M / 177P / 249I, 87M / 198E, 87M / 198E / 199K, 87M / 198E / 208E / 320I, 87M / 208E, 87M / 208E / 320I, 87M / 320I, 88R, 88R / 177P, 88R / 177P / 208E, 88R / 177P / 320I, 88R / 198I, 8 8R / 199K, 88R / 199K / 208E, 88R / 208E, 88R / 208E / 249I / 320I, 88R / 320I, 113S, 134G, 134S, 135A, 158 D. 158E, 159Q / 177P / 198E, 159Q / 177P / 208E, 159Q / 198I / 208E / 320I, 171T, 173N, 173P, 177P / 198E, 1 77P / 208E, 195H, 214L, 222R, 253G, 256P, 257A, 257Q, 268A, 268G, 268H, 272K, 289T, 300G, 302R, 330D, 348C, 374K, 374R, 392D, 399D, 408D, 411Q, 412H, 437I, 437T, 437V, 439A, 445T and 453R, wherein the positions are numbered with reference to SEQ ID NO: 5372.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: E2G, E2H, E2P, F49A, E73P, E73T, W87M, W87M / I88R, W87M / I88R / E94K / N159Q / Q177P / K208E, W87M / I88R / N159Q / D198E, W87M / I88R / Q177P / D198E / Y249I, W87M / I88R / K208E, W87M / N159Q / D198E 59Q / Q177P, W87M / N159Q / V320I, W87M / Q177P / Y249I, W87M / D198E, W87M / D198E / A199K, W87M / D198E / K208E / V320I, W87 M / K208E, W87M / K208E / V320I, W87M / V320I, I88R, I88R / Q177P, I88R / Q177P / K208E, I88R / Q177P / V320I, I88R / D198I, I8 8R / A199K, I88R / A199K / K208E, I88R / K208E, I88R / K208E / Y249I / V320I, I88R / V320I, E113S, D134G, D134S, S135A, P15 8D, P158E, N159Q / Q177P / D198E, N159Q / Q177P / K208E, N159Q / D198I / K208E / V320I, K171T, R173N, R173P, Q177P / D198E, Q177P / K208E, N195H, S214L, K222R, S253G, L256P, L257A, L257Q, D268A, D268G, D268H, P272K, K289T, D300G, K302R, E330D, A348C, S374K, S374R, K392D, N399D, N408D, R411Q, R412H, L437I, L437T, L437V, K439A, E445T and Y453R, wherein the positions are numbered with reference to SEQ ID NO: 5372.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any of the following sequences: SEQ ID NO: 5544, 5546, 5548, 5550, 5552, 5554, 5556, 5558, 5560, 5562, 5564, 5566, 5568, 5570, 5572, 5574, 5576, 5578, 5580, 5582, 5584, 5586, 5588, 5590, 5592, 5594, 5596, 5598, 5600, 5602, 5604, 5606, 5608, 5610, 5612, 5614, 5615 6, 5618, 5620, 5622, 5624, 5626, 5628, 5630, 5632, 5634, 5636, 5638, 5640, 5642, 5644, 5646, 5648, 5650, 5652, 5654, 5656, 5658, 5660, 5662, 5664, 5666, 5668, 5670, 5672, 5674, 5676, 5678, 5680, 5682, 5684, 5686, 5688, and 5690. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: NO:5544, 5546, 5548, 5550, 5552, 5554, 5556, 5558, 5560, 5562, 5564, 5566, 5568, 5570, 5572, 5574, 5576, 5578, 5580, 5582, 5584, 5586, 5588, 5590, 5592, 5594, 5596, 5598, 5600, 5602, 5604, 5606, 5608, 5610, 5612, 5614, 561 6, 5618, 5620, 5622, 5624, 5626, 5628, 5630, 5632, 5634, 5636, 5638, 5640, 5642, 5644, 5646, 5648, 5650, 5652, 5654, 5656, 5658, 5660, 5662, 5664, 5666, 5668, 5670, 5672, 5674, 5676, 5678, 5680, 5682, 5684, 5686, 5688 and 5690.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 5544, 5546, 5548, 5550, 5552, 5554, 5556, 5558, 5560, 5562, 5564, 5566, 5568, 5570, 5572, 5574, 5576, 5578, 5580, 5582, 5584, 5586, 5588, 5590, 5592, 5594, 5596, 5598, 5600, 5602, 5604, 5606, 5608, 5610, 5612, 5614, 5615 6, 5618, 5620, 5622, 5624, 5626, 5628, 5630, 5632, 5634, 5636, 5638, 5640, 5642, 5644, 5646, 5648, 5650, 5652, 5654, 5656, 5658, 5660, 5662, 5664, 5666, 5668, 5670, 5672, 5674, 5676, 5678, 5680, 5682, 5684, 5686, 5688 and 5690.
[0028] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2 / 7 / 107 / 233 / 252 / 253 / 320, 2 / 7 / 107 / 233 / 252 / 253 / 320 / 408 / 428, 2 / 7 / 233 / 252 / 253 / 320 / 427 / 428, 2 / 233 / 252 / 317 / 320, 7 / 107 / 190 / 233 / 252 / 253 / 317 / 408 / 427, 7 / 107 / 233 / 252 / 253 / 320 / 408 / 428. / 317 / 408、7 / 190 / 233 / 252 / 253 / 320 / 427、7 / 190 / 233 / 252 / 317 / 320 / 427 / 428、7 / 190 / 233 / 252 / 408 / 427、7 / 233 / 252 / 253 / 317 / 408 / 427、7 / 233 / 252 / 253 / 408、7 / 233 / 252 / 317 / 320 / 427、7 / 233 / 252 / 317 / 428、64 / 169 / 201 / 347 / 392、64 / 172 / 264 / 268 / 347 / 392 / 417、91 / 94 / 171 / 172 / 201 / 264 / 347、91 / 2 01 / 264 / 347 / 392、94 / 201 / 264 / 347 / 435、107 / 190 / 233 / 252、107 / 190 / 233 / 252 / 317 / 320、107 / 233 / 252 / 253、107 / 252 / 317、169 / 171 / 172 / 264 / 392 / 4 35, 169 / 171 / 201 / 264 / 392 / 435, 169 / 172 / 201 / 264 / 347, 169 / 172 / 201 / 264 / 347 / 392 / 435, 169 / 172 / 201 / 347 / 392, 169 / 172 / 201 / 417 / 435, 171 / 172 / 2 01 / 264 / 392 / 417 / 435、171 / 201 / 392 / 417、190 / 233 / 252、190 / 233 / 252 / 253 / 317 / 320 / 408 / 428、190 / 233 / 252 / 317 / 408、190 / 233 / 252 / 320 / 408、201 / 264 / 347 / 392 / 417 / 435、201 / 264 / 347 / 392 / 435、201 / 264 / 347 / 417 / 435、233 / 252 / 253 / 317 / 320 / 427 / 428、233 / 252 / 253 / 408 / 427、233 / 252 / 317 / 408、233 / 252 / 317 / 427, 233 / 252 / 320, 233 / 252 / 320 / 408 / 428, 348 / 374 / 435 and 374, wherein the positions are numbered with reference to SEQ ID NO: 5562. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2L / 7P / 233K / 252E / 253G / 320I / 427R / 428R, 2N / 7P / 107A / 233K / 252E / 253G / 320I, 2N / 7P / 107A / 233K / 252E / 253G / 320I / 408R / 428R, 2N / 233K / 252E / 317R / 320I, 7P / 107A / 190R / 233K / 252E / 253G / 317R / 408R / 428R, 7P / 107A / 233K / 252E / 253G、7P / 107A / 233K / 252E / 317R / 320I、7P / 107A / 233K / 252E / 317R / 408R、7P / 190R / 233K / 252E / 253G / 320I / 427L、7P / 190R / 233K / 252E / 317R / 320I / 427R / 428R, 7P / 190R / 233K / 252E / 408R / 427R, 7P / 233K / 252E / 253G / 317R / 408R / 427L, 7P / 233K / 252E / 253G / 408R、7P / 233K / 252E / 317R / 320I / 427L、7P / 233K / 252E / 317R / 428R、64S / 169E / 201P / 347P / 392H、64S / 172H / 264A / 268V / 347P / 392H / 41 7P, 91T / 94E / 171T / 172H / 201P / 264A / 347G, 91T / 201P / 264A / 347G / 392H, 94E / 201P / 264A / 347G / 435Q, 107A / 190R / 233K / 252E, 107A / 190R / 233K / 252E / 317R / 320I, 107A / 233K / 252E / 253G, 107A / 252E / 317R, 169E / 171T / 172H / 264A / 392H / 435Q, 169E / 171T / 201P / 264A / 392H / 43 5Q、169E / 172H / 201P / 264A / 347G、169E / 172H / 201P / 264A / 347K / 392H / 435R、169E / 172H / 201P / 347G / 392H、169E / 172H / 201P / 417P / 435R、171T / 172H / 201P / 264A / 392H / 417P / 435R, 171T / 201P / 392H / 417P, 190R / 233K / 252E, 190R / 233K / 252E / 253G / 317R / 320I / 40 8R / 428R, 190R / 233K / 252E / 317R / 408R, 190R / 233K / 252E / 320I / 408R, 201P / 264A / 347K / 392H / 417P / 435R, 201P / 264A / 347K / 52E / 317R / 408R, 233K / 252E / 317R / 427R, 233K / 252E / 320I, 233K / 252E / 320I / 408R / 428R, 348S / 374R / 435R and 374R, wherein the positions are numbered with reference to SEQ ID NO: 5562. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: E2L / T7P / W233K / S252E / S253G / V320I / A427R / K428R, E2N / T7P / L107A / W233K / S252E / S253G / V320I, E2N / T 7P / L107A / W233K / S252E / S253G / V320I / N408R / K428R, E2N / W233K / S252E / S317R / V 320I, T7P / L107A / K190R / W233K / S252E / S253G / S317R / N408R / A427R, T7P / L107A / W 233K / S252E / S253G, T7P / L107A / W233K / S252E / S317R / V320I, T7P / L107A / W233K / S 252E / S317R / N408R, T7P / K190R / W233K / S252E / S253G / V320I / A427L, T7P / K190R / W 233K / S252E / S317R / V320I / A427R / K428R, T7P / K190R / W233K / S252E / N408R / A427R , T7P / W233K / S252E / S253G / S317R / N408R / A427L, T7P / W233K / S252E / S253G / N408R,T7P / W233K / S252E / S317R / V320I / A427L、T7P / W233K / S252E / S317R / K428R、F64S / G169E / E201P / D347P / K392H、F64S / T172H / F264A / D268V / D347P / K392H / R417P、I91T / K94E / K171T / T172H / E201P / F264A / D347G、I91T / E201P / F264A / D347G / K392H、K94E / E201P / F264A / D347G / V435Q、L107A / K190R / W233K / S252E、L107A / K190R / W233K / S252E / S317R / V320I、L107A / W233K / S252E / S253G、L107A / S252E / S317R、G169E / K171T / T172H / F264A / K392H / V435Q、G169E / K171T / E201P / F264A / K392H / V435Q、G169E / T172H / E201P / F264A / D347G、G169E / T172H / E201P / F264A / D347K / K392H / V435R、G169E / T172H / E201P / D347G / K392H、G169E / T172H / E201P / R417P / V435R、K171T / T172H / E201P / F264A / K392H / R417P / V435R、K171T / E201P / K392H / R417P、K190R / W233K / S252E、K190R / W233K / S252E / S253G / S317R / V320I / N408R / K428R、K190R / W233K / S252E / S317R / N408R、K190R / W233K / S252E / V320I / N408R、E201P / F264A / D347K / K392H / R417P / V435R、E201P / F264A / D347K / R417P / V435R、E201P / F264A / D347P / K392H / V435Q、W233K / S252E / S253G / S317R / V320I / A427R / K428R、W233K / S252E / S253G / N408R / A427L、W233K / S252E / S317R / N408R、W233K / S252E / S317R / A427R、W233K / S252E / V320I、W233K / S252E / V320I / N408R / K428R、A348S / S374R / V435R and S374R, wherein the positions are numbered with reference to SEQ ID NO: 5562. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14, 55, 56, 255, 282, 308, 336, 342, 364, 391, 407, and 422, wherein the positions are numbered with reference to SEQ ID NO: 5562. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14I, 55V, 56A, 255L, 282S, 308L, 308Q, 336Q, 342W, 364A, 364S, 391C, 407C, 407V, and 422Q, wherein the positions are numbered with reference to SEQ ID NO: 5562. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: V14I, S55V, L56A, S255L, T282S, R308L, R308Q, K336Q, E342W, G364A, G364S, L391C, E407C, E407V, and M422Q, wherein the positions are numbered with reference to SEQ ID NO: 5562. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: NO:5692, 5694, 5696, 5698, 5700, 5702, 5704, 5706, 5708, 5710, 5712, 5714, 5716, 5718, 5720, 5722, 5724, 5726, 5728, 5730, 5732, 5734, 5736, 5738, 5740, 5742, 5744, 5746, 5748, 5750, 575 2, 5754, 5756, 5758, 5760, 5762, 5764, 5766, 5768, 5770, 5772, 5774, 5776, 5778, 5780, 5782, 5784, 5786, 5788, 5790, 5792, 5794, 5796, 5798, 5800, 5802, 5804, 5806, 5808, 5810, 5812 and 5814. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any of the following sequences: SEQ ID NO: 5692, 5694, 5696, 5698, 5700, 5702, 5704, 5706, 5708, 5710, 5712, 5714, 5716, 5718, 5720, 5722, 5724, 5726, 5728, 5730,732, 734, 736, 738, 740, 742, 744, 746, 748, 750, 752, 754, 756, 758, 760, 762, 764, 766, 768, 770, 772, 774, 776, 778, 780, 782, 784, 786, 788, 790, 792, 794, 796, 798, 798, 800, 802, 804, 806, 808, 810, 812, and 814. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: NO:5692, 5694, 5696, 5698, 5700, 5702, 5704, 5706, 5708, 5710, 5712, 5714, 5716, 5718, 5720, 5722, 5724, 5726, 5728, 5730, 5732, 5734, 5736, 5738, 5740, 5742, 5744, 5746, 5748, 5750, 575 2. 5754, 5756, 5758, 5760, 5762, 5764, 5766, 5768, 5770, 5772, 5774, 5776, 5778, 5780, 5782, 5784, 5786, 5788, 5790, 5792, 5794, 5796, 5798, 5800, 5802, 5804, 5806, 5808, 5810, 5812 and 5814.
[0029] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2 / 4 / 113 / 158 / 163 / 302 / 364 / 399 / 449, 2 / 4 / 113 / 158 / 163 / 330 / 449, 2 / 4 / 113 / 163 / 449, 2 / 4 / 158 / 163 / 364 / 449, 2 / 4 / 158 / 222 / 257 / 302 / 330, 2 / 4 / 158 / 330, 2 / 4 / 163 / 222 / 330 / 364 / 449, 2 / 4 / 163 / 257 / 330 / 449. / 449, 2 / 4 / 163 / 330 / 449, 2 / 4 / 163 / 364, 2 / 4 / 163 / 364 / 453, 2 / 4 / 302, 2 / 113, 2 / 113 / 163, 2 / 113 / 163 / 449, 2 / 113 / 330 / 399, 2 / 113 / 449, 2 / 158 / 163, 2 / 158 / 163 / 364 / 399, 2 / 163 / 364 / 453, 2 / 364 / 449, 4 / 113 / 158 / 163 / 330 / 364 / 399, 4 / 113 / 158 / 302 / 330 / 364, 4 / 113 / 163 / 364 / 399, 4 / 158 / 163 / 364 / 39 9, 4 / 364 / 449, 87, 87 / 95 / 198, 87 / 198, 87 / 266, 87 / 322, 107 / 134 / 135 / 195 / 412 / 417, 107 / 195 / 268 / 322 / 439, 107 / 195 / 272, 107 / 195 / 417 / 439, 107 / 374 / 417 / 439, 113 / 158 / 163 / 364 / 399, 134, 134 / 135 / 195 / 268 / 317, 158 / 163 / 257 / 330 / 364 / 449, 158 / 163 / 302 / 330 / 364 / 399, 158 / 163 / 364, 163 / 257 / 302 / 364、163 / 302 / 330 / 364 / 449、163 / 364、173、173 / 190 / 233 / 252 / 427 / 437、173 / 190 / 252 / 257 / 347 / 427 / 437、173 / 190 / 257 / 374 / 437、173 / 190 / 257 / 427 / 437、173 / 233 / 252 / 257 / 427、173 / 233 / 437、173 / 252、173 / 252 / 268 / 437、173 / 252 / 347 / 411、173 / 257 / 374 / 437、173 / 374 / 437、173 / 427 / 437、190 / 233 / 252 / 257 / 347 / 411 / 437, 190 / 252, 190 / 252 / 257 / 285 / 427, 190 / 252 / 257 / 411 / 437, 190 / 252 / 257 / 427, 190 / 374 / 427 / 437, 195 / 272 / 320 / 439, 195 / 317 / 320, 198, 198 / 244, 198 / 292, 233 / 252, 233 / 252 / 257, 233 / 252 / 257 / 347, 233 / 252 / 257 / 347 / 411 / 437, 233 / 252 / 257 / 427 / 43 7, 233 / 252 / 285, 233 / 252 / 285 / 437, 233 / 252 / 411 / 437, 233 / 252 / 437, 233 / 374, 233 / 374 / 437, 252 / 257, 252 / 257 / 347 / 437, 257 / 347 / 411 / 437, 268 / 417, 285 / 347 / 437, 302 / 364, 330 / 364, 347 / 411 / 437, 347 / 427 / 437, 364 / 399, 374, 374 / 411 / 437, 408 / 417, 411 / 437, and 437, wherein the positions are numbered with reference to SEQ ID NO: 5708. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2P / 4T / 113S / 158D / 163A / 330D / 449R, 2P / 4T / 113S / 158D / 163R / 302R / 364S / 399D / 449R, 2P / 4T / 113S / 163R / 449R, 2P / 4T / 158D / 163A / 364S / 449R, 2P / 4T / 158D / 222R / 257Q / 302R / 330D, 2P / 4T / 158D / 330D, 2P / 4T / 163A / 257Q, 2P / 4T / 163A / 330D / 449R, 2P / 4T / 163A / 364S, 2P / 4T / 163A / 364S / 453R, 2P / 4T / 163R / 222R / 302R / 330D / 364S / 449R, 2P / 4T / 163R / 257Q / 330D / 399D / 449R, 2P / 4T / 302R, 2P / 113S, 2P / 113S / 163A, 2P / 113S / 163R / 449R, 2P / 113S / 330D / 399D, 2P / 113S / 449R, 2P / 1 58D / 163A / 364S / 399D, 2P / 158D / 163R, 2P / 163R / 364S / 453R, 2P / 364S / 449R,4T / 113S / 158D / 163A / 330D / 364S / 399D, 4T / 113S / 158D / 302R / 330D / 364S, 4T / 113S / 163A / 364S / 399D, 4T / 158D / 163A / 364S / 399D, 4T / 364S / 449R, 87W, 87W / 95L / 198E、87W / 198E、87W / 198I、87W / 266L、87W / 322S、107A / 134S / 135 A / 195H / 412H / 417P、107A / 195H / 268A / 322L / 439P、107A / 195H / 272K、107A / 1 95H / 417P / 439P、107A / 374T / 417P / 439P、113S / 158D / 163A / 364S / 399D、113 S / 158D / 163R / 364S / 399D、134S、134S / 135A / 195H / 268A / 317R、158D / 163A / 2 57Q / 330D / 364S / 449R、158D / 163A / 364S、158D / 163R / 302R / 330D / 364S / 399 D、163A / 257Q / 302R / 364S、163A / 364S、163R / 302R / 330D / 364S / 449R、173N、1 73N / 190R / 233K / 252E / 427R / 437V、173N / 190R / 252E / 257A / 347G / 427R / 437 I、173N / 190R / 257A / 374K / 437V、173N / 190R / 257A / 427R / 437I、173N / 233K / 252E / 257A / 427R、173N / 233K / 437I、173N / 252E、173N / 252E / 268H / 437V、17 3N / 252E / 347G / 411Q、173N / 257A / 374K / 437V、173N / 374K / 437I、173N / 427R / 437I、190R / 233K / 252E / 257A / 347G / 411Q / 437I、190R / 252E、190R / 252E / 25 7A / 285Q / 427R、190R / 252E / 257A / 411Q / 437I、190R / 252E / 257A / 427R、190R / 374K / 427R / 437V、195H / 272K / 320I / 439P、195H / 317R / 320I、198E、198E / 29 2P、198I、198I / 244L、233K / 252E、233K / 252E / 257A、233K / 252E / 257A / 347G、233K / 252E / 257A / 347G / 411Q / 437I, 233K / 252E / 257A / 427R / 437V, 233K / 252E / 285Q, 233K / 252E / 285Q / 437V , 233K / 252E / 411Q / 437V, 233K / 252E / 437V, 233K / 374K, 233K / 374K / 437I, 252E / 257A, 252E / 257A / 347G / 437 7I, 374K / 411Q / 437V, 408D / 417P, 411Q / 437V, and 437I, wherein the positions are numbered with reference to SEQ ID NO: 5708. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: E2P / K4T / E113S / P158D / L163A / E330D / S449R, E2P / K4T / E113S / P158D / L163R / K302R / G364S / N399D / S449R, E2P / K4T / E113S / L 163R / S449R, E2P / K4T / P158D / L163A / G364S / S449R, E2P / K4T / P158D / K222R / L257Q / K302R / E 330D, E2P / K4T / P158D / E330D, E2P / K4T / L163A / L257Q, E2P / K4T / L163A / E330D / S449R, E2P / K 4T / L163A / G364S, E2P / K4T / L163A / G364S / Y453R, E2P / K4T / L163R / K222R / K302R / E330D / G36 4S / S449R, E2P / K4T / L163R / L257Q / E330D / N399D / S449R, E2P / K4T / K302R, E2P / E113S, E2P / E 113S / L163A, E2P / E113S / L163R / S449R, E2P / E113S / E330D / N399D, E2P / E113S / S449R, E2P / P 158D / L163A / G364S / N399D, E2P / P158D / L163R, E2P / L163R / G364S / Y453R, E2P / G364S / S449R,K4T / E113S / P158D / L163A / E330D / G364S / N399D、K4T / E113S / P158D / K302R / E330D / G364S、K4T / E113S / L163A / G364S / N399D、K4T / P158D / L163A / G364S / N399D、K4T / G364S / S449R、M87W、M87W / H95L / D198E、M87W / D198E、M87W / D1 98I、M87W / W266L、M87W / P322S、L107A / D134S / S135A / N195H / R412H / R417P、 L107A / N195H / D268A / P322L / K439P、L107A / N195H / P272K、L107A / N195H / R417P / K439P、L107A / S374T / R417P / K439P、E113S / P158D / L163A / G364S / N399 D、E113S / P158D / L163R / G364S / N399D、D134S、D134S / S135A / N195H / D268A / S317R、P158D / L163A / L257Q / E330D / G364S / S449R、P158D / L163A / G364S、P1 58D / L163R / K302R / E330D / G364S / N399D、L163A / L257Q / K302R / G364S、L163A / G364S、L163R / K302R / E330D / G364S / S449R、R173N、R173N / K190R / W233K / S252E / A427R / L437V, R173N / K190R, S252E / L257A / K347G, A427R / L437I, R173N / K190R / L257A / S374K / L437V, R173N / K190R / L257A / A427R / L437I, R173 N / W233K / S252E / L257A / A427R、R173N / W233K / L437I、R173N / S252E、R173N / S252E / D268H / L437V、R173N / S252E / K347G / R411Q、R173N / L257A / S374K / L4 37V、R173N / S374K / L437I、R173N / A427R / L437I、K190R / W233K / S252E / L257A / K347G / R411Q / L437I、K190R / S252E、K190R / S252E / L257A / E285Q / A427R、K190R / S252E / L257A / R411Q / L437I, K190R / S252E / L257A / A427R, K190R / S374K / A427R / L437V, N 195H / P272K / V320I / K439P, N195H / S317R / V320I, D198E, D198E / L292P, D198I, D198I / P244L, W2 33K / S252E, W233K / S252E / L257A, W233K / S252E / L257A / K347G, W233K / S252E / L257A / K347G / R41 1Q / L437I, W233K / S252E / L257A / A427R / L437V, W233K / S252E / E285Q, W233K / S252E / E285Q / L437V , W233K / S252E / R411Q / L437V, W233K / S252E / L437V, W233K / S374K, W233K / S374K / L437I, S252E / L257A, S252E / L257A / K347G / L437V, L257A / K347G / R411Q / L437V, D268A / R417P, E285Q / K347G / L4 7V, K302R / G364S, E330D / G364S, K347G / R411Q / L437I, K347G / A427R / L437V, G364S / N399D, S374K, S374K / R411Q / L437I, S374K / R411Q / L437V, N408D / R417P, R411Q / L437V, and L437I, wherein the positions are numbered with reference to SEQ ID NO: 5708. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: NO:5816, 5818, 5820, 5822, 5824, 5826, 5828, 5830, 5832, 5834, 5836, 5838, 5840, 5842, 5 844, 5846, 5848, 5850, 5852, 5854, 5856, 5858, 5860, 5862, 5864, 5866, 5868, 5870, 5872, 5 874, 5876, 5878, 5880, 5882, 5884, 5886, 5888, 5890, 5892, 5894, 5896, 5898, 5900, 5902, 5904, 5906, 5908, 5910, 5912, 5914, 5916, 5918, 5920, 5922, 5924, 5926, 5928, 5930, 5932,6004, 6006, 6008, 6010, 6012, and 6014. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 5934, 5936, 5938, 5940, 5942, 5944, 5946, 5948, 5950, 5952, 5954, 5956, 5958, 5960, 5962, 5964, 5966, 5968, 5970, 5972, 5974, 5976, 5978, 5980, 5982, 5984, 5986, 5988, 5990, 5992, 5994, 5996, 5998, NO:5816, 5818, 5820, 5822, 5824, 5826, 5828, 5830, 5832, 5834, 5836, 5838 ,5840,5842,5844,5846,5848,5850,5852,5854,5856,5858,5860,5862,58 64, 5866, 5868, 5870, 5872, 5874, 5876, 5878, 5880, 5882, 5884, 5886, 5888, 5890, 5892, 5894, 5896, 5898, 5900, 5902, 5904, 5906, 5908, 5910, 5912, 591 4. 5916, 5918, 5920, 5922, 5924, 5926, 5928, 5930, 5932, 5934, 5936, 5938, 5940, 5942, 5944, 5946, 5948, 5950, 5952, 5954, 5956, 5958, 5960, 5962, 5964 , 5966, 5968, 5970, 5972, 5974, 5976, 5978, 5980, 5982, 5984, 5986, 5988, 5990, 5992, 5994, 5996, 5998, 6000, 6002, 6004, 6006, 6008, 6010, 6012 and 6014. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 5816, 5818, 5820, 5822, 5824, 5826, 5828, 5830, 5832, 5834, 5836, 5838, 5840, 5842, 5844, 5846, 5848, 5850, 5852, 5854, 5856, 5858, 5860, 5862, 5864, 5866, 5868, 5870, 5872, 5874, 5876, 5878, 5880, 5882, 5884, 5886, 5888, 5890, 5892,5894, 5896, 5898, 5900, 5902, 5904, 5906, 5908, 5910, 5912, 5914, 5916, 5918, 5920, 5922, 5924, 5926, 5928, 5930, 5932, 5934, 5936, 5938, 5940, 5942, 5944, 5946, 5948, 5950, 5952, 5953 54, 5956, 5958, 5960, 5962, 5964, 5966, 5968, 5970, 5972, 5974, 5976, 5978, 5980, 5982, 5984, 5986, 5988, 5990, 5992, 5994, 5996, 5998, 6000, 6002, 6004, 6006, 6008, 6010, 6012, and 6014.
[0030] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2 / 4 / 14 / 158 / 282 / 364 / 449, 2 / 4 / 14 / 158 / 282 / 407, 2 / 4 / 14 / 163 / 198, 2 / 4 / 14 / 163 / 282 / 399, 2 / 4 / 14 / 198 / 308 / 407, 2 / 4 / 14 / 282 / 308 / 364, 2 / 4 / 14 / 282 / 364 / 449, 2 / 4 / 14 / 158 / 282 / 364 / 449, 2 / 4 / 14 / 158 / 282 / 407, 2 / 4 / 14 / 163 / 198, 2 / 4 / 14 / 163 / 282 / 399, 2 / 4 / 14 / 198 / 308 / 407. 407, 2 / 4 / 163 / 198 / 282 / 308 / 342, 2 / 4 / 163 / 282 / 342 / 364, 2 / 4 / 163 / 364 / 399 / 449, 2 / 4 / 198 / 282 / 449, 2 / 4 / 198 / 364 / 391 / 449, 2 / 4 / 282 / 342 / 364 / 407, 2 / 14 / 158 / 198 / 407 / 449, 2 / 14 / 163 / 308 / 364, 2 / 14 / 163 / 364 / 407, 2 / 14 / 282, 2 / 14 / 282 / 308, 2 / 14 / 282 / 308 / 364, 2 / 14 / 282 / 399, 2 / 14 / 308, 2 / 14 / 308 / 3 64, 2 / 158 / 163 / 407 / 449, 2 / 163 / 282, 2 / 163 / 282 / 308 / 364, 2 / 198 / 282 / 308 / 342, 2 / 198 / 282 / 399, 2 / 282, 2 / 282 / 308 / 342 / 407, 2 / 282 / 308 / 391 / 407, 2 / 282 / 399, 2 / 282 / 399 / 407, 2 / 308, 2 / 308 / 364 / 399, 4 / 14 / 158 / 163 / 198 / 282 / 407, 4 / 14 / 158 / 282 / 364 / 391 / 407, 4 / 14 / 163 / 282, 4 / 14 / 163 / 282 / 308 / 342 / 407 / 449, 4 / 14 / 198 / 308 / 364, 4 / 14 / 282, 4 / 14 / 282 / 308 / 364 / 407 / 449, 4 / 14 / 282 / 342 / 399 / 407, 4 / 14 / 364 / 391, 4 / 158 / 282 / 364 / 399, 4 / 163 / 282 / 308 / 407、4 / 198 / 399 / 407、4 / 282 / 342 / 364 / 407、4 / 282 / 364 / 407、4 / 364、12、14 / 158 / 163 / 198 / 364、14 / 158 / 163 / 282 / 364、14 / 158 / 198 / 282 / 342 / 364 / 449、14 / 158 / 364、14 / 163 / 198 / 282 / 342 / 364 / 449、14 / 163 / 282 / 308、14 / 282、14 / 282 / 308、14 / 282 / 342 / 364 / 391、14 / 282 / 364、14 / 282 / 364 / 391 / 407 / 449、14 / 282 / 399 / 407 / 449、14 / 407、37、44、70、71 / 331、74、75、90、106、108、112、114、115、131、138、139、156、158 / 282 / 407、158 / 282 / 407 / 449、15 402, 416, 427, 429, 432, 433, and 456, wherein the positions are numbered with reference to SEQ ID NO: 5976. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2P / 4T / 14I / 158D / 282S / 364A / 449R, 2P / 4T / 14I / 158D / 282S / 407V, 2P / 4T / 14I / 163A / 198E, 2P / 4T / 14I / 163A / 282S / 399D, 2P / 4T / 14I / 198E / 308L / 407V, 2P / 4T / 14I / 282S / 308L / 364A, 2P / 4T / 14I / 282S / 308L / 407V, 2P / 4T / 14I / 282S / 364A, 2P / 4T / 158D / 163A / 364A / 399D / 407V, 2P / 4T / 158D / 198E / 282S / 364A / 407V , 2P / 4T / 163A / 198E / 282S / 308L / 342W, 2P / 4T / 163A / 282S / 342W / 364A, 2P / 4T / 163A / 364A / 399D / 449R, 2P / 4T / 198E / 282S / 449R, 2P / 4T / 198E / 364A / 3 91C / 449R, 2P / 4T / 282S / 342W / 364A / 407V, 2P / 14I / 158D / 198E / 407V / 449R,2P / 14I / 163A / 308L / 364A、2P / 14I / 163A / 364A / 407V、2P / 14I / 282S、2P / 14I / 282S / 308L、2P / 14I / 282S / 308L / 364A、2P / 14I / 282S / 399D、2P / 14I / 308L、 2P / 14I / 308L / 364A、2P / 158D / 163A / 407V / 449R、2P / 163A / 282S、2P / 163A / 2 82S / 308L / 364A、2P / 198E / 282S / 308L / 342W、2P / 198E / 282S / 399D、2P / 282S、 2P / 282S / 308L / 342W / 407V、2P / 282S / 308L / 391C / 407V、2P / 282S / 399D、2P / 282S / 399D / 407V、2P / 308L、2P / 308L / 364A / 399D、4T / 14I / 158D / 163A / 198E / 282S / 407V、4T / 14I / 158D / 282S / 364A / 391C / 407V、4T / 14I / 163A / 282S、4T / 14I / 163A / 282S / 308L / 342W / 407V / 449R、4T / 14I / 198E / 308L / 364A、4T / 14I / 282S, 4T / 14I / 282S / 308L / 364A / 407V / 449R, 4T / 14I / 282S / 342W / 399D / 407V, 4T / 14I / 364A / 391C, 4T / 158D / 282S / 364A / 399D, 4T / 163A / 282S / 308L / 40 7V、4T / 198E / 399D / 407V、4T / 282S / 342W / 364A / 407V、4T / 282S / 364A / 407V、4T / 364A、12S、14I / 158D / 163A / 198E / 364A、14I / 158D / 163A / 282S-364A、14I / 158D / 198E / 282S / 342W / 364A / 449R、14I / 158D / 364A、14I / 163A / 198E / 282 S / 342W / 364A / 449R、14I / 163A / 282S / 308L、14I / 282S、14I / 282S / 308L、14I / 282S / 342W / 364A / 391C、14I / 282S / 364A、14I / 282S / 364A / 391C / 407V / 449R 、14I / 282S / 399D / 407V / 449R、14I / 407V、37R、44V、70K、71L / 331K、74H、75G、75M, 90Q, 90S, 90T, 106Y, 108H, 112N, 114P, 115R, 131V, 138V, 139A, 139R, 139S, 156C, 158D / 282S / 407V, 158D / 282S / 407V / 449R, 158D / 364A / 399D / 407V / 449R, 158D / 364A / 449R, 162A, 163A / 198E / 282S / 342W, 163A / 282S / 308L / 364A / 399D, 163A / 282S / 399D / 407V, 163A / 402L, 416L, 416S, 427K, 427R, 429W, 432L, 433L, and 456R, wherein the positions are numbered with reference to SEQ ID NO: 5976. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: E2P / K4T / V14I / P158D / T282S / G364A / S449R, E2P / K4T / V14I / P158D / T282S / E407V, E2P / K4T / V14I / L163A / D198E, E2P / K4T / V14I / L163A / T282S / N399D, E2P / K4T / V14I / D198E / R308L / E407V. 7V, E2P / K4T / V14I / T282S / G364A, E2P / K4T / P158D / L163A / G364A / N399D / E407V, E2P / K4T / P158D / D198E / T282S / G364A / E407V, E2P / K4T / L163A / D198E / T282S / R3 08L / E342W, E2P / K4T / L163A / T282S / E342W / G364A, E2P / K4T / L163A / G364A / N399 D / S449R, E2P / K4T / D198E / T282S / S449R, E2P / K4T / D198E / G364A / L391C / S449R,E2P / K4T / T282S / E342W / G364A / E407V、E2P / V14I / P158D / D198E / E407V / S449R、E2P / V14I / L163A / R308L / G364A、E2P / V14I / L163A / G364A / E407V、E2P / V14I / T282S、E2P / V14I / T282S / R308L、E2P / V14I / T282S / R308L / G364A、E2P / V14I / T282S / N399D、E2P / V14I / R308L、E2P / V14I / R308L / G364A、E2P / P158D / L163A / E407V / S449R、E2P / L163A / T282S、E2P / L163A / T282S / R308L / G364A、E2P / D198E / T282S / R308L / E342W、E2P / D198E / T282S / N399D、E2P / T282S、E2P / T282S / R308L / E342W / E407V、E2P / T282S / R308L / L391C / E407V、E2P / T282S / N399D、E2P / T282S / N399D / E407V、E2P / R308L、E2P / R308L / G364A / N399D、K4T / V14I / P158D / L163A / D198E / T282S / E407V、K4T / V14I / P158D / T282S / G364A / L391C / E407V、K4T / V14I / L163A / T282S、K4T / V14I / L163A / T282S / R308L / E342W / E407V / S449R、K4T / V14I / D198E / R308L / G364A、K4T / V14I / T282S、K4T / V14I / T282S / R308L / G364A / E407V / S449R、K4T / V14I / T282S / E342W / N399D / E407V、K4T / V14I / G364A / L391C、K4T / P158D / T282S / G364A / N399D、K4T / L163A / T282S / R308L / E407V、K4T / D198E / N399D / E407V、K4T / T282S / E342W / G364A / E407V、K4T / T282S / G364A / E407V、K4T / G364A、R12S、V14I / P158D / L163A / D198E / G364A、V14I / P158D / L163A / T282S / G364A、V14I / P158D / D198E / T282S / E342W / G364A / S449R, V14I / P158D / G364A, V14I / L163A / D198E / T282S / E342W / G364A / S449R, V14I / L163A / T282S / R308L, V14I / T282S, V14I / T282S / R308L, V14I / T282S / E342W / G364A / L391C, V14I / T282S / G364A, V14I / T282S / G3 64A / L391C / E407V / S449R, V14I / T282S / N399D / E407V / S449R, V14I / E407V, S37R, I44V, P70K, Q71L / R331K, W74H, L75G, L75M, P 90Q, P90S, P90T, S106Y, M108H, P112N, D114P, E115R, P131V, L138V, P139A, P139R, P139S, S156C, P158D / T282S / E407V, P158D / T 282S / E407V / S449R, P158D / G364A / N399D / E407V / S449R, P158D / G364A / S449R, E162A, L163A / D198E / T282S / E342W, L163A / T28 2S / R308L / G364A / N399D, L163A / T282S / N399D / E407V, L163A / T282S / E407V / S449R, L174P, D198E / T282S / R308L / E342W, D198E / : T282S / E407V, D198E / R308L, K247C, K247L, H248C, H248L, H248W, S254Q, D258N, T282S / R308L / E342W / G364A / S449R, T282S / R308L / S449R, V365I, D389A, D389E, D389S, L401F / E402L, D416L, D416S, A427K, A427R, L429W, K432L, A433L and S456R, wherein the positions are numbered with reference to SEQ ID NO: 5976. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any of the following sequences: SEQ ID NO: 6016, 6018, 6020, 6022, 6024, 6026, 6028, 6030, 6032, 6034, 6036, 6038, 6040, 6042, 6044, 6046, 6048, 6050,6052, 6054, 6056, 6058, 6060, 6062, 6064, 6066, 6068, 6070, 6072, 6074, 6076, 6078, 6080, 6082, 6084, 6086, 6088, 6090, 6092, 6094, 6096, 6098, 6100, 6102, 6103 104, 6106, 6108, 6110, 6112, 6114, 6116, 6118, 6120, 6122, 6124, 6126, 6128, 6130, 6132, 6134, 6136, 6138, 6140, 6142, 6144, 6146, 6148, 6150, 6152, 6154, 61 56, 6158, 6160, 6162, 6164, 6166, 6168, 6170, 6172, 6174, 6176, 6178, 6180, 6182, 6184, 6186, 6188, 6190, 6192, 6194, 6196, 6198, 6200, 6202, 6204, 6206, 620 8, 6210, 6212, 6214, 6216, 6218, 6220, 6222, 6224, 6226, 6228, 6230, 6232, 6234, 6236, 6238, 6240, 6242, 6244, 6246, 6248, 6250, 6252, 6254, 6256, 6258, and 6260. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: NO:6016, 6018, 6020, 6022, 6024, 6026, 6028, 6030, 6032, 6034, 6036, 6038, 6040, 6042, 6044, 6046, 6048, 6050, 6052, 6054, 6056, 6058, 6060, 6062, 6064, 6066, 6068, 6070, 6072, 6074, 6076, 6078, 6080, 6082, 6084, 6086, 6088, 6090, 6092, 6094, 6096, 6098, 610 0, 6102, 6104, 6106, 6108, 6110, 6112, 6114, 6116, 6118, 6120, 6122, 6124, 6126, 6128, 6130, 6132, 6134, 6136, 6138, 6140, 6142, 6144, 6146, 6148, 6150, 6152, 6154, 6156, 6158, 6160, 6162, 6164, 6166, 6168, 6170, 6172, 6174, 6176, 6178, 6180, 6182, 6184, 6186,6188, 6190, 6192, 6194, 6196, 6198, 6200, 6202, 6204, 6206, 6208, 6210, 6212, 6214, 6216, 6218, 6220, 6222, 6224, 6226, 6228, 6230, 6232, 6234, 6236, 6238, 6240, 6242, 6244, 6246, 6248, 6250, 6252, 6254, 6256, 6258, and 6260.
[0031] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14 / 113 / 158, 14 / 113 / 158 / 163, 14 / 113 / 158 / 163 / 190 / 257 / 308 / 342, 14 / 113 / 158 / 163 / 437, 14 / 113 / 158 / 308 / 317 / 330 / 449, 14 / 113 / 163 / 190 / 308 / 317, 14 / 113 / 163 / 257 / 308 / 342 / 437 / 449, 14 / 113 / 163 / 257 / 308 / 342 317 / 320 / 322 / 330 / 449, 14 / 113 / 320 / 437 / 449, 14 / 158, 14 / 158 / 163 / 190 / 257 / 308 / 317 / 330 / 437, 14 / 158 / 163 / 190 / 342 / 437, 14 / 158 / 163 / 257, 14 / 158 / 163 / 257 / 308 / 449、14 / 158 / 257 / 308 / 437 / 449、14 / 158 / 317 / 320 / 330 / 437、14 / 163 / 317 / 320、14 / 190、14 / 190 / 257 / 317 / 320 / 322、14 / 257 / 308 / 320 / 32 2 / 330, 14 / 257 / 308 / 322 / 330 / 437, 14 / 317, 14 / 330, 14 / 449, 19, 29 / 375, 41, 45, 46, 71, 72, 80, 81, 83, 84, 85, 88, 95, 105, 113 / 158 / 163 / 190 / 257 / 437, 1 13 / 158 / 163 / 190 / 308 / 317 / 322、113 / 158 / 163 / 190 / 308 / 320、113 / 158 / 163 / 257 / 308 / 317 / 322 / 437 / 449、113 / 158 / 190 / 257 / 320、113 / 158 / 190 / 320 / 32 2 / 449, 113 / 158 / 320 / 322 / 437, 113 / 257 / 308, 113 / 257 / 317 / 322 / 437, 155, 158 / 163, 158 / 163 / 190 / 257 / 308 / 342 / 449, 158 / 163 / 308, 158 / 163 / 322 / 437 、158 / 308 / 320 / 437、158 / 320 / 437 / 449、163 / 308 / 330 / 437 / 449、168、190 / 449、197、199、202、209、243、249、263、273、317 / 320 / 322 / 330、322 / 330、366、375 and 383, wherein the positions are numbered with reference to SEQ ID NO: 6138. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14I / 113S / 158P, 14I / 113S / 158P / 163A, 14I / 113S / 158P / 163A / 190R / 257Q / 308L / 342W, 14I / 113S / 158P / 163A / 437I, 14I / 113S / 158P / 308L / 317R / 330D / 449R, 14I / 113S / 158P / 163A / 190R / 257Q / 308L / 342W / 437I / 449R、14I / 113S / 163A / 257Q / 437I、14I / 113S / 163A / 308L / 317R / 320I / 322L / 330D / 449R, 14I / 113S / 320I / 437I / 449R, 14I / 158P, 14I / 15 8P / 163A / 190R / 257Q / 308L / 317R / 330D / 437I, 14I / 158P / 163A / 190R / 34 2W / 437I, 14I / 158P / 163A / 257Q, 14I / 158P / 163A / 257Q / 308L / 449R, 14I / 158P / 257Q / 308L / 437I / 449R、14I / 158P / 317R / 320I / 330D / 437I、14I / 163A / 317R / 320I, 14I / 190R, 14I / 190R / 257Q / 317R / 320I / 322L, 14I / 25 7Q / 308L / 320I / 322L / 330D, 14I / 257Q / 308L / 322L / 330D / 437I, 14I / 317 R, 14I / 330D, 14I / 449R, 19Q, 29M / 375P, 41A, 45L, 46S, 71V, 72S, 72T, 80 P, 81T, 83A, 83K, 83N, 83S, 83T, 84D, 84H, 84N, 85L, 88A, 88C, 88H, 88K, 8 8T, 95N, 105A, 113S / 158P / 163A / 190R / 257Q / 437I, 113S / 158P / 163A / 19 0R / 308L / 317R / 322L, 113S / 158P / 163A / 190R / 308L / 320I, 113S / 158P / 1 63A / 257Q / 308L / 317R / 322L / 437I / 449R, 113S / 158P / 190R / 257Q / 320I,113S / 158P / 190R / 320I / 322L / 449R, 113S / 158P / 320I / 322L / 437I, 113S / 257Q / 308L, 113S / 257Q / 317R / 322L / 437I, 155L, 158P / 163A, 158P / 163A / 190R / 257Q / 308L / 342W / 449R, 158P / 163A / 308L, 158P / 163A / 322L / 437I, 158P / 308L / 320I / 437I, 158P / 320I / 437I / 449R, 375A, 375P, 375T, 375V, and 383V, wherein the positions are numbered with reference to SEQ ID NO: 6138. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: V14I / E113S / D158P, V14I / E113S / D158P / L163A, V14I / E113S / D158P / L163A / K190R / L257Q / R308L / E342W, V14I / E113S / D158P / L163A / L437I, V14I / E113S / D158P / R308L / S317R / E330D / S449R, V14I / E113S / D158P / L163A / K190R / L257Q / R308L / E342W. 57Q / R308L / E342W / L437I / S449R, V14I / E113S / L163A / L257Q / L437I, V14I / E11 3S / L163A / R308L / S317R / V320I / P322L / E330D / S449R, V14I / E113S / V320I / L43 7I / S449R, V14I / D158P, V14I / D158P / L163A / K190R / L257Q / R308L / S317R / E330 D / L437I, V14I / D158P / L163A / K190R / E342W / L437I, V14I / D158P / L163A / L257Q,V14I / D158P / L163A / L257Q / R308L / S449R、V14I / D158P / L257Q / R308L / L437I / S449R、V14I / D158P / S317R / V320I / E330D / L437I、V14I / L163A / S317R / V320I、V14I / K190R、V14I / K190R / L257Q / S317R / V320I / P322L、V14I / L257Q / R308L / V320I / P322L / E330D、V14I / L257Q / R308L / P322L / E330D / L437I、V14I / S317R、V14I / E330D、V14I / S449R、V19Q、L29M / D375P、S41A、F45L、H46S、Q71V、D72S、D72T、T80P、H81T、P83A、P83K、P83N、P83S、P83T、G84D、G84H、G84N、A85L、R88A、R88C、R88H、R88K、R88T、H95N、E105A、E113S / D158P / L163A / K190R / L257Q / L437I、E113S / D158P / L163A / K190R / R308L / S317R / P322L、E113S / D158P / L163A / K190R / R308L / V320I、E113S / D158P / L163A / L257Q / R308L / S317R / P322L / L437I / S449R、E113S / D158P / K190R / L257Q / V320I、E113S / D158P / K190R / V320I / P322L / S449R、E113S / D158P / V320I / P322L / L437I、E113S / L257Q / R308L、E113S / L257Q / S317R / P322L / L437I、V155L、D158P / L163A、D158P / L163A / K190R / L257Q / R308L / E342W / S449R、D158P / L163A / R308L、D158P / L163A / P322L / L437I、D158P / R308L / V320I / L437I、D158P / V320I / L437I / S449R、L163A / R308L / E330D / L437I / S449R、P168C、P168T、K190R / S449R、Q197K、A199E、A199H、A199M、A199Q、A199Y、I202H、I202Q、I202T、I202V、E209T、L243I, Y249S, V263T, S273A, S273H, S273R, S317R / V320I / P322L / E330D, P322L / E330D, A366C, A366L, A366S, A366T, A366V, D375A, D375P, D375T, D375V, and N383V, wherein the positions are numbered with reference to SEQ ID NO: 6138.
[0032] In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any of the following sequences: SEQ ID NO: 6262, 6264, 6266, 6268, 6270, 6272, 6274, 6276, 6278, 6280, 6282, 6284, 6286, 6288, 6290, 6292, 6294, 6296, 6298, 6300, 6302, 6304, 6306, 6308, 6310 10, 6312, 6314, 6316, 6318, 6320, 6322, 6324, 6326, 6328, 6330, 6332, 6334, 6336, 6338, 6340, 6342, 6344, 6346, 6348, 6350, 6352, 6354, 6356, 6358, 636 0, 6362, 6364, 6366, 6368, 6370, 6372, 6374, 6376, 6378, 6380, 6382, 6384, 6386, 6388, 6390, 6392, 6394, 6396, 6398, 6400, 6402, 6404, 6406, 6408, 6410 , 6412, 6414, 6416, 6418, 6420, 6422, 6424, 6426, 6428, 6430, 6432, 6434, 6436, 6438, 6440, 6442, 6444, 6446, 6448, 6450, 6452, 6454, 6456, 6458 and 6460.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any of the following sequences: SEQ ID NO: 6262, 6264, 6266, 6268, 6270, 6272, 6274, 6276, 6278, 6280, 6282, 6284, 6286, 6288, 6290, 6292, 6294, 6296, 6298, 6300, 6302, 6304, 6306, 6308, 6310 10, 6312, 6314, 6316, 6318, 6320, 6322, 6324, 6326, 6328, 6330, 6332, 6334, 6336, 6338, 6340, 6342, 6344, 6346, 6348, 6350, 6352, 6354, 6356, 6358, 636 0, 6362, 6364, 6366, 6368, 6370, 6372, 6374, 6376, 6378, 6380, 6382, 6384, 6386, 6388, 6390, 6392, 6394, 6396, 6398, 6400, 6402, 6404, 6406, 6408, 6410 , 6412, 6414, 6416, 6418, 6420, 6422, 6424, 6426, 6428, 6430, 6432, 6434, 6436, 6438, 6440, 6442, 6444, 6446, 6448, 6450, 6452, 6454, 6456, 6458 and 6460.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 6262, 6264, 6266, 6268, 6270, 6272, 6274, 6276, 6278, 6280, 6282, 6284, 6286, 6288, 6290, 6292, 6294, 6296, 6298, 6300, 6302, 6304, 6306, 6308, 6310 310, 6312, 6314, 6316, 6318, 6320, 6322, 6324, 6326, 6328, 6330, 6332, 6334, 6336, 6338, 6340, 6342, 6344, 6346, 6348, 6350, 6352, 6354, 6356, 6358, 63 60, 6362, 6364, 6366, 6368, 6370, 6372, 6374, 6376, 6378, 6380, 6382, 6384, 6386, 6388, 6390, 6392, 6394, 6396, 6398, 6400, 6402, 6404, 6406, 6408, 641 0, 6412, 6414, 6416, 6418, 6420, 6422, 6424, 6426, 6428, 6430, 6432, 6434, 6436, 6438, 6440, 6442, 6444, 6446, 6448, 6450, 6452, 6454, 6456, 6458, and 6460.
[0033] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 37 / 71 / 125 / 174 / 247 / 248 / 427, 37 / 71 / 247 / 331 / 365 / 389 / 401 / 429, 37 / 139 / 329 / 365 / 427 / 433 / 449, 37 / 139 / 427 / 432 / 433 / 449, 37 / 139 / 429 / 432 / 433, 37 / 174 / 401 / 402 / 433 / 449, 37 / 248 / 331 / 389 / 401 / 429, 37 / 248 / 331 / 389 / 427 / 433, 37 / 248 / 331 / 389 / 401 / 429. 9, 37 / 331 / 432 / 433, 71 / 139 / 389 / 427 / 429 / 432 / 433 / 449, 71 / 174 / 329 / 427 / 429 / 432 / 433, 71 / 174 / 365 / 427 / 432, 71 / 248 / 365 / 389 / 401, 71 / 248 / 449 、71 / 254 / 433 / 449、71 / 427 / 432 / 433 / 449、71 / 432 / 433、139 / 156 / 174 / 389 / 401 / 427 / 433 / 449、139 / 156 / 247 / 365 / 401 / 433 / 449、139 / 156 / 247 / 389 / 40 1 / 427 / 433 / 449, 139 / 156 / 248 / 389, 139 / 156 / 248 / 389 / 401 / 416 / 427 / 429 / 433, 139 / 156 / 365, 139 / 174 / 248 / 331 / 389 / 401 / 449, 139 / 174 / 254, 139 / 1 74 / 365 / 401 / 402 / 427 / 433 / 449、139 / 247 / 248 / 331 / 401 / 417 / 432 / 449、139 / 248 / 254 / 449、139 / 248 / 402 / 416 / 427 / 433 / 449、139 / 248 / 432 / 433、139 / 2 54 / 401 / 416 / 427 / 433 / 449、139 / 401 / 449、156 / 248 / 256、156 / 254 / 331 / 365 / 427 / 432 / 449、156 / 389 / 401 / 402 / 416 / 432 / 433、174 / 247 / 248 / 389 / 401 / 432 / 433、174 / 329 / 432 / 449、174 / 365、174 / 389 / 429 / 432 / 433 / 449、247 / 248 / 401、247 / 248 / 449、247 / 331 / 401 / 427 / 432 / 449、247 / 401、247 / 427 / 432、248 / 331 / 427 / 429 / 433、248 / 365 / 389 / 427 / 429 / 432 / 449、248 / 401 / 429 / 432 / 433、248 / 416、248 / 416 / 449、248 / 449、254 / 365、254 / 427 / 433、331 / 365 / 429 / 432 / 433 / 449、365 / 401 / 402 / 429 / 432 / 433, 389 / 401 / 416 / 432 / 449, 389 / 401 / 427 / 432, 401 / 427, 416 / 427 / 433 / 449, 416 / 432 / 433, 416 / 432 / 433 / 449, 427 / 432, 427 / 432 / 449, 432 and 433 / 449, wherein the positions are numbered with reference to SEQ ID NO: 6288. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 37R / 71L / 125M / 174P / 247C / 248W / 427R, 37R / 71L / 247C / 331K / 365I / 389E / 401F / 429W, 37R / 139K / 329P / 365I / 427R / 433L / 449R, 37R / 139K / 427R / 433L / 449R, 2L / 433L / 449R, 37R / 139K / 429W / 432L / 433L, 37R / 174P / 401F / 402L / 433L / 449R, 37R / 248W / 331K / 389E / 427R / 433L, 37R / 248W / 389A / 401F / 429W, 37R / 331K / 432L / 433L, 71L / 139K / 389A / 427R / 429W / 432L / 433 L / 449R、71L / 174P / 329P / 427R / 429W / 432L / 433L、71L / 174P / 365I / 427R / 432L、71L / 248W / 365I / 389A / 4 01F、71L / 248W / 449R、71L / 254Q / 433L / 449R、71L / 427R / 432L / 433L / 449R、71L / 432L / 433L、139K / 156C / 174P / 389E / 401F / 427R / 433L / 449R、139K / 156C / 247C / 365I / 401F / 433L / 449R、139K / 156C / 247L / 389E / 401F / 427R / 433L / 449R, 139K / 156C / 248W / 389A / 401F / 416S / 427R / 429W / 433L, 139K / 156C / 248W / 389E,139K / 156C / 365I、139K / 174P / 248W / 331K / 389A / 401F / 449R、139K / 174P / 254Q、139K / 174P / 365I / 401F / 402L / 427R / 433L / 449R、139K / 247C / 248W / 331K / 401F / 417Q / 432L / 449R、139K / 248W / 254A / 449R、139K / 248W / 402L / 416L / 427R / 433L / 449R、139K / 248W / 432L / 433L、139K / 254Q / 401F / 416S / 427R / 433L / 449R、139K / 401F / 449R、156C / 248W / 256M、156C / 254Q / 331K / 365I / 427R / 432L / 449R、156C / 389E / 401F / 402L / 416L / 432L / 433L、174P / 247C / 248W / 389A / 401F / 432L / 433L、174P / 329P / 432L / 449R、174P / 365I、174P / 389E / 429W / 432L / 433L / 449R、247C / 248W / 401F、247C / 331K / 401F / 427R / 432L / 449R、247C / 427R / 432L、247L / 248W / 449R、247L / 401F、248W / 331K / 427R / 429W / 433L、248W / 365I / 389E / 427R / 429W / 432L / 449R、248W / 401F / 429W / 432L / 433L、248W / 416L、248W / 416L / 449R、248W / 449R、254Q / 365I、254Q / 427R / 433L、331K / 365I / 429W / 432L / 433L / 449R、365I / 401F / 402L / 429W / 432L / 433L、389A / 401F / 416S / 432L / 449R、389E / 401F / 427R / 432L、401F / 427R、416L / 427R / 433L / 449R、416L / 432L / 433L / 449R、416S / 432L / 433L、427R / 432L、427R / 432L / 449R、432L and 433L / 449R, wherein the positions are numbered with reference to SEQ ID NO: 6288. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of S37R / Q71L / L125M / L174P / K247C / H248W / A427R, S37R / Q71L / K247C / R331K / V365I / D389E / L401F / L429W, S37R / P139K / G329P / V365I / A427R / A433L / S449R, S37R / P139K / A427R / K432L / A433L / S449R, S37R / P139K / L429W / K432L / A433L, S37R / L174P / L401F / E402L / A433L / S449R, S37R / H248W / R331K / D389E / A427R / A433L, S37R / H248W / D389A / L401F / L429W, S37R / R331K / K 432L / A433L, Q71L / P139K / D389A / A427R / L429W / K432L / A433L / S449R, Q71L / L174P / G329P / A427R / L429W / K432L / A433L, Q71L / L174P / V365I / A 427R / K432L, Q71L / H248W / V365I / D389A / L401F, Q71L / H248W / S449R, Q 71L / S254Q / A433L / S449R, Q71L / A427R / K432L / A433L / S449R, Q71L / K43 2L / A433L, P139K / S156C / L174P / D389E / L401F / A427R / A433L / S449R, P 139K / S156C / K247C / V365I / L401F / A433L / S449R, P139K / S156C / K247L / D389E / L401F / A427R / A433L / S449R, P139K / S156C / H248W / D389A / L401 F / D416S / A427R / L429W / A433L, P139K / S156C / H248W / D389E, P139K / S15 6C / V365I, P139K / L174P / H248W / R331K / D389A / L401F / S449R, P139K / L 174P / S254Q、P139K / L174P / V365I / L401F / E402L / A427R / A433L / S449R、P139K / K247C / H248W / R331K / L401F / P417Q / K432L / S449R、P139K / H24 8W / S254A / S449R、P139K / H248W / E402L / D416L / A427R / A433L / S449R、P 139K / H248W / K432L / A433L, P139K / S254Q / L401F / D416S / A427R / A433L / S449R, P139K / L401F / S449R, S156C / H248W / L256M, S156C / S254Q / R33 1K / V365I / A427R / K432L / S449R、S156C / D389E / L401F / E402L / D416L / K432L / A433L、L174P / K247C / H248W / D389A / L401F / K432L / A433L、L174 P / G329P / K432L / S449R、L174P / V365I、L174P / D389E / L429W / K432L / A4 33L / S449R、K247C / H248W / L401F、K247C / R331K / L401F / A427R / K432L / S449R、K247C / A427R / K432L、K247L / H248W / S449R、K247L / L401F、H24 8W / R331K / A427R / L429W / A433L、H248W / V365I / D389E / A427R / L429W / K 432L / S449R, H248W / L401F / L429W / K432L / A433L, H248W / D416L, H248W / D416L / S449R, H248W / S449R, S254Q / V365I, S254Q / A427R / A433L, R33 1K / V365I / L429W / K432L / A433L / S449R、V365I / L401F / E402L / L429W / K432L / A433L、D389A / L401F / D416S / K432L / S449R、D389E / L401F / A427 R / K432L、L401F / A427R、D416L / A427R / A433L / S449R、D416L / K432L / A4 33L / S449R、D416S / K432L / A433L、A427R / K432L、A427R / K432L / S449R、K432L and A433L / S449R, wherein the positions are numbered with reference to SEQ ID NO: 6288. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 5 / 449, 6, 10, 25, 25 / 449, 69, 69 / 449, 87, 87 / 449, 91, 91 / 449, 144 / 449, 153, 153 / 449, 159, 159 / 449, 172, 172 / 449, 212 / 449, 233, 233 / 449, 288 / 449, 303, 317, 347 / 449, 361, 369, and 421, wherein the positions are numbered with reference to SEQ ID NO: 6288. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 5S / 449R, 6P, 10K, 25I / 449R, 25M / 449R, 25Q / 449R, 25S, 69A, 69M / 449R, 87A / 449R, 87E, 87K, 87Q, 87R, 91L, 91N / 449R, 91Q, 91T / 449R, 91V, 144Q / 449R, 144R 317Y, 347P / 449R, 369K, 372S, 172T / 449R, 212L / 449R, 233A, 233C, 233G, 233L / 449R, 233M / 449R, 233Q / 449R, 233R, 233S, 233V, 288P / 449R, 303C, 303V, 317Y, 347P / 449R, 361C, 369K and 421I, wherein the positions are numbered with reference to SEQ ID NO: 6288. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: T5S / S449R, E6P, R10K, L25I / S449R, L25M / S449R, L25Q / S449R, L25S, D69A, D69M / S449R, M87A / S449R, M87E, M87K, M87Q, M87R, I91L, I91N / S449R, I91Q, I91T / S449R. 9R, I91V, M144Q / S449R, A153T / S449R, A153V, Q159K, Q159R / S449R, H172S, H172T / S449R, A212L / S449R, W233A , W233C, W233G, W233L / S449R, W233M / S449R, W233Q / S449R, W233R, W233S, W233V, E288P / S449R, Q303C, Q303V,S317Y, K347P / S449R, T361C, V369K, and V421I, wherein the positions are numbered with reference to SEQ ID NO: 6288. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 6462, 6464, 6466, 6468, 6470, 6472, 6474, 6476, 6478, 6480, 6482, 6484, 6486, 6488, 6490, 6492, 6494, 6496, 6498, 6500, 6502, 6504, 6506, 6508, 6510, 6512, 6513, 6514, 6515 14, 6516, 6518, 6520, 6522, 6524, 6526, 6528, 6530, 6532, 6534, 6536, 6538, 6540, 6542, 6544, 6546, 6548, 6550, 6552, 6554, 6556, 6558, 6560, 6562, 6564, 6566, 656 8. 6570, 6572, 6574, 6576, 6578, 6580, 6582, 6584, 6586, 6588, 6590, 6592, 6594, 6596, 6598, 6600, 6602, 6604, 6606, 6608, 6610, 6612, 6614, 6616, 6618, 6620, 6622 , 6624, 6626, 6628, 6630, 6632, 6634, 6636, 6638, 6640, 6642, 6644, 6646, 6648, 6650, 6652, 6654, 6656, 6658, 6660, 6662, 6664, 6666, 6668, 6670, 6672, 6674, and 6676. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: NO:6462, 6464, 6466, 6468, 6470, 6472, 6474, 6476, 6478, 6480, 6482, 6484, 6486, 6488 , 6490, 6492, 6494, 6496, 6498, 6500, 6502, 6504, 6506, 6508, 6510, 6512, 6514, 6516, 6 518、6520、6522、6524、6526、6528、6530、6532、6534、6536、6538、6540、6542、6544、6546、6548、6550、6552、6554、6556、6558、6560、6562、6564、6566、6568、6570、6572、6574、6576, 6578, 6580, 6582, 6584, 6586, 6588, 6590, 6592, 6594, 6596, 6598, 6600, 6602, 6604, 6606, 6608, 6610, 6612, 6614, 6616, 6618, 6620, 6622, 6624, 66 26, 6628, 6630, 6632, 6634, 6636, 6638, 6640, 6642, 6644, 6646, 6648, 6650, 6652, 6654, 6656, 6658, 6660, 6662, 6664, 6666, 6668, 6670, 6672, 6674, and 6676. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: NO:6462, 6464, 6466, 6468, 6470, 6472, 6474, 6476, 6478, 6480, 6482, 6484, 6486 , 6488, 6490, 6492, 6494, 6496, 6498, 6500, 6502, 6504, 6506, 6508, 6510, 6512, 65 14, 6516, 6518, 6520, 6522, 6524, 6526, 6528, 6530, 6532, 6534, 6536, 6538, 6540, 6542, 6544, 6546, 6548, 6550, 6552, 6554, 6556, 6558, 6560, 6562, 6564, 6566, 656 8. 6570, 6572, 6574, 6576, 6578, 6580, 6582, 6584, 6586, 6588, 6590, 6592, 6594, 6596, 6598, 6600, 6602, 6604, 6606, 6608, 6610, 6612, 6614, 6616, 6618, 6620, 6622 , 6624, 6626, 6628, 6630, 6632, 6634, 6636, 6638, 6640, 6642, 6644, 6646, 6648, 6650, 6652, 6654, 6656, 6658, 6660, 6662, 6664, 6666, 6668, 6670, 6672, 6674, and 6676.
[0034] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 37 / 41 / 45 / 72 / 81 / 83 / 84 / 88 / 155 / 163 / 168 / 190 / 331 / 375, 37 / 41 / 45 / 72 / 81 / 83 / 84 / 88 / 155 / 263 / 273 / 331 / 375 / 432, 37 / 41 / 45 / 72 / 81 / 83 / 84 / 88 / 155 / 331 / 366 / 375, 37 / 41 / 45 / 72 / 81 / 83 / 84 / 88 / 155 / 331 / 375, 37 / 41 / 45 / 72 / 81 / 83 / 84 / 88 / 155 / 331 / 375, 84 / 88 / 248 / 375、37 / 41 / 45 / 72 / 81 / 83 / 84 / 88 / 331 / 366 / 432 / 433、37 / 41 / 45 / 72 / 88 / 155 / 168 / 190 / 331 / 366 / 375 / 432、37 / 41 / 45 / 72 / 88 / 155 / 168 / 190 / 331 / 375、37 / 41 / 45 / 72 / 88 / 190 / 263 / 273 / 331 / 366、37 / 41 / 45 / 72 / 155 / 163 / 168 / 190 / 243 / 263 / 273 / 331 / 366 / 432、37 / 41 / 45 / 72 / 155 / 163 / 168 / 243 / 24 8 / 273 / 331 / 366 / 432 / 433、37 / 41 / 45 / 72 / 155 / 163 / 168 / 263 / 366 / 432 / 433、37 / 41 / 45 / 72 / 155 / 163 / 331 / 366 / 375、37 / 41 / 45 / 72 / 155 / 190 / 243 / 248 / 27 3 / 331 / 432 / 433、37 / 41 / 45 / 72 / 155 / 190 / 248 / 263 / 331、37 / 41 / 45 / 72 / 155 / 190 / 263 / 331 / 366、37 / 41 / 45 / 72 / 155 / 190 / 273 / 331 / 366 / 375、37 / 41 / 45 / 72 / 155 / 190 / 273 / 366、37 / 41 / 45 / 72 / 155 / 190 / 273 / 366 / 375 / 432、37 / 41 / 45 / 72 / 155 / 248 / 263 / 273 / 366、37 / 41 / 45 / 72 / 155 / 263 / 331 / 375、37 / 41 / 45 / 72 / 155 / 263 / 375、37 / 41 / 45 / 72 / 155 / 273 / 366、37 / 41 / 45 / 72 / 155 / 331 / 366 / 375 / 432 / 433、37 / 41 / 45 / 72 / 190 / 263 / 273 / 331、37 / 41 / 45 / 72 / 190 / 331 / 366、37 / 41 / 45 / 72 / 190 / 366、37 / 41 / 45 / 72 / 263 / 331 / 366、37 / 41 / 45 / 72 / 263 / 366 / 432 / 433、37 / 41 / 45 / 72 / 331 / 366、37 / 41 / 45 / 81 / 83 / 84 / 88 / 155 / 168 / 190 / 243 / 331 / 366、37 / 41 / 45 / 81 / 83 / 84 / 88 / 155 / 168 / 331 / 375、37 / 41 / 45 / 81 / 83 / 84 / 88 / 155 / 263 / 273 / 331 / 366、37 / 41 / 45 / 81 / 83 / 84 / 88 / 163 / 168 / 263 / 273 / 331 / 366 / 375、37 / 41 / 45 / 155 / 163 / 168 / 263 / 331 / 375、37 / 41 / 45 / 155 / 168 / 248 / 273 / 331 / 375、37 / 41 / 45 / 155 / 190 / 331 / 366 / 375、37 / 41 / 45 / 155 / 366、37 / 41 / 45 / 155 / 366 / 432 / 433、37 / 41 / 45 / 155 / 375、37 / 41 / 45 / 243 / 248 / 273 / 331、37 / 41 / 45 / 263 / 331 / 375 / 432、37 / 41 / 45 / 331 / 366 / 432 / 433、37 / 72 / 81 / 83 / 88 / 155 / 190、37 / 72 / 197 / 273 / 331 / 375 / 432、37 / 83 / 263 / 365 / 366 / 375、37 / 190 / 202、41 / 45 / 72 / 155 / 263 / 331 / 366 / 375 / 432 / 433、41 / 45 / 163 / 168 / 243 / 248 / 273 / 366 / 432、45 / 72 / 84 / 88 / 197 / 375、45 / 72 / 88 / 366、45 / 72 / 163 / 202 / 365 / 366 / 375、45 / 72 / 168 / 243 / 331 / 365 / 366 / 429 / 432、45 / 84 / 168 / 190 / 199 / 254 / 273 / 365 / 366、45 / 163 / 168 / 190 / 199 / 366 / 429 / 432、45 / 163 / 168 / 197 / 263 / 331 / 365 / 366、72 / 81 / 83 / 84 / 88 / 155 / 163 / 168 / 190 / 366、72 / 81 / 83 / 84 / 88 / 155 / 190、72 / 81 / 83 / 84 / 88 / 155 / 190 / 273 / 331 / 366 / 432、72 / 81 / 83 / 84 / 88 / 155 / 273 / 331 / 375、72 / 81 / 83 / 84 / 88 / 155 / 366、72 / 81 / 83 / 84 / 88 / 163 / 168 / 190 / 243 / 263 / 331 / 366、72 / 81 / 83 / 84 / 88 / 163 / 168 / 263 / 331 / 375、72 / 81 / 84 / 190 / 248、72 / 83 / 84 / 88 / 202 / 254 / 273 / 366 / 375、72 / 83 / 84 / 197 / 202 / 243 / 263 / 365 / 366、72 / 83 / 88 / 243 / 263 / 331 / 365 / 366、72 / 155 / 163 / 168 / 190 / 366 / 432 / 433、72 / 155 / 190、72 / 155 / 190 / 263 / 331 / 366、72 / 155 / 190 / 366、72 / 155 / 273 / 331 / 375 / 432、72 / 243 / 248 / 263 / 366 / 432 / 433、72 / 243 / 248 / 273 / 366 / 432 / 433、72 / 243 / 248 / 366 / 432 / 433、72 / 248、81 / 83 / 84 / 88 / 155 / 163 / 168 / 273 / 331 / 375、81 / 83 / 84 / 88 / 155 / 190 / 263 / 331 / 366、81 / 83 / 84 / 88 / 155 / 263 / 366 / 375、81 / 83 / 84 / 88 / 155 / 366、81 / 83 / 84 / 88 / 190 / 263 / 375、81 / 83 / 84 / 88 / 263 / 273 / 331 / 366 / 432、81 / 83 / 169 / 190 / 263、81 / 83 / 190 / 263 / 365 / 366、81 / 83 / 202 / 365 / 366 / 402、81 / 88 / 375 / 402、83 / 88 / 155 / 273 / 366 / 375、84 / 155 / 168 / 197 / 199 / 331 / 366 / 375 / 383 / 402、84 / 168 / 197 / 202 / 263 / 366、84 / 197 / 366 / 402、155 / 168 / 190 / 197 / 199 / 366、155 / 168 / 375、155 / 263 / 366 / 432 / 433、190 / 199 / 202 / 331 / 366、197 / 199 / 202、197 / 202 / 248、197 / 248、199 / 263 / 331 / 365 / 366、248 / 375、365 / 366 and 365 / 375 / 402, wherein the positions are numbered with reference to SEQ ID NO: 6468. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 37R / 41A / 45L / 72T / 81T / 83S / 84N / 88T / 155L / 163A / 168T / 190R / 331K / 375P, 37R / 41A / 45L / 72T / 81T / 83S / 84N / 88T / 155L / 263T / 273R / 331K / 375P / 432L, 37R / 41A / 45L / 72T / 81T / 83S / 84N / 88T / 155L / 331K / 366C / 375P, 37R / 41A / 45L / 72T / 81T / 83S / 84N / 88T / 155L / 331K / 366C / 375P, 2T / 81T / 83S / 84N / 88T / 155L / 331K / 375P, 37R / 41A / 45L / 72T / 81T / 83S / 8 4N / 88T / 248W / 375P, 37R / 41A / 45L / 72T / 81T / 83S / 84N / 88T / 331K / 366V / 4 32L / 433A, 37R / 41A / 45L / 72T / 88T / 155L / 168T / 190R / 331K / 366C / 375P / 4 32L, 37R / 41A / 45L / 72T / 88T / 155L / 168T / 190R / 331K / 375P, 37R / 41A / 45L / 72T / 88T / 190R / 263T / 273R / 331K / 366C, 37R / 41A / 45L / 72T / 155L / 163A / 168T / 190R / 243I / 263T / 273R / 331K / 366C / 432L、37R / 41A / 45L / 72T / 155 L / 163A / 168T / 243I / 248W / 273R / 331K / 366V / 432L / 433A, 37R / 41A / 45L / 7 2T / 155L / 163A / 168T / 263T / 366C / 432L / 433A, 37R / 41A / 45L / 72T / 155L / 1 63A / 331K / 366C / 375P, 37R / 41A / 45L / 72T / 155L / 190R / 243I / 248W / 273R / 331K / 432L / 433A, 37R / 41A / 45L / 72T / 155L / 190R / 248W / 263T / 331K, 37R / 41A / 45L / 72T / 155L / 190R / 263T / 331K / 366C, 37R / 41A / 45L / 72T / 155L / 1 90R / 273R / 331K / 366V / 375P, 37R / 41A / 45L / 72T / 155L / 190R / 273R / 366C,37R / 41A / 45L / 72T / 155L / 190R / 273R / 366C / 375P / 432L、37R / 41A / 45L / 72T / 155L / 248W / 263T / 273R / 366C、37R / 41A / 45L / 72T / 155L / 263T / 331K / 375P、3 7R / 41A / 45L / 72T / 155L / 263T / 375P、37R / 41A / 45L / 72T / 155L / 273R / 366C、37R / 41A / 45L / 72T / 155L / 331K / 366V / 375P / 432L / 433A、37R / 41A / 45L / 72T / 1 90R / 263T / 273R / 331K、37R / 41A / 45L / 72T / 190R / 331K / 366C、37R / 41A / 45L / 72T / 190R / 366C、37R / 41A / 45L / 72T / 263T / 331K / 366C、37R / 41A / 45L / 72T / 2 63T / 366C / 432L / 433A、37R / 41A / 45L / 72T / 331K / 366C、37R / 41A / 45L / 81T / 83S / 84N / 88T / 155L / 168T / 190R / 243I / 331K / 366C、37R / 41A / 45L / 81T / 83S / 84 N / 88T / 155L / 168T / 331K / 375P、37R / 41A / 45L / 81T / 83S / 84N / 88T / 155L / 263 T / 273R / 331K / 366C、37R / 41A / 45L / 81T / 83S / 84N / 88T / 163A / 168T / 263T / 27 3R / 331K / 366C / 375P、37R / 41A / 45L / 155L / 163A / 168T / 263T / 331K / 375P、37R / 41A / 45L / 155L / 168T / 248W / 273R / 331K / 375P、37R / 41A / 45L / 155L / 190R / 3 31K / 366V / 375P、37R / 41A / 45L / 155L / 366C、37R / 41A / 45L / 155L / 366C / 432L / 433A、37R / 41A / 45L / 155L / 375P、37R / 41A / 45L / 243I / 248W / 273R / 331K、37 R / 41A / 45L / 263T / 331K / 375P / 432L、37R / 41A / 45L / 331K / 366V / 432L / 433A、37R / 72T / 81T / 83S / 88T / 155L / 190R、37R / 72T / 197K / 273R / 331K / 375P / 432L、37R / 83S / 263T / 365I / 366V / 375P、37R / 190R / 202H、41A / 45L / 72T / 155L / 263T / 331K / 366V / 375P / 432L / 433A、41A / 45L / 163A / 168T / 243I / 248W / 273R / 366C / 432L、45L / 72T / 84N / 88T / 197K / 375P、45L / 72T / 88T / 366C、45L / 72T / 163A / 202H / 365I / 366V / 375P、45L / 72T / 168T / 243I / 331K / 365I / 366C / 42 9W / 432L、45L / 84N / 168T / 190R / 199Q / 254A / 273R / 365I / 366C、45L / 163A / 168T / 190R / 199Q / 366C / 429W / 432L、45L / 163A / 168T / 197K / 263T / 331K / 36 5I / 366C、72T / 81T / 83S / 84N / 88T / 155L / 163A / 168T / 190R / 366C、72T / 81T / 83S / 84N / 88T / 155L / 190R、72T / 81T / 83S / 84N / 88T / 155L / 190R / 273R / 331K / 366V / 432L、72T / 81T / 83S / 84N / 88T / 155L / 273R / 331K / 375P、72T / 81T / 83S / 84N / 88T / 155L / 366C、72T / 81T / 83S / 84N / 88T / 163A / 168T / 190R / 243I / 263T / 331K / 366C、72T / 81T / 83S / 84N / 88T / 163A / 168T / 263T / 331K / 375P、72T / 81T / 84N / 190R / 248W、72T / 83S / 84N / 88T / 202H / 254A / 273R / 366C / 375P 72T / 83S / 84N / 197K / 202H / 243I / 263T / 365I / 366C, 72T / 83S / 88T / 243I / 263T / 331K / 365I / 366C, 72T / 155L / 163A / 168T / 190R / 366V / 432L / 433A, 72T / 155L / 190R、72T / 155L / 190R / 263T / 331K / 366C、72T / 155L / 190R / 366C、72T / 155L / 273R / 331K / 375P / 432L、72T / 243I / 248W / 263T / 366V / 432L / 433A、72T / 243I / 248W / 273R / 366V / 432L / 433A, 72T / 243I / 248W / 366V / 432L / 433A, 72T / 248W, 81T / 83S / 84N / 88T / 15 5L / 163A / 168T / 273R / 331K / 375P, 81T / 83S / 84N / 88T / 155L / 190R / 263T / 331K / 366C, 81T / 83S / 84N / 88T / 155L / 263T / 366V / 375P, 81T / 83S / 84N / 88T / 155L / 366C, 81T / 83S / 84N / 88T / 190R / 263T / 375P, 81T / 83S / 84N / 88T / 26 3T / 273R / 331K / 366C / 432L, 81T / 83S / 169D / 190R / 263T, 81T / 83S / 190R / 263T / 365I / 366C, 81T / 83S / 202H / 365 I / 366C / 402L, 81T / 88T / 375P / 402L, 83S / 88T / 155L / 273R / 366V / 375P, 84N / 155L / 168T / 197K / 199Q / 331K / 366 V / 375P / 383V / 402L, 84N / 168T / 197K / 202H / 263T / 366C, 84N / 197K / 366C / 402L, 155L / 168T / 190R / 197K / 199Q / 197K / 199Q / 202H, 197K / 202H / 248W, 197K / 248W, 199Q / 263T / 331K / 365I / 366C, 248W / 375P, 365I / 366C, and 365I / 375P / 402L, wherein the positions are numbered with reference to SEQ ID NO: 6468. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: S37R / S41A / F45L / D72T / H81T / P83S / G84N / R88T / V155L / L163A / P168T / K190R / R331K / D375P, S37R / S41A / F45L / D72T / H81T / P83S / G84N / R88T / V155L / V263T / S273R / R331K / D375P / K432L, S37R / S41A / F45L / D72T / H81T / P83S / G84N / R88T / V155L / R331K / A366C / D375P,S37R / S41A / F45L / D72T / H81T / P83S / G84N / R88T / V155L / R331K / D375P、S37R / S41A / F45L / D72T / H81T / P83S / G84N / R88T / H248W / D375P、S37R / S41A / F45L / D72T / H81T / P83S / G84N / R88T / R331K / A366V / K432L / L433A、S37R / S41A / F45L / D72T / R88T / V155L / P168T / K190R / R331K / A366C / D375P / K432L、S37R / S41 A / F45L / D72T / R88T / V155L / P168T / K190R / R331K / D375P、S37R / S41A / F45L / D72T / R88T / K190R / V263T / S273R / R331K / A366C、S37R / S41A / F45L / D72T / V1 55L / L163A / P168T / K190R / L243I / V263T / S273R / R331K / A366C / K432L、S37R / S41A / F45L / D72T / V155L / L163A / P168T / L243I / H248W / S273R / R331K / A366V / K432L / L433A、S37R / S41A / F45L / D72T / V155L / L163A / P168T / V263T / A366C / K432L / L433A、S37R / S41A / F45L / D72T / V155L / L163A / R331K / A366C / D375P 、S37R / S41A / F45L / D72T / V155L / K190R / L243I / H248W / S273R / R331K / K432L / L433A、S37R / S41A / F45L / D72T / V155L / K190R / H248W / V263T / R331K、S37R / S 41A / F45L / D72T / V155L / K190R / V263T / R331K / A366C、S37R / S41A / F45L / D72T / V155L / K190R / S273R / R331K / A366V / D375P、S37R / S41A / F45L / D72T / V155L / K190R / S273R / A366C、S37R / S41A / F45L / D72T / V155L / K190R / S273R / A366C / D375P / K432L、S37R / S41A / F45L / D72T / V155L / H248W / V263T / S273R / A366C、S37R / S41A / F45L / D72T / V155L / V263T / R331K / D375P、S37R / S41A / F45L / D72T / V155L / V263T / D375P、S37R / S41A / F45L / D72T / V155L / S273R / A366C、S37R / S41A / F45L / D72T / V155L / R331K / A366V / D375P / K432L / L433A、S37R / S41A / F45L / D72T / K190R / V263T / S273R / R331K、S37R / S41A / F45L / D72T / K190R / R3 31K / A366C、S37R / S41A / F45L / D72T / K190R / A366C、S37R / S41A / F45L / D72T / V263T / R331K / A366C、S37R / S41A / F45L / D72T / V263T / A366C / K432L / L433A、 S37R / S41A / F45L / D72T / R331K / A366C、S37R / S41A / F45L / H81T / P83S / G84N / R88T / V155L / P168T / K190R / L243I / R331K / A366C、S37R / S41A / F45L / H81T / P8 3S / G84N / R88T / V155L / P168T / R331K / D375P、S37R / S41A / F45L / H81T / P83S / G84N / R88T / V155L / V263T / S273R / R331K / A366C、S37R / S41A / F45L / H81T / P8 3S / G84N / R88T / L163A / P168T / V263T / S273R / R331K / A366C / D375P、S37R / S41A / F45L / V155L / L163A / P168T / V263T / R331K / D375P、S37R / S41A / F45L / V15 5L / P168T / H248W / S273R / R331K / D375P、S37R / S41A / F45L / V155L / K190R / R331K / A366V / D375P、S37R / S41A / F45L / V155L / A366C、S37R / S41A / F45L / V155 L / A366C / K432L / L433A、S37R / S41A / F45L / V155L / D375P、S37R / S41A / F45L / L243I / H248W / S273R / R331K、S37R / S41A / F45L / V263T / R331K / D375P / K432L、S37R / S41A / F45L / R331K / A366V / K432L / L433A、S37R / D72T / H81T / P83S / R88T / V155L / K190R、S37R / D72T / Q197K / S273R / R331K / D375P / K432L、S37 R / P83S / V263T / V365I / A366V / D375P、S37R / K190R / I202H、S41A / F45L / D72T / V155L / V263T / R331K / A366V / D375P / K432L / L433A、S41A / F45L / L163 A / P168T / L243I / H248W / S273R / A366C / K432L、F45L / D72T / G84N / R88T / Q 197K / D375P、F45L / D72T / R88T / A366C、F45L / D72T / L163A / I202H / V365I / A366V / D375P、F45L / D72T / P168T / L243I / R331K / V365I / A366C / L429W / K432L、F45L / G84N / P168T / K190R / A199Q / S254A / S273R / V365I / A366C、F45L / L163A / P168T / K190R / A199Q / A366C / L429W / K432L、F45L / L163A / P168T / Q197K / V263T / R331K / V365I / A366C、D72T / H81T / P83S / G84N / R88T / V155 L / L163A / P168T / K190R / A366C、D72T / H81T / P83S / G84N / R88T / V155L / K19 0R、D72T / H81T / P83S / G84N / R88T / V155L / K190R / S273R / R331K / A366V / K4 32L、D72T / H81T / P83S / G84N / R88T / V155L / S273R / R331K / D375P、D72T / H 81T / P83S / G84N / R88T / V155L / A366C、D72T / H81T / P83S / G84N / R88T / L163 A / P168T / K190R / L243I / V263T / R331K / A366C、D72T / H81T / P83S / G84N / R8 8T / L163A / P168T / V263T / R331K / D375P、D72T / H81T / G84N / K190R / H248W、D72T / P83S / G84N / R88T / I202H / S254A / S273R / A366C / D375P、D72T / P83S / G84N / Q197K / I202H / L243I / V263T / V365I / A366C、D72T / P83S / R88T / L243I / V263T / R331K / V365I / A366C、D72T / V155L / L163A / P168T / K190R / A366V / K432L / L433A、D72T / V155L / K190R、D72T / V155L / K190R / V263T / R331K / A36 6C、D72T / V155L / K190R / A366C、D72T / V155L / S273R / R331K / D375P / K432L、D72T / L243I / H248W / V263T / A366V / K432L / L433A、D72T / L243I / H248W / S2 73R / A366V / K432L / L433A、D72T / L243I / H248W / A366V / K432L / L433A、D72T / H248W、H81T / P83S / G84N / R88T / V155L / L163A / P168T / S273R / R331K / D375 P、H81T / P83S / G84N / R88T / V155L / K190R / V263T / R331K / A366C、H81T / P83 S / G84N / R88T / V155L / V263T / A366V / D375P、H81T / P83S / G84N / R88T / V155L / A366C、H81T / P83S / G84N / R88T / K190R / V263T / D375P、H81T / P83S / G84N / R88T / V263T / S273R / R331K / A366C / K432L、H81T / P83S / E169D / K190R / V263 T、H81T / P83S / K190R / V263T / V365I / A366C、H81T / P83S / I202H / V365I / A3 66C / E402L、H81T / R88T / D375P / E402L、P83S / R88T / V155L / S273R / A366V / D 375P、G84N / V155L / P168T / Q197K / A199Q / R331K / A366V / D375P / N383V / E402L、G84N / P168T / Q197K / I202H / V263T / A366C、G84N / Q197K / A366C / E402L、V155L / P168T / K190R / Q197K / A199Q / A366C, V155L / P168T / D375P, V155L / V263T / A366C / K432L / L433A, K190R / A199Q / I202H / R331K / A366C, Q197K / A199Q / I202H, Q197K / I202H / H248W, Q197K / H248W, A199Q / V263T / R331K / V365I / A366C, H248W / D375P, V365I / A366C and V365I / D375P / E402L, wherein the positions are referred to in SEQ ID NO: NO: 6468. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2, 3, 4, 9, 53 / 437, 61, 64, 72 / 170, 72 / 405, 94, 96, 98, 113, 118, 118 / 120, 120, 129, 134 / 158, 158, 165, 170, 171, 173, 183, 193, 214, 214 / 222, 222 , 226, 229, 234, 253, 265, 269, 272, 289, 296, 300, 302, 304, 322, 322 / 407, 330, 390, 395 / 439, 396, 398, 399, 403, 405, 408, 411, 412, 423, 428, 434, 435, 438, 439, 442, 444, 448, 449, 452, and 454, wherein the positions are numbered with reference to SEQ ID NO: 6468. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2F, 2H, 2K, 2M, 2Q, 2R, 2V, 3F, 3L, 3M, 4N, 4S, 9A, 9G, 9K, 9M, 9S, 53E / 437T, 61Q, 64L, 64M, 72E / 170A, 72E / 405S, 94R, 96C, 96K, 98E, 98S, 98T, 113D, 113G, 113P, 118C, 118T / 120V, 118V 18V, 120V, 129P, 134E / 158N, 158T, 165L, 170A, 170G, 170H, 170P, 170V, 171A, 171L, 171P, 171Q, 173I, 173K, 173L, 173 S, 183I, 183L, 183P, 193F, 214K, 214R, 214R / 222H, 222A, 222N, 222Q, 222R, 226S, 229M, 229Q, 234N, 234S, 234T, 253D,253E, 253N, 253P, 253T, 253V, 265H, 269L, 269M, 269N, 269R, 272S, 289D, 289G , 289N, 289R, 296Q, 300A, 300E, 302G, 304K, 304P, 322A, 322G, 322K, 322P, 322 P / 407I, 322S, 322T, 322V / 407I, 330S, 390I, 390R, 395I / 439V, 396T, 396V, 39 8S, 399P, 399Q, 399S, 403V, 405A, 405D, 405P, 405S, 405T, 408D, 408K, 408S, 4 11H, 411K, 411T, 412K, 423T, 428E, 428G, 428I, 428L, 428N, 428Q, 428R, 428S, 428T, 428V, 428Y, 434E, 434G, 435A, 435D, 435E, 435G, 435I, 435K, 435L, 435N , 435S, 435V, 435Y, 438E, 438R, 438S, 439A, 439E, 439G, 439H, 439M, 439R, 439W, 442F, 442T, 444A, 448K, 448Q, 449G, 449L, 449S, 452T and 454V, wherein the positions are numbered with reference to SEQ ID NO: 6468. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: P2F, P2H, P2K, P2M, P2Q, P2R, P2V, N3F, N3L, N3M, T4N, T4S, V9A, V9G, V9K, V9M, V9S, K53E / I437T, S61Q, F64L, F64M, D72E / D170A, D72E / E405S, K94R, G96C, G96K, D98E, D98S, D98T, S113D, S113G, S113P, A118C, A118T / L120V, A118 V, L120V, A129P, D134E / P158N, P158T, Y165L, D170A, D170G, D170H, D17 0P, D170V, K171A, K171L, K171P, K171Q, R173I, R173K, R173L, R173S, M1 83I, M183L, M183P, Y193F, S214K, S214R, S214R / K222H, K222A, K222N, K 222Q, K222R, E226S, L229M, L229Q, R234N, R234S, R234T, S253D, S253E,S253N, S253P, S253T, S253V, Q265H, Q269L, Q269M, Q269N, Q269R, P272S, K289D, K289G, K28 9N, K289R, R296Q, D300A, D300E, K302G, S304K, S304P, L322A, L322G, L322K, L322P, L322P / V 407I, L322S, L322T, L322V / V407I, E330S, V390I, V390R, V395I / P439V, Y396T, Y396V, E398 S, N399P, N399Q, N399S, R403V, E405A, E405D, E405P, E405S, E405T, N408D, N408K, N408S, R4 11H, R411K, R411T, R412K, R423T, K428E, K428G, K428I, K428L, K428N, K428Q, K428R, K428S , K428T, K428V, K428Y, D434E, D434G, R435A, R435D, R435E, R435G, R435I, R435K, R435L, R43 5N, R435S, R435V, R435Y, A438E, A438R, A438S, P439A, P439E, P439G, P439H, P439M, P439R, P439W, S442F, S442T, Y444A, E448K, E448Q, R449G, R449L, R449S, S452T, and I454V, wherein the positions are numbered with reference to SEQ ID NO: 6468. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: NO:6678, 6680, 6682, 6684, 6686, 6688, 6690, 6692, 6694, 6696, 6698, 6700, 6702, 6704, 6706, 6708 ,6710,6712,6714,6716,6718,6720,6722,6724,6726,6728,6730,6732,6734,6736,6738,6740,6 742, 6744, 6746, 6748, 6750, 6752, 6754, 6756, 6758, 6760, 6762, 6764, 6766, 6768, 6770, 6772, 6774, 6776, 6778, 6780, 6782, 6784, 6786, 6788, 6790, 6792, 6794, 6796, 6798, 6800, 6802, 6804, 6806,6808、6810、6812、6814、6816、6818、6820、6822、6824、6826、6828、6830、6832、6834、6836、6838、6840、6842、6844、6846、6848、6850、6852、6854、6856、6858、6860、6862、6864、6866、6868、6870、6872、6874、6876、6878、6880、6882、6884、6886、6888、6890、6892、6894、6896、6898、6900、6902、6904、6906、6908、6910、6912、6914、6916、6918、6920、6922、6924、6926、6928、6930、6932、6934、6936、6938、6940、6942、6944、6946、6948、6950、6952、6954、6956、6958、6960、6962、6964、6966、6968、6970、6972、6974、6976、6978、6980、6982、6984、6986、6988、6990、6992、6994、6996、6998、7000、7002、7004、7006、7008、7010、7012、7014、7016、7018、7020、7022、7024、7026、7028、7030、7032、7034、7036、7038、7040、7042、7044、7046、7048、7050、7052、7054、7056、7058、7060、7062、7064、7066、7068、7070、7072、7074、7076、7078、7080、7082、7084、7086、7088、7090、7092、7094、7096、7098、7100、7102、7104、7106、7108、7110、7112、7114、7116、7118、7120、7122、7124、7126、7128、7130、7132、7134、7136、7138、7140、7142、7144、7146、7148、7150、7152、7154、7156、7158、7160、7162、7164、7166、7168、7170、7172、7174、7176、7178、7180、7182、7184、7186、7188、7190、7192、7194、7196、7198、7200、7202、7204、7206、7208, 7210, 7212, and 7214. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 95% identical to any of the following sequences: SEQ ID NO:6678, 6680, 6682, 6684, 6686, 6688, 6690, 6692, 6694, 6696, 6698, 6700, 6702, 6704, 6706, 6708, 6710, 6712, 6714, 6716, 6718, 6720, 672 2. 6724, 6726, 6728, 6730, 6732, 6734, 6736, 6738, 6740, 6742, 6744, 6 746, 6748, 6750, 6752, 6754, 6756, 6758, 6760, 6762, 6764, 6766, 6768 、6770、6772、6774、6776、6778、6780、6782、6784、6786、6788、6790、6792、6794、6796、6798、6800、6802、6804、6806、6808、6810、6812、6814、6816、6818、6820、6822、6824、6826、6828、6830、6832、6834、6836、6838、6840、6842、6844、6846、6848、6850、6852、6854、6856、6858、6860、6 862, 6864, 6866, 6868, 6870, 6872, 6874, 6876, 6878, 6880, 6882, 6884, 6886, 6888, 6890, 6892, 6894, 6896, 6898, 6900, 6902, 6904, 6906, 6908, 6910, 6912, 6914, 6916, 6918, 6920, 6922, 6924, 6926, 6928, 6930, 6932, 6934, 6936, 6938, 6940, 6942, 6944, 6946, 6948, 6950, 6952, 695 4. 6956, 6958, 6960, 6962, 6964, 6966, 6968, 6970, 6972, 6974, 6976, 6978, 6980, 6982, 6984, 6986, 6988, 6990, 6992, 6994, 6996, 6998, 7000, 7002, 7004, 7006, 7008, 7010, 7012, 7014, 7016, 7018, 7020, 7022, 7024, 7026, 7028, 7030, 7032, 7034, 7036, 7038, 7040, 7042, 7044, 7046,7048, 7050, 7052, 7054, 7056, 7058, 7060, 7062, 7064, 7066, 7068, 7070, 7072, 7074, 7076, 7078, 7080, 7082, 7084, 7086, 7088, 7090, 7092, 7094, 7096, 7098, 7100, 7102, 7104, 7106, 7108, 7110, 7112, 7114, 7116, 7118, 7120, 7122, 7124, 7126, 7128, 7130, 7132, 7134, 7136, 7138, 7140, 7142, 7144, 7146, 7148, 7150, 7152, 7154, 7156, 7158, 7160, 7162, 7164, 7166, 7168, 7170, 7172, 7174, 7176, 7178, 7180, 7182, 7184, 7186, 7188, 7190, 7192, 7194, 7196, 7198, 7200, 7202, 7204, 7206, 7208, 7210, 7212, and 7214. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: NO:6678, 6680, 6682, 6684, 6686, 6688, 6690, 6692, 6694, 6696, 6698, 6700, 6702 ,6704,6706,6708,6710,6712,6714,6716,6718,6720,6722,6724,6726,6728,6 730, 6732, 6734, 6736, 6738, 6740, 6742, 6744, 6746, 6748, 6750, 6752, 6754, 6756, 6758, 6760, 6762, 6764, 6766, 6768, 6770, 6772, 6774, 6776, 6778, 6780, 6782, 6 784, 6786, 6788, 6790, 6792, 6794, 6796, 6798, 6800, 6802, 6804, 6806, 6808, 6810, 6812, 6814, 6816, 6818, 6820, 6822, 6824, 6826, 6828, 6830, 6832, 6834, 6836, 6838, 6840, 6842, 6844, 6846, 6848, 6850, 6852, 6854, 6856, 6858, 6860, 6862, 6864, 6866, 6868, 6870, 6872, 6874, 6876, 6878, 6880, 6882, 6884, 6886, 6888, 6890,6892, 6894, 6896, 6898, 6900, 6902, 6904, 6906, 6908, 6910, 6912, 6914, 6916, 6918, 6920, 6922, 6924, 6926, 6928, 6930, 6932, 6934, 6936, 6938, 6940, 6942, 6944, 6946, 6948, 6950, 6952, 6954, 6956, 6958, 6960, 6962, 6964, 6966, 6968, 6970, 69 72, 6974, 6976, 6978, 6980, 6982, 6984, 6986, 6988, 6990, 6992, 6994, 6996, 6998, 7000, 7002, 7004, 7006, 7008, 7010, 7012, 7014, 7016, 7018, 7020, 7022, 7024, 7026, 7028, 7030, 7032, 7034, 7036, 7038, 7040, 7042, 7044, 7046, 7048, 7050, 7052, 7054, 7056, 7058, 7060, 7062, 7064, 7066, 7068, 7070, 7072, 7074, 7076, 7078, 7080, 7082, 7084, 7086, 7088, 7090, 7092, 7094, 7096, 7098, 7100, 7102, 7104, 7106, 7108, 7110, 7112, 7114, 7116, 7118, 7120, 7122, 7124, 7126, 7128, 7130, 7132, 71 34, 7136, 7138, 7140, 7142, 7144, 7146, 7148, 7150, 7152, 7154, 7156, 7158, 7160, 7162, 7164, 7166, 7168, 7170, 7172, 7174, 7176, 7178, 7180, 7182, 7184, 7186, 7188, 7190, 7192, 7194, 7196, 7198, 7200, 7202, 7204, 7206, 7208, 7210, 7212 and 7214.
[0035] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 5 / 6 / 25 / 317, 5 / 6 / 69 / 288 / 303, 5 / 6 / 91 / 288 / 317, 5 / 25 / 91 / 212 / 303 / 317, 5 / 25 / 91 / 263, 5 / 25 / 288, 5 / 69 / 91 / 212 / 288, 5 / 69 / 91 / 212 / 303, 5 / 91 / 288 / 303, 5 / 91 / 303, 5 / 91 / 317 / 421, 5 / 288, 6 / 91 / 212 / 288 / 303 / 369 / 421, 6 / 212 / 288 / 303, 6 / 288, 25 / 91 / 212 / 288, 25 / 91 / 263 / 288 / 303, 25 / 91 / 303 / 317 / 369, 25 / 91 / 317 / 369, 25 / 263 / 317, 87 / 144, 87 / 144 / 159 / 361, 87 / 144 / 159 / 361 / 433, 87 / 433, 88 / 144, 88 / 144 / 159, 91 / 263 / 31 7 / 369, 91 / 288 / 303 / 317 / 369, 91 / 288 / 317 / 369 / 421, 91 / 303, 91 / 317, 91 / 317 / 369, 109 / 144 / 153 / 155 / 159 / 433, 144, 212 / 288, 263 / 288 / 303 / 317 and 288, wherein the positions are numbered with reference to SEQ ID NO: 6864.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 5S / 6P / 25I / 317Y, 5S / 6P / 69A / 288P / 303V, 5S / 6P / 91Q / 288P / 317Y, 5S / 25Q / 91Q / 212L / 303V / 317Y, 5S / 25Q / 91Q / 263T, 5S / 25Q / 288P, 5S / 69A / 91Q / 212L / 288P, 5S / 69A / 91Q / 212L / 303V, 5S / 91Q / 288P / 303V, 5S / 91Q / 303V, 5S / 91Q / 317Y / 421I, 5S / 288 P、6P / 91Q / 212L / 288P / 303V / 369K / 421I、6P / 212L / 288P / 303V、6P / 288P、25Q / 91Q / 212L / 288P、25Q / 91 Q / 263T / 288P / 303V, 25Q / 91Q / 317Y / 369K, 25Q / 91T / 303V / 317Y / 369K, 25Q / 263T / 317Y, 87K / 144Q, 87K / 144Q / 159K / 361C, 87K / 144Q / 159K / 361C / 433A, 87K / 433A, 88T / 144Q, 88T / 144Q / 159K, 91Q / 263T / 317 Y / 369K, 91Q / 288P / 303V / 317Y / 369K, 91Q / 288P / 317Y / 369K / 421I, 91Q / 303V, 91Q / 317Y, 91Q / 317Y / 369K, 109W / 144Q / 153V / 155L / 159K / 433A, 144Q, 212L / 288P, 263T / 288P / 303V / 317Y and 288P, wherein the positions are numbered with reference to SEQ ID NO: 6864.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: T5S / E6P / L25I / S317Y, T5S / E6P / D69A / E288P / Q303V, T5S / E6P / I91Q / E288P / S317Y, T5S / L25Q / I91Q / A212L / Q303V / S317Y, T5S / L25Q / I91Q / V263T, T5S / L25Q / E288P, T5S / D69A / I91Q / A212L 2L / E288P, T5S / D69A / I91Q / A212L / Q303V, T5S / I91Q / E288P / Q303V, T5S / I91Q / Q303V, T5S / I91Q / S317Y / V421I, T5S / E288P , E6P / I91Q / A212L / E288P / Q303V / V369K / V421I, E6P / A212L / E288P / Q303V, E6P / E288P, L25Q / I91Q / A212L / E288P, L25Q / I9 1Q / V263T / E288P / Q303V, L25Q / I91Q / S317Y / V369K, L25Q / I91T / Q303V / S317Y / V369K, L25Q / V263T / S317Y, M87K / M144Q, M8 7K / M144Q / Q159K / T361C, M87K / M144Q / Q159K / T361C / L433A, M87K / L433A, R88T / M144Q, R88T / M144Q / Q159K, I91Q / V263T / S 317Y / V369K, I91Q / E288P / Q303V / S317Y / V369K, I91Q / E288P / S317Y / V369K / V421I, I91Q / Q303V, I91Q / S317Y, I91Q / S317Y / V369K, R109W / M144Q / A153V / V155L / Q159K / L433A, M144Q, A212L / E288P, V263T / E288P / Q303V / S317Y and E288P, wherein the positions are numbered with reference to SEQ ID NO: 6864.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NOs: 7362, 7364, 7366, 7368, 7370, 7372, 7374, 7376, 7378, 7380, 7382, 7384, 7386, 7388, 7390, 7392, 7394, 7396, 7398, 7400, 7402, 7404, 7406, 7408, 7410, 7412, 7414, 7416, 7418, 7420, 7422, 7424, 7426, 7428, 7430, 7432, 7434, and 7436, wherein the positions are numbered with reference to SEQ ID NO: 6864. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 7362, 7364, 7366, 7368, 7370, 7372, 7374, 7376, 7378, 7380, 7382, 7384, 7386, 7388, 7390, 7392, 7394, 7396, 7398, 7400, 7402, 7404, 7406, 7408, 7410, 7412, 7414, 7416, 7418, 7420, 7422, 7424, 7426, 7428, 7430, 7432, 7434, and 7436. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 7362, 7364, 7366, 7368, 7370, 7372, 7374, 7376, 7378, 7380, 7382, 7384, 7386, 7388, 7390, 7392, 7394, 7396, 7398, 7400, 7402, 7404, 7406, 7408, 7410, 7412, 7414, 7416, 7418, 7420, 7422, 7424, 7426, 7428, 7430, 7432, 7434, and 7436.
[0036] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2 / 3 / 433 / 435 / 442, 2 / 81, 9 / 37 / 113 / 396, 9 / 87, 9 / 144 / 331, 37 / 113 / 144 / 396, 37 / 233, 53 / 144 / 233 / 269 / 331 / 428, 53 / 233 / 269 / 390 / 395 / 396, 53 / 234, 61 / 120 / 156 / 163 / 165 / 197 / 303 / 308, 61 / 120 / 159 / 300 / 308 / 407. 03 / 407、61 / 156 / 159 / 163 / 165 / 243 / 248 / 253 / 300 / 303 / 308、61 / 156 / 163 / 243 / 248 / 300 / 303 / 308 / 407、61 / 156 / 163 / 300 / 365 / 411、61 / 156 / 197 / 253、6 1 / 163 / 300 / 303 / 308 / 405 / 407 / 411、61 / 165 / 248 / 253 / 407 / 411、61 / 214、61 / 214 / 300 / 308、61 / 243 / 300 / 308 / 407 / 411、61 / 300 / 303 / 308、61 / 300 / 303 / 405, 61 / 365 / 405, 69, 69 / 81, 69 / 134, 69 / 263, 69 / 263 / 434 / 438 / 439, 69 / 439, 81, 81 / 134, 81 / 222, 81 / 222 / 263 / 322 / 435 / 442, 81 / 433 / 435 / 438 / 442, 8 5 / 156 / 159 / 243 / 248 / 253 / 308 / 405 / 407 / 411、87 / 144、87 / 144 / 396、113 / 233 / 234、120 / 156 / 159 / 169 / 197 / 214 / 303 / 308 / 365 / 405 / 407、120 / 156 / 159 / 248 / 300 / 308, 120 / 156 / 248 / 303 / 308 / 411, 120 / 159, 120 / 159 / 165 / 197, 120 / 159 / 197 / 308 / 407 / 411, 120 / 159 / 197 / 365 / 411, 120 / 197 / 253 / 300 / 308, 120 / 253 / 300 / 303 / 308 / 407、120 / 308 / 407 / 411、134 / 222 / 263、144 / 234 / 269、156 / 165 / 248 / 300 / 303 / 308、156 / 197 / 248 / 300 / 411、156 / 214 / 308 / 411、156 / 248 / 253 / 308、159 / 163 / 165 / 197 / 214 / 243 / 300 / 303 / 308 / 407、163 / 197 / 253 / 300 / 303 / 308 / 365、171 / 263、183 / 233 / 234 / 331 / 428、197 / 253 / 308 / 407、197 / 300 / 303 / 308 / 365, 197 / 300 / 308 / 411, 222, 222 / 263 / 435 / 442, 233 / 396 / 399, 263, 269, 269 / 428 / 437, 300 / 303 / 308, 300 / 308 / 405 / 411, 308 and 322, wherein the positions are numbered with reference to SEQ ID NO: 7388. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2K / 3M / 433A / 435E / 442F, 2K / 81T, 9G / 37S / 113D / 396T, 9G / 87K, 9G / 144Q / 331R, 37S / 113D / 144Q / 396T, 37S / 233S, 53E / 144Q / 233Q / 269R / 331R / 428I, 53E / 23 3Q / 269R / 390I / 395I / 396T, 53E / 234N, 61Q / 120V / 156S / 163A / 165L / 197K / 303V / 308L, 61Q / 120V / 159K / 300 A / 308L / 407I, 61Q / 120V / 300A / 303V / 407I, 61Q / 156S / 159K / 163A / 165L / 243I / 248W / 253T / 300A / 303V / 308L , 61Q / 156S / 163A / 243I / 248W / 300A / 303V / 308L / 407I, 61Q / 156S / 163A / 300A / 365I / 411T, 61Q / 156S / 197K / 253E, 61Q / 163A / 300A / 303V / 308L / 405P / 407I / 411T, 61Q / 165L / 248W / 253T / 407I / 411T, 61Q / 214R, 61Q / 214 R / 300A / 308L, 61Q / 243I / 300A / 308L / 407I / 411T, 61Q / 300A / 303V / 308L, 61Q / 300A / 303V / 405P, 61Q / 365I / 4 05P, 69A, 69A / 81T, 69A / 134E, 69A / 263T, 69A / 263T / 434E / 438S / 439H, 69A / 439H, 81T, 81T / 134E, 81T / 222A,81T / 222A / 263T / 322S / 435E / 442F, 81T / 433A / 435I / 438R / 442F, 85V / 156S / 159K / 243I / 248W / 253T / 308L / 405P / 407I / 411T, 87K / 144Q、87K / 144Q / 396T、113D / 233Q / 234N、120V / 156S / 159K / 169D / 197K / 214R / 303V / 308L / 365I / 405P / 407I、120V / 156S / 159K / 2 48W / 300A / 308L, 120V / 156S / 248W / 303V / 308L / 411T, 120V / 159K, 120V / 159K / 165L / 197K, 120V / 159K / 197K / 308L / 407I / 411T, 12 0V / 159K / 197K / 365I / 411T, 120V / 197K / 253T / 300A / 308L, 120V / 253T / 300A / 303V / 308L / 407I, 120V / 308L / 407I / 411T, 134E / 222 A / 263T, 144Q / 234N / 269R, 156S / 165L / 248W / 300A / 303V / 308L, 156S / 197K / 248W / 300A / 411T, 156S / 214R / 308L / 411T, 156S / 248 W / 253T / 308L, 159K / 163A / 165L / 197K / 214R / 243I / 300A / 303V / 308L / 407I, 163A / 197K / 253E / 300A / 303V / 308L / 365I, 171P / 263T , 183L / 233Q / 234N / 331R / 428I, 197K / 253T / 308L / 407I, 197K / 300A / 303V / 308L / 365I, 197K / 300A / 308L / 411T, 222A, 222A / 263T / 435I / 442F, 233Q / 396T / 399Q, 263T, 269R, 269R / 428I / 437L, 300A / 303V / 308L, 300A / 308L / 405P / 411T, 308L, and 322S, wherein the positions are numbered with reference to SEQ ID NO: 7388. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: P2K / N3M / L433A / R435E / S442F, P2K / H81T, V9G / R37S / S113D / Y396T, V9G / M87K, V9G / M144Q / K331R,R37S / S113D / M144Q / Y396T、R37S / W233S、K53E / M144Q / W233Q / Q269R / K331R / K428I、K53E / W233Q / Q269R / V390I / V395I / Y396T、K53E / R234N、S61Q / L120V / C156S / L163A / Y165L / Q197K / Q303V / R308L、S61Q / L120V / Q159K / D300A / R308L / V407I、S61Q / L120V / D300A / Q303V / V407I、S61Q / C156S / Q159K / L163A / Y165L / L243I / H248W / S253T / D300A / Q303V / R308L、S61Q / C156S / L163A / L243I / H248W / D300A / Q303V / R308L / V407I、S61Q / C156S / L163A / D300A / V365I / R411T、S61Q / C156S / Q197K / S253E、S61Q / L163A / D300A / Q303V / R308L / E405P / V407I / R411T、S61Q / Y165L / H248W / S253T / V407I / R411T、S61Q / S214R、S61Q / S214R / D300A / R308L、S61Q / L243I / D300A / R308L / V407I / R411T、S61Q / D300A / Q303V / R308L、S61Q / D300A / Q303V / E405P、S61Q / V365I / E405P、D69A、D69A / H81T、D69A / D134E、D69A / V263T、D69A / V263T / D434E / A438S / P439H、D69A / P439H、H81T、H81T / D134E、H81T / K222A、H81T / K222A / V263T / L322S / R435E / S442F、H81T / L433A / R435I / A438R / S442F、A85V / C156S / Q159K / L243I / H248W / S253T / R308L / E405P / V407I / R411T、M87K / M144Q、M87K / M144Q / Y396T、S113D / W233Q / R234N、L120V / C156S / Q159K / E169D / Q197K / S214R / Q303V / R308L / V365I / E405P / V407I、L120V / C156S / Q159K / H248W / D300A / R308L、L120V / C156S / H248W / Q303V / R308L / R411T, L120V / Q159K, L120V / Q159K / Y165L / Q197K, L120V / Q159K / Q197K / R3 08L / V407I / R411T, L120V / Q159K / Q197K / V365I / R411T, L120V / Q197K / S253T / D300A / R308L, L120V / S253T / D300A / Q303V / R308L / V407I, L120V / R308L / V407I / R411T, D134E / K222A / V263T, M144Q / R234N / Q269R, C156S / Y165L / H2 48W / D300A / Q303V / R308L, C156S / Q197K / H248W / D300A / R411T, C156S / S214R / R308L / R411T, C156S / H248W / S253T / R308L、Q159K / L163A / Y165L / Q197K / S214R / L243I / D300A / Q303V / R308L / V407I、L163A / Q197K / S253E / D300A / Q3 03V / R308L / V365I, K171P / V263T, M183L / W233Q / R234N / K331R / K428I, Q197K / S253T / R308L / V407I, Q197K / D300A / Q303V / R308L, D300A / R308L / E405P / R411T, R308L and L322S, wherein the positions are numbered with reference to SEQ ID NO: 7388. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 41, 56, 61, 72, 76, 87, 88, 107, 139, 156, 338, and 407, wherein the positions are numbered with reference to SEQ ID NO: 7388. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 41E, 56D, 61D, 61E, 72P, 76S, 87E, 88L, 88M, 107L, 107V, 139N, 156S,338V and 407T, wherein the positions are numbered with reference to SEQ ID NO: 7388. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: A41E, L56D, S61D, S61E, T72P, R76S, M87E, R88L, R88M, A107L, A107V, K139N, C156S, C338V, and V407T, wherein the positions are numbered with reference to SEQ ID NO: 7388. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: NO:7946, 7948, 7950, 7952, 7954, 7956, 7958, 7960, 7962, 7964, 7966, 7968, 7970, 7972, 7974, 7976, 7978, 7980, 7982, 7984, 7986, 79 88, 7990, 7992, 7994, 7996, 7998, 8000, 8002, 8004, 8006, 8008, 8010, 8012, 8014, 8016, 8018, 8020, 8022, 8024, 8026, 8028, 8030, 803 2. 8034, 8036, 8038, 8040, 8042, 8044, 8046, 8048, 8050, 8052, 8054, 8056, 8058, 8060, 8062, 8064, 8066, 8068, 8070, 8072, 8074, 8076, 8078, 8080, 8082, 8084, 8086, 8088, 8090, 8340, 8342, 8344, 8346, 8348, 8350, 8352, 8354, 8356, 8358, 8360, 8362, 8364, 8366, and 8368. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any of the following sequences: SEQ ID NO: 7946, 7948, 7950, 7952, 7954, 7956, 7958, 7960, 7962, 7964, 7966, 7968, 7970, 7972, 7974, 7976, 7978, 7980, 7982, 7984, 7986, 7988, 7990, 7992, 7994, 7995. 996、7998、8000、8002、8004、8006、8008、8010、8012、8014、8016、8018、8020、8022、8024、8026、8028、8030、8032、8034、8036、8038、8040、8042、8044、8046、8048, 8050, 8052, 8054, 8056, 8058, 8060, 8062, 8064, 8066, 8068, 8070, 8072, 8074, 8076, 8078, 8080, 8082, 8084, 8086, 8088, 8090, 8340, 8342, 8344, 8346, 8348, 8350, 8352, 8354, 8356, 8358, 8360, 8362, 8364, 8366, and 8368. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: NO:7946, 7948, 7950, 7952, 7954, 7956, 7958, 7960, 7962, 7964, 7966, 7968, 7970, 7972, 7974, 7976, 7978, 7980, 7982, 7984, 7986, 79 88, 7990, 7992, 7994, 7996, 7998, 8000, 8002, 8004, 8006, 8008, 8010, 8012, 8014, 8016, 8018, 8020, 8022, 8024, 8026, 8028, 8030, 803 2. 8034, 8036, 8038, 8040, 8042, 8044, 8046, 8048, 8050, 8052, 8054, 8056, 8058, 8060, 8062, 8064, 8066, 8068, 8070, 8072, 8074, 8076, 8078, 8080, 8082, 8084, 8086, 8088, 8090, 8340, 8342, 8344, 8346, 8348, 8350, 8352, 8354, 8356, 8358, 8360, 8362, 8364, 8366, and 8368.
[0037] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 37 / 72 / 76 / 81, 37 / 72 / 76 / 107 / 156 / 331, 37 / 72 / 195 / 331, 53 / 81 / 195 / 197, 69 / 72 / 76 / 107, 72 / 76 / 107 / 156, 72 / 76 / 107 / 195 / 197, 72 / 269, 81 / 107 / 195, 87, 87 / 91, 87 / 91 / 94, 87 / 94 / 95. / 120, 87 / 91 / 94 / 233, 87 / 91 / 94 / 233 / 259, 87 / 91 / 94 / 263 / 389, 87 / 91 / 120 / 233, 87 / 91 / 120 / 233 / 411 / 431 / 435 / 437, 87 / 91 / 144 / 259, 87 / 91 / 163, 87 / 91 / 163 / 233, 87 / 91 / 163 / 233 / 263, 87 / 91 / 163 / 389, 87 / 91 / 233, 87 / 91 / 233 / 389, 87 / 91 / 259 / 263 / 389 / 4 28 / 431 / 435 / 437、87 / 91 / 263 / 389、87 / 91 / 322、87 / 91 / 389、87 / 94、87 / 94 / 144 / 263 / 428 / 435、87 / 94 / 263、87 / 163 / 233、87 / 233、87 / 233 / 259、87 / 233 / 322 / 389 / 411、87 / 233 / 389、87 / 259、87 / 263、87 / 428 / 431 / 435、87 / 435、91、91 / 94、91 / 94 / 120 / 233、91 / 9 89, 428 / 431 / 435, wherein the positions are numbered with reference to SEQ ID NO: 8088. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 37S / 72P / 76S / 81T, 37S / 72P / 76S / 107L / 156S / 331R, 37S / 72P / 195Q / 331R, 53E / 81T / 195Q / 197K, 69A / 72P / 76S / 107L,72P / 76S / 107L / 156S、72P / 76S / 107L / 195Q / 197K、72P / 269R、81T / 107L / 195Q、87A、87A / 91L、87A / 91L / 94C / 233Q、87A / 91L / 94C / 233Q / 259T、 87A / 91L / 120L / 233Q, 87A / 91L / 120L / 233Q / 411T / 431M / 435E / 437L, 87A / 91L / 163A, 87A / 91L / 233Q, 87A / 91L / 233Q / 389L, 87A / 91L / 259T / 263 T / 389L / 428I / 431M / 435I / 437L、87A / 91L / 322S、87A / 94C、87A / 94C / 2 63T、87A / 233Q、87A / 233Q / 259T、87A / 233Q / 322S / 389L / 411T、87A / 233 Q / 389L, 87A / 259T, 87A / 263T, 87A / 428I / 431M / 435E, 87A / 435E, 87K, 87K / 91L, 87K / 91L / 94C, 87K / 91L / 94C / 120L, 87K / 91L / 94C / 233Q, 87K / 9 1L / 94C / 263T / 389L、87K / 91L / 120L / 233Q、87K / 91L / 144Q / 259T、87K / 91L / 163A / 233Q、87K / 91L / 163A / 233Q / 263T、87K / 91L / 163A / 389L、87K / 91L / 233Q、87K / 91L / 263T / 389L、87K / 91L / 389L、87K / 94C / 144Q / 263T / 428I / 435E、87K / 163A / 233Q、91L、91L / 94C、91L / 94C / 120L / 233Q、91L / 94C / 120L / 233Q / 389L / 431M / 438S、91L / 94C / 233Q / 259T、91L / 120L、91L / 120L / 233Q、91L / 233Q、91L / 233Q / 259T / 389L、91L / 233Q / 389L、94C / 233Q / 411T、144Q / 389L、163A / 233Q、195Q / 197K、197K、233Q、233Q / 259T / 263T、233Q / 259T / 389L、233Q / 438S、259T、263T、263T / 389L、322S、389L and 428I / 431M / 435E, wherein the positions are numbered with reference to SEQ ID NO: 8088. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: R37S / T72P / R76S / H81T, R37S / T72P / R76S / A107L / C156S / K331R, R37S / T72P / H195Q / K331R, K53E / H81T / H195Q / Q197K, D69A / T72P / R76S / A107L, T72P / R76S / A107L / C156S, T72P / R76S / A107L / H195Q / Q197K, T72P / Q269R, H81T. 1T / A107L / H195Q, M87A, M87A / Q91L, M87A / Q91L / K94C / W233Q, M87A / Q91L / K94C / W233Q / E259T, M87A / Q91L / V120L / W233Q, M87A / Q91L / V120L / W233Q / R411T / D431M / R435E / I437L, M87A / Q91L / L163A, M87A / Q91L / W233Q, M87A / Q91L / W233Q / E389L, M87A / Q91L / E259T / V263T / E389L / K42 8I / D431M / R435I / I437L, M87A / Q91L / L322S, M87A / K94C, M87A / K94C / V263T, M87A / W233Q, M87A / W233Q / E259T, M87A / W233Q / L322S / E389L / R 411T, M87A / W233Q / E389L, M87A / E259T, M87A / V263T, M87A / K428I / D43 1M / R435E, M87A / R435E, M87K, M87K / Q91L, M87K / Q91L / K94C, M87K / Q91 L / K94C / V120L, M87K / Q91L / K94C / W233Q, M87K / Q91L / K94C / V263T / E389L, M87K / Q91L / V120L / W233Q, M87K / Q91L / M144Q / E259T, M87K / Q91L / L163A / W233Q, M87K / Q91L / L163A / W233Q / V263T, M87K / Q91L / L163A / E389L, M87K / Q91L / W233Q, M87K / Q91L / V263T / E389L, M87K / Q91L / E389L,M87K / K94C / M144Q / V263T / K428I / R435E, M87K / L163A / W233Q, Q91L, Q91L / K94C, Q91L / K94C / V120L / W233Q, Q91L / K94C / V12 0L / W233Q / E389L / D431M / A438S, Q91L / K94C / W233Q / E259T, Q91L / V120L, Q91L / V120L / W233Q, Q91L / W233Q, Q91L / W233Q / E25 9T / E389L, Q91L / W233Q / E389L, K94C / W233Q / R411T, M144Q / E389L, L163A / W233Q, H195Q / Q197K, Q197K, W233Q, W233Q / E259T / V263T, W233Q / E259T / E389L, W233Q / A438S, E259T, V263T, V263T / E389L, L322S, E389L, and K428I / D431M / R435E, wherein the positions are numbered with reference to SEQ ID NO: 8088. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 55, 111, 252, 255, 324, 328, 413, and 451, wherein the positions are numbered with reference to SEQ ID NO: 8088. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 55G, 111T, 252P, 255T, 324D, 324G, 328T, 413L, and 451Q, wherein the positions are numbered with reference to SEQ ID NO: 8088. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: S55G, S111T, S252P, S255T, P324D, P324G, L328T, V413L, and V451Q, wherein the positions are numbered with reference to SEQ ID NO: 8088. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 8482, 8484, 8486, 8488, 8490, 8492, 8494, 8496, 8498, 8500, 8502, 8504, 8506, 8508, 8510, 8512, 8514, 8516, 8518, 8520, 8522, 8524, 8526, 8528, 8530, 8532, 8534, 8536, 8538, 8540, 8542, 8544, 8546, 8548,8550, 8552, 8554, 8556, 8558, 8560, 8562, 8564, 8566, 8568, 8570, 8572, 8574, 8576, 8578, 8580, 8582, 8584, 8586, 8588, 8590, 8592, 8594, 8596, 8598, 8600, 8602, 8604, 8606, 8608, 8610, 8612, 8614, 8616, 8618, 8620, 8622, 9224, 9226, 9228, 9230, 9232, 9234, 9236, 9238, and 9240. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 8482, 8484, 8486, 8488, 8490, 8492, 8494, 8496, 8498, 8500, 8502, 8504, 8506, 8508, 8510, 8512, 8514, 8516, 8518, 8520, 8522, 8524, 8526, 8528, 8530, 8532, 8534, 8536, 8538, 8540, 8542, 8544, 8546, 8548, 8550, 8552, 8554, 8556, 8558, 856 0, 8562, 8564, 8566, 8568, 8570, 8572, 8574, 8576, 8578, 8580, 8582, 8584, 8586, 8588, 8590, 8592, 8594, 8596, 8598, 8600, 8602, 8604, 8606, 8608, 8610, 8612, 8614, 8616, 8618, 8620, 8622, 9224, 9226, 9228, 9230, 9232, 9234, 9236, 9238, and 9240. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO:8482, 8484, 8486, 8488, 8490, 8492, 8494, 8496, 8498, 8500, 8502, 8504, 8506, 8508, 8510, 8512, 8514, 8516, 8518, 8520, 8522, 8524, 8526, 8528, 8530, 8532, 853 4.8536,8538,8540,8542,8544,8546,8548,8550,8552,8554,8556,8558,8560,8562,8564,8566,8568,8570,8572,8574,8576,8578,8580,8582,8584,8586,8588,8590, 8592, 8594, 8596, 8598, 8600, 8602, 8604, 8606, 8608, 8610, 8612, 8614, 8616, 8618, 8620, 8622, 9224, 9226, 9228, 9230, 9232, 9234, 9236, 9238, and 9240.
[0038] In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, and / or 108. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, and / or 108. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises SEQ ID NO: 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, and / or 108.
[0039] The present invention also provides engineered glycosyltransferases, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 69 / 173 / 175 / 243 / 246 / 354 / 365 / 383 / 399, 69 / 173 / 243 / 383 / 399, 56 / 191 / 354 / 383 / 399, 70 / 225 / 246 / 409 / 413, 70 / 115 / 225 / 409, 70 / 225 / 413, 70 / 225 / 247, 74 / 310 / 396 / 424, 74 / 396, and 173 / 175 / 191 / 365 / 383 / 399, wherein the positions are numbered with reference to SEQ ID NO: 758. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 69H / 173N / 175S / 243A / 246K / 354I / 365I / 383V / 399A, 69H / 173N / 243A / 383V / 399A, 56T / 191D / 354I / 383V / 399A , 70L / 225G / 246P / 409K / 413V, 70L / 115S / 225G / 409K, 70L / 225G / 413V, 70L / 225G / 247G, 74T / 310D / 396E / 424S, 74T / 396E and 173H / 175S / 191D / 365I / 383V / 399A, wherein the positions are numbered with reference to SEQ ID NO: 758. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: R69H / Y173N / P175S / V243A / M246K / L354I / M365I / M383V / T399A, R69H / Y173N / V243A / M383V / T399A, I56T / N191D / L354I / M383V / T399A, F70 L / N225G / M246P / E409K / I413V, F70L / Q115S / N225G / E409K, F70L / N225G / I413V, F70L / N225G / E247G, H74T / K310D / G396E / N424S, H74T / G396E, and Y173H / P175S / N191D / M365I / M383V / T399A, wherein the positions are numbered with reference to SEQ ID NO: 758. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 770, 772, 774, 776, 778, 780, 782, 784, 786, and / or 788.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 770, 772, 774, 776, 778, 780, 782, 784, 786, and / or 788. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 770, 772, 774, 776, 778, 780, 782, 784, 786, and / or 788.
[0040] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24 / 28, 24 / 28 / 262, 24 / 28 / 262 / 264, 24 / 28 / 262 / 264 / 423, 24 / 264 / 294, 28, 28 / 262 / 264, 28 / 423, 69 / 173 / 175 / 243 / 246 / 354 / 365 / 383 / 399, : 69 / 173 / 243 / 383 / 399, 56 / 191 / 354 / 383 / 399, 70 / 115 / 225 / 409, 70 / 225 / 246 / 409 / 413, 70 / 225 / 247, 70 / 225 / 413, 74 / 310 / 396 / 424, 74 / 396, 159, 173 / 175 / 191 / 365 / 383 / 399, 199, 262 / 264 and 264 / 29, wherein the positions are numbered with reference to SEQ ID NO: 770. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24E / 28N, 24E / 28N / 262Y, 24E / 28N / 262Y / 264S, 24E / 28N / 262Y / 264S / 423E, 24E / 264S / 294V, 28N, 28N / 262Y / 264S, 28N / 423E, 69H / 173N / 175S / 243A / 246K / 354I / 365I / 383V / 399A, 69H / 173N / 24 770, 3A / 383V / 399A, 56T / 191D / 354I / 383V / 399A, 70L / 115S / 225G / 409K, 70L / 225G / 246P / 409K / 413V, 70L / 225G / 247G, 70L / 225G / 413V, 74T / 310D / 396E / 424S, 74T / 396E, 159R, 173H / 175S / 191D / 365I / 383V / 399A, 199H, 262Y / 264S, and 264S / 291V, wherein the positions are numbered with reference to SEQ ID NO: 770.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: Y24E / S28N, Y24E / S28N / F262Y, Y24E / S28N / F262Y / C264S, Y24E / S28N / F262Y / C264S / K423E, Y24E / C264S / A294V, S28N, S28N / F262Y / C264S, S28N / K423E, R69H / Y173N / P175S / V243A / M246K / L354I / M365I / M383V / T399A, R69H / Y173N / V243A / M383V / T399A, I56T / N191D / L354I / M383V / T399A, F70L / Q115S / N225G / E409K, F70L / N225G / M246P / E409K / I413V, F70L / N225G / E247G, F70L / N225G / I413V, H74T / K310D / G396E / N424S, H74T / G396E, F156R, Y173H / P175S / N191D / M365I / M383V / T399A, G199H, F262Y / C264S and C264S / I291V, wherein the positions are referred to in SEQ In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 790, 792, 794, 796, 798, 800, 802, 804, 806, 808, 1292, and / or 1294. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 790, 792, 794, 796, 798, 800, 802, 804, 806, 808, 1292, and / or 1294. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 790, 792, 794, 796, 798, 800, 802, 804, 806, 808, 1292 and / or 1294.
[0041] The present invention also provides engineered glycosyltransferases, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24, 28, 32, 264, 269, 325, 341, 351, and 366, wherein the positions are numbered with reference to SEQ ID NO: 770. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24L / V, 28G / K / L, 32C / R / S, 264A / G, 269S / W, 325G / H, 341V, 351L, and 366L / Q / T, wherein the positions are numbered with reference to SEQ ID NO: 770. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: Y24L / V, S28G / K / L, N32C / R / S, C264A / G, Y269S / W, K325G / H, F341V, M351L, and H366L / Q / T, wherein the positions are numbered with reference to SEQ ID NO: 770. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 810, 812, 814, 816, 818, 820, 822, 824, 826, 828, 830, 832, 834, 836, 838, 840, 842, 844, and / or 846. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 810, 812, 814, 816, 818, 820, 822, 824, 826, 828, 830, 832, 834, 836, 838, 840, 842, 844, and / or 846. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 810, 812, 814, 816, 818, 820, 822, 824, 826, 828, 830, 832, 834, 836, 838, 840, 842, 844, and / or 846.
[0042] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 56 / 69 / 70 / 175 / 191 / 246, 56 / 69 / 70 / 175 / 191 / 246 / 354, 56 / 69 / 70 / 175 / 354, 56 / 69 / 70 / 191 / 246 / 354 / 365, 56 / 69 / 70 / 246 / 354, 56 / 69 / 175 / 191 / 246 / 354, 56 / 69 / 175 / 246 / 354 / 365. / 175 / 246 / 354 / 365, 56 / 69 / 246 / 354, 56 / 69 / 246 / 365, 56 / 70 / 175 / 191 / 246, 56 / 70 / 175 / 191 / 246 / 354, 56 / 70 / 175 / 191 / 354 / 365, 56 / 70 / 175 / 246 / 354, 56 / 70 / 175 / 246 / 365, 56 / 70 / 191 / 246 / 354 / 365, 56 / 70 / 191 / 354, 56 / 175 / 246, 56 / 175 / 354, 56 / 175 / 3 54 / 365, 56 / 191 / 246 / 354, 56 / 246, 56 / 246 / 354 / 365, 56 / 354, 69, 69 / 70 / 175 / 191 / 246 / 354 / 365, 69 / 70 / 191 / 246 / 354 / 365, 69 / 70 / 246, 69 / 70 / 354 / 365, 69 / 175 / 191 / 246 / 354, 69 / 175 / 354, 69 / 246 / 354 / 365, 69 / 354, 70, 70 / 175 / 191 / 246 / 354 / 365, 70 / 175 4, 175 / 246 / 354, 175 / 246 / 354 / 365, 175 / 354, 191 / 246 / 354, 246 / 354, 354, and 354 / 365, wherein the positions are numbered with reference to SEQ ID NO: 770. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 56T / 69Q / 70L / 175S / 191D / 246K, 56T / 69Q / 70L / 175S / 191D / 246K / 354I, 56T / 69Q / 70L / 175S / 354I,56T / 69Q / 70L / 191D / 246K / 354I / 365I, 56T / 69Q / 70L / 246K / 354I, 56T / 69Q / 175S / 191D / 246K / 354I, 56T / 69Q / 175S / 246K / 354I, 56T / 69Q / 175S / 246K / 354I / 365I, 56T / 69Q / 246K / 354I, 56T / 69Q / 246K / M65I, 56T / 70L / 175S / 191D / 246K, 56T / 70L / 175S / 191D / 246K / 354I, 56T / 7 0L / 175S / 191D / 354I / 365I, 56T / 70L / 175S / 246K / 354I, 56T / 70L / 175S / 246K / 365I, 56T / 70L / 191D / 246K / 354I / 365I, 56T / 70L / 191D / 35 4I, 56T / 175S / 246K, 56T / 175S / 354I, 56T / 175S / 354I / 365I, 56T / 191D / 246K / 354I, 56T / 246K, 56T / 246K / 354I / 365I, 56T / 354I, 69Q, 69Q / 70L / 175S / 191D / 246K / 354I / 365I、69Q / 70L / 191D / 246K / 354I / 365I、69Q / 70L / 246K、69Q / 70L / 354I / 365I、69Q / 175S / 191D / 246K / 354I , 69Q / 175S / 354I, 69Q / 246K / 354I / 365I, 69Q / 354I, 70L, 70L / 175S / 191D / 246K / 354I / 365I, 70L / 175S / 191D / 354I / 365I, 70L / 191D / 246K / 354I / 365I, 70L / 191D / 246K / 365I, 126F, 126F / 220L, 126F / 403R, 175S, 175S / 191D, 175S / 191D / 246K / 354I / 365I, 175S / 191D / 354I, 175S / 191D / 354I / 365I, 175S / 246K / 354I, 175S / 246K / 354I / 365I, 175S / 354I, 191D / 246K / 354I, 246K / 354I, 354I, and 354I / 365I, wherein the positions are numbered with reference to SEQ ID NO: 770. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: I56T / H69Q / F70L / P175S / N191D / M246K,I56T / H69Q / F70L / P175S / N191D / M246K / L354I、I56T / H69Q / F70L / P175S / L354I、I56T / H69Q / F70L / N191D / M246K / L354I / M365I、I56T / H69Q / F70L / M246K / L354I、I56T / H69Q / P175S / N191D / M246K / L354I、I56T / H69Q / P175S / M246K / L354I、I56T / H69Q / P175S / M246K / L354I / M365I、I56T / H69Q / M246K / L354I、I56T / H69Q / M246K / M365I、I56T / F70L / P175S / N191D / M246K、I56T / F70L / P175S / N191D / M246K / L354I、I56T / F70L / P175S / N191D / L354I / M365I、I56T / F70L / P175S / M246K / L354I、I56T / F70L / P175S / M246K / M365I、I56T / F70L / N191D / M246K / L354I / M365I、I56T / F70L / N191D / L354I、I56T / P175S / M246K、I56T / P175S / L354I、I56T / P175S / L354I / M365I、I56T / N191D / M246K / L354I、I56T / M246K、I56T / M246K / L354I / M365I、I56T / L354I、H69Q、H69Q / F70L / P175S / N191D / M246K / L354I / M365I、H69Q / F70L / N191D / M246K / L354I / M365I、H69Q / F70L / M246K、H69Q / F70L / L354I / M365I、H69Q / P175S / N191D / M246K / L354I、H69Q / P175S / L354I、H69Q / M246K / L354I / M365I、H69Q / L354I、F70L、F70L / P175S / N191D / M246K / L354I / M365I、F70L / P175S / N191D / L354I / M365I、F70L / N191D / M246K / L354I / M365I、F70L / N191D / M246K / M365I、I126F、I126F / C220L、I126F / K403R、P175S、P175S / N191D、P175S / N191D / M246K / L354I / M365I、P175S / N191D / L354I, P175S / N191D / L354I / M365I, P175S / M246K / L354I, P175S / M246K / L354I / M365I, P175S / L354I, N191D / M246K / L354I, M246K / L354I, L354I and L354I / M365I, wherein the positions are numbered with reference to SEQ ID NO: 770. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 848, 850, 852, 854, 856, 858, 860, 862, 864, 866, 868, 870, 872, 874, 876, 878, 880, 882, 884, 886, 888, 890, 892, 894, 896, 898, 900, 902, 904, 906, 908, 910, 912, 914, 916, 918, 920, 922, 924, 926, 928, 930, 932, 934, 936, 938, 940, 942, 944, 946, 948, 950 and / or 952. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 848, 850, 852, 854, 856, 858, 860, 862, 864, 866, 868, 870, 872, 874, 876, 878, 880, 882, 884, 886, 888, 890, 892, 894, 896, 898, 900, 902, 904, 906, 908, 910, 912, 914, 916, 918, 920, 922, 924, 926, 928, 930, 932, 934, 936, 938, 940, 942, 944, 946, 948, 950, and / or 952. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 848, 850, 852, 854, 856, 858, 860, 862, 864, 866, 868, 870, 872, 874, 876, 878, 880, 882, 884, 886, 888, 890, 892, 894, 896, 898, 900, 902, 904, 906, 908, 910, 912, 914, 916, 918, 920, 922, 924, 926, 928, 930, 932, 934, 936, 938, 940, 942, 944, 946, 948, 950, and / or 952.
[0043] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24 / 32 / 264 / 269 / 330 / 402 / 403, 24 / 32 / 264 / 269 / 382 / 403 / 406, 24 / 32 / 264 / 330, 24 / 32 / 269, 24 / 32 / 2 69 / 382 / 385 / 389 / 402 / 406、24 / 32 / 269 / 403、24 / 32 / 330、24 / 264 / 269 / 389 / 402 / 406、70 / 126 / 175 / 191 / 246 / 325 / 354 / 366、70 / 126 / 175 / 325 / 330 / 351 / 354 / 366、70 / 126 / 19 1 / 246 / 325 / 351 / 354 / 366 / 423、70 / 126 / 191 / 246 / 325 / 351 / 354 / 423、70 / 126 / 191 / 246 / 325 / 351 / 366 / 423、70 / 126 / 191 / 246 / 354 / 366、70 / 126 / 246 / 330 / 366、70 / 126 / 246 / and 220 / 260 / 423, wherein the positions are numbered with reference to SEQ ID NO: 792.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24L / 32S / 264A / 269S / 330Q / 402V / 403R, 24L / 32S / 264A / 269S / 382G / 403R / 406M, 24L / 32S / 264A / 330Q, 24L / 32S / 269S, 24L / 32S / 269S / 382G / 385V / 386M. 9E / 402I / 406M, 24L / 32S / 269S / 403R, 24L / 32S / 330Q, 24L / 264A / 269S / 389E / 402V / 406M, 70L / 126F / 175S / 191D / 246K / 325H / 354I / 366Q、70L / 126F / 175S / 325H / 330Q / 351L / 354I / 366Q、70L / 126F / 191D / 246K / 32 5H / 351L / 354I / 366Q / 423K, 70L / 126F / 191D / 246K / 325H / 351L / 354I / 423K, 70L / 126F / 191D / 246K / 325H / 351L / 366Q / 423K、70L / 126F / 191D / 246K / 354I / 366Q、70L / 126F / 246K / 330Q / 366Q、70L / 126F / 246K / 354 : 1 / 366Q, 126F / 211E / 220L / 253D / 316V / 342L, 126F / 211E / 220L / 275Q / 279L / 323V, 126F / 211E / 260V / 423K, 126F / 220L / 260V, 126F / 220L / 316V, 56V / 220L / 260V / 423K, 220L / 260V, and 220L / 260V / 423K, wherein the positions are numbered with reference to SEQ ID NO: 792.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: E24L / N32S / S264A / Y269S / P330Q / L402V / K403R, E24L / N32S / S264A / Y269S / A382G / K403R / I406M, E24L / N32S / S264A / P330Q, E24L / N32S / Y269S, E24L / N32S / Y269S / A382G / I385V / D389E / L402V / K403R. 2I / I406M, E24L / N32S / Y269S / K403R, E24L / N32S / P330Q, E24L / S264A / Y269S / D389E / L402V / I406M, F70L / I126F / P175S / N19 1D / M246K / K325H / L354I / H366Q, F70L / I126F / P175S / K325H / P330Q / M351L / L354I / H366Q, F70L / I126F / N191D / M246K / K325H / M351L / L354I / H366Q / E423K, F70L / I126F / N191D / M246K / K325H / M351L / L354I / E423K, F70L / I126F / N191D / M246K / K325H / M 351L / H366Q / E423K, F70L / I126F / N191D / M246K / L354I / H366Q, F70L / I126F / M246K / P330Q / H366Q, F70L / I126F / M246K / L354 I / H366Q, I126F / T211E / C220L / G253D / I316V / I342L, I126F / T211E / C220L / D275Q / V279L / L323V, I126F / T211E / T260V / E423K, I126F / C220L / T260V, I126F / C220L / I316V, I56V / C220L / T260V / E423K, C220L / T260V, and C220L / T260V / E423K, wherein the positions are numbered with reference to SEQ ID NO: 792. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any of the following sequences: SEQ ID NO: 954, 956, 958, 960, 962, 964, 966, 968, 970, 972, 974, 976, 978, 980, 982, 984, 986, 988, 990, 992, 994, 996, 998 and / or 1000.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any of the following sequences: SEQ ID NO: 954, 956, 958, 960, 962, 964, 966, 968, 970, 972, 974, 976, 978, 980, 982, 984, 986, 988, 990, 992, 994, 996, 998 and / or 1000. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 954, 956, 958, 960, 962, 964, 966, 968, 970, 972, 974, 976, 978, 980, 982, 984, 986, 988, 990, 992, 994, 996, 998 and / or 1000.
[0044] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24 / 32 / 97 / 162 / 202, 24 / 32 / 126 / 198 / 201 / 367, 24 / 32 / 126 / 198 / 202 / 220 / 226 / 260 / 269S, 24 / 32 / 146 / 226, 24 / 32 / 198 / 201 / 220 / 226, 24 / 32 / 198 / 201 / 226, 24 / 97 / 260 / 367, 24 / 32 / 9 7 / 198 / 202 / 226 / 260、32 / 202 / 367、32 / 226 / 367、56 / 175 / 197 / 211 / 330 / 382 / 385、56 / 175 / 197 / 253 / 385 / 389、56 / 175 / 264 / 382 / 385 / 389 / 402 / 406、56 / 197 / 264 / 279 / 330 / 382 / 389 / 402 / 403 / 406、56 / 211 / 253 / 316 / 323、56 / 211 / 264 / 316 / 389、56 / 211 / 279 / 323 / 330 / 402、56 / 264 / 385 / 389、97 / 202 / 367、162 / 220 / 226 / 367、175 / 197 / 211 / 264 / 330、175 / 211 / 264 / 279 / 316 / 323、175 / 211 / 279 / 323 / 330 / 402 / 403 / 406、175 / 211 / 323 / 382 / 402 / 403 / 406、175 / 211 / 403 / 406、175 / 264 / 316 / 323 / 330 / 403 / 40 6, 175 / 264 / 316 / 389 / 402, 175 / 264 / 323 / 330, 197 / 211 / 316 / 342 / 406, 197 / 211 / 316 / 382 / 389 / 402 / 403, 197 / 211 / 402, 197 / 279 / 323, 198 / 201 / 367, 198 / 202 / 220 / 269 / 367, 201 / 202 / 367, 211 / 382 / 406, 211 / 385 / 389, 211 / 402 / 403 and 389, wherein the positions are numbered with reference to SEQ ID NO:954. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24L / 32S / 97G / 162R / 202G, 24L / 32S / 126A / 198P / 201G / 367W, 24L / 32S / 126A / 198P / 202G / 220L / 226V / 260V / 269S, 24L / 32S / 146A / 226V,24L / 32S / 198P / 201G / 220L / 226V, 24L / 32S / 198P / 201G / 226V, 24L / 97G / 260V / 367W, 32S / 97G / 198P / 202G / 226V / 260V, 32S / 202G / 367W、32S / 226V / 367W、56V / 175S / 197P / 211E / 330Q / 382G / 385V、56V / 175S / 197P / 253D / 385V / 389E、56V / 175S / 264A / 382G / 385V / 389E / 402V / 406M, 56V / 197P / 264A / 279L / 330Q / 382G / 389E / 402V / 403R / 406M, 56V / 211E / 253D / 316V / 323V, 56V / 211E / 264A / 31 6V / 389E, 56V / 211E / 279L / 323V / 330Q / 402I, 56V / 264A / 385V / 389E, 97G / 202G / 367W, 162R / 220L / 226V / 367W, 175S / 197P / 211E / 2 64A / 330Q, 175S / 211E / 264A / 279L / 316V / 323V, 175S / 211E / 279L / 323V / 330Q / 402I / 403R / 406M, 175S / 211E / 323V / 382G / 402I / 4 03R / 406M, 175S / 211E / 403R / 406M, 175S / 264A / 316V / 323V / 330Q / 403R / 406M, 175S / 264A / 316V / 389E / 402V, 175S / 264A / 323V / 33 97P / 211E / 316V / 342L / 406M, 197P / 211E / 316V / 382G / 389E / 402I / 403R, 197P / 211E / 402I, 197P / 279L / 323V, 198P / 201G / 367W, 198P / 202G / 220L / 269S / 367W, 201G / 202G / 367W, 211E / 382G / 406M, 211E / 385V / 389E, 211E / 402I / 403R and D389E, wherein the positions are numbered with reference to SEQ ID NO: 954. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: E24L / N32S / H97G / N162R / Q202G, E24L / N32S / F126A / E198P / M201G / N367W,E24L / N32S / F126A / E198P / Q202G / C220L / W226V / T260V / Y269S、E24L / N32S / L146A / W226V、E24L / N32S / E198P / M201G / C220L / W226V、E24L / N32S / E198P / M201G / W226V、E24L / H97G / T260V / N367W、N32S / H97G / E198P / Q202G / W226V / T260V、N32S / Q202G / N367W、N32S / W226V / N367W、I56V / P175S / A197P / T211E / P330Q / A382G / I385V、I56V / P175S / A197P / G253D / I385V / D389E、I56V / P175S / S264A / A382G / I385V / D389E / L402V / I406M、I56V / A197P / S264A / V279L / P330Q / A382G / D389E / L402V / K403R / I406M、I56V / T211E / G253D / I316V / L323V、I56V / T211E / S264A / I316V / D389E、I56V / T211E / V279L / L323V / P330Q / L402I、I56V / S264A / I385V / D389E、H97G / Q202G / N367W、N162R / C220L / W226V / N367W、P175S / A197P / T211E / S264A / P330Q、P175S / T211E / S264A / V279L / I316V / L323V、P175S / T211E / V279L / L323V / P330Q / L402I / K403R / I406M、P175S / T211E / L323V / A382G / L402I / K403R / I406M、P175S / T211E / K403R / I406M、P175S / S264A / I316V / L323V / P330Q / K403R / I406M、P175S / S264A / I316V / D389E / L402V、P175S / S264A / L323V / P330Q、A197P / T211E / I316V / I342L / I406M、A197P / T211E / I316V / A382G / D389E / L402I / K403R、A197P / T211E / L402I、A197P / V279L / L323V、E198P / M201G / N367W、E198P / Q202G / C220L / Y269S / N367W、M201G / Q202G / N367W, T211E / A382G / I406M, T211E / I385V / D389E, T211E / L402I / K403R and D389E, wherein the positions are numbered with reference to SEQ ID NO: 954. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 1002, 1004, 1006, 1008, 1010, 1012, 1014, 1016, 1018, 1020, 1022, 1024, 1026, 1028, 1030, 1032, 1034, 1036, 1038, 1040, 1042, 1044, 1046, 1048, 1050, 1052, 1054, 1056, 1058, 1060, 1062, 1064, 1066, 1068, 1070, 1072, 1074, 1076, and / or 1078. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 1002, 1004, 1006, 1008, 1010, 1012, 1014, 1016, 1018, 1020, 1022, 1024, 1026, 1028, 1030, 1032, 1034, 1036, 1038, 1040, 1042, 1044, 1046, 1048, 1050, 1052, 1054, 1056, 1058, 1060, 1062, 1064, 1066, 1068, 1070, 1072, 1074, 1076, and / or 1078. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 1002, 1004, 1006, 1008, 1010, 1012, 1014, 1016, 1018, 1020, 1022, 1024, 1026, 1028, 1030, 1032, 1034, 1036, 1038, 1040, 1042, 1044, 1046, 1048, 1050, 1052, 1054, 1056, 1058, 1060, 1062, 1064, 1066, 1068, 1070, 1072, 1074, 1076, and / or 1078.
[0045] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24 / 32 / 175 / 211 / 260 / 330 / 403 / 406, 24 / 32 / 175 / 226 / 253 / 275 / 316, 24 / 32 / 201 / 226 / 260 / 264 / 330 / 402 / 406, 24 / 162 / 175 / 198 / 211 / 226 / 275 / 316 / 323 / 389, 24 / 162 / 175 / 201 / 275 / 316, 24 / 162 / 198 / 201 / 211 / 226 / 323 / 351, 24 / 162 / 198 / 201 / 226 / 351, 24 / 162 / 201 / 253 / 264 / 351 / 402 / 406, 24 / 175 / 198 / 211 / 226 / 253 / 316, 24 / 175 / 201 / 275 / 316 / 351, 24 / 175 / 201 / 316, 24 / 175 / 211 / 220 / 260 / 275 / 330 / 389, 24 / 175 / 211 / 253 / 316, 24 / 175 / 211 / 316 / 330, 24 / 175 / 226 / 323 / 351, 24 / 198 / 201, 24 / 198 / 201 / 211, 24 / 198 / 201 / 211 / 220 / 260, 24 / 198 / 201 / 220 / 275 / 389 / 402 / 406, 24 / 198 / 201 / 226 / 330 / 389 , 24 / 198 / 201 / 351, 24 / 201 / 211 / 253 / 323 / 351 / 366 / 389 / 402 / 403, 24 / 201 / 226 / 253 / 402 / 403 / 406, 24 / 226 / 330 / 351 / 403, 175 / 198 / 201 / 211 / 226 / 260 / 264 / 323 / 402 / 406, and 175 / 198 / 226 / 260 / 351 / 402 / 403 / 406, wherein the positions are numbered with reference to SEQ ID NO: 1054. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24L / 32S / 175S / 211E / 260V / 330Q / 403R / 406M, 24L / 32S / 175S / 226V / 253D / 275Q / 316V, 24L / 32S / 201G / 226V / 260V / 264A / 330Q / 402I / 406M, 24L / 162R / 175S / 198P / 211E / 226V / 275Q / 316V / 323V / 389E, 24L / 162R / 175S / 201G / 275Q / 316V,24L / 162R / 198P / 201G / 211E / 226V / 323V / 351M, 24L / 162R / 198P / 201G / 226V / 351M, 24L / 162R / 201G / 253D / 264A / 351M / 402I / 406M, 24L / 175S / 198P / 211E / 226V / 253D / 316V, 24L / 175S / 201G / 275Q / 316V / 351M、24L / 175S / 201G / 316V、24L / 175S / 211E / 220L / 260V / 275Q / 330Q / 389E、24L / 175S / 211E / 253D / 316V、24L / 175S / 211E / 316V / 330Q、24L / 175S / 226V / 323V / 351M、24L / 198P / 201G、24L / 198P / 201G / 211E, 24L / 198P / 201G / 211E / 220L / 260V, 24L / 198P / 201G / 220L / 275Q / 389E / 402I / 406M, 24L / 198P / 201G / 226V / 330Q / 389E, 24L / 198P / 201G / 351M, 24L / 201G / 211E / 253D / 323V / 351M / 366H / 389E / 402I / 403R, 24L / 201G / 226V / 253D / 402I / 403R / 406M, 24L / 226V / 330Q / 351M / 403R, 175S / 198P / 201G / 211E / 226V / 260V / 264A / 323V / 402I / 406M and 175S / 198P / 226V / 260V / 351M / 402I / 403R / 406M, wherein the positions are numbered with reference to SEQ ID NO: 1054. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: E24L / N32S / P175S / T211E / T260V / P330Q / K403R / I406M, E24L / N32S / P175S / W226V / G253D / D275Q / I316V, E24L / N32S / M201G / W226V / T260V / S 264A / P330Q / L402I / I406M, E24L / N162R / P175S / E198P / T211E / W226V / D275Q / I316V / L323V / D389E, E24L / N162R / P175S / M201G / D275Q / I316V, E24L / N162R / E198P / M201G / T211E / W226V / L323V / L351M,E24L / N162R / E198P / M201G / W226V / L351M, E24L / N162R / M201G / G253D / S264A / L351M / L402I / I406M, E24L / P175S / E198P / T211E / W226V / G253D / I316V, E24L / P175S / M201G / D275Q / I316V / L351M, E24L / P175S / M201G / I316V, E24L / P175S / T211E / C220L / T260V / D275Q / P330Q / D389E, E24L / P175S / T211E / G253D / I316V, E24L / P175S / T211E / I316 V / P330Q, E24L / P175S / W226V / L323V / L351M, E24L / E198P / M201G, E24L / E198P / M201G / T211E, E24L / E198P / M201G / T211E / C220L / T260V, E24L / E198P / M201G / C220L / D275Q / D389E / L402I / I406M, E24L / E198P / M201G / W226V / P330 Q / D389E, E24L / E198P / M201G / L351M, E24L / M201G / T211E / G253D / L323V / L351M / Q366H / D389E / L402I / K403R, E24 L / M201G / W226V / G253D / L402I / K403R / I406M, E24L / W226V / P330Q / L351M / K403R, P175S / E198P / M201G / T211E / W226V / T260V / S264A / L323V / L402I / I406M and P175S / E198P / W226V / T260V / L351M / L402I / K403R / I406M, wherein the positions are numbered with reference to SEQ ID NO: 1054. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any of the following sequences: SEQ ID NO: 2596, 2598, 2600, 2602, 2604, 2606, 2608, 2610, 2612, 2614, 2616, 2618, 2620, 2622, 2624, 2626, 2628, 2630, 2632, 2634, 2636, 2638, 2640, 2642,2644 and 2646. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 2596, 2598, 2600, 2602, 2604, 2606, 2608, 2610, 2612, 2614, 2616, 2618, 2620, 2622, 2624, 2626, 2628, 2630, 2632, 2634, 2636, 2638, 2640, 2642, 2644, and 2646. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 2596, 2598, 2600, 2602, 2604, 2606, 2608, 2610, 2612, 2614, 2616, 2618, 2620, 2622, 2624, 2626, 2628, 2630, 2632, 2634, 2636, 2638, 2640, 2642, 2644, and 2646.
[0046] The present invention also provides engineered glycosyltransferases, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 21 / 127 / 129 / 161, 21 / 127 / 129 / 161 / 162, 21 / 127 / 129 / 162 / 199 / 200, 127 / 129 / 161 / 162 / 199, 127 / 129 / 161 / 199 / 200, 127 / 129 / 162, 156, 156 / 161, 156 / 161 / 162, 156 / 162 / 199, and 156 / 199 / 200, wherein the positions are numbered with reference to SEQ ID NO: 1002. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 21Y / 127H / 129A / 161S, 21Y / 127H / 129A / 161S / 162G, 21Y / 127H / 129A / 162T / 199H / 200A, 127H / 129A / 162T, 127Q / 129A / 161S / 162G / 199H, 127Q / 129A / 161S / 199H / 200A, 156R, 156R / 161S, 156R / 161S / 162G, 156R / 161S / 162T, 156R / 162G / 199H, and 156R / 199H / 200A. NO: 1002. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: W21Y / L127H / P129A / K161S, W21Y / L127H / P129A / K161S / N162G, W21Y / L127H / P129A / N162T / G199H / N200A, L127H / P129A / N162T, L12 7Q / P129A / K161S / N162G / G199H, L127Q / P129A / K161S / G199H / N200A, F156R, F156R / K161S, F156R / K161S / N162G, F156R / K161S / N162T, F156R / N162G / G199H and F156R / G199H / N200A, wherein the positions are numbered with reference to SEQ ID NO: 1002.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 2648, 2650, 2652, 2654, 2656, 2658, 2660, 2662, 2664, 2666, 2668, 2670, 2672, 2674, 2676, 2678, 2680, 2682, and 2684. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 2648, 2650, 2652, 2654, 2656, 2658, 2660, 2662, 2664, 2666, 2668, 2670, 2672, 2674, 2676, 2678, 2680, 2682, and 2684. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 2648, 2650, 2652, 2654, 2656, 2658, 2660, 2662, 2664, 2666, 2668, 2670, 2672, 2674, 2676, 2678, 2680, 2682, and 2684.
[0047] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2 / 7 / 12 / 15 / 175 / 260 / 318, 7 / 12 / 400 / 435, 7 / 318 / 451, 12 / 15 / 57 / 71 / 175 / 260 / 400 / 402, 12 / 15 / 57 / 220 / 254 / 260 / 318 / 402, 12 / 15 / 57 / 318 / 402 / 435, 12 / 15 / 318 / 400 / 402 / 406, 12 / 57 / 175 / 451, 12 / 175 / 260 / 264 / 402, 152 / 192 / 195, 160 / 186 / 195, 195, 260, and 400 / 402, wherein the positions are numbered with reference to SEQ ID NO: 2600.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2- / 7E / 12S / 15K / 175S / 260V / 318D, 7E / 12S / 400Q / 435V, 7E / 318D / 451N, 12S / 15K / 57K / 71I / 175S / 260V / 400Q / 40 2I, 12S / 15K / 57K / 220L / 254K / 260V / 318D / 402I, 12S / 15K / 57K / 318D / 402I / 435V, 12S / 15K / 318D / 400Q / 402I / 406M, 12S / 57K / 175S / 451N, 12S / 175S / 260V / 264A / 318D / 400Q , 12S / 175S / 400Q / 402I / 406M, 12S / 318D / 402I / 404S / 406M / 451N, 12S / 318D / 402I / 40 4S / 451N, 15K / 175S / 318D / 400Q / 402I, 57K / 175S / 220L / 260V / 264A / 402I, 57K / 175S / 4 04G, 57K / 220L / 260V / 400Q / 402I / 406M, 57K / 260V / 400Q / 402I / 404S, 57K / 400Q / 402I, 57K / 402I, 152V / 192D / 195P, 160V / 186M / 195P, 195P, 260V, and 400Q / 402I, wherein the positions are numbered with reference to SEQ ID NO: 2600.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: H2- / H7E / A12S / R15K / P175S / T260V / E318D, H7E / A12S / E400Q / A435V, H7E / E318D / K451N, A12S / R15K / I57K / V71I / P175S / T260V / E400Q / L402I, A1 2S / R15K / I57K / C220L / T254K / T260V / E318D / L402I, A12S / R15K / I57K / E318D / L402I / A435V, A12S / R15 K / E318D / E400Q / L402I / I406M, A12S / I57K / P175S / K451N, A12S / P175S / T260V / S264A / E318D / E400Q, A 12S / P175S / E400Q / L402I / I406M, A12S / E318D / L402I / D404S / I406M / K451N, A12S / E318D / L402I / D404 S / K451N, R15K / P175S / E318D / E400Q / L402I, I57K / P175S / C220L / T260V / S264A / L402I, I57K / P175S / D : 404G, I57K / C220L / T260V / E400Q / L402I / I406M, I57K / T260V / E400Q / L402I / D404S, I57K / E400Q / L402I, I57K / L402I, L152V / E192D / R195P, L160V / F186M / R195P, R195P, T260V, and E400Q / L402I, wherein the positions are numbered with reference to SEQ ID NO: 2600. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 32, 135, 148, 152, 186, 237, 239, 240, 323, 325, 326, 327, 330, 331, and 356, wherein the positions are numbered with reference to SEQ ID NO: 2600. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 32R, 135A, 148A, 152V, 186V, 237T, 239E, 239F, 239Y, 240A, 240P, 323L, 325G, 325R, 326M, 327V, 330A, 331C, 331H, 331S, and 356G, wherein the positions are numbered with reference to SEQ ID NO: 2600.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: N32R, V135A, S148A, L152V, F186V, D237T, I239E, I239F, I239Y, T240A, T240P, V323L, H325G, H325R, F326M, A327V, P330A, R331C, R331H, R331S, and F356G, wherein the positions are numbered with reference to SEQ ID NO: 2600. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: NO:2686, 2688, 2690, 2692, 2694, 2696, 2698, 2700, 2702, 2704, 2706, 2708, 2710, 2712, 2714, 2716, 2718, 2720, 2722, 2724, 2726, 2728, 2 730, 2732, 2734, 2736, 2738, 2740, 2742, 2744, 2746, 2748, 2750, 2752, 2754, 2756, 2758, 2760, 2762, 2764, 2766, 2768, 2770, 2772 and 2774. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 95% identical to any of the following sequences: SEQ ID NO:2686, 2688, 2690, 2692, 2694, 2696, 2698, 2700, 2702, 2704, 2706, 2708, 2710, 2712, 2714, 2716, 2718, 2720, 2722, 2724, 2726, 2728, 2 730, 2732, 2734, 2736, 2738, 2740, 2742, 2744, 2746, 2748, 2750, 2752, 2754, 2756, 2758, 2760, 2762, 2764, 2766, 2768, 2770, 2772 and 2774.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO:2686, 2688, 2690, 2692, 2694, 2696, 2698, 2700, 2702, 2704, 2706, 2708, 2710, 2712, 2714, 2716, 2718, 2720, 2722, 2724, 2726, 2728, 2 730, 2732, 2734, 2736, 2738, 2740, 2742, 2744, 2746, 2748, 2750, 2752, 2754, 2756, 2758, 2760, 2762, 2764, 2766, 2768, 2770, 2772 and 2774.
[0048] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14 / 23 / 274 / 326 / 329, 14 / 31 / 184 / 274 / 322 / 326 / 329 / 330, 14 / 56 / 184 / 185 / 194 / 238 / 239 / 274 / 329 / 399, 14 / 56 / 184 / 19 4 / 234 / 315 / 326 / 329 / 399 / 401、14 / 56 / 194 / 238 / 315 / 325 / 326 / 329 / 330 / 399、14 / 56 / 252 / 274 / 315 / 326 / 329 / 330 / 401、14 / 184 / 185 / 194 / 234 / 325 / 326 / 329、14 / 184 / 185 / 194 / 388 / 399 / 401、 14 / 184 / 194 / 355 / 399、14 / 185 / 194 / 238 / 399、14 / 185 / 236 / 238 / 239 / 274 / 322 / 326 / 329 / 355 / 399 / 401、14 / 194、14 / 322 / 326 / 330、14 / 326 / 330、14 / 355、14 / 355 / 399、23 / 31 / 147 / 184 / 185 / 23 8 / 252 / 325 / 329 / 330 / 388 / 401, 31 / 56 / 315 / 329 / 330, 65, 65 / 114 / 132 / 238, 65 / 238 / 240, 147 / 236 / 238 / 243 / 315 / 329 / 330 / 399 / 401, 185 / 194 / 236 / 239 / 325 / 326, 223 / 412 and 238, wherein the positions are numbered with reference to SEQ ID NO: 2718.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14R / 23Q / 274Q / 326V / 329A, 14R / 31R / 184A / 274Q / 322L / 326V / 329A / 330H, 14R / 56K / 184A / 185M / 194P / 238M / 239A / 274Q / 329A / 399Q, 14R / 56K / 184A / 194P / 234Y / 315V / 326V / 329Q / 399Q / 401I、14R / 56K / 194P / 238M / 315V / 325M / 326V / 329A / 330H / 399Q、14R / 56K / 252D / 274Q / 315V / 326V / 329 A / 330H / 401I, 14R / 184A / 185M / 194P / 234Y / 325M / 326V / 329A, 14R / 184A / 185M / 194P / 388E / 399Q / 401I, 14R / 184A / 1 94P / 355G / 399Q, 14R / 185M / 194P / 238M / 399Q, 14R / 185M / 236T / 238M / 239A / 274Q / 322L / 326V / 329Q / 355G / 399Q / 401 I, 14R / 194P, 14R / 322L / 326V / 330H, 14R / 326V / 330H, 14R / 355G, 14R / 355G / 399Q, 23Q / 31R / 147A / 184A / 185M / 238M / M / 236T / 239A / 325M / 326V, 223T / 412S and 238M, wherein the positions are numbered with reference to SEQ ID NO: 2718.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: K14R / L23Q / D274Q / A326V / P329A, K14R / N31R / M184A / D274Q / V322L / A326V / P329A / R330H, K14R / I56K / M184A / F185M / R194P / I238M / T239A / D274Q / P329A / E399Q, K14R / I56K / M184A / R194P / F234Y / I315V / A326V / P329Q / E399Q / L401I, K14R / I56K / R194P / I238M / I315V / F325M / A326V / P329A / R330H / E399Q, K14R / I56K / G252D / D274Q / I315V / A326V / P329A / R3 30H / L401I, K14R / M184A / F185M / R194P / F234Y / F325M / A326V / P329A, K14R / M184A / F185M / R194P / D388E / E399Q / L401I, K14R / M184A / R194P / F355G / E399Q、K14R / F185M / R194P / I238M / E399Q、K14R / F185M / D236T / I238M / T239A / D274Q / V322L / A326V / P329Q / F355G / E399Q / L401I、 K14R / R194P, K14R / V322L / A326V / R330H, K14R / A326V / R330H, K14R / F355G, K14R / F355G / E399Q, L23Q / N31R / S147A / M184A / F185M / I238M / G : 252D / F325M / P329A / R330H / D388E / L401I, N31R / I56K / I315V / P329A / R330H, E65D, E65D / Q114E / H132R / I238M, E65D / I238T / N240S, S147A / D236T / I238M / D243G / I315V / P329A / R330H / E399Q / L401I, F185M / R194P / D236T / T239A / F325M / A326V, S223T / I412S and I238M, wherein the positions are numbered with reference to SEQ ID NO: 2718.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 11, 45, 55, 56, 58, 65, 104, 113, 114, 132, 135, 138, 165, 238, 256, 273, 286, 309, 391, 422, 430, and 449, wherein the positions are numbered with reference to SEQ ID NO: 2718. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 11G, 11Q, 45F, 45V, 55L, 56T, 58R, 65N, 65S, 104L, 113V, 114R, 132Q, 132S, 135L, 138G, 138K, 165P, 238G, 256P, 273R, 286R, 309E, 309H, 391R, 422R, 430L, 430V, and 449F, wherein the positions are numbered with reference to SEQ ID NO: 2718. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: S11G, S11Q, L45F, L45V, I55L, I56T, K58R, E65N, E65S, M104L, L113V, Q114R, H132Q, H132S, N135L, N138G, N138K, E165P, I238G, E256P, E273R, N286R, K309E, K309H, N391R, K422R, E430L, E430V, and Y449F, wherein the positions are numbered with reference to SEQ ID NO: 2718. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: 2718. NO:2776, 2778, 2780, 2782, 2784, 2786, 2788, 2790, 2792, 2794, 2796, 2798, 2800, 2802, 2804, 2806, 2808, 2810, 2812, 2814, 2816, 2818, 2820, 2822, 2824, 2826, 282 8, 2830, 2832, 2834, 2836, 2838, 2840, 2842, 2844, 2846, 2848, 2850, 2852, 2854, 2856, 2858, 2860, 2862, 2864, 2866, 2868, 2870, 2872, 2874, 2876, 2878, 2880 and 2882.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any of the following sequences: SEQ ID NO: 2776, 2778, 2780, 2782, 2784, 2786, 2788, 2790, 2792, 2794, 2796, 2798, 2800, 2802, 2804, 2806, 2808, 2810, 2812, 2814, 2816, 2818, 2820, 2822, 2824, 2826, 2827. 8, 2830, 2832, 2834, 2836, 2838, 2840, 2842, 2844, 2846, 2848, 2850, 2852, 2854, 2856, 2858, 2860, 2862, 2864, 2866, 2868, 2870, 2872, 2874, 2876, 2878, 2880, and 2882. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO:2776, 2778, 2780, 2782, 2784, 2786, 2788, 2790, 2792, 2794, 2796, 2798, 2800, 2802, 2804, 2806, 2808, 2810, 2812, 2814, 2816, 2818, 2820, 2822, 2824, 2826, 282 8, 2830, 2832, 2834, 2836, 2838, 2840, 2842, 2844, 2846, 2848, 2850, 2852, 2854, 2856, 2858, 2860, 2862, 2864, 2866, 2868, 2870, 2872, 2874, 2876, 2878, 2880 and 2882.
[0049] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 23 / 31 / 185 / 324 / 401, 23 / 31 / 185 / 355, 31 / 134 / 185 / 252 / 274 / 324 / 388, 31 / 134 / 238 / 252 / 322 / 324 / 388, 31 / 134 / 252 / 324, 31 / 31 / 185 / 355, 31 / 134 / 185 / 252 / 274 / 324 / 388, 184 / 185 / 238 / 239 / 322, 31 / 236, 31 / 322, 31 / 388, 134 / 184 / 185 / 234 / 236 / 239 / 274 / 324 / 388, 184 / 185 / 322, 234 / 236 / 238 / 322 / 324 / 355, 236, 238 / 324 / 329 / 355, 322 / 324 and 324 / 329 / 355 / 401 are numbered with reference to SEQ ID NO: 2814. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 23Q / 31R / 185M / 324G / 401I, 23Q / 31R / 185M / 355G, 31R / 134A / 185M / 252D / 274Q / 324G / 388E, 31R / 134A / 238E / 252D / 322L / 324G / 388E, 31R / 134A / 252D / 324G, 31R / 184A / 185M / 55G, 236T, 238Y / 324G / 329Q / 355G, 322L / 324G, and 324G / 329Q / 355G / 401I are numbered with reference to SEQ ID NO: 2814.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: L23Q / N31R / F185M / H324G / L401I, L23Q / N31R / F185M / F355G, N31R / V134A / F185M / G252D / D274Q / H324G / D388E, N31R / V134A / M238E / G252D / V322L / H324G / D388E, N31R / V134A / G252D / H324G, N31R / M184A / F185M / M238 Y / T239A / V322L, N31R / D236T, N31R / V322L, N31R / D388E, V134A / M184A / F185M / F234Y / D236T / T239A / D274Q / H324G / D388E, M184A / F185M / V322L, F234Y / D236T / M238E / V322L / H324G / F355G, D236T, M238Y / H324G / A329Q / F355G, V322L / H324G and H324G / A329Q / F355G / L401I are numbered with reference to SEQ ID NO: 2814. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 122, 164, 176, 177, 316, 325, 400, 425, 426, 427, 440, and 446, numbered with reference to SEQ ID NO: 2814. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 122L, 164H, 164M, 164R, 176K, 176L, 176N, 176R, 177A, 316R, 325L, 400V, 425R, 426A, 426R, 427R, 440R, and 446R, numbered with reference to SEQ ID NO: 2814. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from I122L, V164H, V164M, V164R, V176K, V176L, V176N, V176R, E177A, G316R, M325L, T400V, K425R, S426A, S426R, I427R, I440R, and S446R, numbered with reference to SEQ ID NO: 2814.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NOs: 2884, 2886, 2888, 2890, 2892, 2894, 2896, 2898, 2900, 2902, 2904, 2906, 2908, 2910, 2912, 2914, 2916, 2918, 2920, 2922, 2924, 2926, 2928, 2830, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, and 2950, numbered with reference to SEQ ID NO: 2814. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 2884, 2886, 2888, 2890, 2892, 2894, 2896, 2898, 2900, 2902, 2904, 2906, 2908, 2910, 2912, 2914, 2916, 2918, 2920, 2922, 2924, 2926, 2928, 2830, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, and 2950. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 2884, 2886, 2888, 2890, 2892, 2894, 2896, 2898, 2900, 2902, 2904, 2906, 2908, 2910, 2912, 2914, 2916, 2918, 2920, 2922, 2924, 2926, 2928, 2830, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, and 2950.
[0050] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 11, 11 / 45 / 58 / 132 / 138 / 286, 11 / 58, 11 / 58 / 65 / 104 / 107 / 138 / 286, 11 / 58 / 65 / 107 / 135 / 223 / 286 / 391 / 430, 11 / 58 / 65 / 135 / 138, 11 / 58 / 104 / 107 / 138 / 286 7 / 114 / 138 / 223 / 391、11 / 58 / 114 / 286 / 309 / 391、11 / 58 / 132 / 165 / 286 / 391 / 422 / 430、11 / 58 / 138 / 309、11 / 65 / 104 / 107 / 138 / 165 / 286 / 391 / 430、11 / 65 / 107 / 135 / 165 / 391 / 430、11 / 65 / 132 / 135 / 138 / 223 / 391、11 / 65 / 132 / 135 / 252, 11 / 65 / 132 / 391 / 430, 11 / 65 / 135 / 138, 11 / 104 / 132 / 138 / 309 / 391, 11 / 104 / 132 / 138 / 391, 11 / 107 / 114 / 223 / 309 / 430, 11 / 107 / 138, 11 / 114 / 135 / 138 / 223, 11 / 114 / 223 / 252 / 286 / 391, 11 / 132 / 135 / 138 8 / 223 / 286, 11 / 132 / 138 / 223 / 286 / 391, 11 / 138 / 165 / 223 / 309, 58 / 65 / 138, 58 / 65 / 138 / 165, 58 / 65 / 165 / 309 / 430, 58 / 104 / 114 / 165 / 391, 107 / 114 / 132 / 138, 107 / 430, 135 / 138 / 165 / 309 / 430, and 223 / 309, wherein the positions are numbered with reference to SEQ ID NO: 2884. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 11G / 45V / 58R / 132Q / 138G / 286R, 11G / 58R / 104L / 107G / 114R / 138K / 223T / 391R, 11G / 58R / 114R / 286R / 309H / 391R、11G / 58R / 132Q / 165P / 286R / 391R / 422S / 430L、11G / 65N / 132Q / 391R / 430L、1 1G / 104L / 132Q / 138G / 309H / 391R, 11G / 107G / 114R / 223T / 309H / 430L, 11Q, 11Q / 58R,11Q / 58R / 65N / 104L / 107G / 138G / 286R, 11Q / 58R / 65N / 107G / 135L / 223T / 286R / 391R / 430L , 11Q / 58R / 65N / 135L / 138G, 11Q / 58R / 138G / 309E, 11Q / 65N / 104L / 107G / 138G / 165P / 286R / 391R / 430L, 11Q / 65N / 107G / 135L / 165P / 391R / 430L, 11Q / 65N / 132Q / 135L / 138G / 223T / 391 R、11Q / 65N / 132Q / 135L / 252D、11Q / 65N / 135L / 138G、11Q / 104L / 132Q / 138K / 391R、11Q / 107 G / 138G, 11Q / 114R / 135L / 138G / 223T, 11Q / 114R / 223T / 252D / 286R / 391R, 11Q / 132Q / 135L / 138K / 223T / 286R, 11Q / 132Q / 138G / 223T / 286R / 391R, 11Q / 138K / 165P / 223T / 309H, 58R / 65 N / 138G / 165P, 58R / 65N / 138K, 58R / 65N / 165P / 309H / 430L, 58R / 104L / 114R / 165P / 391R, 107G / 114R / 132Q / 138G, 107G / 430L, 135L / 138G / 165P / 309H / 430L and 223T / 309E, wherein the positions are numbered with reference to SEQ ID NO: 2884. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: S11G / L45V / K58R / H132Q / N138G / N286R, S11G / K58R / M104L / P107G / Q114R / N138K / S223T / N391R, S11G / K58R / Q114R / N286R / K309H / N391R, S11G / K58R / H132Q / E1 65P / N286R / N391R / K422S / E430L, S11G / E65N / H132Q / N391R / E430L, S11G / M104L / H132Q / N138G / K309H / N391R , S11G / P107G / Q114R / S223T / K309H / E430L, S11Q, S11Q / K58R, S11Q / K58R / E65N / M104L / P107G / N138G / N286R,S11Q / K58R / E65N / P107G / N135L / S223T / N286R / N391R / E430L, S11Q / K58R / E65N / N135L / N138G, S11Q / K 58R / N138G / K309E, S11Q / E65N / M104L / P107G / N138G / E165P / N286R / N391R / E430L, S11Q / E65N / P107G / N135L / E165P / N391R / E430L, S11Q / E65N / H132Q / N135L / N138G / S223T / N391R, S11Q / E65N / H132Q / N135 L / G252D, S11Q / E65N / N135L / N138G, S11Q / M104L / H132Q / N138K / N391R, S11Q / P107G / N138G, S11Q / Q114 R / N135L / N138G / S223T, S11Q / Q114R / S223T / G252D / N286R / N391R, S11Q / H132Q / N135L / N138K / S223T / N286R, S11Q / H132Q / N138G / S223T / N286R / N391R, S11Q / N138K / E165P / S223T / K309H, K58R / E65N / N138G / E165P, K58R / E65N / N138K, K58R / E65N / E165P / K309H / E430L, K58R / M104L / Q114R / E165P / N391R, P107G / Q114R / H132Q / N138G, P107G / E430L, N135L / N138G / E165P / K309H / E430L and S223T / K309E, wherein the positions are numbered with reference to SEQ ID NO: 2884. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 2952, 2954, 2956, 2958, 2960, 2962, 2964, 2966, 2968, 2970, 2972, 2974, 2976, 2978, 2980, 2982, 2984, 2986, 2988, 2990, 2992, 2994, 2996, 2998, 3000, 3002, 3004, 3006, 3008, 3010, 3012, 3014, and 3016. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 95% identical to any of the following sequences: SEQ ID NO: 2952, 2954, 2956, 2958, 2960, 2962,2964, 2966, 2968, 2970, 2972, 2974, 2976, 2978, 2980, 2982, 2984, 2986, 2988, 2990, 2992, 2994, 2996, 2998, 3000, 3002, 3004, 3006, 3008, 3010, 3012, 3014 and 3016. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 2952, 2954, 2956, 2958, 2960, 2962, 2964, 2966, 2968, 2970, 2972, 2974, 2976, 2978, 2980, 2982, 2984, 2986, 2988, 2990, 2992, 2994, 2996, 2998, 3000, 3002, 3004, 3006, 3008, 3010, 3012, 3014, and 3016.
[0051] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 8 / 448, 58 / 107 / 122 / 176 / 236 / 324 / 325 / 400 / 426 / 427, 58 / 107 / 122 / 236 / 324 / 400 / 425 / 446, 58 / 107 / 122 / 322 / 400 / 425 / 427 / 440 / 446, 58 / 107 / 164 / 400, 58 / 107 / 236 / 400, 58 / 107 / 400, 58 / 122 / 164 / 236 / 446, 58 / 122 / 176 / 236 / 400 / 446, 58 / 122 / 176 / 322 / 324 / 426 / 427, 58 / 122 / 322 / 325, 58 / 122 / 325, 58 / 122 / 440, 58 / 164 / 176, 58 / 164 / 324 / 425 / 427, 58 / 176 / 236, 58 / 236, 107 / 122 / 236 / 425 / 426 / 446, 107 / 164 / 236 / 400 / 446, 107 / 176 / 322 / 325 / 440 / 446, 107 / 176 / 400 / 425 / 427 / 440, 107 / 236, 107 / 440, 122 / 164 / 176 / 324 / 400, 122 / 164 / 400 / 440, 122 / 164 / 400 / 440 / 446, 122 / 176 / 236 / 400, 122 / 176 / 324 / 400 / 440, 122 / 400, 122 / 425 / 426 / 446, 122 / 440 / 446, 139, 139 / 252, 164, 164 / 271 / 425 / 426, 164 / 322 / 324 / 325 / 400 / 425 / 440 / 446, 164 / 400, 176 / 400, 189 and 324 / 400 / 425 / 426 / 440 / 446, wherein the positions are numbered with reference to SEQ ID NO: 3016. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 8S / 448A, 58R / 107G / 122L / 176R / 236T / 324G / 325L / 400V / 426R / 427R, 58R / 107G / 122L / 236T / 324G / 400V / 425R / 446R, 58R / 107G / 122L / 322L / 400V / 425R / 427R / 440R / 446R, 58R / 107G / 164H / 400V, 58R / 107G / 236T / 400V, 58R / 107G / 400V, 58R / 122L / 164H / 236T / 446R,58R / 122L / 176R / 236T / 400V / 446R, 58R / 122L / 176R / 322L / 324G / 426A / 427R, 58R / 122L / 322L / 325L、58R / 122L / 325L、58R / 122L / 440R、58R / 164H / 176R、58R / 164H / 324G / 425R / 427R、58R / 1 76R / 236T, 58R / 236T, 107G / 122L / 236T / 425R / 426A / 446R, 107G / 164H / 236T / 400V / 446R, 107 G / 176R / 322L / 325L / 440R / 446R, 107G / 176R / 400V / 425R / 427R / 440R, 107G / 236T, 107G / 440R, 122L / 164H / 176R / 324G / 400V, 122L / 164H / 400V / 440R, 122L / 164H / 400V / 440R / 446R, 122L / 1 76R / 236T / 400V, 122L / 176R / 324G / 400V / 440R, 122L / 400V, 122L / 425R / 426R / 446R, 122L / 440 R / 446R, 139V, 139V / 252D, 164H, 164H / 271G / 425R / 426R, 164H / 322L / 324G / 325L / 400V / 425R / 440R / 446R, 164H / 400V, 176R / 400V, 189R and 324G / 400V / 425R / 426R / 440R / 446R, wherein the positions are numbered with reference to SEQ ID NO: 3016. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: G8S / K448A, K58R / P107G / I122L / V176R / D236T / H324G / M325L / T400V / S426R / I427R, K58R / P107G / I122L / D236T / H324G / M325L / T400V / S426R / I427R, 07G / I122L / V322L / T400V / K425R / I427R / I440R / S446R, K58R / P107G / V164H / T400V, K58R / P107G / D236T / T400V, K58R / P107G / T400V, K58R / I122L / V164H / D236T / S446R, K58R / I122L / V176R / D236T / T400V / S446R,K58R / I122L / V176R / V322L / H324G / S426A / I427R, K58R / I122L / V322L / M325L, K58R / I122L / M325L, K58R / I 122L / I440R, K58R / V164H / V176R, K58R / V164H / H324G / K425R / I427R, K58R / V176R / D236T, K58R / D236T, P1 07G / I122L / D236T / K425R / S426A / S446R, P107G / V164H / D236T / T400V / S446R, P107G / V176R / V322L / M325L / I440R / S446R, P107G / V176R / T400V / K425R / I427R / I440R, P107G / D236T, P107G / I440R, I122L / V164H / V17 6R / H324G / T400V, I122L / V164H / T400V / I440R, I122L / V164H / T400V / I440R / S446R, I122L / V176R / D236T / T400V, I122L / V176R / H324G / T400V / I440R, I122L / T400V, I122L / K425R / S426R / S446R, I122L / I440R / S446 R, I139V, I139V / G252D, V164H, V164H / S271G / K425R / S426R, V164H / V322L / H324G / M325L / T400V / K425R / I440R / S446R, V164H / T400V, V176R / T400V, P189R and H324G / T400V / K425R / S426R / I440R / S446R, wherein the positions are numbered with reference to SEQ ID NO: 3016. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 9, 65, 106, 115, 116, 172, 178, 200, 210, 213, 240, 242, 245, 255, 324 / 423, 385, 408, 409, 411, 412, 415, 416, 423, and 447, wherein the positions are numbered with reference to SEQ ID NO: 3016. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 9C, 9M, 65S, 106A, 115D, 115R, 116V, 172R, 172S, 178K, 200A, 200T, 200V, 210L,423R, 447L and 447R, wherein the positions are numbered with reference to SEQ ID NO: 3016. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: S9C, S9M, N65S, K106A, N115D, N115R, L116V, N172R, N172S, Q178K, G200A, G200T, G200V, E210L, E210V, A213G, N240C, N240 E, N240L, N240P, N240V, A242I, A242Y, K245M, D255P, H324R / N423R, V385R, E408P, T409L, E411Q, I412R, G415A, G415H, G415K, G415R, K416R, N423A, N423R, N447L, and N447R, wherein the positions are numbered with reference to SEQ ID NO: 3016. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: NO:3018, 3020, 3022, 3024, 3026, 3028, 3030, 3032, 3034, 3036, 3038, 3040, 3042, 3044, 3046, 3048, 3050, 3052, 3054, 30 56, 3058, 3060, 3062, 3064, 3066, 3068, 3070, 3072, 3074, 3076, 3078, 3080, 3082, 3084, 3086, 3088, 3090, 3092, 3094, 309 6. 3098, 3100, 3102, 3104, 3106, 3108, 3110, 3112, 3114, 3116, 3118, 3120, 3122, 3124, 3126, 3128, 3130, 3132, 3134, 3136, 3138, 3140, 3142, 3144, 3146, 3148, 3150, 3152, 3154, 3156, 3158, 3160, 3162, 3164, 3166, 3168, 3170, 3172, 3174, 3176,3178 and 3180. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 3018, 3020, 3022, 3024, 3026, 3028, 3030, 3032, 3034, 3036, 3038, 3040, 3042, 3044, 3046, 3048, 3050, 3052, 3054, 3056, 3058, 3060, 3062, 3064, 3066, 3068, 3070, 3072, 3074, 3076, 3078, 3080, 3082, 3084, 3086, 3088, 3090, 3092, 3094, 3096, 3097. 8, 3100, 3102, 3104, 3106, 3108, 3110, 3112, 3114, 3116, 3118, 3120, 3122, 3124, 3126, 3128, 3130, 3132, 3134, 3136, 3138, 3140, 3142, 3144, 3146, 3148, 3150, 3152, 3154, 3156, 3158, 3160, 3162, 3164, 3166, 3168, 3170, 3172, 3174, 3176, 3178, and 3180. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: NO:3018, 3020, 3022, 3024, 3026, 3028, 3030, 3032, 3034, 3036, 3038, 3040, 3042, 3044, 3046, 3048, 3050, 3052, 3054, 3056, 3058, 3060, 3062, 3064, 3066, 3068, 3070, 3072, 3074, 3076, 3078, 3080, 3082, 3084, 3086, 3088, 3090, 3092, 3094, 3096, 309 8. 3100, 3102, 3104, 3106, 3108, 3110, 3112, 3114, 3116, 3118, 3120, 3122, 3124, 3126, 3128, 3130, 3132, 3134, 3136, 3138, 3140, 3142, 3144, 3146, 3148, 3150, 3152, 3154, 3156, 3158, 3160, 3162, 3164, 3166, 3168, 3170, 3172, 3174, 3176, 3178, and 3180.
[0052] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2-, 8, 8 / 107 / 139 / 164 / 415 / 416 / 440 / 448, 8 / 107 / 139 / 255 / 322 / 325 / 415 / 416 / 440 / 448, 8 / 107 / 164 / 255, 8 / 107 / 164 / 423 / 440, 8 / 139, 8 / 139 / 164 / 200 / 236 / 240 / 322 / 440 / 448, 8 / 139 / 164 / 236 / 416 / 423 / 440、8 / 139 / 189 / 240 / 325 / 416、8 / 139 / 200 / 236 / 240 / 255 / 423、8 / 139 / 255 / 415 / 416、8 / 164、8 / 164 / 189 / 200 / 322 / 324 / 325 / 416 / 448、8 / 164 / 240 / 423、8 / 164 / 252 / 255 / 448、8 / 164 / 448、8 / 236 / 240 / 252 / 448、8 / 240 / 423、8 / 252 / 255 / 322 / 325 / 448、12 / 164 / 440、107 / 139、107 / 139 / 200 / 240 / 322 / 324 / 325 / 448、107 / 236 / 240 / 325 / 440、107 / 240 / 252 / 423 / 448、107 / 423、139、139 / 164 / 236 / 240、139 / 255 / 325 / 415 / 440、164 / 189、164 / 189 / 236 / 240、164 / 189 / 240 / 252 / 415 / 423、164 / 200 / 236、164 / 200 / 236 / 240 / 324 / 416 / 440、164 / 200 / 236 / 255 / 322 / 3 423, 325, and 415 / 416 / 448, wherein the positions are numbered with reference to SEQ ID NO: 3082. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2-, 8S,8S / 107G / 139V / 164H / 415A / 416R / 440R / 448A、8S / 107G / 139V / 255P / 322L / 325L / 415A / 416R / 440R / 448A、8S / 107G / 164H / 255P、8S / 107G / 164H / 423R / 440R、8S / 139V、8S / 139V / 164H / 200A / 236T / 240E / 322L / 440R / 448A、8S / 139V / 164H / 236T / 416R / 423R / 440R、8S / 139V / 189R / 240E / 325L / 416R、8S / 139V / 200A / 236T / 240E / 255P / 423R、8S / 139V / 255P / 415A / 416R、8S / 164H、8S / 164H / 189R / 200A / 322L / 324G / 325L / 416R / 448A、8S / 164H / 240E / 423R、8S / 164H / 252D / 255P / 448A、8S / 164H / 448A、8S / 236T / 240E / 252D / 448A、8S / 240E / 423R、8S / 252D / 255P / 322L / 325L / 448A、12S / 164H / 440R、107G / 139V、107G / 139V / 200A / 240E / 322L / 324G / 325L / 448A、107G / 236T / 240E / 325L / 440R、107G / 240E / 252D / 423R / 448A、107G / 423R、139V、139V / 164H / 236T / 240E、139V / 255P / 325L / 415A / 440R、164H / 189R、164H / 189R / 236T / 240E、164H / 189R / 240E / 252D / 415A / 423R、164H / 200A / 236T、164H / 200A / 236T / 240E / 324G / 416R / 440R、164H / 200A / 236T / 255P / 322L / 324G / 423R / 440R、164H / 236T、164H / 236T / 240E / 440R、164H / 236T / 423R、164H / 322L / 325L、164H / 322L / 325L / 416R / 423R、164H / 416R / 448A、200A / 236T / 322L / 325L / 416R、200A / 322L / 325L / 415A / 448A、236T / 415A / 416R、240E、240E / 252D / 255P / 322L / 415A / 416R、240E / 252D / 255P / 415A / 448A, 255P / 423R, 325L and 415A / 416R / 448A, wherein the positions are numbered with reference to SEQ ID NO: 3082. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: H2-, G8S, G8S / P107G / I139V / V164H / G415A / K416R / I440R / K448A, G8S / P107G / I139V / D255P / V322L / M325L / G415A / K416R / I440R / K448A, G8S / P107G / V164H / D255P, G8S / P107G / V164H / N423R / I440R, G8S / I139V, G8S / I139V / V164H / G200A / D236T / N240E / V322L / I440R / K448A, G8S / I139V / V164H / D236T / K416R / N423R / I440R, G8S / I139V / P189R / N240E / M325L / K416 R、G8S / I139V / G200A / D236T / N240E / D255P / N423R、G8S / I139V / D255P / G415A / K416R、G8S / V164H、G8S / V164H / P189R / G200A / V322L / H324G / M 325L / K416R / K448A, G8S / V164H / N240E / N423R, G8S / V164H / G252D / D255P / K448A, G8S / V164H / K448A, G8S / D236T / N240E / G252D / K448A, G8S / N240E / N423R, G8S / G252D / D255P / V322L / M325L / K448A, T12S / V164H / I440R, P107G / I139V, P107G / I139V / G200A / N240E / V322L / H324G / M325 L / K448A, P107G / D236T / N240E / M325L / I440R, P107G / N240E / G252D / N423R / K448A, P107G / N423R, I139V, I139V / V164H / D236T / N240E, I139V / D255P / M325L / G415A / I440R, V164H / P189R, V164H / P189R / D236T / N240E, V164H / P189R / N240E / G252D / G415A / N423R, V164H / G200A / D236T,V164H / G200A / D236T / N240E / H324G / K416R / I440R, V164H / G200A / D236T / D255P / V322L / H324G / N423R / I440R, V164H / D236T , V164H / D236T / N240E / I440R, V164H / D236T / N423R, V164H / V322L / M325L, V164H / V322L / M325L / K416R / N423R, V164H / K416R / K448A, G200A / D236T / V322L / M325L / K416R, G200A / V322L / M325L / G415A / K448A, D236T / G415A / K416R, N240E, N240E / G252D / D255P / V322L / G415A / K416R, N240E / G252D / D255P / G415A / K448A, D255P / N423R, M325L and G415A / K416R / K448A, wherein the positions are numbered with reference to SEQ ID NO: 3082. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2, 3, 8, 34, 72, 73, 75, 113, 114, 186, 189, 221, 235, 237, 239, 256, 286, 299, 305, 309, 312, 313, 323, 355, 389, 406, 422, 438, and 446, wherein the positions are numbered with reference to SEQ ID NO: 3082. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2N, 2S, 2T, 3I, 8S, 34R, 72Y, 73A, 73P, 73T, 73V, 75H, 113I, 114V, 186G, 186I, 189S, 221K, 235M, 237L, 237M, 237V, 239A, 256I, 257Y ... 6L, 256S, 256T, 286L, 286S, 299A, 299L, 299R, 299V, 305G, 309R, 312S, 312T, 312V, 313D, 323P, 355A, 389F, 389G, 406F, 406G, 406N, 406Q, 422C, 422R, 422S, 438T, 446H, and 446P, wherein the positions are numbered with reference to SEQ ID NO: 3082. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from: H2N, H2S, H2T, H3I, G8S, K34R,L72Y, H73A, H73P, H73T, H73V, P75H, L113I, Q114V, E186G, E186I, P189S, E221K, Q235M , P237L, P237M, P237V, T239A, E256I, E256L, E256S, E256T, N286L, N286S, E299A, E299L , E299R, E299V, D305G, K309R, L312S, L312T, L312V, E313D, D323P, F355A, D389F, D389G, T406F, T406G, T406N, T406Q, K422C, K422R, K422S, E438T, R446H, and R446P, wherein the positions are numbered with reference to SEQ ID NO: 3082. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 20 / 126 / 128 / 155 / 161, 20 / 126 / 128 / 160 / 161, 20 / 126 / 128 / 160 / 161 / 198, 20 / 126 / 128 / 161, 20 / 126 / 128 / 161 / 198 / 199, 20 / 126 / 155 / 160 / 198, 20 / 126 / 128 / 161 / 198 / 199. 6 / 155 / 161、20 / 126 / 160、20 / 126 / 160 / 161、20 / 126 / 161、20 / 128 / 155 / 160 / 161 / 198、20 / 128 / 155 / 161 / 199、20 / 128 / 155 / 199、20 / 128 / 160 / 161 / 198、20 / 155 / 160、20 / 155 / 160 / 161、20 / 155 / 161、20 / 155 / 161 / 19 9, 20 / 160 / 161 / 198, 121 / 126 / 128 / 161 / 369, 126 / 128 / 155 / 160 / 161, 126 / 128 / 155 / 160 / 161 / 199, 126 / 128 / 155 / 161 / 199, 126 / 128 / 160 / 161 / 369, 126 / 128 / 160 / 198 / 369, 126 / 128 / 160 / 199 / 369, 126 / 128 / 160 / 369、126 / 128 / 161 / 199 / 369、126 / 128 / 161 / 369、126 / 128 / 369、126 / 160 / 161 / 199 / 369、126 / 160 / 198 / 369、126 / 196 / 198 / 369、126 / 198 / 369、126 / 199 / 369、126 / 369、128 / 155 / 160 / 161、128 / 155 / 160 / 161 / 199、128 / 155 / 160 / 198, 128 / 155 / 199, 128 / 160 / 161 / 369, 128 / 161 / 199 / 369, 128 / 198 / 199 / 369, 128 / 199 / 369, 128 / 369, 155 / 161 / 198 / 199, 155 / 199, 160 / 161 / 369, 161 / 198 / 369, 161 / 369 and 199 / 369, wherein the positions are numbered with reference to SEQ ID NO: 3082. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 20Y / 126H / 128A / 155R / 161T, 20Y / 126H / 128A / 161T, 20Y / 126H / 155R / 160S / 198P, 20Y / 126H / 160S, 20Y / 126H / 160S / 161T, 20Y / 126Q / 128A / 160S / 161T, 20Y / 126Q / 128A / 160S / 161T / 198H, 20Y / 126Q / 128A / 161T / 198H / 199A, 20Y / 126Q / 155R / 161G, 20Y / 126Q / 161G, 20Y / 128A / 155R / 160S / 161T / 198H, 20Y / 128A / 1 55R / 161T / 199A, 20Y / 128A / 155R / 199A, 20Y / 128A / 160S / 161T / 198P, 20Y / 155R / 160S, 20Y / 155R / 160S / 161G, 20Y / 155R / 161 T、20Y / 155R / 161T / 199A、20Y / 160S / 161T / 198H、121F / 126H / 128A / 161T / 369N、126H / 128A / 155R / 160S / 161T、126H / 128A / 1 60S / 198H / 369N, 126H / 128A / 161G / 199A / 369N, 126H / 128A / 161G / 369N, 126H / 128A / 369N, 126H / 160S / 161G / 199A / 369N, 12 6H / 160S / 198P / 369N, 126H / 196V / 198P / 369N, 126Q / 128A / 155R / 160S / 161T / 199A, 126Q / 128A / 155R / 161G / 199A, 126Q / 128 A / 160S / 161T / 369N, 126Q / 128A / 160S / 199A / 369N, 126Q / 128A / 160S / 369N, 126Q / 198P / 369N, 126Q / 199A / 369N, 126Q / 369N,128A / 155R / 160S / 161T, 128A / 155R / 160S / 161T / 199A, 128A / 155R / 160S / 198P, 12 8A / 155R / 199A, 128A / 160S / 161G / 369N, 128A / 161G / 199A / 369N, 128A / 198H / 199A / 369N, 128A / 199A / 369N, 128A / 369N, 155R / 161G / 198H / 199A, 155R / 199A, 160S / 161G / 369N, 160S / 161T / 369N, 161T / 198P / 369N, 161T / 369N and 199A / 369N, wherein the positions are numbered with reference to SEQ ID NO: 3082. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: W20Y / L126H / P128A / F155R / R161T, W20Y / L126H / P128A / R161T, W20Y / L126H / F155R / K160S / G198P, W20Y / L126H / K160S, W20Y / L126H / K160S / R161T, W20Y / L126H / P128A / R161T, 0Y / L126Q / P128A / K160S / R161T, W20Y / L126Q / P128A / K160S / R161T / G198H, W20Y / L126Q / P128A / R161T / G 198H / N199A, W20Y / L126Q / F155R / R161G, W20Y / L126Q / R161G, W20Y / P128A / F155R / K160S / R161T / G198H, W 20Y / P128A / F155R / R161T / N199A, W20Y / P128A / F155R / N199A, W20Y / P128A / K160S / R161T / G198P, W20Y / F 155R / K160S, W20Y / F155R / K160S / R161G, W20Y / F155R / R161T, W20Y / F155R / R161T / N199A, W20Y / K160S / R 161T / G198H, V121F / L126H / P128A / R161T / P369N, L126H / P128A / F155R / K160S / R161T, L126H / P128A / K16 0S / G198H / P369N, L126H / P128A / R161G / N199A / P369N, L126H / P128A / R161G / P369N, L126H / P128A / P369N,L126H / K160S / R161G / N199A / P369N, L126H / K160S / G198P / P369N, L126H / A196V / G198P / P3 69N, L126Q / P128A / F155R / K160S / R161T / N199A, L126Q / P128A / F155R / R161G / N199A, L126Q / P128A / K160S / R161T / P369N, L126Q / P128A / K160S / N199A / P369N, L126Q / P128A / K160S / P3 69N, L126Q / G198P / P369N, L126Q / N199A / P369N, L126Q / P369N, P128A / F155R / K160S / R161T , P128A / F155R / K160S / R161T / N199A, P128A / F155R / K160S / G198P, P128A / F155R / N199A, P1 28A / K160S / R161G / P369N, P128A / R161G / N199A / P369N, P128A / G198H / N199A / P369N, P128A / N199A / P369N, P128A / P369N, F155R / R161G / G198H / N199A, F155R / N199A, K160S / R161G / P369N, K160S / R161T / P369N, R161T / G198P / P369N, R161T / P369N, and N199A / P369N, wherein the positions are numbered with reference to SEQ ID NO: 3082. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: NO:3182, 3184, 3186, 3188, 3190, 3192, 3194, 3196, 3198, 3200, 3202, 3204, 3206, 3208, 3210, 3212, 3214, 3216, 3218, 3220, 3222, 3224, 3226, 3228, 3230, 3232, 3234, 3236, 3238, 3240, 3242, 3244, 324 6. 3248, 3250, 3252, 3254, 3256, 3258, 3260, 3262, 3264, 3266, 3268, 3270, 3272, 3274, 3276, 3278, 3280, 3282, 3284, 3286, 3288, 3290, 3292, 3294, 3296, 3298, 3300, 3302, 3304, 3306, 3308, 3310, 3312,3314, 3316, 3318, 3320, 3322, 3324, 3326, 3328, 3330, 3332, 3334, 3336, 3338, 3340, 3342, 3344, 3346, 3348, 3350, 3352, 3354, 3356, 3358, 3360, 3362, 3364, 3366, 3368, 3370, 3372, 3374, 3376, 3378, 3380, 3382, 3384, 3386, 3388, 3390, 3392, 3394, 3396, 3398, 3400, 34 02, 3404, 3406, 3408, 3410, 3412, 3414, 3416, 3418, 3420, 3422, 3424, 3426, 3428, 3430, 3432, 3434, 3436, 3438, 3440, 3442, 3444, 3446, 3448, 3450, 3452, 3454, 3456, 3458, 3460, 3462, 3464, 3466, 3468, 3470, 3472, 3474, 3476, 3478, 3480, 3482, 3484, 3486, 3488, and 3490. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any of the following sequences: SEQ ID NO: 3182, 3184, 3186, 3188, 3190, 3192, 3194, 3196, 3198, 3200, 3202, 3204, 3206, 3208, 3210, 3212, 3214, 3216, 3218, 3220, 3222, 3224, 3226, 3228, 3229 30, 3232, 3234, 3236, 3238, 3240, 3242, 3244, 3246, 3248, 3250, 3252, 3254, 3256, 3258, 3260, 3262, 3264, 3266, 3268, 3270, 3272, 3274, 3276, 3278, 328 0, 3282, 3284, 3286, 3288, 3290, 3292, 3294, 3296, 3298, 3300, 3302, 3304, 3306, 3308, 3310, 3312, 3314, 3316, 3318, 3320, 3322, 3324, 3326, 3328, 3330 、3332、3334、3336、3338、3340、3342、3344、3346、3348、3350、3352、3354、3356、3358、3360、3362、3364、3366、3368、3370、3372、3374、3376、3378、3380、3382, 3384, 3386, 3388, 3390, 3392, 3394, 3396, 3398, 3400, 3402, 3404, 3406, 3408, 3410, 3412, 3414, 3416, 3418, 3420, 3422, 3424, 3426, 3428, 3430, 3432, 3434, 3435 36, 3438, 3440, 3442, 3444, 3446, 3448, 3450, 3452, 3454, 3456, 3458, 3460, 3462, 3464, 3466, 3468, 3470, 3472, 3474, 3476, 3478, 3480, 3482, 3484, 3486, 3488, and 3490. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: NO:3182, 3184, 3186, 3188, 3190, 3192, 3194, 3196, 3198, 3200, 3202, 3204, 3206, 3208, 3210, 3212, 32 14, 3216, 3218, 3220, 3222, 3224, 3226, 3228, 3230, 3232, 3234, 3236, 3238, 3240, 3242, 3244, 3246, 32 48, 3250, 3252, 3254, 3256, 3258, 3260, 3262, 3264, 3266, 3268, 3270, 3272, 3274, 3276, 3278, 3280, 3282, 3284, 3286, 3288, 3290, 3292, 3294, 3296, 3298, 3300, 3302, 3304, 3306, 3308, 3310, 3312, 3314, 331 6. 3318, 3320, 3322, 3324, 3326, 3328, 3330, 3332, 3334, 3336, 3338, 3340, 3342, 3344, 3346, 3348, 3350, 3352, 3354, 3356, 3358, 3360, 3362, 3364, 3366, 3368, 3370, 3372, 3374, 3376, 3378, 3380, 3382, 3384 、3386、3388、3390、3392、3394、3396、3398、3400、3402、3404、3406、3408、3410、3412、3414、3416、3418、3420、3422、3424、3426、3428、3430、3432、3434、3436、3438、3440、3442、3444、3446、3448、3450、3452、3454, 3456, 3458, 3460, 3462, 3464, 3466, 3468, 3470, 3472, 3474, 3476, 3478, 3480, 3482, 3484, 3486, 3488, and 3490.
[0053] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 106 / 164 / 172 / 200 / 409, 106 / 164 / 172 / 210 / 240 / 415, 106 / 164 / 172 / 242 / 409 / 416, 106 / 164 / 200 / 210 / 242, 106 / 164 / 200 / 210 / 415, 106 / 164 / 200 / 240 / 408 / 409 / 416, 106 / 164 / 210 / 240 / 408 / 409 / 416. 164 / 210 / 408 / 409、106 / 164 / 240 / 415、106 / 164 / 409 / 415 / 423、106 / 172 / 200 / 210 / 240 / 242 / 408 / 415 / 416 / 423、106 / 172 / 200 / 210 / 242、106 / 172 / 240、106 / 172 / 240 / 242 / 409 / 415、106 / 172 / 242、106 / 172 / 242 / 416 / 423、106 / 172 / 408 / 409、106 / 172 / 409 / 423、106 / 200 / 210 / 40 9. 106 / 210 / 240, 106 / 210 / 240 / 408 / 415, 106 / 240 / 242, 106 / 240 / 242 / 409, 106 / 242 / 408 / 409, 164 / 172 / 200 / 210 / 242 / 409, 164 / 172 / 240 / 242 / 415, 164 / 172 / 242 / 408, 164 / 200 / 408 / 415 / 416, 164 / 240 / 242 / 408, 164 / 240 / 242 / 415 / 423, 164 / 423, 172 / 200 / 210 / 240 / 408, 172 / 408, 240 / 415, and 409 / 415, wherein the positions are numbered with reference to SEQ ID NO: 3244. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 106A / 164H / 172R / 200A / 409L,106A / 164H / 172R / 210V / 240E / 415R、106A / 164H / 172R / 242I / 409L / 416R、106A / 164H / 200A / 210V / 242I、106A / 164H / 200A / 210V / 415A、106A / 164H / 200A / 240E / 408P / 409L / 416R、106A / 164H / 210V / 240E / 408P / 409L / 416R、106A / 164H / 210V / 408P / 409L、106A / 164H / 240E / 415A、106A / 164H / 409L / 415A / 423R、106A / 172R / 200A / 210V / 240E / 242I / 408P / 415A / 416R / 423R、106A / 172R / 200A / 210V / 242I、106A / 172R / 240E、106A / 172R / 240E / 242I / 409L / 415R、106A / 172R / 242I、106A / 172R / 242I / 416R / 423R、106A / 172R / 408P / 409L、106A / 172R / 409L / 423R、106A / 200A / 210V / 409L、106A / 210V / 240E、106A / 210V / 240E / 408P / 415R、106A / 240E / 242I、106A / 240E / 242I / 409L、106A / 242I / 408P / 409L、164H / 172R / 200A / 210V / 242I / 409L、164H / 172R / 240E / 242I / 415R、164H / 172R / 242I / 408P、164H / 200A / 408P / 415A / 416R、164H / 240E / 242I / 408P、164H / 240E / 242I / 415R / 423R、164H / 423R、172R / 200A / 210V / 240E / 408P、172R / 200A / 240E、172R / 200A / 408P / 416R、172R / 210V / 415A、172R / 240E、172R / 240E / 242I / 415R、172R / 240E / 409L、200A / 210V / 240E / 242I / 409L、200A / 240E / 242I / 407S、200A / 242I / 415A / 416R / 423R、200A / 408P / 409L、210V / 240E、240E、240E / 242I、240E / 242I / 408P / 416R、240E / 242I / 415A / 423R、240E / 408P、240E / 415R and 409L / 415R, wherein the positions are numbered with reference to SEQ ID NO: 3244. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: K106A / V164H / N172R / G200A / T409L, K106A / V164H / N172R / E210V / N240E / G415R, K106A / V164H / N172R / A242I / T409L / K416R, K106A / V164H / G200A / E210V / A242I, K106A / V164H / G200A / E210V / G415A, K106A / V164H / G200A / N240E / E408P / T409L / K416R, K106A / V164H / E210V / N240E / E408P / T409L / K416R , K106A / V164H / E210V / E408P / T409L, K106A / V164H / N240E / G415A, K106 A / V164H / T409L / G415A / N423R, K106A / N172R / G200A / E210V / N240E / A24 2I / E408P / G415A / K416R / N423R, K106A / N172R / G200A / E210V / A242I, K1 06A / N172R / N240E, K106A / N172R / N240E / A242I / T409L / G415R, K106A / N 172R / A242I, K106A / N172R / A242I / K416R / N423R, K106A / N172R / E408P / T409L, K106A / N172R / T409L / N423R, K106A / G200A / E210V / T409L, K106A / E210V / N240E, K106A / E210V / N240E / E408P / G415R, K106A / N240E / A242 I. K106A / N240E / A242I / T409L, K106A / A242I / E408P / T409L, V164H / N17 2R / G200A / E210V / A242I / T409L, V164H / N172R / N240E / A242I / G415R, V1 64H / N172R / A242I / E408P, V164H / G200A / E408P / G415A / K416R, V164H / N 240E / A242I / E408P, V164H / N240E / A242I / G415R / N423R, V164H / N423R,N172R / G200A / E210V / N240E / E408P, N172R / G200A / N240E, N172R / G200A / E408P / K416R, N172R / E210V / G415A, N1 72R / N240E, N172R / N240E / A242I / G415R, N172R / N240E / T409L, G200A / E210V / N240E / A242I / T409L, G200A / N240E / A242I / G407S, G200A / A242I / G415A / K416R / N423R, G200A / E408P / T409L, E210V / N240E, N240E, N240E / A242I, N240E / A242I / E408P / K416R, N240E / A242I / G415A / N423R, N240E / E408P, N240E / G415R and T409L / G415R, wherein the positions are numbered with reference to SEQ ID NO: 3244. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14, 35, 42, 46, 49, 105, 134, 143, 179, 181, 232, 278, 290, 336, 373, 381, 401, and 441, wherein the positions are numbered with reference to SEQ ID NO: 3244. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14K, 35D, 42F, 42I, 42V, 46T, 46V, 49A, 49M, 49P, 49Q, 49S, 105A, 134A, 134C, 134S, 143P, 179A, 179D, 179T, 181L, 232T, 278I, 278L, 290L, 336A, 373R, 381G, 401V, 441I, and 441R, wherein the positions are numbered with reference to SEQ ID NO: 3244. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: R14K, Q35D, L42F, L42I, L42V, C46T, C46V, L49A, L49M, L49P, L49Q, L49S, S105A, V134A, V134C, V134S, K143P, V179A, V179D, V179T, M181L, P232T, V278I, V278L, I290L, S336A, K373R, A381G, L401V,Q441I and Q441R, wherein the positions are numbered with reference to SEQ ID NO: 3244. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: NO:3492, 3494, 3496, 3498, 3500, 3502, 3504, 3506, 3508, 3510, 3512, 3514, 3516, 3518, 3520, 3522, 3524, 3526, 3528, 3530 ,3532,3534,3536,3538,3540,3542,3544,3546,3548,3550,3552,3554,3556,3558,3560,3562,3564,3566,3568,3570,3 , 3640, 3642, 3644, 3646, 3648, 3650, and 3652. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: 572, 3574, 3576, 3578, 3580, 3582, 3584, 3586, 3588, 3590, 3592, 3594, 3596, 3598, 3600, 3602, 3604, 3606, 3608, 3610, 3612, 3614, 3616, 3618, 3620, 3622, 3624, 3626, 3628, 3630, 3632, 3634, 3636, 3638, 3640, 3642, 3644, 3646, 3648, 3650, and 3652. NO:3492, 3494, 3496, 3498, 3500, 3502, 3504, 3506, 3508, 3510, 3512, 3514, 3516, 3518, 3520, 3522, 3524, 3526, 3528, 3 530, 3532, 3534, 3536, 3538, 3540, 3542, 3544, 3546, 3548, 3550, 3552, 3554, 3556, 3558, 3560, 3562, 3564, 3566, 3568, 3 570, 3572, 3574, 3576, 3578, 3580, 3582, 3584, 3586, 3588, 3590, 3592, 3594, 3596, 3598, 3600, 3602, 3604, 3606, 3608, 3610, 3612, 3614, 3616, 3618, 3620, 3622, 3624, 3626, 3628, 3630, 3632, 3634, 3636, 3638, 3640, 3642, 3644, 3646, 3648,3650 and 3652. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 3492, 3494, 3496, 3498, 3500, 3502, 3504, 3506, 3508, 3510, 3512, 3514, 3516, 3518, 3520, 3522, 3524, 3526, 3528, 3530, 3532, 3534, 3536, 3538, 3540, 3542, 3544, 3546, 3548, 3550, 3552, 3554, 3556, 3558, 3560, 3562, 3564, 3566, 3568, 3570, 3571, 3572, 3573, 3574, 3575, 3576, 3577, 3578, 3579, 3580. 572, 3574, 3576, 3578, 3580, 3582, 3584, 3586, 3588, 3590, 3592, 3594, 3596, 3598, 3600, 3602, 3604, 3606, 3608, 3610, 3612, 3614, 3616, 3618, 3620, 3622, 3624, 3626, 3628, 3630, 3632, 3634, 3636, 3638, 3640, 3642, 3644, 3646, 3648, 3650, and 3652.
[0054] The present invention also provides engineered glycosyltransferases, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 21, 91, 125, 127, 130 / 187, 143, 143 / 150, 145, 152, 156, 186, 187, 195, 197, 200, 201, 202, 264, 268, 364, 365, and 415, wherein the positions are numbered with reference to SEQ ID NO: 3346. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 21M, 21P, 91M, 125C, 125M, 125V, 127G, 130T / 187Q, 143H, 143P / 150S, 145W, 152L, 156P, 156Q, 186N, 186V, 187S, 195F, 195 47F, 47F, 47Q, 47W, 484S, 485F, 486Q, 486W, 487S, 487F, 487Q, 487W, 487E, 487F, 487Q, 487W, 487F, 487Q, 487W, 487E, 487F, 487Q, 487W, 487F, 487Q, 487W, 487F, 487Q, 487W, 487F, 487Q, 487W, 487F, 487Q, 487W, 487F, 487Q, 487W, 487F, 487Q, 487W, 487F, 487Q, 487 In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: L21M, L21P, P91M, F125C, F125M, F125V, Q127G, A130T / K187Q, K143H, K143P / A150S, L145W, F152L, F156P, F156Q, E186N, E186V, K187S, L195F, L195G, 415D, wherein the positions are numbered with reference to SEQ ID NO: 3346.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any of the following sequences: SEQ ID NO:3760, 3762, 3764, 3766, 3768, 3770, 3772, 3774, 3776, 3778, 3780, 3782, 3784, 3786, 3788, 3790, 3792, 3794, 3796, 3798, 3800, 3802, 380 4. 3806, 3808, 3810, 3812, 3814, 3816, 3818, 3820, 3822, 3824, 3826, 3 828, 3830, 3832, 3834, 3836, 3838, 3840, 3842, 3844, 3846, 3848 and 3850. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 95% identical to any of the following sequences: SEQ ID NO:3760, 3762, 3764, 3766, 3768, 3770, 3772, 3774, 3776, 3778, 3780, 3782, 3784, 3786, 3788, 3790, 3792, 3794, 3796, 3798, 3800, 3802, 380 4. 3806, 3808, 3810, 3812, 3814, 3816, 3818, 3820, 3822, 3824, 3826, 3 828, 3830, 3832, 3834, 3836, 3838, 3840, 3842, 3844, 3846, 3848 and 3850. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO:3760, 3762, 3764, 3766, 3768, 3770, 3772, 3774, 3776, 3778, 3780, 3782, 3784, 3786, 3788, 3790, 3792, 3794, 3796, 3798, 3800, 3802, 380 4. 3806, 3808, 3810, 3812, 3814, 3816, 3818, 3820, 3822, 3824, 3826, 3 828, 3830, 3832, 3834, 3836, 3838, 3840, 3842, 3844, 3846, 3848 and 3850.
[0055] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2 / 5 / 113 / 186 / 237 / 406, 2 / 73 / 186 / 237, 2 / 189 / 286, 2 / 286 / 355 / 416 / 422, 5 / 34 / 73 / 113 / 406, 5 / 73 / 186 / 406, 5 / 113 / 237 / 406, 5 / 186 / 237 / 245 / 256 / 406, 5 / 186 / 237 / 406, 5 / 189 / 286, 2 / 286 / 355 / 416 / 422. 256 / 406、34 / 113 / 186 / 237 / 406、72 / 73 / 172 / 235 / 240 / 242 / 438、72 / 172 / 239 / 240 / 242 / 408、72 / 172 / 240 / 242、73 / 172、73 / 172 / 235 / 239 / 240、73 / 172 / 235 / 239 / 242、73 / 172 / 239 / 240、73 / 172 / 239 / 240 / 242、73 / 172 / 240 / 242 / 408、73 / 172 / 240 / 4 08, 73 / 186 / 237 / 406, 73 / 235 / 240 / 323, 73 / 235 / 240 / 408, 73 / 237, 73 / 239 / 242, 113 / 186 / 406, 172, 172 / 188 / 323, 172 / 235, 172 / 235 / 239 / 240 / 242, 172 / 235 / 239 / 408, 172 / 235 / 240, 172 / 235 / 240 / 242 / 438, 172 / 239 / 240 / 242 / 323 / 408, 172 / 24 0, 172 / 240 / 299 / 323, 186, 186 / 237, 186 / 237 / 286, 186 / 406, 189 / 333 / 355 / 421, 235 / 239 / 240, 235 / 240 / 242, 237, 239 / 240, 239 / 240 / 242 / 256 / 323, 239 / 240 / 242 / 323 / 408, 239 / 240 / 408, 239 / 242 / 408, 240 / 242 / 256 / 438, and 242 / 408, wherein the positions are numbered with reference to SEQ ID NO: 3502. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2- / 5N / 113I / 186G / 237V / 406Q, 2- / 73A / 186G / 237V, 2S / 189S / 286Q, 2S / 286Q / 355A / 416R / 422R, 5N / 34R / 73A / 113I / 406N, 5N / 73A / 186G / 406N, 5N / 113I / 237V / 406N,5N / 186G / 237V / 245T / 256I / 406Q, 5N / 186G / 237V / 406Q, 5N / 256L / 406Q, 34R / 113I / 186G / 237L / 406N, 72Y / 73P / 172R / 235M / 240E / 242I / 438T, 72Y / 172R / 239A / 240E / 242I / 408P, 72Y / 172R / 240E / 242I, 73A / 186G / 237L / 406Q, 73A / 237V, 73P / 172R, 73 P / 172R / 235M / 239A / 240E, 73P / 172R / 235M / 239A / 242I, 73P / 172R / 239A / 240E, 73P / 172R / 239A / 240E / 242I, 73P / 172R / 240 E / 242I / 408P, 73P / 172R / 240E / 408P, 73P / 235M / 240E / 323P, 73P / 235M / 240E / 408P, 73P / 239A / 242I, 113I / 186G / 406Q, 172R , 172R / 188G / 323P, 172R / 235M, 172R / 235M / 239A / 240E / 242I, 172R / 235M / 239A / 408P, 172R / 235M / 240E, 172R / 235M / 240E / 242I / 438T, 172R / 239A / 240E / 242I / 323P / 408P, 172R / 240E, 172R / 240E / 299A / 323P, 186G, 186G / 237L, 186G / 237V / 286S, 18 6G / 406N, 186G / 406Q, 189S / 333H / 355A / 421Q, 235M / 239A / 240E, 235M / 240E / 242I, 237L, 239A / 240E, 239A / 240E / 242I / 256S / 323P, 239A / 240E / 242I / 323P / 408P, 239A / 240E / 408P, 239A / 242I / 408P, 240E / 242I / 256S / 438T and 242I / 408P, wherein the positions are numbered with reference to SEQ ID NO: 3502. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: H2- / H5N / L113I / E186G / P237V / T406Q, H2- / H73A / E186G / P237V, H2S / P189S / N286Q, H2S / N286Q / F355A / K416R / K422R, H5N / K34R / H73A / L113I / T406N,H5N / H73A / E186G / T406N、H5N / L113I / P237V / T406N、H5N / E186G / P237V / K 245T / E256I / T406Q、H5N / E186G / P237V / T406Q、H5N / E256L / T406Q、K34R / L 113I / E186G / P237L / T406N、L72Y / H73P / N172R / Q235M / N240E / A242I / E438 T、L72Y / N172R / T239A / N240E / A242I / E408P、L72Y / N172R / N240E / A242I、H 73A / E186G / P237L / T406Q、H73A / P237V、H73P / N172R、H73P / N172R / Q235M / T239A / N240E、H73P / N172R / Q235M / T239A / A242I、H73P / N172R / T239A / N24 0E、H73P / N172R / T239A / N240E / A242I、H73P / N172R / N240E / A242I / E408P、H73P / N172R / N240E / E408P、H73P / Q235M / N240E / D323P、H73P / Q235M / N240 E / E408P、H73P / T239A / A242I、L113I / E186G / T406Q、N172R、N172R / E188G / D323P、N172R / Q235M、N172R / Q235M / T239A / N240E / A242I、N172R / Q235M / T239A / E408P、N172R / Q235M / N240E、N172R / Q235M / N240E / A242I / E438T、N172R / T239A / N240E / A242I / D323P / E408P、N172R / N240E、N172R / N240E / E2 99A / D323P、E186G、E186G / P237L、E186G / P237V / N286S、E186G / T406N、E18 6G / T406Q、P189S / N333H / F355A / S421Q、Q235M / T239A / N240E、Q235M / N240 E / A242I、P237L、T239A / N240E、T239A / N240E / A242I / E256S / D323P、T239A / N240E / A242I / D323P / E408P、T239A / N240E / E408P、T239A / A242I / E408P、N240E / A242I / E256S / E438T and A242I / E408P, wherein the positions are numbered with reference to SEQ ID NO: 3502. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 96, 127, 132, 144, 153, 155, 156, 186, 187, 196, 199, and 200, wherein the positions are numbered with reference to SEQ ID NO: 3502. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 96A, 96P, 127I, 127L, 127V, 132H, 132K, 132T, 144V, 153A, 153G, 155M, 156W, 186A, 186G, 186R, 187A, 187R, 187T, 196S, 199A, 199S, 199Y, and 200S, wherein the positions are numbered with reference to SEQ ID NO: 3502. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of G96A, G96P, Q127I, Q127L, Q127V, Q132H, Q132K, Q132T, I144V, S153A, S153G, F155M, F156W, E186A, E186G, E186R, K187A, K187R, K187T, A196S, N199A, N199S, N199Y, and A200S, wherein the positions are numbered with reference to SEQ ID NO: 3502.
[0056] In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any of the following sequences: SEQ ID NO: 3654, 3656, 3658, 3660, 3662, 3664, 3666, 3668, 3670, 3672, 3674, 3676, 3678, 3680, 3682, 3684, 3686, 3688, 3690, 3692, 3694, 3696, 3698, 3700, 3702, 3704, 3706, 3708, 3710, 3712, 3714, 3716, 3718, 3720, 3722, 3724, 3726, 3728, 3729, 3730, 3731, 3732, 3733, 3734, 3735 730, 3732, 3734, 3736, 3738, 3740, 3742, 3744, 3746, 3748, 3750, 3752, 3754, 3756, 3758, 3852, 3854, 3856, 3858, 3860, 3862, 3864, 3866, 3868, 3870, 3872, 3874, 3876, 3878, 3880, 3882, 3884, 3886, 3888, 3890, 3892, 3894, 3896, and 3898. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: NO:3654, 3656, 3658, 3660, 3662, 3664, 3666, 3668, 3670, 3672, 3674, 3676, 3678, 3680, 3682, 3684, 3686, 3688, 3690 ,3692,3694,3696,3698,3700,3702,3704,3706,3708,3710,3712,3714,3716,3718,3720,3722,3724,3726,3728,3 730, 3732, 3734, 3736, 3738, 3740, 3742, 3744, 3746, 3748, 3750, 3752, 3754, 3756, 3758, 3852, 3854, 3856, 3858, 3860, 3862, 3864, 3866, 3868, 3870, 3872, 3874, 3876, 3878, 3880, 3882, 3884, 3886, 3888, 3890, 3892, 3894, 3896 and 3898.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: 3654, 3656, 3658, 3660, 3662, 3664, 3666, 3668, 3670, 3672, 3674, 3676, 3678, 3680, 3682, 3684, 3686, 3688, 3690, 3692, 3694, 3696, 3698, 3700, 3702, 3704, 3706, 3708, 3710, 3712, 3714, 3716, 3718, 3720, 3722, 3724, 3726, 3728, 3730, 3732, 3734, 3736, 3738, 3740, 3742, 3744, 3746, 3748, 3750, 3752, 3754, 3756, 3758, 3852, 3854, 3856, 3858, 3860, 3862, 3864, 3866, 3868, 3870, 3872, 3874, 3876, 3878, 3880, 3882, 3884, 3886, 3888, 3890, 3892, 3894, 3896 and 3898.
[0057] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2 / 5 / 35 / 105 / 143 / 237 / 373 / 416 / 422, 2 / 5 / 35 / 143 / 232 / 237 / 416 / 422 / 441, 2 / 5 / 35 / 232 / 278 / 373 / 416, 2 / 5 / 105 / 143 / 232 / 373 / 416 / 422, 2 / 5 / 278, 2 / 105 / 143 / 232 / 237 / 278 / 373 / 441, 2 / 143 / 232 / 373 / 441, 2 / 143 / 232 / 373 / 441. / 35 / 232 / 373 / 416 / 422, 5 / 105 / 232 / 237 / 373 / 416 / 441, 5 / 105 / 237 / 278 / 422 / 441, 5 / 105 / 237 / 416 / 422 / 441, 5 / 143 / 189 / 232 / 237 / 441, 5 / 143 / 232 / 237 / 278, 5 / 143 / 232 / 237 / 416 / 422, 5 / 143 / 232 / 373 / 422 / 441, 5 / 143 / 237 / 278 / 373 / 416 / 422, 5 / 143 / 373, 5 / 189 / 237 / 278 / 373 / 416 / 422 / 441, 5 / 2 32 / 416 / 422、5 / 237 / 373 / 422、5 / 373 / 416、26 / 42、26 / 42 / 46 / 49、26 / 42 / 46 / 49 / 134、26 / 42 / 46 / 49 / 134 / 186、26 / 42 / 46 / 134、26 / 42 / 49 / 134、26 / 42 / 49 / 134 / 186 / 355、26 / 42 / 49 / 134 / 401、26 / 42 / 134 / 401、26 / 49 / 134、26 / 134、26 / 134 / 186 / 355 / 401、26 / 134 / 355、26 / 134 / 401、26 / 355 / 401、35、35 / 105 / 189 / 232 / 373 / 416、42 / 46 / 49 / 97 / 134 / 401、42 / 46 / 49 / 134、42 / 46 / 49 / 134 / 186、42 / 46 / 49 / 134 / 186 / 355、42 / 46 / 49 / 134 / 235 / 355 / 401、42 / 46 / 49 / 134 / 401、42 / 46 / 49 / 186、42 / 49 / 134 / 186 / 355、42 / 49 / 134 / 186 / 401、42 / 49 / 134 / 355 / 401、42 / 134 / 186、42 / 186 / 355、46 / 49 / 134、49 / 134 / 355、105 / 143 / 232 / 237 / 373 / 416 / 422 / 441、105 / 143 / 278 / 373、105 / 189 / 237、105 / 237 / 278 / 373 / 416 / 422、105 / 237 / 373 / 422 / 441、105 / 373、105 / 373 / 441、134 / 401、143、143 / 189、143 / 189 / 232 / 422 / 441, 143 / 189 / 237 / 373 / 416 / 422, 143 / 232, 143 / 237, 143 / 237 / 422 / 441, 186 / 355, 189 / 232 / 373 / 416 / 422 / 441, 189 / 237 / 278 / 416 / 441, 232 / 237, 237 / 373, 237 / 373 / 441, and 237 / 422, wherein the positions are numbered with reference to SEQ ID NO: 3696. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2- / 5N / 35D / 105A / 143P / 237V / 373R / 416R / 422R, 2- / 5N / 35D / 143P / 232T / 237L / 416R / 422R / 441R, 2- / 5N / 35D / 232T / 278L / 373R / 416R, 2 - / 5N / 105A / 143P / 232T / 373R / 416R / 422R, 2- / 5N / 278L, 2- / 105A / 143P / 232T / 237L / 278L / 373R / 4 41R, 2- / 143P / 232T / 373R / 441R, 2- / 143P / 373R / 441R, 5N / 35D / 232T / 373R / 416R / 422R, 5N / 105A / 232T / 237L / 373R / 416R / 441R, 5N / 105A / 237L / 278I / 422R / 441R, 5N / 105A / 237V / 416R / 422R / 441R , 5N / 143P / 189S / 232T / 237V / 441R, 5N / 143P / 232T / 237L / 278L, 5N / 143P / 232T / 237L / 416R / 422R, 5N / 143P / 232T / 373R / 422R / 441R, 5N / 143P / 237L / 278L / 373R / 416R / 422R, 5N / 143P / 373R, 5N / 189 S / 237V / 278I / 373R / 416R / 422R / 441R, 5N / 232T / 416R / 422R, 5N / 237L / 373R / 422R, 5N / 373R / 416R,26V / 42I / 49Q / 134C / 186G / 355A、26V / 42I / 49Q / 134C / 401V、26V / 42V、26V / 42V / 46V / 49A、26V / 42V / 46V / 49A / 134A、26V / 42V / 46V / 49A / 134C / 186G、26V / 42V / 46V / 134A、26V / 42V / 49S / 134C、26V / 42V / 134C / 401V、26V / 49Q / 134A、26V / 134A、26V / 134A / 186G / 355A / 401V、26V / 134C / 355A、26V / 134T / 401V、26V / 355A / 401V、35D、35D / 105A / 189S / 232T / 373R / 416R、42I / 46V / 49A / 134A、42I / 46V / 49S / 134C / 186G、42I / 46V / 49S / 186G、42V / 46V / 49A / 134A / 401V、42V / 46V / 49A / 134T / 186G / 355A、42V / 46V / 49P / 134C / 235R / 355A / 401V、42V / 46V / 49S / 97P / 134C / 401V、42V / 49A / 134C / 186G / 355A、42V / 49S / 134A / 186G / 401V、42V / 49S / 134C / 355A / 401V、42V / 134C / 186G、42V / 186G / 355A、46V / 49Q / 134T、49S / 134C / 355A、105A / 143P / 232T / 237V / 373R / 416R / 422R / 441R、105A / 143P / 278L / 373R、105A / 189S / 237V、105A / 237L / 278L / 373R / 416R / 422R、105A / 237L / 373R / 422R / 441R、105A / 373R、105A / 373R / 441R、134C / 401V、143P、143P / 189S、143P / 189S / 232T / 422R / 441R、143P / 189S / 237L / 373R / 416R / 422R、143P / 232T、143P / 237L / 422R / 441R、143P / 237V、186G / 355A、189S / 232T / 373R / 416R / 422R / 441R、189S / 237L / 278I / 416R / 441R、232T / 237L、237L / 422R、237V / 373R and 237V / 373R / 441R, wherein the positions are numbered with reference to SEQ ID NO: 3696. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: H2- / H5N / Q35D / S105A / K143P / P237V / K373R / K416R / K422R, H2- / H5N / Q35D / K143P / P232T / P237L / K416R / K422R / Q441R, H2- / H5N / Q35D / P232T / V278L / K373R / K416R, H2- / H5N / S105A / K143P / P232T / K373R / K416R / K422R, H2- / H5N / Q35D / K143P / P232T / P237L / K416R / K422R / Q441R. / V278L、H2- / S105A / K143P / P232T / P237L / V278L / K373R / Q441R、H2- / K 143P / P232T / K373R / Q441R, H2- / K143P / K373R / Q441R, H5N / Q35D / P232T / K373R / K416R / K422R、H5N / S105A / P232T / P237L / K373R / K416R / Q441R、 H5N / S105A / P237L / V278I / K422R / Q441R, H5N / S105A / P237V / K416R / K42 2R / Q441R, H5N / K143P / P189S / P232T / P237V / Q441R, H5N / K143P / P232T / P237L / V278L, H5N / K143P / P232T / P237L / K416R / K422R, H5N / K143P / P2 32T / K373R / K422R / Q441R, H5N / K143P / P237L / V278L / K373R / K416R / K42 2R, H5N / K143P / K373R, H5N / P189S / P237V / V278I / K373R / K416R / K422R / Q441R, H5N / P232T / K416R / K422R, H5N / P237L / K373R / K422R, H5N / K373 R / K416R, I26V / L42I / L49Q / V134C / E186G / F355A, I26V / L42I / L49Q / V13 4C / L401V, I26V / L42V, I26V / L42V / C46V / L49A, I26V / L42V / C46V / L49A / V134A, I26V / L42V / C46V / L49A / V134C / E186G, I26V / L42V / C46V / V134A,I26V / L42V / L49S / V134C、I26V / L42V / V134C / L401V、I26V / L49Q / V134A、I26V / V134A、I26V / V134A / E186G / F355A / L401V、I26V / V134C / F355A、I26V / V134T / L401V、I26V / F355A / L401V、Q35D、Q35D / S105A / P189S / P232T / K373R / K416R、L42I / C46V / L49A / V134A、L42I / C46V / L49S / V134C / E186G、L42I / C46V / L49S / E186G、L42V / C46V / L49A / V134A / L401V、L42V / C46V / L49A / V134T / E186G / F355A、L42V / C46V / L49P / V134C / Q235R / F355A / L401V、L42V / C46V / L49S / T97P / V134C / L401V、L42V / L49A / V134C / E186G / F355A、L42V / L49S / V134A / E186G / L401V、L42V / L49S / V134C / F355A / L401V、L42V / V134C / E186G、L42V / E186G / F355A、C46V / L49Q / V134T、L49S / V134C / F355A、S105A / K143P / P232T / P237V / K373R / K416R / K422R / Q441R、S105A / K143P / V278L / K373R、S105A / P189S / P237V、S105A / P237L / V278L / K373R / K416R / K422R、S105A / P237L / K373R / K422R / Q441R、S105A / K373R、S105A / K373R / Q441R、V134C / L401V、K143P、K143P / P189S、K143P / P189S / P232T / K422R / Q441R、K143P / P189S / P237L / K373R / K416R / K422R、K143P / P232T、K143P / P237L / K422R / Q441R、K143P / P237V、E186G / F355A、P189S / P232T / K373R / K416R / K422R / Q441R、P189S / P237L / V278I / K416R / Q441R、P232T / P237L、P237L / K422R、P237V / K373R and P237V / K373R / Q441R, wherein the positions are numbered with reference to SEQ ID NO: 3696. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 3, 8, 50, 61, 62, 101, 137, 158, 161, 164, 176, 193, 223, 223 / 243, 235, 237, 239, 240, 243, 244, 248, 249, 301, 323, 330, 352, 364, 426, and 427, wherein the positions are numbered with reference to SEQ ID NO: 3696. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 3N, 8R, 8V, 50P, 50V, 61N, 61Y, 62A, 101L, 137R, 158W, 161L, 164A, 164E, 164F, 164L, 176P, 176Q, 176T, 193F, 223A, 223L / 2 43G, 235R, 237A, 237L, 239F, 239G, 239M, 239P, 239Q, 239Y, 240V, 243G, 243H, 243R, 243S, 243Y, 244N, 248T, 249G, 249H, 301A, 323T, 330C, 352A, 364Q, 426L, 427S and 427T, wherein the positions are numbered with reference to SEQ ID NO: 3696. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: H3N, S8R, S8V, I50P, I50V, E61N, E61Y, K62A, A101L, Q137R, F158W, R161L, H164A, H164E, H164F, H164L, R176P, R176Q, R176T, D193F, T223A, T223L / D243 427S, and R427T, wherein the positions are numbered with reference to SEQ ID NO: 3696. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 90% identical to any one of the following sequences: SEQ ID NO: 3900, 3902, 3904, 3906,3908, 3910, 3912, 3914, 3916, 3918, 3920, 3922, 3924, 3926, 3928, 3930, 3932, 3934, 3936, 3938, 3940, 3942, 3944, 3946, 3948, 3950, 3952, 3954, 3956, 3958, 3960, 3962, 3964, 3966, 3968, 3970, 3972, 3974, 3976, 3978, 3980, 3982, 3984, 3986, 3988, 3990, 3992, 3994, 3996, 3998, 4000, 4002, 4004, 4006, 4008, 4010, 4012, 4014, 4016, 4018, 4020, 4022, 4024, 4026, 4028, 4030, 4032, 4034, 4036, 4038, 4040, 4042, 4044, 4046, 4048, 4050, 4052, 4054, 4056, 4058, 4060, 4062, 4064, 4066, 4068, 4070, 4072, 4074, 4076, 4078, 4080, 4082, 4084, 4086, 4088, 4090, 4092, 4094, 4096, 4098, 4100, 4102, 4104, 4106, 4108, 4110, 4112, 4114, 4116, 4118, 4120, 4122, 4124, 4126, 4128, 4130, 4132, 4134, 4136, 4138, 4140, 4142, 4144, and 4146. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence at least 95% identical to any one of the following sequences: SEQ ID NO: NO:3900, 3902, 3904, 3906, 3908, 3910, 3912, 3914, 3916, 3918, 3920, 3922, 3924, 3926, 3928, 3930, 3932 ,3934,3936,3938,3940,3942,3944,3946,3948,3950,3952,3954,3956,3958,3960,3962,3964,3966,3 968, 3970, 3972, 3974, 3976, 3978, 3980, 3982, 3984, 3986, 3988, 3990, 3992, 3994, 3996, 3998, 4000, 4002, 4004, 4006, 4008, 4010, 4012, 4014, 4016, 4018, 4020, 4022, 4024, 4026, 4028, 4030, 4032, 4034, 4036,4038, 4040, 4042, 4044, 4046, 4048, 4050, 4052, 4054, 4056, 4058, 4060, 4062, 4064, 4066, 4068, 4070, 4072, 4074, 4076, 4078, 4080, 4082, 4084, 4086, 4088, 4090, 4091 92, 4094, 4096, 4098, 4100, 4102, 4104, 4106, 4108, 4110, 4112, 4114, 4116, 4118, 4120, 4122, 4124, 4126, 4128, 4130, 4132, 4134, 4136, 4138, 4140, 4142, 4144, and 4146. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO: NO:3900, 3902, 3904, 3906, 3908, 3910, 3912, 3914, 3916, 3918, 3920, 3922, 3924, 3926, 3928 ,3930,3932,3934,3936,3938,3940,3942,3944,3946,3948,3950,3952,3954,3956,3958,39 60, 3962, 3964, 3966, 3968, 3970, 3972, 3974, 3976, 3978, 3980, 3982, 3984, 3986, 3988, 3990, 3992, 3994, 3996, 3998, 4000, 4002, 4004, 4006, 4008, 4010, 4012, 4014, 4016, 4018, 4020, 402 2. 4024, 4026, 4028, 4030, 4032, 4034, 4036, 4038, 4040, 4042, 4044, 4046, 4048, 4050, 4052, 4054, 4056, 4058, 4060, 4062, 4064, 4066, 4068, 4070, 4072, 4074, 4076, 4078, 4080, 4082, 4084 , 4086, 4088, 4090, 4092, 4094, 4096, 4098, 4100, 4102, 4104, 4106, 4108, 4110, 4112, 4114, 4116, 4118, 4120, 4122, 4124, 4126, 4128, 4130, 4132, 4134, 4136, 4138, 4140, 4142, 4144, and 4146.
[0058] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 5 / 73 / 113 / 186 / 187 / 373 / 423, 5 / 73 / 143 / 144 / 179 / 186 / 187 / 422, 5 / 73 / 144 / 179 / 186 / 373 / 423, 5 / 73 / 144 / 179 / 186 / 373 / 423, 5 / 73 / 144 / 187 / 373 / 422, 5 / 143 / 144 / 179 / 181 / 186 / 187 / 373, 5 / 144 / 179 / 181 / 373 / 422, 5 / 144 / 373 / 422, 5 / 144 / 179 / 181 / 186 / 187 / 373. 9 / 96 / 127 / 153 / 278、49 / 96 / 132 / 153 / 155 / 156 / 237 / 278 / 406、49 / 96 / 132 / 153 / 199 / 200、49 / 96 / 132 / 155、49 / 96 / 132 / 155 / 237 / 278、49 / 96 / 155 / 199 / 200 / 406、49 / 153 / 155、73 / 113 / 143 / 179 / 181 / 422、73 / 113 / 179 / 181 / 186 / 187、73 / 143 / 144 / 179 / 186 / 187 / 373 / 423、73 / 179 / 181 / 186 / 187 / 373、73 / 17 9 / 181 / 186 / 373 / 422, 73 / 181 / 186 / 187, 96 / 127 / 132 / 153 / 278, 96 / 127 / 153 / 155, 96 / 132 / 153 / 155, 96 / 132 / 153 / 155 / 156, 96 / 132 / 153 / 155 / 156 / 200 、96 / 132 / 153 / 156、96 / 132 / 196 / 199、96 / 132 / 278、96 / 153 / 155 / 156、96 / 153 / 155 / 199 / 200 / 237、96 / 153 / 406、113 / 143 / 179 / 186 / 187、113 / 144 / 186 / 4 23, 113 / 144 / 373, 113 / 181 / 186 / 373 / 422, 113 / 373 / 422, 127 / 132, 127 / 132 / 153 / 156, 127 / 132 / 155 / 156 / 406, 127 / 153 / 155 / 199 / 200 / 237, 127 / 406, 132 / 153 / 155、132 / 153 / 237 / 406、132 / 155、132 / 237、143 / 144 / 179 / 181 / 186 / 187 / 422、143 / 179 / 181 / 186 / 187 / 422 / 423、144 / 179 / 181 / 186 / 187 / 373、187 / 373 / 422, 181 / 186 / 187 / 422 / 423 and 373 / 423, wherein the positions are numbered with reference to SEQ ID NO: 3956. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 5N / 73A / 113I / 186G / 187R / 373R / 423R, 5N / 73A / 143P / 144V / 179D / 186G / 187R / 422R, 5N / 73A / 144V / 179D / 186A / 373R / 423R, 5N / 73A / 144V / 187R / 373R / 422R, 5N / 143P / 144V / 179T / 181L / 186G / 187R / 373R, 5N / 144V / 179T / 181L / 373R / 422R, 5N / 144V / 373R / 422R, 49S / 96A / 127I / 132K / 156W / 196S, 49S / 96A / 132 H / 153A / 199S / 200S, 49S / 96P / 127I / 153A / 278L, 49S / 96P / 132H / 153A / 155M / 156W / 237L / 278L / 406Q, 49S / 96P / 132H / 155M, 49S / 96P / 132K / 155M / 237L / 278L, 49S / 96P / 155M / 199S / 200S / 406Q, 49S / 153A / 155M, 73A / 113I / 143P / 179T / 181L / 422R, 7 3A / 113I / 179T / 181L / 186A / 187R, 73A / 143P / 144V / 179D / 186G / 187T / 373R / 423R, 73A / 179D / 181L / 186A / 373R / 422R, 73A / 1 79D / 181L / 186G / 187R / 373R, 73A / 181L / 186A / 187T, 96A / 132H / 153A / 156W, 96A / 132K / 153A / 155M / 156W, 96A / 132K / 153A / 155M / 156W / 200S, 96A / 153A / 155M / 156W, 96P / 127I / 132H / 153A / 278L, 96P / 127I / 153A / 155M, 96P / 132H / 153A / 155M / 156W,96P / 132H / 196S / 199S, 96P / 132K / 153A / 155M, 96P / 132K / 278L, 96P / 153A / 155M / 199S / 200S / 237L, 96P / 153A / 406Q、113I / 143P / 179D / 186G / 187R、113I / 144V / 186G / 423R、113I / 144V / 373R、113I / 181L / 186 A / 373R / 422R, 113I / 373R / 422R, 127I / 132H, 127I / 132H / 153A / 156W, 127I / 132H / 155M / 156W / 406Q, 12 7I / 153A / 155M / 199S / 200S / 237L, 127I / 406Q, 132H / 153A / 237L / 406Q, 132H / 155M, 132K / 153A / 155M, 1 32K / 237L, 143P / 144V / 179T / 181L / 186G / 187R / 422R, 143P / 179T / 181L / 186G / 187R / 422R / 423R, 144V / 179T / 181L / 186A / 187R / 373R, 144V / 179T / 186A / 187T / 373R, 153A / 155M / 156W / 237L, 153A / 155M / 196S / 199S / 237L, 153A / 199S / 406Q, 153A / 237L, 155M / 199S, 179D / 181L / 186G / 187R / 423R, 179D / 187T / 373R / 422R, 179T / 181L / 186A, 179T / 186A / 187T, 181L / 186G / 187R / 422R / 423R and 373R / 423R, wherein the positions are numbered with reference to SEQ ID NO: 3956. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: H5N / P73A / L113I / E186G / K187R / K373R / N423R, H5N / P73A / K143P / I144V / V179D / E186G / K187R / K422R, H5N / P73A / I144V / V179D / E186A / K373R / N423R、H5N / P73A / I144V / K187R / K373R / K422R、H5N / K143P / I144V / V179T / M18 1L / E186G / K187R / K373R, H5N / I144V / V179T / M181L / K373R / K422R, H5N / I144V / K373R / K422R,A49S / G96A / Q127I / Q132K / F156W / A196S、A49S / G96A / Q132H / S153A / N199S / A200S、A49S / G96P / Q127I / S153A / V278L、A49S / G96P / Q132H / S153A / F155M / F156W / P237L / V278L / T406Q、A49S / G96P / Q132H / F155M、A49S / G96P / Q132K / F155M / P237L / V278L、A49S / G96P / F155M / N199S / A200S / T406Q、A49S / S153A / F155M、P73A / L113I / K143P / V179T / M181L / K422R、P73A / L113I / V179T / M181L / E186A / K187R、P73A / K143P / I144V / V179D / E186G / K187T / K373R / N423R、 P73A / V179D / M181L / E186A / K373R / K422R、P73A / V179D / M181L / E186G / K187R / K373R、P73A / M181L / E186A / K187T、G96A / Q132H / S153A / F156W、G96A / Q13 2K / S153A / F155M / F156W、G96A / Q132K / S153A / F155M / F156W / A200S、G96A / S153A / F155M / F156W、G96P / Q127I / Q132H / S153A / V278L、G96P / Q127I / S153A / F155M、G96P / Q132H / S153A / F155M / F156W、G96P / Q132H / A196S / N199S、G96P / Q132K / S153A / F155M、G96P / Q132K / V278L、G96P / S153A / F155M / N199S / A2 00S / P237L、G96P / S153A / T406Q、L113I / K143P / V179D / E186G / K187R、L113I / I144V / E186G / N423R、L113I / I144V / K373R、L113I / M181L / E186A / K373R / K 422R、L113I / K373R / K422R、Q127I / Q132H、Q127I / Q132H / S153A / F156W、Q127I / Q132H / F155M / F156W / T406Q、Q127I / S153A / F155M / N199S / A200S / P237L、Q127I / T406Q, Q132H / S153A / P237L / T406Q, Q132H / F155M, Q132K / S153A / F155M, Q132K / P237L, K143P / I144V / V179T / M181L / E186G / K187R / K4 22R、K143P / V179T / M181L / E186G / K187R / K422R / N423R、I144V / V179T / M181L / E186A / K187R / K373R, I144V / V179T / E186A / K187T / K373R, S153A / F155M / F156W / P237L, S153A / F155M / A196S / N199S / P237L, S153A / N199S / T406Q, S153A / P237L, F155M / N199S, V179D / M181L / E186G / K187R / N423R, V179D / K187T / K373R / K422R, V179T / M181L / E186A, V179T / E186A / K187T, M181L / E186G / K187R / K422R / N423R, and K373R / N423R, wherein the positions are numbered with reference to SEQ ID NO: 3956. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 11, 12, 41, 44, 44 / 187, 45, 55, 56, 57, 65, 66, 70, 72, 73, 74 / 238, 82, 83, 85, 103, 111, 113, 114, 117, 132, 135, 138, 140, 159, 160, 162, 167, 182, 214, 220, 222, 223, 226, 236, 238, 256, 286, 299, 309, 387, 388, 389, 391, 393, 406, 408, 412, 418, 422, 429, 430, 449 and 450, wherein the positions are numbered with reference to SEQ ID NO: 3956. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 11D, 11L, 12I, 12L, 41H, 44H, 44S / 187T, 45Y, 55A, 55G, 55L, 56R, 57G, 57H, 57P, 65C, 65G, 65P, 65Q, 65R, 66L, 70W, 72V, 73H, 73S, 74M / 238V, 82S, 83R, 85W, 103H, 103Q, 111F, 113S, 114G, 114I, 117N, 117S, 132G, 135E,138K, 138S, 138T, 140C, 140G, 159N, 160D, 160Q, 160T, 162L, 167L, 182I, 182L, 182Q, 182T, 182V, 182Y, 214H, 214T, 220G, 220S, 222F, 223D, 226Q, 236L, 236T, 236V, 238A, 238G, 238I, 238R, 238S, 238T, 256R, 286G, 299V, 309P, 309R, 91A, 391L, 391S, 391V, 393P, 393T, 406G, 406S, 408L, 408T, 412G, 412R, 418A, 418H, 418M, 422L, 429D, 430P, 449G, 449H, 449L, 449R, 449S, 450N and 450V, wherein the positions are numbered with reference to SEQ ID NO: 3956. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: Q11D, Q11L, T12I, T12L, F41H, Y44H, Y44S / K187T, L45Y, I55A, I55G, I55L, K56R, K57G, K57H, K57P, N65C, N65G, N65P, N65Q, N65R, S66L, V70W, L72V, P73H, P73S, L74M / M238V, P82S, H83R, H85W, K103H, K103Q, K111F, L 113S, Q114G, Q114I, K117N, K117S, Q132G, L135E, G138K, G138S, G138T, P140C, P140G, L159N , K160D, K160Q, K160T, P162L, P167L, R182I, R182L, R182Q, R182T, R182V, R182Y, K214H, K2 14T, T220G, T220S, L222F, T223D, K226Q, D236L, D236T, D236V, M238A, M238G, M238I, M238R , M238S, M238T, E256R, N286G, E299V, K309P, K309R, K309S, K309T, D387P, D387Q, D387R, E3 88A, E388S, D389A, D389G, D389L, D389V, R391A, R391L, R391S, R391V, H393P, H393T, T406G,T406S, P408L, P408T, I412G, I412R, R418A, R418H, R418M, K422L, E429D, E430P, Y449G, Y449H, Y449L, Y449R, Y449S, K450N, and K450V, wherein the positions are numbered with reference to SEQ ID NO: 3956. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: NO:4148, 4150, 4152, 4154, 4156, 4158, 4160, 4162, 4164, 4166, 4168, 4170, 4172, 4174, 4176, 4178, 4180, 4182, 4184, 418 6. 4188, 4190, 4192, 4194, 4196, 4198, 4200, 4202, 4204, 4206, 4208, 4210, 4212, 4214, 4216, 4218, 4220, 4222, 4224, 4226, 4228, 4230, 4232, 4234, 4236, 4238, 4240, 4242, 4244, 4246, 4248, 4250, 4252, 4254, 4256, 4258, 4260, 4262, 4264, 4266, 4268, 4270, 4272, 4274, 4276, 4278, 4280, 4282, 4284, 4286, 4288, 4290, 4292, 4294, 4296, 4298, 4300, 4302, 4304, 4306, 430 8, 4310, 4312, 4314, 4316, 4318, 4320, 4322, 4324, 4326, 4328, 4330, 4332, 4334, 4336, 4338, 4340, 4342, 4344, 4346, 4348, 4350, 4352, 4354, 4356, 4358, 4360, 4362, 4364, 4366, 4368, 4370, 4372, 4374, 4376, 4378, 4380, 4382, 4384, 4386, 4388, 4390 390, 4392, 4394, 4396, 4398, 4400, 4402, 4404, 4406, 4408, 4410, 4412, 4414, 4416, 4418, 4420, 4422, 4424, 4426, 4428, 4430, 4432, 4434, 4436, 4438, 4440, 4442, 4444, 4446, 4448, 4450, 4452, 4454, 4456, 4458, 4460, 4462, 4464, 4466, 4468, 4470,4472, 4474, 4476, 4478, 4480, 4482, 4484, 4486, 4488, 4490, 4492, 4494, and 4496. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 95% identical to any one of the following sequences: SEQ ID NO:4148, 4150, 4152, 4154, 4156, 4158, 4160, 4162, 4164, 4166, 4168, 4170, 4172, 4174, 4176, 4178, 4180, 4182, 4184, 4186, 4188, 4190, 4192, 4194, 4196, 4198, 4200, 4202, 4204, 4206, 4208, 4210, 4212, 4214, 4216, 4218, 4220, 4222, 4224, 4226, 4228, 4230, 4232 ,4234,4236,4238,4240,4242,4244,4246,4248,4250,4252,4254,4256,4258,4260,4262,4264,4266,4268,4270,4272,4274,4276,4278,4280,4282,4284,4286,4288,4290,4292,4294,4296,4298,4300,4302,4304,4306,4308,4310,4312,4314,4316,4318,4 320, 4322, 4324, 4326, 4328, 4330, 4332, 4334, 4336, 4338, 4340, 4342, 4344, 4346, 4348, 4350, 4352, 4354, 4356, 4358, 4360, 4362, 4364, 4366, 4368, 4370, 4372, 4374, 4376, 4378, 4380, 4382, 4384, 4386, 4388, 4390, 4392, 4394, 4396, 4398, 4400, 4402, 4404, 440 6. 4408, 4410, 4412, 4414, 4416, 4418, 4420, 4422, 4424, 4426, 4428, 4430, 4432, 4434, 4436, 4438, 4440, 4442, 4444, 4446, 4448, 4450, 4452, 4454, 4456, 4458, 4460, 4462, 4464, 4466, 4468, 4470, 4472, 4474, 4476, 4478, 4480, 4482, 4484, 4486, 4488, 4490, 4492,4494 and 4496. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO:4148, 4150, 4152, 4154, 4156, 4158, 4160, 4162, 4164, 4166, 4168, 4170, 4172, 4174, 4176, 4178, 4180, 4182, 4184, 4186, 4188, 4 190, 4192, 4194, 4196, 4198, 4200, 4202, 4204, 4206, 4208, 4210, 4212, 4214, 4216, 4218, 4220, 4222, 4224, 4226, 4228, 4230, 4232, 4 234, 4236, 4238, 4240, 4242, 4244, 4246, 4248, 4250, 4252, 4254, 4256, 4258, 4260, 4262, 4264, 4266, 4268, 4270, 4272, 4274, 4276, 4278, 4280, 4282, 4284, 4286, 4288, 4290, 4292, 4294, 4296, 4298, 4300, 4302, 4304, 4306, 4308, 4310, 4312, 4314, 4316, 4318, 4320, 4321 322, 4324, 4326, 4328, 4330, 4332, 4334, 4336, 4338, 4340, 4342, 4344, 4346, 4348, 4350, 4352, 4354, 4356, 4358, 4360, 4362, 4364, 4366, 4368, 4370, 4372, 4374, 4376, 4378, 4380, 4382, 4384, 4386, 4388, 4390, 4392, 4394, 4396, 4398, 4400, 4402, 4404, 4406, 4408, 4410, 4412, 4414, 4416, 4418, 4420, 4422, 4424, 4426, 4428, 4430, 4432, 4434, 4436, 4438, 4440, 4442, 4444, 4446, 4448, 4450, 4452, 4454, 4456, 4458, 4460, 4462, 4464, 4466, 4468, 4470, 4472, 4474, 4476, 4478, 4480, 4482, 4484, 4486, 4488, 4490, 4492, 4494, and 4496.
[0059] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 8 / 375, 50 / 137 / 189 / 375, 62 / 153 / 155 / 156 / 159, 62 / 153 / 155 / 156 / 159 / 427, 62 / 153 / 155 / 199 / 406, 137 / 164 / 375, 153, 153 / 155 / 156, 153 / 155 / 156 / 159 / 199 / 238 / 406, 153 / 155 / 237 / 238 / 239 / 406, 153 / 155 / 237 / 238 / 239 / 427. / 238 / 239, 153 / 155 / 427, 153 / 156 / 159, 153 / 156 / 199 / 237 / 427, 153 / 156 / 427, 153 / 159 / 237 / 238 / 352, 153 / 176 / 181 / 427, 155 / 156, 155 / 156 / 176 / 181 / 199, 155 / 156 / 176 / 238 / 427, 155 / 181 / 199 / 238 / 406, 156 / 199, 156 / 199 / 427, 164 / 375 / 433, 223 / 375, 375 and 427, wherein the positions are numbered with reference to SEQ ID NO: 4256.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 8V / 375L, 50V / 137R / 189G / 375L, 62A / 153A / 155M / 156W / 159V, 62A / 153A / 155M / 156W / 159V / 427T, 62A / 153 A / 155M / 199S / 406Q, 137R / 164E / 375L, 153A, 153A / 155M / 156W, 153A / 155M / 156W / 1 59V / 199S / 238G / 406Q, 153A / 155M / 237L / 238T / 239F / 406Q, 153A / 155M / 238T / 239F , 153A / 155M / 427T, 153A / 156W / 159V, 153A / 156W / 199S / 237L / 427T, 153A / 156W / 42 7T, 153A / 159V / 237L / 238G / 352A, 153A / 176Q / 181L / 427S, 155M / 156W, 155M / 156W / 176Q / 181L / 199S, 155M / 156W / 176Q / 238T / 427S, 155M / 181L / 199S / 238G / 406Q, 156W / 199S, 156W / 199S / 427T, 164E / 375L / 433D, 223A / 375L, 375L and 427S, wherein the positions are numbered with reference to SEQ ID NO: 4256.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: S8V / I375L, I50V / Q137R / P189G / I375L, K62A / S153A / F155M / F156W / L159V, K62A / S153A / F155M / F156W / L159V / R427T, K62A / S153A / F155M / F156W / L159V 5M / N199S / T406Q, Q137R / H164E / I375L, S153A, S153A / F155M / F156W, S153A / F155M / F156W / L159V / N199S / M238G / T406Q, S153A / F155M / P237L / M238T / T239F / T406Q, S153A / F155M / M238T / T239F, S1 53A / F155M / R427T, S153A / F156W / L159V, S153A / F156W / N199S / P237L / R427T, S153A / F156W / R427 T, S153A / L159V / P237L / M238G / S352A, S153A / R176Q / M181L / R427S, F155M / F156W, F155M / F156W / R176Q / M181L / N199S, F155M / F156W / R176Q / M238T / R427S, F155M / M181L / N199S / M238G / T406Q, F156W / N199S, F156W / N199S / R427T, H164E / I375L / N433D, T223A / I375L, I375L and R427S, wherein the positions are numbered with reference to SEQ ID NO: 4256. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 7, 9, 10, 12, 53, 65, 68, 99, 106, 110, 115, 116, 131, 132, 136, 170, 178, 190, 192, 194, 200, 220, 238, 242, 245, 257, 272, 280, 302, 304, 335, 385, 395, 399, 402, 408, 412, 416, 423, 445, 447, and 449, wherein the positions are numbered with reference to SEQ ID NO: 4256.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 7H, 9G, 10D, 12S, 53N, 65F, 68I, 99R, 106K, 106R, 106S, 110G, 115A, 115T, 116I, 131C, 131S, 132G, 132R, 132T, 136D, 136G, 136R, 136S, 170E, 178L, 190T, 192A, 192L, 192P, 1 423L, 445H, 445K, 445R, 447L, 449K, 449L, 449Q, and 449R, wherein the positions are numbered with reference to SEQ ID NO: 4256. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: G7H, S9G, G10D, T12S, E53N, N65F, H68I, H99R, A106K, A106R, A106S, S110G, N115A, N115T, L116I, E131C, E131S, Q132G, Q132R, Q132T, E136D, E136G, E136R, E136S, A170E, Q178L, D190T, E192A, E192L, E192P, P194 F, A200S, T220M, T220Q, T220S, M238I, M238L, I242L, K245P, N257H, R272H, F280W, N302P, N302S, E304I, P335K, P335R, V385A, V385C, V385P, V385S, G395Q, Q399K, K402R, P408E, I412R, K416R, R423L, N445H, N445K, N445R, N447L, Y449K, Y449L, Y449Q, and Y449R, wherein the positions are numbered with reference to SEQ ID NO: 4256.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any of the following sequences: SEQ ID NO:4498, 4500, 4502, 4504, 4506, 4508, 4510, 4512, 4514, 4516, 4518, 4520, 4522, 4524, 4526, 4528, 4530, 4532, 4534, 4536, 4538, 4540, 4542 ,4544,4546,4548,4550,4552,4554,4556,4558,4560,4562,4564,45 66, 4568, 4570, 4572, 4574, 4576, 4578, 4580, 4582, 4584, 4586, 4588, 4 4648, 4650, 4652, 4654, 4656, 4658, 4660, 4662, 4664, 4666, 4668, 4670, 4672, 4674, 4676, 4678, 4680, and 4682.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 95% identical to any of the following sequences: SEQ ID NO:4498, 4500, 4502, 4504, 4506, 4508, 4510, 4512, 4514, 4516, 4518, 4520, 4522, 4524, 4526, 4528, 4530, 4532, 4534, 4536, 4538, 4540, 4542 ,4544,4546,4548,4550,4552,4554,4556,4558,4560,4562,4564,45 66, 4568, 4570, 4572, 4574, 4576, 4578, 4580, 4582, 4584, 4586, 4588, 4 4648, 4650, 4652, 4654, 4656, 4658, 4660, 4662, 4664, 4666, 4668, 4670, 4672, 4674, 4676, 4678, 4680, and 4682.In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises any one of the following sequences: SEQ ID NO:4498, 4500, 4502, 4504, 4506, 4508, 4510, 4512, 4514, 4516, 4518, 4520, 4522, 4524, 4526, 4528, 4530, 4532, 4534, 4536, 4538, 4540, 4542 ,4544,4546,4548,4550,4552,4554,4556,4558,4560,4562,4564,45 66, 4568, 4570, 4572, 4574, 4576, 4578, 4580, 4582, 4584, 4586, 4588, 4 4648, 4650, 4652, 4654, 4656, 4658, 4660, 4662, 4664, 4666, 4668, 4670, 4672, 4674, 4676, 4678, 4680, and 4682.
[0060] The present invention also provides an engineered glycosyltransferase, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 11 / 41 / 44 / 127 / 132 / 406, 11 / 41 / 44 / 127 / 278 / 406, 11 / 41 / 45 / 73 / 127 / 278 / 406 / 408, 11 / 41 / 45 / 127 / 278 / 406, 11 / 41 / 45 / 127 / 278 / 406, 11 / 41 / 45 / 127 / 278 / 406, 11 / 41 / 41 / 45 / 127 / 278 / 406, 11 / 41 / 41 / 45 / 127 / 278 / 406, 11 / 41 / 41 / 45 / 127 / 278 / 406, 11 / 41 / 41 / 45 / 127 / 278 / 406, 278 / 406、11 / 45 / 73 / 127 / 135、11 / 45 / 127 / 132 / 135 / 138 / 182、11 / 45 / 406、11 / 73 / 127 / 132 / 135 / 182 / 278、11 / 73 / 127 / 132 / 278 / 406 / 408、11 / 73 / 127 / 132 / 406 / 408, 11 / 73 / 132, 11 / 73 / 132 / 135 / 408, 11 / 127 / 132 / 135, 11 / 127 / 132 / 135 / 182, 11 / 127 / 132 / 135 / 406, 11 / 127 / 132 / 138 / 182, 11 / 127 / 132 / 1 82, 11 / 132 / 135 / 406, 11 / 182 / 406, 41 / 44 / 45 / 73 / 127 / 132 / 278, 41 / 45 / 127 / 132 / 135 / 278 / 406, 41 / 73 / 132 / 135 / 406, 44 / 45 / 73 / 132 / 135 / 406, 44 / 45 / 127 / 132 / 135 / 138 / 182 / 406 / 408、44 / 45 / 127 / 132 / 278、44 / 73 / 127 / 135、44 / 73 / 127 / 135 / 182 / 278 / 406 / 408、44 / 73 / 132 / 135 / 406 / 408、45 / 73 / 127 / 1 32 / 135 / 406 / 408、45 / 73 / 132、45 / 73 / 132 / 135 / 182、45 / 73 / 278 / 406 / 408、45 / 127 / 132、45 / 127 / 132 / 135 / 182、45 / 127 / 132 / 135 / 182 / 406 / 408、45 / 12 7 / 135, 45 / 132 / 408, 45 / 406, 56 / 309 / 449, 57, 65 / 114 / 422 / 427, 65 / 114 / 427, 65 / 143, 65 / 143 / 235 / 427, 73 / 127, 73 / 127 / 132, 127, 127 / 132 / 135 / 182,427, 427 / 429, and 449, wherein the positions are numbered with reference to SEQ ID NO: 4550. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 11L / 41H / 44H / 127I / 132K / 406G, 11L / 41H / 44H / 127I / 278L / 406S, 11L / 41H / 45Y / 73H / 127I / 278L / 406G / 408A, 11L / 41H / 45Y / 127I / 278L / 406G, 11L / 41H / 132K / 278L, 11L / 44H / 45Y / 127I / 11L / 44H / 73H / 127I / 132K / 135E, 11L / 44H / 73S / 127I / 132K / 135E / 406G / 408A, 11L / 44H / 127I, 11L / 44H / 132K / 278L / 406G, 11L / 45Y / 73H / 127I / 135E, 11L / 45Y / 127I / 132K / 135E / 138T / 182T, 11L / 45Y / 406G, 11L / 73H / 127I / 132K / 278L / 406G / 408A, 11L / 73H / 1 27I / 132K / 406G / 408A, 11L / 73H / 132K, 11L / 73S / 127I / 132K / 135E / 182L / 278L, 11L / 73S / 132K / 135E / 408A, 11L / 127I / 132K / 135E, 11L / 127I / 132K / 135E / 182L, 11L / 127I / 132K / 135E / 406S, 11L / 127I / 132K / 138T / 182L, 11L / 127I / 132K / 182T, 11L / 132 K / 135E / 406G, 11L / 182L / 406S, 41H / 44H / 45Y / 73H / 127I / 132K / 278L, 41H / 45Y / 127I / 132K / 135E / 278L / 406S, 41H / 73H / 132K / 135E / 406G, 44H / 45Y / 73H / 132K / 135E / 406G, 44H / 45Y / 127I / 132K / 135E / 138T / 182L / 406S / 408A, 44H / 45Y / 127I / 132K / 278L,44H / 73H / 127I / 135E, 44H / 73S / 127I / 135E / 182L / 278L / 406G / 408A, 44H / 73S / 132K / 135E / 406 G / 408A, 45Y / 73H / 127I / 132K / 135E / 406G / 408A, 45Y / 73H / 132K, 45Y / 73H / 132K / 135E / 182L, 45 Y / 73S / 278L / 406G / 408A, 45Y / 127I / 132K, 45Y / 127I / 132K / 135E / 182L, 45Y / 127I / 132K / 135E / 182T / 406G / 408A, 45Y / 127I / 135E, 45Y / 132K / 408A, 45Y / 406G, 56R / 309P / 449L, 57G, 65G / 114I / 422L / 427S, 65G / 114I / 427S, 65G / 143K, 65G / 143K / 235R / 427S, 73H / 127I, 73H / 127I / 132K, 12 7I, 127I / 132K / 135E / 182I / 406G, 127I / 132K / 135E / 182L, 132K / 135E, 132K / 135E / 182I, 132K / 427S, 427S / 429D and 449L, wherein the positions are numbered with reference to SEQ ID NO: 4550. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: Q11L / F41H / Y44H / Q127I / Q132K / T406G, Q11L / F41H / Y44H / Q127I / V278L / T406S, Q11L / F41H / L45Y / A73H / Q127I / V278L / T406G / P408A, Q11L / F41H / L45Y / Q127I I / V278L / T406G, Q11L / F41H / Q132K / V278L, Q11L / Y44H / L45Y / Q127I, Q11L / Y44H / A73H / Q127I / Q132K / L135E , Q11L / Y44H / A73S / Q127I / Q132K / L135E / T406G / P408A, Q11L / Y44H / Q127I, Q11L / Y44H / Q132K / V278L / T406G,Q11L / L45Y / A73H / Q127I / L135E、Q11L / L45Y / Q127I / Q132K / L135E / G138T / R182T、Q11L / L45Y / T406G、Q11L / A73H / Q127I / Q132K / V278L / T406G / P408A、Q11L / A73H / Q127I / Q132K / T406G / P408A、Q11L / A73H / Q132K、Q11L / A73S / Q127I / Q132K / L135E / R182L / V278L、Q11L / A73S / Q132K / L135E / P408A、Q11L / Q127I / Q132K / L135E、Q11L / Q127I / Q132K / L135E / R182L、Q11L / Q127I / Q132K / L135E / T406S、Q11L / Q127I / Q132K / G138T / R182L、Q11L / Q127I / Q132K / R182T、Q11L / Q132K / L135E / T406G、Q11L / R182L / T406S、F41H / Y44H / L45Y / A73H / Q127I / Q132K / V278L、F41H / L45Y / Q127I / Q132K / L135E / V278L / T406S、F41H / A73H / Q132K / L135E / T406G、Y44H / L45Y / A73H / Q132K / L135E / T406G、Y44H / L45Y / Q127I / Q132K / L135E / G138T / R182L / T406S / P408A、Y44H / L45Y / Q127I / Q132K / V278L、Y44H / A73H / Q127I / L135E、Y44H / A73S / Q127I / L135E / R182L / V278L / T406G / P408A、Y44H / A73S / Q132K / L135E / T406G / P408A、L45Y / A73H / Q127I / Q132K / L135E / T406G / P408A、L45Y / A73H / Q132K、L45Y / A73H / Q132K / L135E / R182L、L45Y / A73S / V278L / T406G / P408A、L45Y / Q127I / Q132K、L45Y / Q127I / Q132K / L135E / R182L、L45Y / Q127I / Q132K / L135E / R182T / T406G / P408A、L45Y / Q127I / L135E、L45Y / Q132K / P408A、L45Y / T406G、K56R / K309P / Y449L、K57G、N65G / Q114I / K422L / R427S, N65G / Q114I / R427S, N65G / P143K, N65G / P143K / Q235R / R427S, A73H / Q127I, A73H / Q127I / Q132K、Q127I、Q127I / Q132K / L135E / R182I / T406G、Q127I / Q132K / L135E / R182L、Q132K / L135E、Q132K / L135E / R182I , Q132K / L135E / T406G, Q132K / T406S, H164E, H164E / T220G / K309S / Y449H, H164E / T220G / Y449L, H164E / Y449H, R182L, T220G / Y449H, K309P / Y449L, K309R, K309T / Y449H, T406G, R418A / R427S, R427S, R427S / E429D, and Y449L, wherein the positions are numbered with reference to SEQ ID NO: 4550. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises a sequence that is at least 90% identical to any one of the following sequences: SEQ ID NO: NO:7216, 7218, 7220, 7222, 7224, 7226, 7228, 7230, 7232, 7234, ...
Claims
1. An engineered glycosyltransferase comprising a polypeptide sequence having at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:758, 770, 792, 954, 1002, 1054, 2600, 2718, 2814, 2884, 3016, 3082, 3244, 3346, 3502, 3696, 3956, 4256 and / or 4550.
2. The engineered glycosyltransferase of claim 1, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from the group consisting of: 375, 8 / 375, 7, 9, 10, 12, 50 / 137 / 189 / 375, 53, 62 / 153 / 155 / 156 / 159, 62 / 153 / 155 / 156 / 159 / 427, 62 / 153 / 1 55 / 199 / 406、65、68、99、106、110、115、116、131、132、136、137 / 164 / 375、153、153 / 155 / 156、153 / 155 / 156 / 159 / 199 / 238 / 406、153 / 155 / 237 / 238 / 239 / 406、153 / 155 / 238 / 239、153 / 155 / 427、 153 / 156 / 159、153 / 156 / 199 / 237 / 427、153 / 156 / 427、153 / 159 / 237 / 238 / 352、153 / 176 / 181 / 427、155 / 156、155 / 156 / 176 / 181 / 199、155 / 156 / 176 / 238 / 427、155 / 181 / 199 / 238 / 406、156 / 199 , 156 / 199 / 427, 164 / 375 / 433, 170, 178, 190, 192, 194, 200, 220, 223 / 375, 238, 242, 245, 257, 272, 280, 302, 304, 335, 385, 395, 399, 402, 408, 412, 416, 423, 427, 445, 447 and 449, wherein the positions are numbered with reference to SEQ ID NO:4256.
3. The engineered glycosyltransferase of claim 1 or claim 2, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 375L and 8V / 375L, wherein the positions are numbered with reference to SEQ ID NO: 4256.
4. The engineered glycosyltransferase of claim 1, wherein the polypeptide sequence of the engineered glycosyltransferase comprises: (a) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 69 / 173 / 175 / 243 / 246 / 354 / 365 / 383 / 399, 69 / 173 / 243 / 383 / 399, 56 / 191 / 354 / 383 / 399, 70 / 225 / 246 / 409 / 413, 70 / 115 / 225 / 409, 70 / 225 / 413, 70 / 225 / 247, 74 / 310 / 396 / 424, 74 / 396, and 173 / 175 / 191 / 365 / 383 / 399, wherein the positions are numbered with reference to SEQ ID NO: 758; (b) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24, 24 / 28, 24 / 28 / 262, 24 / 28 / 262 / 264, 24 / 28 / 262 / 264 / 423, 24 / 264 / 294, 28, 28 / 262 / 264, 28 / 423, 32, 56 / 69 / 70 / 175 / 191 / 246, 56 / 69 / 70 / 175 / 191 / 246 / 354, 56 / 69 / 70 / 175 / 354, 56 / 69 / 70 / 191 / 246 / 354 / 365, 56 / 69 / 70 / 246 / 354, 56 / 69 / 175 / 191 / 246 / 354, 56 / 69 / 70 / 175 / 191 / 246 / 354, 175 / 246 / 354、56 / 69 / 175 / 246 / 354 / 365、56 / 69 / 246 / 354、56 / 69 / 246 / 365、56 / 70 / 175 / 191 / 246、56 / 70 / 175 / 191 / 246 / 354、56 / 70 / 175 / 191 / 246 / 354、56 / 70 / 175 / 191 / 354 / 365、5 6 / 70 / 175 / 246 / 354, 56 / 70 / 175 / 246 / 365, 56 / 70 / 191 / 246 / 354 / 365, 56 / 70 / 191 / 354, 56 / 175 / 246, 56 / 175 / 354, 56 / 175 / 354 / 365, 56 / 191 / 246 / 354, 56 / 191 / 354 / 383 / 399、56 / 246、56 / 246 / 354 / 365、56 / 354、69、69 / 70 / 175 / 191 / 246 / 354 / 365、69 / 70 / 191 / 246 / 354 / 365、69 / 70 / 246、69 / 70 / 354 / 365、69 / 1 73 / 175 / 243 / 246 / 354 / 365 / 383 / 399、69 / 173 / 243 / 383 / 399、69 / 175 / 191 / 246 / 354、69 / 175 / 354、69 / 246 / 354 / 365、69 / 354、70、70 / 115 / 225 / 409、70 / 17 5 / 191 / 246 / 354 / 365, 70 / 175 / 191 / 354 / 365, 70 / 191 / 246 / 354 / 365, 70 / 191 / 246 / 365, 70 / 191 / 246 / 365, 70 / 225 / 246 / 409 / 413, 70 / 225 / 247, 70 / 225 / 413, 74 / 310 / 396 / 42 4.74 / 396,126,126 / 220,126 / 403,173 / 175 / 191 / 365 / 383 / 399,175,175 / 191,175 / 191 / 246 / 354 / 365,175 / 191 / 354,175 / 191 / 354 / 365,175 / 246 / 354,175 / 246 / 354 / 365, 175 / 354, 191 / 246 / 354, 246 / 354, 262 / 264, 264, 264 / 29, 269, 325, 341, 351, 354, 354 / 365 and 366, wherein the positions are numbered with reference to SEQ ID NO: 770; (c) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24 / 32 / 264 / 269 / 330 / 402 / 403, 24 / 32 / 264 / 269 / 382 / 403 / 406, 24 / 32 / 264 / 330, 24 / 32 / 269, 24 / 32 / 269 / 382 / 385 / 389 / 402 / 403 6. 24 / 32 / 269 / 403, 24 / 32 / 330, 24 / 264 / 269 / 389 / 402 / 406, 70 / 126 / 175 / 191 / 246 / 325 / 354 / 366, 70 / 126 / 175 / 325 / 330 / 351 / 354 / 366, 70 / 126 / 191 / 246 / 325 / 351 / 354 / 366 / 423、70 / 126 / 191 / 246 / 325 / 351 / 354 / 423、70 / 126 / 191 / 246 / 325 / 351 / 366 / 423、70 / 126 / 191 / 246 / 354 / 366、70 / 126 / 246 / 330 / 366、70 / 126 / 246 / 354 / 366 , 126 / 211 / 220 / 253 / 316 / 342, 126 / 211 / 220 / 275 / 279 / 323, 126 / 211 / 260 / 423, 126 / 220 / 260, 126 / 220 / 316, 56 / 220 / 260 / 423, 220 / 260 and 220 / 260 / 423, wherein the positions are numbered with reference to SEQ ID NO:792; (d) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24 / 32 / 97 / 162 / 202, 24 / 32 / 126 / 198 / 201 / 367, 24 / 32 / 126 / 198 / 202 / 220 / 226 / 260 / 269S, 24 / 32 / 146 / 226, 24 / 32 / 198 / 201 / 220 / 226, 24 / 32 / 198 / 201 / 226, 24 / 97 / 260 / 367, 32 / 97 / 198 / 202 / 226 / 260, 32 / 202 / 367、32 / 226 / 367、56 / 175 / 197 / 211 / 330 / 382 / 385、56 / 175 / 197 / 253 / 385 / 389、56 / 175 / 264 / 382 / 385 / 389 / 402 / 406、56 / 197 / 264 / 279 / 330 / 382 / 389 / 402 / 403 / 406、56 / 211 / 253 / 316 / 323、56 / 211 / 264 / 316 / 389、56 / 211 / 279 / 323 / 330 / 40 2. 56 / 264 / 385 / 389, 97 / 202 / 367, 162 / 220 / 226 / 367, 175 / 197 / 211 / 264 / 330, 175 / 211 / 264 / 279 / 316 / 323, 175 / 211 / 279 / 323 / 330 / 402 / 403 / 406, 175 / 211 / 323 / 382 / 402 / 403 / 406, 175 / 211 / 403 / 406, 175 / 264 / 316 / 323 / 330 / 403 / 406, 175 / 2 64 / 316 / 389 / 402, 175 / 264 / 323 / 330, 197 / 211 / 316 / 342 / 406, 197 / 211 / 316 / 382 / 389 / 402 / 403, 197 / 211 / 402, 197 / 279 / 323, 198 / 201 / 367, 198 / 202 / 220 / 269 / 367, 201 / 202 / 367, 211 / 382 / 406, 211 / 385 / 389, 211 / 402 / 403 and 389, wherein the positions are numbered with reference to SEQ ID NO:954; (e) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 21 / 127 / 129 / 161, 21 / 127 / 129 / 161 / 162, 21 / 127 / 129 / 162 / 199 / 200, 127 / 129 / 161 / 162 / 199, 127 / 129 / 161 / 199 / 200, 127 / 129 / 162, 156, 156 / 161, 156 / 161 / 162, 156 / 162 / 199, and 156 / 199 / 200, wherein the positions are numbered with reference to SEQ ID NO: 1002; (f) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 24 / 32 / 175 / 211 / 260 / 330 / 403 / 406, 24 / 32 / 175 / 226 / 253 / 275 / 316, 24 / 32 / 201 / 226 / 260 / 264 / 330 / 402 / 406, 24 / 162 / 175 / 198 / 211 / 226 / 275 / 316 / 323 / 389, 24 / 162 / 175 / 201 / 27 5 / 316、24 / 162 / 198 / 201 / 211 / 226 / 323 / 351、24 / 162 / 198 / 201 / 226 / 351、24 / 162 / 201 / 253 / 264 / 351 / 402 / 406、24 / 175 / 198 / 211 / 226 / 253 / 316、24 / 175 / 201 / 275 / 316 / 351、24 / 175 / 201 / 316、24 / 175 / 211 / 220 / 260 / 27 5 / 330 / 389、24 / 175 / 211 / 253 / 316、24 / 175 / 211 / 316 / 330、24 / 175 / 226 / 323 / 351、24 / 198 / 201、24 / 198 / 201 / 211、24 / 198 / 201 / 211 / 220 / 260、24 / 198 / 201 / 220 / 275 / 389 / 402 / 406、24 / 198 / 201 / 226 / 330 / 389、24 / 198 / 201 / 351, 24 / 201 / 211 / 253 / 323 / 351 / 366 / 389 / 402 / 403, 24 / 201 / 226 / 253 / 402 / 403 / 406, 24 / 226 / 330 / 351 / 403, 175 / 198 / 201 / 211 / 226 / 260 / 264 / 323 / 402 / 406 and 175 / 198 / 226 / 260 / 351 / 402 / 403 / 406, wherein the positions are numbered with reference to SEQ ID NO: 1054; (g) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2 / 7 / 12 / 15 / 175 / 260 / 318, 7 / 12 / 400 / 435, 7 / 318 / 451, 12 / 15 / 57 / 71 / 175 / 260 / 400 / 402, 12 / 15 / 57 / 220 / 254 / 260 / 318 / 402, 12 / 15 / 57 / 318 / 402 / 435, 12 / 15 / 318 / 400 / 402 / 406, 12 / 57 / 175 / 451, 12 / 175 / 260 / 264 / 318 / 400, 12 / 175 / 400 / 402 / 406, 12 / 318 / 402 / 404 / 406. 6 / 451, 12 / 318 / 402 / 404 / 451, 15 / 175 / 318 / 400 / 402, 32, 57 / 175 / 220 / 260 / 264 / 402, 57 / 175 / 404, 57 / 220 / 260 / 400 / 402 / 406, 57 / 260 / 400 / 402 / 404, 57 / 400 / 402, 57 / 402, 135, 148, 152, 152 / 192 / 195, 160 / 186 / 195, 186, 195, 260, 237, 239, 240, 323, 325, 326, 327, 330, 331, 356 and 400 / 402, wherein the positions are with reference to SEQ ID NO:2600 to number; (h) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 11, 14 / 23 / 274 / 326 / 329, 14 / 31 / 184 / 274 / 322 / 326 / 329 / 330, 14 / 56 / 184 / 185 / 194 / 238 / 239 / 274 / 329 / 399, 14 / 56 / 184 / 194 / 234 / 315 / 326 / 329 / 399 / 401, 14 / 56 / 194 / 238 / 315 / 325 / 326 / 329 / 330 / 399、14 / 56 / 252 / 274 / 315 / 326 / 329 / 330 / 401、14 / 184 / 185 / 194 / 234 / 325 / 326 / 329、14 / 184 / 185 / 194 / 388 / 399 / 401、14 / 184 / 194 / 355 / 399、14 / 185 / 194 / 238 / 399、14 / 185 / 236 / 238 / 239 / 274 / 322 / 326 / 329 / 355 / 399 / 401、14 / 194、14 / 322 / 326 / 330、14 / 326 / 330、14 / 355、14 / 355 / 399、23 / 31 / 147 / 184 / 185 / 238 / 252 / 325 / 329 / 330 / 388 / 401、31 / 56 / 315 / 329 / 330、45、55、56、58、65、6 5 / 114 / 132 / 238, 65 / 238 / 240, 104, 113, 114, 132, 135, 138, 147 / 236 / 238 / 243 / 315 / 329 / 330 / 399 / 401, 165, 185 / 194 / 236 / 239 / 325 / 326, 223 / 412, 238, 256, 273, 286, 309, 391, 422, 430 and 449, wherein the positions are numbered with reference to SEQ ID NO: 2718; (i) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 23 / 31 / 185 / 324 / 401, 23 / 31 / 185 / 355, 31 / 134 / 185 / 252 / 274 / 324 / 388, 31 / 134 / 238 / 252 / 322 / 324 / 388, 31 / 134 / 252 / 324, 31 / 184 / 185 / 238 / 239 / 322, 31 / 236, 31 / 322, 31 / 388, 122, 134 / 184 / 185 / 234 / 236 / 239 / 274 / 324 / 388, 164, 176, 177, 184 / 185 / 322, 234 / 236 / 238 / 322 / 324 / 355, 236, 238 / 324 / 329 / 355, 316, 322 / 324, 324 / 329 / 355 / 401, 325, 400, 425, 426, 427, 440 and 446, wherein the positions are numbered with reference to SEQ ID NO: 2814; (j) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 11, 11 / 45 / 58 / 132 / 138 / 286, 11 / 58, 11 / 58 / 65 / 104 / 107 / 138 / 286, 11 / 58 / 65 / 107 / 135 / 223 / 286 / 391 / 430, 11 / 58 / 65 / 135 / 138, 11 / 58 / 104 / 107 / 114 / 138 / 223 / 391, 11 / 58 / 114 / 286 / 309 / 391、11 / 58 / 132 / 165 / 286 / 391 / 422 / 430、11 / 58 / 138 / 309、11 / 65 / 104 / 107 / 138 / 165 / 286 / 391 / 430、11 / 65 / 107 / 135 / 165 / 391 / 430、11 / 65 / 132 / 135 / 138 / 223 / 391、11 / 65 / 132 / 135 / 252、11 / 65 / 132 / 391 / 430, 11 / 65 / 135 / 138, 11 / 104 / 132 / 138 / 309 / 391, 11 / 104 / 132 / 138 / 391, 11 / 107 / 114 / 223 / 309 / 430, 11 / 107 / 138, 11 / 114 / 135 / 138 / 223, 11 / 114 / 223 / 252 / 286 / 391, 11 / 132 / 135 / 138 / 223 / 2 86, 11 / 132 / 138 / 223 / 286 / 391, 11 / 138 / 165 / 223 / 309, 58 / 65 / 138, 58 / 65 / 138 / 165, 58 / 65 / 165 / 309 / 430, 58 / 104 / 114 / 165 / 391, 107 / 114 / 132 / 138, 107 / 430, 135 / 138 / 165 / 309 / 430, and 223 / 309, wherein the positions are numbered with reference to SEQ ID NO: 2884; (k) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 8 / 448, 9, 58 / 107 / 122 / 176 / 236 / 324 / 325 / 400 / 426 / 427, 58 / 107 / 122 / 236 / 324 / 400 / 425 / 446, 58 / 107 / 122 / 322 / 400 / 425 / 427 / 440 / 446, 58 / 107 / 164 / 400, 58 / 107 / 236 / 400, 58 / 107 / 400, 58 / 122 / 164 / 236 / 446, 58 / 107 / 122 / 322 / 400 / 425 / 446 / 122 / 176 / 236 / 400 / 446、58 / 122 / 176 / 322 / 324 / 426 / 427、58 / 122 / 176 / 400 / 425 / 426 / 427 / 446、58 / 122 / 322 / 325、58 / 122 / 325、58 / 122 / 440、58 / 164 / 176、58 / 164 / 324 / 425 / 427、58 / 176 / 236、58 / 236、65、106、107 / 122 / 236 / 425 / 426 / 446、107 / 164 / 236 / 400 / 446, 107 / 176 / 322 / 325 / 440 / 446, 107 / 176 / 400 / 425 / 427 / 440, 107 / 236, 107 / 440, 115, 116, 122 / 164 / 176 / 324 / 400, 122 / 164 / 400 / 440, 122 / 164 / 400 / 440 / 446, 122 / 176 / 236 / 400, 122 / 176 / 324 / 400 / 440, 122 / 400, 122 / 425 / 426 / 446, 122 / 440 / 4 46, 139, 139 / 252, 164, 164 / 271 / 425 / 426, 164 / 322 / 324 / 325 / 400 / 425 / 440 / 446, 164 / 400, 172, 176 / 400, 178, 189, 200, 210, 213, 240, 242, 245, 255, 324 / 400 / 425 / 426 / 440 / 446, 324 / 423, 385, 408, 409, 411, 412, 415, 416, 423, 447 and 448, wherein the positions are numbered with reference to SEQ ID NO: 3016; (l) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2, 3, 8, 8 / 107 / 139 / 164 / 415 / 416 / 440 / 448, 8 / 107 / 139 / 255 / 322 / 325 / 415 / 416 / 440 / 448, 8 / 107 / 164 / 255, 8 / 107 / 164 / 423 / 440, 8 / 139, 8 / 139 / 164 / 200 / 236 / 240 / 322 / 440 / 448, 8 / 139 / 164 / 236 / 416 / 423 / 440, 8 / 139 / 189 / 240 / 325 / 416, 8 / 139 / 200 / 236 / 240 / 255 / 423 / 440.
3. 8 / 139 / 255 / 415 / 416, 8 / 164, 8 / 164 / 189 / 200 / 322 / 324 / 325 / 416 / 448, 8 / 164 / 240 / 423, 8 / 164 / 252 / 255 / 448, 8 / 164 / 448, 8 / 236 / 240 / 252 / 448, 8 / 24 0 / 423, 8 / 252 / 255 / 322 / 325 / 448, 12 / 164 / 440, 20 / 126 / 128 / 155 / 161, 20 / 126 / 128 / 160 / 161, 20 / 126 / 128 / 160 / 161 / 198, 20 / 126 / 128 / 161, 20 / 126 / 128 8 / 161 / 198 / 199、20 / 126 / 155 / 160 / 198、20 / 126 / 155 / 161、20 / 126 / 160、20 / 126 / 160 / 161、20 / 126 / 161、20 / 128 / 155 / 160 / 161 / 198、20 / 128 / 155 / 161 / 1 99, 20 / 128 / 155 / 199, 20 / 128 / 160 / 161 / 198, 20 / 155 / 160, 20 / 155 / 160 / 161, 20 / 155 / 161, 20 / 155 / 161 / 199, 20 / 160 / 161 / 198, 34, 72, 73, 75, 107 / 139, 107 / 139 / 200 / 240 / 322 / 324 / 325 / 448、107 / 236 / 240 / 325 / 440、107 / 240 / 252 / 423 / 448、107 / 423、113、114、121 / 126 / 128 / 161 / 369、126 / 128 / 155 / 160 / 161、126 / 128 / 155 / 160 / 161 / 199、126 / 128 / 155 / 161 / 199、126 / 128 / 160 / 161 / 369、126 / 128 / 160 / 198 / 369、126 / 128 / 160 / 199 / 369、126 / 128 / 160 / 369、126 / 128 / 161 / 199 / 369、126 / 128 / 161 / 369、126 / 128 / 369、126 / 160 / 161 / 199 / 369、126 / 160 / 198 / 369、126 / 196 / 198 / 369、126 / 198 / 369、126 / 199 / 369、126 / 369、128 / 155 / 160 / 161、128 / 155 / 160 / 161 / 199、128 / 155 / 160 / 198、128 / 155 / 199 、128 / 160 / 161 / 369、128 / 161 / 199 / 369、128 / 198 / 199 / 369、128 / 199 / 369、128 / 369、139、139 / 164 / 236 / 240、139 / 255 / 325 / 415 / 440、155 / 161 / 198 / 199、155 / 199、160 / 161 / 369、161 / 198 / 369、161 / 369、164 / 189、164 / 189 / 236 / 240、164 / 189 / 240 / 252 / 415 / 423, 164 / 200 / 236, 164 / 200 / 236 / 240 / 324 / 416 / 440, 164 / 200 / 236 / 255 / 322 / 324 / 423 / 440, 164 / 236, 164 / 236 / 240 / 440, 164 / 236 / 423, 164 / 322 / 325, 164 / 322 / 325 / 416 / 423, 164 / 416 / 448, 186, 189, 199 / 369, 200 / 236 / 322 306, 415 / 416 / 448, 422, 438 and 446, wherein the positions are numbered with reference to SEQ ID NO: 3082; (m) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 14, 35, 42, 46, 49, 105, 106 / 164 / 172 / 200 / 409, 106 / 164 / 172 / 210 / 240 / 415, 106 / 164 / 172 / 242 / 409 / 416, 106 / 164 / 200 / 210 / 242, 106 / 164 / 200 / 210 / 415, 106 / 164 / 200 / 240 / 408 / 409 / 416, 106 / 164 / 210 / 240 / 408 / 409 / 416. / 164 / 240 / 415, 106 / 164 / 409 / 415 / 423, 106 / 172 / 200 / 210 / 240 / 242 / 408 / 415 / 416 / 423, 106 / 172 / 200 / 210 / 242, 106 / 172 / 240, 106 / 172 / 240 / 242 / 409 / 415, 106 / 172 / 242, 106 / 172 / 242 / 416 / 423, 106 / 172 / 408 / 409, 106 / 172 / 409 / 423, 106 / 200 / 210 / 409, 106 / 210 / 240, 106 / 210 / 240 / 408 / 415, 106 / 240 / 242, 106 / 240 / 242 / 409, 106 / 242 / 408 / 409, 134, 143, 164 / 172 / 200 / 210 / 242 / 409, 164 / 172 / 240 / 242 / 415, 164 / 172 / 242 / 408, 164 / 200 / 408 / 415 / 416, 164 / 240 / 242 / 408, 164 / 240 / 242 / 415 / 423, 164 / 423, 172 / 200 / 210 / 240 / 408, 172 / 200 / 240, 172 / 200 / 408 / 416, 172 / 210 324, 326, 336, 351, 381, 392, 406, 410, 424, 432, 440, 450, 460, 472, 480, 490, 501, 510, 520, 530, 540, 550, 560, 570, 580, 590, 601, 610, 620, 630, 640, 650, 660, 670, 680, 710, 720, 730, 740, 750, 760, 770, 780, 790, 801, 802, 803, 804, 805, 806, 807, 808, 809, (n) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 21, 91, 125, 127, 130 / 187, 143, 143 / 150, 145, 152, 156, 186, 187, 195, 197, 200, 201, 202, 264, 268, 364, 365, and 415, wherein the positions are numbered with reference to SEQ ID NO: 3346; (o) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2 / 5 / 113 / 186 / 237 / 406, 2 / 73 / 186 / 237, 2 / 189 / 286, 2 / 286 / 355 / 416 / 422, 5 / 34 / 73 / 113 / 406, 5 / 73 / 186 / 406, 5 / 113 / 237 / 406, 5 / 186 / 237 / 245 / 256 / 406, 5 / 186 / 237 / 406, 5 / 256 / 406, 34 / 113 / 186 / 237 / 406, 72 / 73 / 172 / 235 / 240 / 242 / 438, 72 / 172 / 239 / 240 / 242 / 408, 72 / 172 / 240 / 242, 73 / 172, 73 / 172 / 235 / 239 / 240, 73 / 172 / 235 / 239 / 242, 73 / 172 / 239 / 240, 73 / 172 / 239 / 240 / 242, 73 / 172 / 240 / 242 / 408, 73 / 172 / 240 / 408, 73 / 186 / 237 / 406, 73 / 235 / 240 / 323, 73 / 235 / 240 / 408, 73 / 237, 73 / 239 / 242, 96, 113 / 186 / 406, 127, 132, 144, 153, 155, 156, 172, 172 / 188 / 323, 172 / 235, 172 / 235 / 239 / 240 / 242, 172 / 235 / 239 / 408, 172 / 235 / 240, 172 / 235 / 240 / 242 / 438, 172 / 239 / 240 / 242 / 323 / 408, 172 / 240, 172 / 240 / 29 9 / 323, 186, 186 / 237, 186 / 237 / 286, 186 / 406, 187, 189 / 333 / 355 / 421, 196, 199, 200, 235 / 239 / 240, 235 / 240 / 242, 237, 239 / 240, 239 / 240 / 242 / 256 / 323, 239 / 240 / 242 / 323 / 408, 239 / 240 / 408, 239 / 242 / 408, 240 / 242 / 256 / 438, and 242 / 408, wherein the positions are numbered with reference to SEQ ID NO: 3502; (p) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2 / 5 / 35 / 105 / 143 / 237 / 373 / 416 / 422, 2 / 5 / 35 / 143 / 232 / 237 / 416 / 422 / 441, 2 / 5 / 35 / 232 / 278 / 373 / 416, 2 / 5 / 105 / 143 / 232 / 373 / 416 / 422, 2 / 5 / 278, 2 / 105 / 143 / 232 / 237 / 278 / 373 / 441, 2 / 143 / 232 / 373 / 441, 2 / 143 / 232 / 373 / 416 / 422. 37 / 373 / 416 / 441、5 / 105 / 237 / 278 / 422 / 441、5 / 105 / 237 / 416 / 422 / 441、5 / 143 / 189 / 232 / 237 / 441、5 / 143 / 232 / 237 / 278、5 / 143 / 232 / 237 / 416 / 422、5 / 1 43 / 232 / 373 / 422 / 441、5 / 143 / 237 / 278 / 373 / 416 / 422、5 / 143 / 373、5 / 189 / 237 / 278 / 373 / 416 / 422 / 441、5 / 232 / 416 / 422、5 / 237 / 373 / 422、5 / 373 / 416、8 、26 / 42、26 / 42 / 46 / 49、26 / 42 / 46 / 49 / 134、26 / 42 / 46 / 49 / 134 / 186、26 / 42 / 46 / 134、26 / 42 / 49 / 134、26 / 42 / 49 / 134 / 186 / 355、26 / 42 / 49 / 134 / 401、26 / 42 / 134 / 401、26 / 49 / 134、26 / 134、26 / 134 / 186 / 355 / 401、26 / 134 / 355、26 / 134 / 401、26 / 355 / 401、35、35 / 105 / 189 / 232 / 373 / 416、42 / 46 / 49 / 97 / 134 / 401、 42 / 46 / 49 / 134、42 / 46 / 49 / 134 / 186、42 / 46 / 49 / 134 / 186 / 355、42 / 46 / 49 / 134 / 235 / 355 / 401、42 / 46 / 49 / 134 / 401、42 / 46 / 49 / 186、42 / 49 / 134 / 186 / 355、 42 / 49 / 134 / 186 / 401、42 / 49 / 134 / 355 / 401、42 / 134 / 186、42 / 186 / 355、46 / 49 / 134、49 / 134 / 355、50、61、62、101、105 / 143 / 232 / 237 / 373 / 416 / 422 / 441、105 / 143 / 278 / 373、105 / 189 / 237、105 / 237 / 278 / 373 / 416 / 422、105 / 237 / 373 / 422 / 441、105 / 373、105 / 373 / 441、134 / 401、137、143、143 / 189、143 / 189 / 232 / 422 / 441、143 / 189 / 237 / 373 / 416 / 422、143 / 232、143 / 237、143 / 237 / 422 364, 366, 377, 384, 392, 408, 410, 427, 436, 440, 451, 464, 472, 482, 490, 501, 512, 524, 536, 542, 550, 564, 572, 582, 590, 610, 624, 636, 640, 650, 660, 670, 680, 7010, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 730, 7310, 7320, 7330, 7340, 7350, 736, 737 (q) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 5 / 73 / 113 / 186 / 187 / 373 / 423, 5 / 73 / 143 / 144 / 179 / 186 / 187 / 422, 5 / 73 / 144 / 179 / 186 / 373 / 423, 5 / 73 / 144 / 187 / 373 / 422, 5 / 143 / 144 / 179 / 181 / 186 / 187 / 373, 5 / 144 / 179 / 181 / 373 / 422, 5 / 144 / 373 / 422, 11, 12, 41, 44, 44 / 187, 45, 49 / 96 / 127 / 132 / 156 / 196, 49 / 96 / 127 / 132 / 156 / 196. 6 / 127 / 153 / 278、49 / 96 / 132 / 153 / 155 / 156 / 237 / 278 / 406、49 / 96 / 132 / 153 / 199 / 200、49 / 96 / 132 / 155、49 / 96 / 132 / 155 / 237 / 278、49 / 96 / 155 / 199 / 20 0 / 406、49 / 153 / 155、55、56、57、65、66、70、72、73、73 / 113 / 143 / 179 / 181 / 422、73 / 113 / 179 / 181 / 186 / 187、73 / 143 / 144 / 179 / 186 / 187 / 373 / 423、73 / 17 9 / 181 / 186 / 187 / 373、73 / 179 / 181 / 186 / 373 / 422、73 / 181 / 186 / 187、74 / 238、82、83、85、96 / 127 / 132 / 153 / 278、96 / 127 / 153 / 155、96 / 132 / 153 / 155、96 / 132 / 153 / 155 / 156、96 / 132 / 153 / 155 / 156 / 200、96 / 132 / 153 / 156、96 / 132 / 196 / 199、96 / 132 / 278、96 / 153 / 155 / 156、96 / 153 / 155 / 199 / 200 / 237、96 / 153 / 406、103、111、113、113 / 143 / 179 / 186 / 187、113 / 144 / 186 / 423、113 / 144 / 373、113 / 181 / 186 / 373 / 422、113 / 373 / 422、114、117、127 / 132、127 / 132 / 153 / 156、127 / 132 / 155 / 156 / 406、127 / 153 / 155 / 199 / 200 / 237、127 / 406、132、132 / 153 / 155、132 / 153 / 237 / 406、132 / 155、132 / 237、135、138、140、143 / 144 / 179 / 181 / 186 / 187 / 422、143 / 179 / 181 / 186 / 187 / 422 / 423、144 / 179 / 181 / 186 / 187 / 373、144 / 179 / 186 / 187 / 373、153 / 155 / 156 / 237、153 / 155 / 196 / 199 / 237、153 / 199 / 406、153 / 237、155 / 199、159、160、162、167、179 / 181 / 186、179 / 181 / 186 / 187 / 423, 179 / 186 / 187, 179 / 187 / 373 / 422, 181 / 186 / 187 / 422 / 423, 182, 214, 220, 222, 223, 226, 236, 238, 256, 286, 299, 309, 373 / 423, 387, 388, 389, 391, 393, 406, 408, 412, 418, 422, 429, 430, 449 and 450 and 373 / 423, wherein the positions are numbered with reference to SEQ ID NO: 3956; (r) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 11 / 41 / 44 / 127 / 132 / 406, 11 / 41 / 44 / 127 / 278 / 406, 11 / 41 / 45 / 73 / 127 / 278 / 406 / 408, 11 / 41 / 45 / 127 / 278 / 406, 11 / 41 / 132 / 278, 11 / 44 / 45 / 127, 11 / 44 / 73 / 127 / 132 / 135, 11 / 44 / 73 / 127 / 132 / 135 / 406 / 408, 11 / 44 / 127, 11 / 44 / 132 / 278 / 406, 11 / 45 / 73 / 127 / 135 127 / 132 / 135 / 138 / 182、11 / 45 / 406、11 / 73 / 127 / 132 / 135 / 182 / 278、11 / 73 / 127 / 132 / 278 / 406 / 408、11 / 73 / 127 / 132 / 406 / 408、11 / 73 / 132、11 / 73 / 132 / 1 35 / 408, 11 / 127 / 132 / 135, 11 / 127 / 132 / 135 / 182, 11 / 127 / 132 / 135 / 406, 11 / 127 / 132 / 138 / 182, 11 / 127 / 132 / 182, 11 / 132 / 135 / 406, 11 / 182 / 406, 41 / 44 / 45 / 73 / 127 / 132 / 278、41 / 45 / 127 / 132 / 135 / 278 / 406、41 / 73 / 132 / 135 / 406、44 / 45 / 73 / 132 / 135 / 406、44 / 45 / 127 / 132 / 135 / 138 / 182 / 406 / 408、44 / 45 / 1 27 / 132 / 278、44 / 73 / 127 / 135、44 / 73 / 127 / 135 / 182 / 278 / 406 / 408、44 / 73 / 132 / 135 / 406 / 408、45 / 73 / 127 / 132 / 135 / 406 / 408、45 / 73 / 132、45 / 73 / 132 / 13 5 / 182、45 / 73 / 278 / 406 / 408、45 / 127 / 132、45 / 127 / 132 / 135 / 182、45 / 127 / 132 / 135 / 182 / 406 / 408、45 / 127 / 135、45 / 132 / 408、45 / 406、56 / 309 / 449、57、6 5 / 114 / 422 / 427、65 / 114 / 427、65 / 143、65 / 143 / 235 / 427、73 / 127、73 / 127 / 132、127、127 / 132 / 135 / 182、127 / 132 / 135 / 182 / 406、132 / 135、132 / 135 / 182、132 / 135 / 406, 132 / 406, 164, 164 / 220 / 309 / 449, 164 / 220 / 449, 164 / 449, 182, 220 / 449, 309, 309 / 449, 406, 418 / 427, 427, 427 / 429 and 449, wherein the positions are numbered with reference to SEQ ID NO: 4550; (s) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 2, 4, 7 / 10 / 73 / 127 / 132 / 385 / 423, 10, 10 / 53 / 73 / 99, 10 / 53 / 272 / 423 / 427, 10 / 53 / 423, 10 / 73, 10 / 73 / 127, 10 / 127 / 132 / 385, 10 / 132 / 302 / 385, 11 / 44, 11 / 71, 11 / 287, 11 / 441, 37, 40, 42, 42 / 138, 42 / 141, 43, 46, 47, 48 / 398, 49, 49 / 406 / 408, 51, 53 / 73 / 200 / 423, 53 / 1 27 / 132 / 385、53 / 127 / 136 / 385、53 / 132 / 136 / 302 / 423 / 427、53 / 132 / 302 / 385 / 423 / 427、64、65 / 106 / 445 / 447 / 449、65 / 143 / 220、65 / 220 / 309 / 445 / 447、 65 / 220 / 445 / 449、65 / 399 / 406 / 447 / 449、65 / 402 / 406 / 445 / 449、65 / 445 / 447 / 449、65 / 447 / 449、71、73、73 / 127 / 427、73 / 132 / 136 / 385 / 427、73 / 385、73 / 385 / 427、76、97、100、106 / 220 / 399 / 402 / 406、108、108 / 172、109、112、115 / 116 / 278、115 / 170 / 190 / 238 / 412、115 / 190 / 194、115 / 245 / 278、116 / 170 / 190、116 / 190 / 406 / 408、116 / 238、116 / 238 / 245、116 / 416、117 / 157 / 301、118、118 / 406 / 408、119、119 / 172、127、130、132、133、134、141、143 / 220 / 445 / 447, 143 / 309 / 402, 143 / 309 / 445 / 447 / 449, 157, 169, 170, 170 / 190 / 192 / 194, 170 / 192, 170 / 192 / 194 / 278, 170 / 192 / 194 / 335, 170 / 194, 170 / 194 / 335 / 416、170 / 238、170 / 335、170 / 335 / 416、172 / 420、172 / 437、179、181、190、190 / 192 / 194、190 / 194、190 / 194 / 238 / 245、190 / 194 / 335 / 416、190 / 194 / 412、190 / 245 / 412、192 / 194、192 / 194 / 242 / 406 / 408、194、200、200 / 385、220 / 399、220 / 445、220 / 445 / 447、257 / 385、259、272 / 302、272 / 385、274、275、278、287、288、302 / 385、309 / 399 / 449、309 / 445 / 447 / 449、333 / 398、333 / 406 / 408、338、356、3 57, 376, 381, 385, 394 / 420, 396, 397 / 406 / 408, 398, 401, 385, 385 / 427, 399 / 406, 399 / 406 / 449, 402 / 445 / 449, 406 / 408, 406 / 445 / 447 / 449, 406 / 445 / 449, 410, 417, 420, 423 / 427, 434, 437, 441, 445 / 447 / 449, 445 / 449, 447 and 449, wherein the positions are numbered with reference to SEQ ID NO: 7324; or, (t) at least one mutation or set of mutations at one or more positions selected from the group consisting of: 10, 10 / 144, 10 / 199, 11, 11 / 64 / 109, 11 / 445, 13, 14, 15, 15 / 394, 16, 22, 36, 42 / 43, 42 / 44 / 71 / 73 / 116, 43 / 73 / 141, 46 / 47 / 51, 46 / 51, 47 / 49, 47 / 51, 64, 64 / 65 / 109, 64 / 65 / 112, 64 / 112, 64 / 134, 64 / 445, 65 / 112、65 / 112 / 445、71、71 / 73、71 / 73 / 141、71 / 141、71 / 302、73、73 / 116 / 141、73 / 141、73 / 302、89、93、96、109、109 / 112、109 / 115 / 118、109 / 134、109 / 406、112、112 / 445、116、116 / 123、116 / 287、116 / 143、116 / 350、123、125、127、127 / 169 / 172、12 7 / 169 / 287、127 / 169 / 376 / 398 / 399、127 / 169 / 398 / 399、127 / 287、127 / 376、141、141 / 302、143、144、149、156、169 / 172 / 287、169 / 172 / 288、169 / 172 / 288 / 398 / 399 / 420 / 423 / 427、169 / 172 / 398 / 399、169 / 287、169 / 398、169 / 398 / 399、186、187、 197, 198, 199, 201, 202, 203, 268, 287, 287 / 288, 287 / 376, 287 / 398, 287 / 399, 287 / 420 / 423 / 427, 288, 288 / 376 / 398, 288 / 398, 288 / 399, 302, 324, 331, 350, 376, 376 / 398, 376 / 399, 398, 398 / 399, 398 / 399 / 420, 398 / 427, 399 and 420, wherein the positions are numbered with reference to SEQ ID NO: 7784.
5. The engineered glycosyltransferase according to any one of the preceding claims, wherein: (a) the engineered glycosyltransferase preferentially uses a sugar donor other than uridine diphosphate; and / or (b) the engineered glycosyltransferase is an NDP-glycosyltransferase selected from ADP-glucose-dependent glycosyltransferase (AGT), CDP-glucose-dependent glycosyltransferase (CGT), GDP-glucose-dependent glycosyltransferase (GGT), TDP-glucose-dependent glycosyltransferase (TGT) and IDP-glucose-dependent glycosyltransferase (IGT), optionally, wherein the engineered glycosyltransferase is an ADP-glucose-dependent glycosyltransferase.
6. The engineered glycosyltransferase of any of the preceding claims, wherein the polypeptide sequence of the engineered glycosyltransferase comprises Table 14.1, 15.1, 15.2, 15.3, 16.1, 17.1, 43.1, 43.2, 44.2, 45.1, 45.3, 46.1, 46.2, 46.3, 47.1, 47.2, 47.3, 48.1, 48.2, 49.1 , 49.3, 50.1, 50.2, 50.3, 50.4, 51.1, 51.2, 52.1, 53.1, 53.3, 54.1, 54.2, 54.3, 55.1, 55.2, 55.3, 56.1, 56.2, 56.3, 57.1, 58.1, 58.2, 58.3, 59.1, 59.2 and / or 59.
3.
7. An engineered polynucleotide encoding at least one engineered glycosyltransferase polypeptide provided in any one of claims 1-6.
8. A vector comprising at least one engineered polynucleotide according to claim 7, optionally wherein the vector further comprises at least one control sequence.
9. A host cell, comprising: (a) at least one engineered polynucleotide according to claim 7; or (b) at least one vector according to claim 8, Optionally, wherein the host cell is selected from eukaryotic organisms and prokaryotic organisms.
10. A method for producing at least one engineered glycosyltransferase provided in any one of claims 1-6, comprising culturing the host cell according to claim 9 under conditions such that the host cell produces the engineered glycosyltransferase, optionally wherein the method further comprises the step of recovering the engineered glycosyltransferase.
11. A composition comprising at least one engineered glycosyltransferase according to any one of claims 1-6.
12. A method for: (a) glycosylation of a substrate, the method comprising providing at least one substrate, at least one engineered glycosyltransferase according to any one of claims 1 to 6, and contacting the substrate with the engineered glycosyltransferase under conditions such that the substrate is glycosylated to produce at least one glycosylated product, optionally wherein: (i) the substrate comprises at least one steviol glycoside; and / or (ii) the glycosylation product comprises at least one monoglycosylation product and / or polyglycosylation product; (b) producing rebaudioside M, the method comprising providing a rebaudioside I substrate, NDP-glucose, and at least one engineered glycosyltransferase according to any one of claims 1-6, and combining the rebaudioside I substrate, NDP-glucose and the engineered glycosyltransferase under conditions such that rebaudioside M is produced; or (c) producing rebaudioside D, the method comprising providing a stevioside substrate, NDP-glucose, and at least one engineered glycosyltransferase according to any one of claims 1 to 6, and combining the stevioside substrate, NDP-glucose and the engineered glycosyltransferase under conditions such that rebaudioside D is produced.
13. The method according to claim 12, wherein: (a) the NDP-glucose is selected from ADP-glucose, CDP-glucose, TDP-glucose, GDP-glucose and / or IDP-glucose; (b) the NDP-glucose is not UDP-glucose; (c) the engineered glycosyltransferase comprises the engineered glycosyltransferase according to any one of claims 1 to 6; and / or (d) The NDP-glucose is ADP-glucose.
14. A method for producing: (a) rebaudioside D, the method comprising providing a stevioside substrate, NDP, sucrose, sucrose synthase, and at least one engineered glycosyltransferase according to any one of claims 1 to 6, and combining the stevioside substrate, NDP, sucrose, sucrose synthase and the engineered glycosyltransferase under conditions such that rebaudioside D is produced; (b) rebaudioside M, the method comprising providing a stevioside substrate comprising at least one stevioside and / or a mixture of stevioside and rebA, NDP, sucrose, sucrose synthase, and at least one engineered glycosyltransferase according to any one of claims 1-6, and combining the stevioside substrate, NDP, sucrose, sucrose synthase and the engineered glycosyltransferase under conditions such that rebaudioside M is produced; or (c) A method for producing rebaudioside M, comprising providing a stevioside substrate, NDP, sucrose, at least one sucrose synthase, and at least one engineered glycosyltransferase according to any one of claims 1-6, and combining the stevioside substrate, NDP and the engineered glycosyltransferase under conditions such that rebaudioside A is produced first, then rebaudioside D and / or rebaudioside I is produced, and finally rebaudioside M is produced.
15. The method according to claim 14, wherein: (a) the sucrose synthase is an engineered sucrose synthase comprising a polypeptide sequence having one or more residue differences compared to SEQ ID NO: 74; (b) the method is carried out in a one-pot reaction; (c) the methods are performed sequentially; (d) the method further comprises repeating the steps of the method; optionally, wherein: (i) the sucrose is recycled during the repeating steps; and / or (ii) the engineered glycosyltransferase and / or other reaction components are recycled; (e) the stevioside substrate is extracted from Stevia rebaudiana or is synthetically produced; (f) the engineered glycosyltransferase and / or the sucrose synthase is immobilized; (g) the method produces a reaction product comprising fructose, optionally wherein the fructose is removed from the reaction product; and / or (h) The method further comprises a washing step and / or at least one column chromatography step.
Citation Information
Cited By
Beta-1, 3-glycosyltransferase mutant and application thereof in catalytic synthesis of rebaudioside M
CN121718520A
